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AIC Akaike infonnation criterion 
ANOVA analysis of variance 
°C degrees centigrade 
Co-Var coefficient of variation 
COX cyclooxygenase 
CPF carprofen 
cPLA2 cytoplasmic phospholipase A2 
cNOS constitutive fonn of nitric oxide synthase 
cpm counts per minute 
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Fig figure 
FM flunixin meglumine 
g gramme 
g gravity, 1O-llN.m1s2 
GLM general linear model 
h hour 
HETE hydroxyeicosatetraenoic acid 
HPETE hydroperoxyeicosatetraenoic acid 
HPLC high perfonnance liquid chromatography 
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IL interleukin 
i.m. intramuscular or intramuscularly 
iNOS inducible fonn of nitric oxide synthase 
I.V. intravenous or intravenously 
kg kilo gramme 
III 
KPF 
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LOX 
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M 
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NO 
NOS 
NSAID 
OPBZ 
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PD 
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litre 
~ -nitro-L-arginine methyl ester 
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lipoxygenase 
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leukotriene 
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nanogramme 
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nitric oxide 
nitric oxide synthase 
nonsteroidal antiinflammatory drug 
oxyphenbutazone 
platelet activating factor 
phosphate buffered saline 
phenylbutazone 
pharmacodynamic or pharmacodynamics 
prostaglandin 
prostaglandin G 
prostaglandin H 
prostacyclin 
negative logarithm of hydrogen ion concentration 
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PK phannacokinetic or phannacokinetics 
PL phospholipase 
PLB placebo 
PLT platelets 
PMN polymorphonuclears 
p.o. oral or orally 
PPB minus background 
PRT paracetamol 
r correlation coefficient 
R2 square of correlation coefficient. 
Rac racemIC 
RIA radioimmunoassay 
SD standard deviation 
SE standard error of the mean 
sPLA2 secretory phospholipase A2 
SSV sheep seminal vesicles 
TNF tumour necrosis factor 
TX thromboxane 
~g microgram 
J.1M micromole 
WBC white blood cells 
v 
A,P,B 
a,1t,p 
AVC 
AVCO-1ast 
AVCo-oo 
AUMC 
AUMCo_1ast 
Cmax 
C 
D 
E 
ECso 
F 
FO-last 
Fo-oo 
Pharmacokinetic and pharmacodynamic parameters 
The zero time intercepts associated with the a, 1t, and p phase, 
respectively, following intravenous administration. 
"Macro" rate constants associated with the distribution, slow 
distribution phase and elimination phase, respectively, following 
intravenous administration. 
Area under the curve. 
AVC computed to the last observation. 
AVC extrapolated to infinity 
Area under the moment curve. 
AUMC computed to the last observation. 
AUMC when the time concentration curve IS extrapolated to 
infinity. 
Total body clearance. CIs= Dose/ AVC. 
The peak or maximum drug concentration in plasma following 
extravascular administration or the maximum concentration In 
tissue-cage fluids following intravenous administration. 
Drug concentration. 
Initial concentration of the drug in plasma following an intravenous 
bolus administration calculated from the sum of intercepts. 
Dose. 
Effect. 
The drug concentration which produces 50% of maximum effect at 
the effect site. 
Maximum effect attributed to the drug. 
Bioavailability calculated by dividing AVC following oral 
administration by AVC following intravenous administration. 
F which is associated with AUCO_last' 
F which is associated with AUCo-co. 
VI 
y 
IC50 
kol 
M 
MAT 
MATo-last 
MATo-<Xl 
MRT 
MRTo-last 
MRTO-<Xl 
f'a 1 
t'kOJ 
I 
Hill constant. 
The drug concentration which produces 50% of maximum inhibition 
achieved at the effect site. 
The rate at which the drug enters the central compartment from 
outside the system. The absorption rate. 
The rate at which the drug leaves the system from the central 
compartment. The elimination rate. 
First-order transfer rate constants calculated for drug distribution 
between the central and peripheral compartments of a twO-
compartment model. 
First-order transfer rate constants calculated for drug distribution 
between the central and peripheral compartments of a three-
compartment model. 
Hybrid parameter of one compartmental model with first order 
input. 
Mean absorption time for a drug from an administered site into the 
central compartment or mean distribution time for a drug from 
central (plasma) compartment into tissue-cage fluid. 
MAT calculated based on MRTo_1as• 
MAT calculated based on MRTo-<Xl. 
Mean residence time. It is the average amount of time a particle 
remains in a compartment or system 
MRT when the drug concentration profile is not extrapolated to 
infinity, but rather is based on values up to and including the last 
measured concentration. MRTo-last = AUMCo-last 1 AUCO-1ast• 
MRT when the drug concentration profile is extrapolated to infinity. 
MRTo-<Xl = AUMCo-<Xl 1 AUCo-<Xl 
Distribution half life following intravenous administration 
calculated from 0.693/(1. 
Elimination half life following intravenous administration calculated 
from 0.693/~. 
Distribution half life following intravenous administration 
calculated from 0.693ht. 
Absorption half life following extravascular administration or 
distribution half life from plasma compartment into tissue-cage 
VII 
t, klO 
l 
fluids. It is calculated from 0.639/k01. 
Elimination half life following extravascular administration or 
distribution half life from plasma compartment into tissue-cage 
fluids. It is calculated from 0.639/kl o. 
Time at which the Cmax is reached following an extravascular 
administration or time at which the Cmax in tissue-cage fluids IS 
reached following an intravenous administration. 
Apparent volume of central compartment. 
Volume of distribution at steady state. V ss = MR T X CIs 
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Absorption rate 
Akaike criteria 
Compartments 
Curve stripping 
Distribution rate 
Elimination rate 
Extravascular 
First-order 
Initial estimates 
Lag time 
Pharmacokinetic and pharmacodynamic terms 
The rate at which the drug IS absorbed into the central 
compartment. 
A measure of goodness of fit based on maximum likelihood. 
When comparing several models for a given set of data, the 
model associated with the smallest value of Akaike criteria is 
regarded as giving the best fit out of that set of models. 
Akaike Criteria is only appropriate for use when comparing 
models using the same weighting scheme. 
AIC = NOBS x LOG(WSS) + 2 x NP ARM 
where NOBS is number of observations, NP ARM is number 
of parameters and WSS is weighted sum of squared residuals. 
Many biological systems are made up of a finite number of 
homogenous, well mixed subsystems called compartments. 
Classically compartments have been used to represent blood 
plasma, kidneys, lungs or other organs. 
A graphical method for estimating parameters associated with 
models that can be written as a sum of exponential. This 
method can be used to determine initial estimates required as a 
prelude to non-linear least-squares regression. 
The rate at which the drug is distributed between 
compartments. 
The rate at which the drug is eliminated from a compartment. 
Drug administration via routes other than directly into the 
blood stream. Oral, intramuscular and topical are examples of 
extravascular administration. 
Used to denote rate constants when the transfer rates are 
proportional to the amount in the source compartment. 
Starting values for parameters. All iterative estimation 
procedures require initial estimates of the parameters. 
Lag time is a time delay between drug administration and the 
onset of drug absorption. An example of such a process is 
stomach emptying time following oral administration of a 
drug which is not absorbed from the stomach. When a drug is 
administered by bolus intravenous injection there is no lag 
phase 
IX 
Least squares fitting In least squares fitting, the estimates are those which minimise 
the sum of the squares of the deviations between the observed 
values and the values predicted by the model. 
NeIder-Mead 
algorithm 
simplex A model fitting algorithm which does not require the 
estimated variance - covariance matrix as part of its algorithm. 
Pharmacodynamic Models which are used to model effect as a function of a drug 
models concentration 
Pharmacokinetic models Models which are used to model drug concentrations as a 
function of time. 
PK / PD link model A pharmacokinetic / pharmacodynamic link model uses the 
pharmacokinetic concentration data to estimate concentrations 
at an effect site which are then used to model the 
pharmacodynamics. 
Secondary parameters 
Sigmoid 
Simulation 
Parameters which are functions of the primary model 
parameters. 
The "S" shaped nature of certain curves. 
Predict the drug concentrations from given model and time 
points. 
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Summary 
The present study was conducted to investigate the phannacokinetics (PK) and 
phannacodynamics (PD) of some nonsteroidal antiinflammatory drugs (NSAIDs), including 
phenylbutazone (PBZ, in sheep, goats and donkeys), flunixin meglumine (FM, in sheep and 
donkeys), carprofen and its enantiomers (CPF, in sheep), paracetamol (PRT, in goats and 
camels) and N"-nitro-L-arginine methyl ester (L-NAME, in sheep). 
Eight sheep were prepared with subcutaneous tissue-cages and acute inflammation was 
induced by injection of 0.3 ml of 1 % carrageenan into the cages and maintained by a further 
injection of 0.2 ml carrageenan after 8 hours. Flunixin meglumine (FM, 1.1 mg/kg) and PBZ 
(4.4 mg/kg) were administered intravenously (Lv.) as a single dose in the sheep. Plasma 
kinetics showed that elimination of PBZ was slow, indicated by an elimination half life (t 1 ~) 
2 
of 17.92 ± 1.74 h, a body clearance (CIs) of 4.56 ± 0.53 ml/kglh and an area under 
concentration time curve (AUC1asJ of 963.54 ± 95.35 J.1g/ml.h. The elimination ofFM (tlp = 
2 
2.33 ± 0.18 h, CIs = 39.67 ± 4.27 mVkglh and AUC1ast = 30.56 ± 3.41 J.1g/ml.h) was faster than 
PBZ. Both PBZ and FM distributed well into exudate and transudate although the penetration 
was slow, indicated by maximal drug concentration (CmaJ for PBZ of 22.32 ± 1.29 J.1g/ml at 
9.50 ± 0.73 h (exudate) and 22.07 ± 1.57 J.1g/ml at 11.50 ±I .92 h (transudate), and Cmax for 
FM of 1.82 ± 0.22 J.1g/ml at 5.50 ± 0.73 h (exudate) and 1.58 ± 0.30 J.1g/ml at 8.00 h 
(transudate), and a high mean tissue-cage fluid: plasma AUC1ast ratio obtained in the PBZ and 
FM groups (80-98 %). These values are higher than previous reports in horses (Lees et al., 
1986) and calves (Landoni et al., 1995a) using the same or higher dose rates. Elimination of 
PBZ and FM from exudate and transudate was slower than from plasma. Consequently the 
drug concentrations in plasma were initially higher and subsequently lower than in exudate 
and transudate. Intra-caveal injection of carrageenan induced the generation of exudate 
prostaglandin (PG) E2 from an undetectable level « 0.5 ng/ml) to 35.65 ± 4.92 ng/ml at 12 h 
and was accompanied by significant increases (p<0.05) in leukocyte numbers (41.96 ± 8.59 x 
109 celllL at 24 h), skin temperature over the inflamed cages (increased by 1.06 ± 0.45 °C at 
12 h) and exudate leukotriene (LT) B4 concentration (1.63 nglml at 12 h). Phenylbutazone 
produced partial inhibition of serum thromboxane (TX) B2 and exudate PGE2 generation and 
the inhibitory effect was significant for up to 32 h for serum TXB2, and at 4 and 12 h for 
xm 
exudate PGE2. The maximal inhibitory effects (EmaJ for serum TXB2 was 80 ± 6 % and the 
ICso (drug concentration which produces 50 % of Emax) was 10.86 ± 1.81 Jlg/ml and occurred 
at 29.96 ± 2.62 h. A maximal exudate PBZ concentration of 22.32 ± 1.29 Jlglml only 
produced about 10 % inhibitory effect against exudate PGE2 generation. Phenylbutazone did 
not inhibit the skin temperature rise over the inflamed cages or the recruitment of exudate 
white blood cell (WBC) numbers significantly (P>0.05). Intravenous injection of FM 
abolished or significantly (P<0.05) inhibited serum TXB2 and exudate PGE2 formation for up 
to 32 h (P<0.05). The Emax for exudate PGE2 and serum TXB2 generation was 100 %. The 
ICso was estimated to be 0.0053 ± 0.0032 Jlg/ml and 0.00019 ± 0.00012 Jlg/ml against serum 
TXB2 and exudate PGE2 generation, respectively. Flunixin meglumine also significantly 
inhibited skin temperature over the cages and accumulation of exudate WBC numbers 
(P<0.05). Phenylbutazone and FM slightly increased the exudate L TB4 generation, indicating 
that these NSAIDs are not 5-lipoxygenase (5-LOX) inhibitors and that a metabolic diversion 
of arachidonic acid occurred. This experiment suggests that PBZ and FM have distinct effects 
on carrageenan-induced cycooxygenase (COX) and platelet COX. Flunixin meglumine but 
not PBZ is a potent COX inhibitor and antiinflammatory drug in sheep and a dose rate of 1.1 
mg/ml ofFM may be sufficient to produce antiinflammatory effect. 
A single dose rate of racemic (rac)-CPF (4.0 mglkg), R(-)CPF (2.0 mglkg), S(+)CPF (2.0 
mglkg) and L-NAME (25 mglkg) were administered Lv. to the same sheep as described above 
for the assessment of their antiinflammatory effects. Racemic-CPF and S(+)CPF inhibited 
serum TXB2 and exudate PGE2 generation significantly for up to 32 h (P<0.05). The Emax for 
serum TXB2 was 79 ± 3 % for rac-CPF and 68 ± 6 % for S( + )CPF. Racemic CPF inhibited 
over 50 % ofEmax for serum TXB2 for up to 19.00 ± 3.20 h and S(+)CPF inhinbited over 50 % 
of Emax for up to 24.40 ± 4.89 h. Compared with placebo treated group, rac-CPF and S( + )CPF 
produced 50-98 % inhibition for exudate PGE2 generation over a 4-32 h period. The 
inhibitory effect of rac-CPF for serum TXB2 was significantly higher than that of S(+)CPF 
(P<0.05) in spite of small difference while the inhibitory potency for exudate PGE2 between 
rac-CPF and S(+)CPF was similar (P>O.05). R(-)-carprofen attenuated serum TXB2 
generation by < 10 % while it potentiated exudate PGE2 generation by 5-30 % over a period 
of 4-32 h. Racemic CPF and S(+)CPF enantiomer slightly increased LTB4 generation and 
leukocyte recruitment in the exudate although statistic significance was achieved only at a few 
time points. The increase in skin temperature over inflammatory cages was effectively 
XIV 
inhibited by rac-CPF and S( + )CPF but not by R( -)CPF. This study indicates that CPF is a 
potentially useful NSAID in sheep and that the S(+) enantiomer only acts as a conventional 
NSAIDs for its the antiinflammatory effects. Intra-caveal injection of carrageenan induced 
increased nitric oxide (NO) generation by 89 ± 9 % in the exudate over a 96 h period. 
Administration of L-NAME upregulated the exudate nitric oxide production with a maximal 
increase of21 % at 2 h (P<0.05). It inhibited serum TXB2 generation by 19 ± 2 % over a 72 h 
period whereas it increased PGE2 generation by 34 %, L TB4 generation by 35 % and 
leukocyte recruitment by 50 % in the inflammatory exudate. This suggests that L-NAME may 
be converted into L-arginine in sheep in the metabolic process and that NO may playa role in 
acute inflammation by upregulating the activity ofCOX-2, 5-LOX and leukocyte recruitment. 
Phenylbutazone (4.4 mglkg) and FM (1.1 mglkg) were given i.v. to 3 donkeys prepared with 
subcutaneous tissue-cages and in which carrageenan-induced acute inflammation had been 
developed. The elimination of PBZ from plasma was very fast, indicated by at! 13 of 0.63 ± 
2 
0.13 h, a mean residence time (MRT\asJ of 0.69 ± 0.12 h, a CIs of214.18 ± 18.04 mllkglh and 
a AVC\ast of 19.21 ± 2.11 Jlg/ml.h. The conversion ofPBZ to oxyphenbutazone (OPBZ) was 
rapid and extensive (AVC ratio for OPBZ to PBZ = 67 %). The elimination of FM from the 
plasma in the donkeys (t! 13 = 2.09 ± 0.45 h and CIs = 50.27 ± 9.42 mllkg/h) was similar to the 
! 
time reported in the horses (t! p = 1.94 ± 0.10 h and CIs = 57.3 ± 2.9 mllkg/h). The 
2 
elimination ofPBZ and FM in exudate was slower than in plasma. The AVC ratio for exudate 
to plasma for PBZ (42 %) was similar to that ofFM (47 %) while the ratio for transudate to 
plasma for PBZ (26 %) was smaller than that for FM (55%). Phenylbutazone and FM 
inhibited the generation of serum TXB2 and exudate PGE2, and skin temperature over 
inflammatory foci significantly in a time-related fashion (P<0.05) while they did not modify 
leukocyte numbers and 12-hydroxyeicosatetraenoic acid (12-HETE) significantly (P>0.05). 
This study indicates that PBZ and FM are potent antiinflammatory drugs in donkeys, the 
dosage of PBZ should be higher and dosage interval shorter in donkeys compared to horses 
whereas the dose rate of FM used in horses can be extended to donkeys although tolerance 
studies are required to ensure safety in the donk~y. 
Phenylbutazone was administered Lv. and orally (p.o.) to 6 goats at a single dose rate of 4.4 
mglkg. The disposition and bioavailability (F) of PBZ and the disposition of its active 
xv 
metabolite, OPBZ in plasma were investigated. The effect of PBZ administration on serum 
TXB2 generation was studied. The elimination of PBZ was slow, indicated by at! p of 15.34 
2 
± 1.15 h and 21.99 ± 3.32 h after i.v. and p.o. administration, respectively. Following PBZ 
paste administration p.o., F was 61 ± 7 % (corrected by the t! p) and a relatively slow 
2 
absorption was observed, illustrated by a time to maximum drug concentration (tmax) of 3.47 
± 0.39 h and a mean absorption time (MAT) of 10.43 ± 8.61 h. The concentration ofOPBZ in 
plasma was low throughout and AVe ratios of OPBZ to PBZ were approximately 2 % after 
i.v. and p.o. administration. Thromboxane B2 generation in the platelets was significantly 
inhibited (p<0.05) from 1 to 12 h following Lv. and from 2 to 12 h after p.o. administration. 
The Emax was 70.63 ± 11.96 % for Lv. and 61.06 ± 11.83 % for p.o. administration. 
Paracetamol was administered at dose rates of 5 mglkg to camels and 10 mglkg to goats by 
the i.v. and intramuscular (Lm.) routes. Parent paracetamol had a significantly slower 
clearance (21.9 ± 1.4 ml/kglmin vs 52.8 ± 7.3 ml/kglmin) (P < 0.01) in camels than goats. In 
camels the predominant metabolite in plasma was the sulphate although the ratios of 
glucuronide: paracetamol and sulphate: paracetamol were similar (5.20 ± 0.50 vs 6.59 ± 
0.51) following i.v. administration. In goats the glucuronide metabolite was the predominant 
moiety in plasma and the AVe of the sulphate was only 4 % of that of the glucuronide 
conjugate. The apparent AVe for paracetamol in the camels following Lm. administration was 
larger than that following i.v. administration, however when the F was determined with 
correction for altered t! P within animal and between study phases it was 71 ± 17 % in goats 
2 
and 105 ± 26 % in camels. 
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Chapter 1 
General introduction 
1.1 Inflammation 
Inflammation may be defined as a protective response to the injury and is essentially a beneficial 
pathological process. It can occur in all tissues and organs in the body and the causal stimuli are 
diverse and include physical, chemical and biological factors. Each type of stimulus provokes a 
characteristic pattern of response that represents a relatively minor variation on a theme. The 
responses are usually accompanied by the familiar clinical signs of heat, redness, pain and 
swelling and were described by Celsus (30 BC-AD 38). If the stimulus persists, the fifth 
cardinal sign of inflammation, loss of function, may appear as tissue degeneration and fibrosis 
develops. Inflammation is a common pathological process involved in many diseases in animals. 
Examples seen daily in veterinary clinical practice include laminitis, dermatitis, enteritis, 
tendonitis, mastitis, metritis, pneumonitis, myositis, bursitis and countless of other ailments all 
characterised by the suffix-itis. 
Many different mechanism are involved in the inflammatory process (Gallin et al., 1992; Kelly 
et al., 1993; Higgins & Lees, 1984d). The major responses can be classified as 1) vascular, 2) 
cellular, 3) formation and release of chemical mediators and 4) tissue degeneration and fibrosis. 
The first three processes are mainly associated with the acute phase and the fourth process is 
associated with the development of chronic inflammation (Fig. 1.1.). 
It is now recognised that that the inflammatory mediators playa pivotal role in the inflammatory 
processes. Inflammatory mediators are a large family of biochemical substances which are 
formed and released during the inflammatory reaction and possess biological effects which 
initiate and maintain the inflammatory process. They include histamine, bradykinin, L Ts, PGs, 
P AF and cytokines. Recently a number of new chemical mediators have been found and 
established as inflammatory mediators, including NO and families of adhesion molecules. 
Undoubtedly there are other mediators awaiting discovery. 
1 
1.2. Pharmacology of inflammation 
1.2.1. Vascular responses 
Inflammation is nonnally a localised protective response which serves to destroy, dilute, or wall-
offboth the injurious agent and the injured tissue. The early events which occur in response to an 
inflammatory stimulus are changes in blood flow through the affected tissues and an increase in 
vascular penneability. These events facilitate the exudation of plasma proteins and the 
immigration of leukocytes from the vascular fluid into the tissues. Alteration of blood flow also 
accompanies the early stage of inflammation. Following induction of inflammation, an initial 
constriction of the arterioles due to a vasomotor reflex which last only for a short time, is 
followed by a widespread dilation of venules and lymphatics. This response is mediated by 
vasoactive agents liberated from locally damaged tissues, which are now collectively named 
inflammatory mediators. Inflammatory mediators play an important role in initialising and 
maintaining the vascular dilation and hence increasing vascular penneability. Dilation of the 
blood vessels causes an increased blood flow through the affected tissues, but eventually the rate 
of flow decreases. It is during the time of decreased blood flow rate that the circulating 
leukocytes begin to adhere to the vascular endothelium, a process know as "pavementing" in 
preparation for migration into the extravascular tissues. 
Increased vascular penneability is a result of the opening of the vascular endothelial cell 
junction. This is brought about by the contraction of endothelial cells, with the tough underlying 
basement membrane nonnally remaining intact. Gaps appear between endothelial cells, the cell 
body bulges into the lumen of vessel, the nucleus become rounded and nuclear and cell 
membranes crenellate (Majno & Palade, 1961). The mechanism for the development of 
endothelial cell constriction is rather complicated and a number of chemical mediators are 
involved. Vascular responses are mediated by a number of biologically active substances (Fig 
1.2.). The early reports indicated that histamine from adjacent tissue mast cell is the first 
substance to be released. The initial increased vascular permeability and dilatation seems to be 
maintained at first by kinins, 5-HT and the complement system and sequentially by products 
deriving from arachidonic acid under the action of a fatty acid COX enzyme. The demonstration 
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that two soluble mediators (bradykinin and PGs) are required to influence blood flow and 
vascular permeability and that the presence of only one will not produce the symptoms of 
inflammation (Williams, 1979) highlights the ability of the body to regulate its own response to 
stimuli. 
Increase in vascular permeability permits exudation of plasma proteins and inflammatory cells 
into the extravascular tissues. The accumulation of the fluids and cells at the damaged site is now 
collectively termed the inflammatory exudate. Unlike transudate or oedema fluids, this 
inflammatory exudate contains large amount of proteins, inflammatory cells and inflammatory 
mediators. 
1.2.2. Cellular response 
The accumulation and subsequent activation of leukocytes in the affected sites is an important 
event in the pathogenesis of virtually all forms of inflammation. In order to minimise or remove 
the injury from the body, it must serve to provide, as soon as possible, killers (including 
phagocytes and antibodies) to the site of injury. Infiltration of neutrophils and PLT occurs first. 
Polymorphonuclear leukocytes predominate in the early stages of acute inflammation and are the 
characteristic cell of the acute inflammatory process but their predominance is short-lived since 
they can not reproduce. Subsequently mononuclear phagocytes invade and predominate. These 
cells are capable of replication at the site of inflammation (Spector & Ryan, 1970). During 
resolution or progression to chronicity, macrophages become the dominant white cell type 
(Atherton & Born, 1972) although within 24 h of injury the macrophages are well mobilised. 
Macrophages normally circulate in the blood as monocytes (mononuclear phagocytes) from 
which they migrate and enlarge following injury. They engulf and ingest large particulate matter 
and can coalesce to form a giant cell (macrophage polykaryon). 
Polymorphonuclears, monocytes and lymphocytes, and PL T have all been shown to have a role 
in the inflammatory process. They can been collectively termed inflammatory cells. The roles of 
the phagocytic cells in acute inflammation are to identify, attack, ingest and dispose of foreign 
biological or other particulate matter. They can also generate and release inflammatory chemical 
mediators, such as PGs and cytokines. The PMNs are, however, end cells; after they accomplish 
3 
phagocytosis they are degraded or die at the inflammatory site. The role of the mononuclear 
phagocyte clearly is to cope with the removal of debris following the death of these PMNs 
(Hurley, 1978). The phagotocytic process is thought to release sufficient hydrolytic enzymes to 
cause damage to host tissues (Henson et al., 1992). Lymphocytes also playa role in the 
inflammatory process. Apart from neutrophils, lymphocytes are present in inflamed exudate in 
relatively large quantities following the inflammatory stimulus (Higgins et al., 1987). In the 
immunoinflammatory process, immunised T -lymphocytes activate macrophages rapidly to 
respond to a repeat attack by the process known as cell mediated immunity while B-lymphocytes 
are responsible for the production of antibodies (Welch & Winfield, 1992). 
Circulating leukocytes do not adhere to vascular tissues in normal physiological conditions. For a 
cell to arrive at a site of inflammation it needs firstly to move from the lumen of the blood vessel 
(margination), then to adhere to the vascular endothelium, next to move through the vascular 
wall (diapedesis) and its associated tissue, and finally to move to the extravascular site of 
inflammation (chemotaxis). Ihis overall process of migration may thus be divided into phases 
known respectively as margination, adherence, diapedesis, and chemotaxis. Recent studies have 
illustrated that the chemical substances released from microvasculature play important roles in 
cell adhesion and recruitment. A number of adhesion molecules have been identified, including 
E-selectin, P-selectin, L-selectin, intracellular adhesion molecule 1 (ICAM -1), vascular cell 
adhesion molecule 1 (VCAM-1), and leukocyte integrins in the adhesion ofleukocytes, PLI, and 
endothelium at sites of inflammation. Activated endothelial cells play a key role in "targeting" 
circulating cells to inflammatory sites by expression of various adhesion molecules, which serve 
as the receptors for cell adhesion (Gallin et al., 1992; Bevilacqua & Nelson, 1993; Cronstein & 
Weissman, 1993). A number of chemical mediators are involved in regulation of inflammatory 
cellular recruitment and these will be discussed in section 1-3. 
1. 2.3. Inflammatory mediators 
It is now generally accepted that the pathophysiological changes in the inflammatory process are 
brought about or regulated by chemical mediators acting locally within the affected tissues. 
These biologically active substances are many in number and diverse in structure. The 
identification of inflammatory mediators, and their roles and regulation has become one of the 
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most interesting research areas. In 1918, Dale and Richards identified certain specific 
characteristics which a substance required to be defined as a mediator of a biological event. Vane 
(1972) refined the criteria for defining an inflammatory mediator as follows: it should be 
demonstrably present at the site of inflammation and absent when the reaction subsides; it should 
produce one or more of the cardinal signs of inflammation if introduced into normal tissue; 
antagonists of the substance should have antiinflammatory effects; the inflammatory response in 
tissues should be inhibited following depletion of the substance or inhibition of its synthesis; and 
administration of antagonists of the inactivation of the substance should increase the effects of 
the stimulus. Based on these criteria, a number of classical methods were developed to examine 
the roles and regulation of the inflammatory mediators. Recently with the development of 
cellular and molecular biology, a number of isoenzyemes responsible for the generation of 
inflammatory mediators have been identified and these provide a good basis for understanding of 
the roles of the mediators in both physiological and pathological processes. The use of antisense 
oligonucleotides provide an method of differentially regulating the isoenzymes and enzymes in 
vitro. Gene knockout techniques allow the investigator to remove a particular gene which 
encodes an inflammatory mediator in experimental animals and thus use the animal and its cells 
to unequivocally define the roles of the inflammatory mediator. A number of new inflammatory 
mediators and receptors have been identified so that the family of inflammatory mediators has 
become larger and larger in number (Gallin et al.. 1992; Wei et al .. 1995; Williams and DuBois, 
1996). 
Mediators known to contribute importantly to the inflammatory process include cytokines, 
eicosanoids, PLT-activating factor, complement and the kinin systems, histamine and 5-HT. 
Selectins, adherent molecules, sensory neuropeptides, substance P, calcitonin gene-related 
peptide, NO and pro-inflammatory neurokinins have been recently shown to significantly 
contribute to the inflammatory process. Most of the above substances are like a double edged 
sword acting in the body. They are involved in physiological processes to maintain homeostasis 
in the body, but their excessive generation can lead to pathological processe~inflammation 
(Gallin et al., 1992). 
5 
Histamine 
Histamine is one of the earliest identified mediators of the inflammatory process. This simple 
amine [4-(2-aminoethyl) imidazole] is derived from the amino acid histidine by decarboxylation 
and is stored as a complex with heparin in mast cells and basophils. It has also been found in 
PLT, nervous tissues, lungs, skin, intestinal mucosa and in the parietal region of the stomach 
(Levy 1974). Histamine is readily released from its granules by many stimuli which may be 
physical, chemical, pharmacological or immunological. Its release can be regulated by 
intracellular levels of cAMP or cGMP and by the disruption of microtubule (Atkinson et al., 
1992). Histamine causes dilatation of the terminal arterioles and increases the vascular 
permeability of post-capillary venules by initiating the contraction of the vascular endothelial 
cells. This effect is only transient however, and contributes only to the early stages of an acute 
inflammatory response. Thus HI histamine-receptor antagonists are generally only useful for the 
treatment of vascular events in the early transient phase of inflammation. The effect of histamine 
on vascular permeability is potentiated by COX products of arachidonic acid metabolism 
(Williams & Morley, 1973). 
Histamine has effects on inflammatory cells. It was shown to inhibit the release of lysosomal 
enzymes from human PMN (Zurier et al., 1974) and to inhibit the chemotaxis of human PMN 
and basophils (Hill et al., 1975). The chemotactic response of eosinophils, however, is 
selectively enhanced by histamine, although high concentrations induce desensitisation of these 
cells to chemoattractants (Clark et al., 1975). 
Recent studies have suggested that mast cells evoked leukocyte-endothelial cell interaction by 
release of histamine. Thromboxane A2 rapidly induces mast cell degranulation, leading to release 
and accumulation of histamine in the perivenular compartment. The mast cell-derived histamine 
appears to mediate at least part of the leukocyte-endothelial and PLT -leukocyte adhesion by 
engaging HI-receptors on endothelial cells and PLT, respectively, to increase the expression of 
P-selectin. Activation of the leukocyte adhesion glycoprotein CDIl1CD18 and its subsequent 
interaction with constitutively expressed ICAM-I also contributes to the leukocyte recruitment 
elicited by C difficile toxin A (Kubes & Granger, 1996). The interaction of leukocyte-endothelial 
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cells leads to the generation of a broad spectrum of other inflammatory mediators, such as the 
eicosanoids. 
5-Hydroxytryptamine 
5-Hydroxytryptamine is stored in PLT and also in mast cells of rats and mice. The main storage 
site in mammals is the enterochromaffin cell of the gastro-intestinal tract, which contains 90 % 
of the total 5-HT present in the body. 5-Hydroxytryptamine is considerably more potent than 
histamine in increasing vascular penneability. In experimental animals, the early stages of a 
carrageenan-induced paw oedema have been shown to be dependent on a simultaneous release of 
both histamine and 5-HT. Treatment with histamine and 5-HT antagonists (mepyramine and 
methysergide), or depletion of both agents with compound 48/80 prior to carrageenan injection, 
effectively suppresses the early development of the oedema (Crunkhom & Meacock, 1971; Di 
Rosa et al., 1971). Recent studies showed that 5-HT potentiated pain produced by other 
inflammatory mediators and activation of 5-HT 2A receptors produced the same results (Abbott et 
aI., 1996). However its involvement in acute inflammation in man seems to be minor, although it 
may have a more important place in inflammatory conditions of the bowel. 
Complement 
Complement is composed of 20 plasma proteins. Complements can be activated by a variety of 
stimuli and are involved in maintaining host defences and mediating inflammation and tissue 
injury. The most important products of complement in host defensive and inflammatory process 
include large fragments of C3 (e.g., C3b, C3bi) with opsonic activity, as well as low-molecular-
weight peptides (derived from C3 and Cs) that exhibit anaphylatoxin activity and that directly 
stimulate leukocytes (Goldstein, 1992). 
Kin ins 
Kinins, including the peptides bradykinin and kallidin, are generated in the inflamed tissues by 
the stimulation of a variety of factors including tissue damage, allergic reactions, viral infections 
and other inflammatory events (Wachtfogel et al., 1993). These peptides are autacoids that act 
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locally to produce pain, vasodilatation, increased vascular penneability and the synthesis of PGs. 
Thus they comprise a subset of the large number of mediators that contribute to the inflammatory 
response (Sharma & Mohsin, 1990; Dray & Perkins, 1993; Geppetti, 1993; Lerner, 1994). 
Cytokines 
Cytokines are a heterogeneous group of substances generated by cells in response to antigenic or 
mitogenic stimulation. They are identified by virtue of their cellular origin and by the effects 
they produce on target cells such as lymphocytes and macrophages. Cytokines appear to fall into 
three groups: cytokines that act primarily as positive or negative growth factors for a variety of 
cells (IL-l, IL-3, IL-4, IL-5, IL-7, IL-I0, IL-l1 and IL-12), cytokines that possess pro-
inflammatory properties (TNF-a.lp, IL-la/p, IL-6, IPN-a/y, IL-8, macrophage inhibitory protein-
1) and cytokines that act as antiinflammatory factors [IL-lra (a competitive antagonist oflL-l), 
soluble IL-l receptors, TNF-a and IL-binding proteins] (Van Miert, 1994). 
The involvement of IL-l and TNF in inflammation has been well documented. Both IL-l and 
TNF are derived from mononuclear cells and macrophages (as well as other cell types) and 
induce expression of numerous genes to promote the synthesis of a variety of proteins that 
contribute to inflammatory events. lnterleukin-l and TNF produce many of the same 
inflammatory responses, which include induction of fever, sleep, and anorexia; mobilisation and 
activation of PMN; induction of COX and LOX enzymes; increase in adhesion molecule 
expression; activation of B-cells, T -cells and natural killer cells; and stimulation of production of 
other cytokines. Other actions of these agents likely contribute to the fibrosis and tissue 
degeneration of the chronic proliferative phase of inflammation; stimulation of fibroblast 
proliferation, induction of collagenase, and activation of osteoblasts and osteoclasts. Interleukin-
1 and TNF are considered principal mediators of the biological response to bacterial 
lipopolysaccharides and many other infectious stimuli and may work in concert with each other 
and with growth factors and other cytokines, such as IL-8 and related chemotactic cytokines 
(chemokines), which can promote neutrophil infiltration and activation (Dinarello, 1992). 
Pro-inflammatory cytokines may cause acute phase responses in ruminants (including goats). It 
has been reported that IL-l and TNF-a caused fever, tachycardia, anorexia, forestomach 
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hypomotility, neutropaenia, neutrophilia, lymphopaenia, hyperglycaemia, hypoglycaemia, 
hypoferraemia, hypozincaemia, cachexia, increase in acute-phase proteins and decrease in P450, 
and these clinical effects, haematological and blood biochemical changes resembled those 
observed after i.v. LPS. In addition, the time of onset of the effects after injection of these 
cytokines was significantly shorter than after LPS, which is in accordance with the well-
documented roles ofIL-l and TNF-u as pivotal mediators ofLPS toxicity (Van Miert, 1994). 
Nitric Oxide 
Nitric oxide is generated during the metabolism of L-arginine by the NADPH-dependent 
enzyme, NOS. In macrophages, NO is an intermediate in the production of both nitrate (NO·3) 
and nitrite (NO·2). There are at least two isotypes of NOS. One is constitutive, Ca2+ Icalmodulin-
dependent and is expressed mainly in the brain, PLT and endothelial cells. The other is inducible 
NOS which is Ca2+/calmodulin-independent, existing in a variety of cell types, including 
macrophages, neutrophils and smooth muscle. Its expression can be induced by cytokines and 
bacterial products. (Liew & Cox, 1991; Moncada et at., 1991). 
Nitric oxide is the first gas known to act as a biological mediator and plays important roles in a 
number of homeostatic processes and host defence mechanisms. Nitric oxide participates in 
intercellular signalling when produced in small amounts by constitutive NOS in neurons and 
endothelial cells. However, immunologic and inflammatory stimuli induce the expression of 
iNOS to produce much larger amounts of NO over longer periods. In the latter circumstances, 
NO can exert cytostatic or cytotoxic effects against microbes, tumour cells, macrophages, and 
lymphocytes, as well as (3 cells in the pancreas (Moncada et at., 1991). At the same time, NO can 
suppress the proliferation ofT cells and the emigration ofneutrophils (Kubes et at., 1991). 
The mechanisms by which NO promotes tissue damage have not been established. The targets of 
destruction by NO are non-specific and appear to involve both reactions with Fe-S groups, 
leading to inactivation of enzymes in the mitochondrial electron transport chain, and at high 
concentrations, inhibition of DNA replication (Nathan & Hibbs, 1991) and the induction of 
apoptosis (Sarih et al., 1993). Other effects of NO, such as increase in permeability of the 
microvasculature, inhibition of suppressor T cells or antiproteases (McCartney-Francis et al., 
9 
1993), and induction of the expression of inflammatory cytokines (Ianaro et ai., 1994) which 
induce the expression of other inflammatory mediators, might also have a role. 
A role for NO has been demonstrated in acute inflammation. In rats, NO is involved in the acute 
inflammatory response following footpad injection of carrageenan (Lalenti et ai., 1992) or the 
topical application of mustard (Lippe et ai., 1993). It was also reported that NO was directly or 
indirectly linked to immune complex-induced tissue injury (Mulligan et ai., 1991). Wei et ei. 
(1995) have used iNOS knockout mice to confirmed the roles of NO in inflammatory and 
immune responses. Their experiment demonstrated that wild-type and heterozygous mice are 
highly resistant to the protozoal parasite Leishmania major while the mutant mice are uniformly 
susceptible, the infected mutant mice developed a significantly stronger Th1 type of immune 
response than the wild-type or heterozygous mice, and the mutant mice also showed a reduced 
non-specific inflammatory response to carrageenan induction, and were resistant to LPS induced 
mortality. In most of the studies, the pathology was significantly reduced by inhibiting NO 
synthesis in vivo by treating the animals with L-NMMA while D-NMMA did not show any 
inhibitory effects. 
Nitric oxide also plays a role in chronic inflammation. Adjuvant arthritis in rats is a model of 
chronic inflammation characterised by T cell- and monocyte- mediated immune response, and 
erosive destruction of the subchondral and periarticular bone and cartilage. The development of 
arthritis was accompanied by induction of iNOS and production of NO both in synovial tissue 
and blood mononuclear cells. The inhibition of NO synthase reduced the accumulation of 
inflammatory leukocytes and erosion of the joint (Lalenti et al., 1993). In man, serum from 
patients with rheumatoid arthritis or osteoarthritis contains significantly higher levels of nitrite 
compared to that of matched controls (Farell et ai, 1992). 
Selectins 
Recent studies have determined that a variety of cell adhesion molecules within the 
microvasculature play an important role in recruitment of inflammatory cells, especially the 
adhesion of leukocytes, PLT and endothelium at sites of inflammation. These includes 
selectins, intracellular adhesion molecule 1, vascular cell adhesion molecule 1, and leukocyte 
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integrins. Of these cell adhesion molecules, the selectin family is particularly important and has 
been studied in detail (Bevilacqua & Nelson, 1993). They have also been grouped as 
inflammatory mediators (Schlag & Redl, 1996). 
Selectins are a group of molecules present on the surface of leukocytes, PL T and endothelium. 
Each molecule contains an NH2 terminal lectin-like domain, an epidermal growth factor repeat 
and a discrete number of molecules similar to those found in certain complement binding 
proteins. Three types of selectins have been identified, L-selectin, P-selectin and E-selectin 
(Bevilacqua & Nelson, 1993). Their expression varies among the different cell types involved in 
the inflammatory response. Only L-selectin is constitutively expressed at the cell surface. The 
other two selectins are inducibly expressed. E-selectin is expressed in a restricted fashion in 
endothelial cells and is enhanced at sites of inflammation. P-selectin is expressed predominantly 
on PL T and endothelial cells and is enhanced by cytokines. L-selectin, in contrast, is a receptor 
for P-selectin, and it is expressed on leukocytes and is shed when these cells are activated. The 
enhanced selectins on resident cells can recognise and interact with the cell surface glycoprotein 
and the carbohydrate on circulating cells to form selectin-carbohydrate ligands and thus lead to 
recruitment of inflammatory cells. Although this suggests that selectins on the cell surface act 
like a receptor, recent reports have illustrated that soluble forms of P-selectin and L-selectin act 
as a functional circulating protein present at detectable concentrations (P-selectin, 0.1-0.3 J.1g1ml) 
(Dunop et al., 1992) or relatively high concentrations (L-selectin, about 1.5 J.1g1ml) 
(Scheiffenbaum et al., 1992) in normal human plasma. This indicates that soluble forms of 
selectins modulate inflammatory responses. 
Selectins may act as a new therapeutic target for antiinflammatory drug development. From the 
perspective of invading microorganisms, the host presents a formidable array of defences. 
Central to this process is the host's ability to recruit leukocytes to specific sites in the body 
where they are most needed. Leukocyte recruitment involves an orchestration of soluble 
mediators (e.g. cytokines) and cell-surface molecules that results in focal leukocyte attachment to 
the vessel wall and extravasation. The importance of the selectins in this process is now widely 
accepted. On the other hand, the accumulation and degeneration of inflammatory cells at the 
affected sites can cause tissue damage. Thus the blockage of selectin-carbohydrate interaction 
may help the host to recover from the inflammation (Rao et al., 1994). 
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Platelet-activating factor 
When PLA2 catalyses the release of arachidonic acid from lipids for the synthesis of eicosanoids, 
it also leads to the generation of modified phospholipids, importantly represented by PAF. Two 
metabolic steps are involved in the biosynthesis of P AF: the action of a PLA2 on choline-
containing membrane alkyl-ether lipids results in the production of lyso-P AF acether and 
acetylation of the lyso compound by an acetyltransferase yields the biologically active molecule. 
Platelet-activating factor is one of the potent pro-inflammatory mediators released from and 
acting on most cells that participate in the inflammatory response, including PL T, neutrophils, 
monocytes, mast cells, eosinophils and vascular endothelial cells. It induces the aggregation of 
PMNs and also promotes their aggregation and generation of lysosomal enzymes and 
eicosanoids and initiates the release of oxygen radicals. It also acts as an endogenous mediator of 
activation in a number of cell types (McDonald et al., 1994). It mediates IL-l-induced leukocyte 
extravasation across rat mesenteric microvessels. (Nourshargh et al., 1995). Platelet-activating 
factor is a potent vasodilator, and it lowers peripheral vascular resistance and systemic blood 
pressure and induces intravascular aggregation ofPLT when injected i.v. in dogs (Sybertz et al., 
1985). Intradermal injection of P AF duplicates many of the signs and symptoms of 
inflammation, including increased vascular permeability, hyperalgesia, edema and infiltration of 
neutrophils, and inhaled P AF increases the infiltration of eosinophils into the airways. 
Eicosanoids 
The families of PGs, L Ts, TXs and related compounds are called eicosanoids because they are 
derived from 20-carbon essential fatty acids, most notably arachidonic acid by COX and LOX 
enzyme systems. These compounds have a vital role in the initiation and maintenance of several 
components of the inflammatory process. Arachidonate is esterified to the phospholipids of cell 
membranes or other complex lipids. Since the concentration of free arachidonate in the cells is 
very low, the biosynthesis of eicosanoids depends primarily upon its availability to the 
eicosanoid-synthesizing enzymes; this results from its release from cellular stores oflipid by acyl 
hydro lases, especially PLA2 and in PLT, by diacyglycerol lipase (prescott & Majerus, 1983). 
Expression of PLA2 can be induced by widely divergent physical, chemical and hormonal 
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stimuli. At least two isotypes of PLA2 have been identified in mammalian cells, cPLA2 and 
sPLA2. There is increasing evidence that cPLA2 generates an arachidonic acid pool used by 
defensive mechanism and sPLA2 generates arachidonic acid for physiologic uses (Kawada et al., 
1995; Reddy & Herschman, 1996). Once released, a portion of the arachidonate is metabolised 
rapidly to oxygenated products by several distinct enzymes, including COX and LOXs, to form 
different groups of eicosanoids (Fig. 1.3.). 
a) Cyclooxygenase pathway 
The COX pathway leads to the formation of PGs and TXs. A ubiquitous complex of microsomal 
enzymes are involved in these synthetic processes in a stepwise manner. Cyclooxygenase also 
called PG endoperoxide synthase (PGHS), is the first enzyme in the pathway leading from 
arachidonic acid to PGI2, PGs and TXs. Increasingly biological data have shown that mammalian 
cells contain two isoforms of COX, termed COX-I and COX-2. Cyclooxygenase-l is a 
constitutive enzyme, generating PGs to modulate physiological processes whereas COX-2 is an 
inducible enzyme expressed following induction with stimuli, including certain serum factors, 
cytokines and growth factors. Cyclooxygenase-2 is thought to be responsible for inflammation 
and its expression can be inhibited by glucocorticoids (Kujubu et al., 1991; Xie et. al., 1991; 
O'Banion et ai., 1992; Sirois et al., 1992; DeWitt & Meade 1993; Jones et al., 1993; Herschman, 
1994). Phospholipase A2 releases arachidonic acid to provide substrate for COX. Previous 
studies have also shown that COX-l is linked to sPLA2 and uses the arachidonic acid pool 
generated by sPLA2. Cyclooxygenase-2 is associated with cPLA2 and uses the arachidonic acid 
pool generated by cPLA2 (Kawada et al. 1995). The COXs have two distinct activities: an 
endoperoxide synthase activity that oxygenates and cyclizes the unesterified precursor fatty acid 
to form the PGG, and a peroxidase activity that converts PGG to PGH. Cyclic endoperoxide and 
PGH are chemically unstable, but they can be transformed enzymatically into a variety of 
products, including PGI, TXA, PGEs, PGFs, or PGD (in the mast cells). (Fig 1.3.). 
The endoperoxide PGH2 is also converted into two unstable and highly active compounds. 
Thromboxane A2 is formed by TX synthase; TXA2 breaks down nonenzymatically (t! = 30 
2 
seconds) into the stable, but inactive, TXB2. Prostacyclin is formed from PGH2 by PGI2 
13 
synthase; it is hydrolysed nonenzymatically (t! = 3 min) to the inactive 6-keto-PGF lao The 
2 
activity of COX in this pathway can be estimated by determination of their stable metabolites. 
It has been reported that PGE2 is a predominant PG in carrageenan-induced inflammatory 
exudate. Willis (1969) developed an acute inflammatory model by intraperitoneal injection of 
carrageenan in rats and first illustrated the presence of PGE2 in the inflammatory exudate. A 
further study by Higgs et al. (1983) confirmed these results and found that detectable 
concentrations of TXB2, 6-keto-PGF la were also present in acute inflammatory exudate but 
PGE2 was predominant. These findings were also confirmed in other animal species. Higgins and 
Lees (1984a) used a subcutaneous tissue-cage acute inflammatory model in ponies to 
demonstrate that following the injection of carrageenan into the cages the concentrations of 
PGE2, 6-keto-PGF la and TXB2 all temporally increased in the inflammatory exudate and reached 
a peak at 6-12 h. The maximal concentration for PGE2 was 197.0 ± 64.9 ng/ml while the 
maximal concentrations for 6-keto-PGFla and TXB2 were 18.9 ± 9.4 ng/ml and 11.5 ± 7.3 ng/ml, 
respectively. Similar methods were used in dogs (McKellar et ai, 1994a, 1994b) and calves 
(Landoni et al., 1995a, 1995b; 1996; Lees et al., 1996), in which the concentrations of PGE2 
were significantly elevated in the inflammatory exudate after the injection of carrageenan into 
the cages. 
The above experiments in domestic animals also showed that before injection of carrageenan the 
concentration of PGE2 was very low or undetectable. This is in accordance with the finding that 
COX-2 is not expressed unless stimulated and suggests that exudate PGE2 was predominantly 
generated by COX-2. A study using a rat carrageenan subcutaneous air pouch model has 
confirmed this hypothesis, in which selective COX-2 inhibitors (NS-398) significantly reduced 
exudate PGE2 generation and subsequent inflammation without a concomitant decrease in gastric 
PG production (by COX-I) or development of gastric lesions (Masferrer et al., 1994). 
The products of the COX pathway of arachidonic acid metabolism form a group of important 
inflammatory mediators which substantially induce the cardinal signs of acute inflammation 
through their direct and indirect actions. Prostaglandin 12 and E2 have a prolonged vasodilatory 
effect which causes erythema (Williams, 1979). Although PGs do not appear to have direct 
effects on vascular permeability, both PGE2 and PGI2 markedly enhance oedema formation and 
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leukocyte infiltration by promoting blood flow in the inflamed region. They potentiate the 
increases in vascular permeability produced by histamine and bradykinin leading to increased 
oedema formation (Williams & Morley, 1973). The E PGs enhanced the pain-producing effects 
of bradykinin (Moncada et al., 1974). Prostaglandins and PGI2 sensitise the afferent nerve 
endings to the effects of chemical or mechanical stimuli by lowering the threshold of the 
nociceptors (Moncada et al., 1978). The studies in our laboratory demonstrated that COX 
inhibitors reduced the hyperalgesia evoked by intradermal injection of carrageenan in sheep and 
this suggests that PGs playa role in pain perception (Welsh & Nolan, 1994b). Prostaglandins 
cause an increased inflammatory local temperature by raising blood flow in the affected region. 
The roles ofPGs in inflammatory heat generation have been established in horses (Higgins et al., 
1987; Lees et al., 1987b, 1987c), cattle (Lees et al.. 1996) and dogs (McKellar et al., 1994a; 
1994b). These studies showed that intracaveal injection of carrageenan led to an increase in skin 
temperature over the cages which is correlated with the increase in exudate PGE2 generation 
within the cages. Administration of COX inhibitors reduced the formation of PGs and the 
subsequent increase in temperature. Thromboxane A2 is a potent vasoconstrictor and a powerful 
inducer of PL T aggregation and of the PL T release reaction which leads to the release of a 
number of inflammatory mediators and the adhesion of PL T to leukocytes and endothelia to 
leukocytes (Moncada & Vane, 1979; Spagnuolo et al., 1980). 
The effects of PGs are diverse and their mechanisms of action can be explained by the existence 
of a number of distinct receptors. The receptors have been named according to their natural 
affinity and have been allocated into five main types, designated DP (PGD), FP (PGF), IP 
(PGI2), TP (TXA2), and EP (PGE) (Davies & MacIintyre, 1992). The actions of PGs have been 
extensively studied in PLT. The PG endoperoxides and TXA2 stimulate the TP receptors and 
thereby activate PLT aggregation, a response associated with PLC. Subsequent release of 
intracellular Ca ++ promotes aggregation and production of additional TXA2 (Davies & MacIntyre, 
1992). 
b) Lipoxygenase pathway 
As free arachidonic acid is released from the body's phospholipid "pools", its unsaturated carbon 
atoms are susceptible to oxygenation by various positional LOXs (Fig. 1.3.). These carbon atoms 
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include those at the 5, 11, 12, and 15 positions and a variety of products are possible, including 
mono and di HPETEs. The HPETEs are unstable and may be further converted to their 
corresponding hydroxy fatty acids, HETEs, by a peroxidase or nonenzymatically (Fig. 1.3.). 
Lipoxygenases differ in their specificity for placing the hydroxy group, and tissues differ in the 
LOXs that they contain. For example, PLT have only 12-LOX and synthesise 12-HPETE, 
whereas leukocytes contain both 5-LOX and 12-LOX and produce both 5-HPETE and 12-
HPETE. 
The formation ofLTA4 by 5-LOX perhaps is the most important of these steps, since it leads to 
the formation of LTB4 (5,12-diHETE) by one pathway and LTC4, LTD4 and LTE4 by another. 
Leukotriene B4 is a dihydroxy acid formed from L T A4 through the action of L T ~ hydrolase. 
Leukotriene B4 can undergo further oxidation at the 20 carbon atom to less active metabolites 
(Henderson, 1991). Leukotriene A4 may be conjugated with glutathione by LTC4 synthase to 
form L TC4. Leukotriene D4 is produced by the removal of glutamic acid from LTC4, and L TE4 
results from the subsequent cleavage of glycine; the reincorporation of glutamic acid yields a y-
glutamylcysteinyl derivative called LTF4 (Piper, 1984; Samuelsson et ai., 1987). 
The metabolites of arachidonic acid formed via LOX pathway comprise a group of important 
inflammatory mediators. 12-HETE is chemotactic for PMN leukocytes (Turner et ai., 1975). 
Leukotrine C4, LTD4 and LTE4 modulate vasoconstriction and vascular permeability (William, 
1994), and the mixture of them is now believed to be "slow reacting substance" of anaphylaxis 
(SRS-A). Leukotriene B4 has been shown to be an extremely potent chemotactic agent for many 
cell types but notably for PMNs in many experimental animal species (Ford-Hutchinson et ai., 
1980) and horses (Sedgwick et ai., 1987). Leukotriene B4 plays a role in induction of neutrophil-
endothelial cell adhesion, neutrophil degranulation, lysosomal enzyme release and in immune 
modulation by upregulation of cytokines (William, 1994). Leukotriene B4 may be an important 
mediator of inflammatory pain. Injecting L TB4 into rat paw results in a prolonged, neutrophil-
dependent hyperalgesic reaction, which is associated with a sustained reduction in the 
nociceptive pressure threshold (Levine et ai., 1984). 
The metabolism of arachidonic acid via the LOX pathway has been studied in several domestic 
animal species, including horses (Higgins & Lees 1984b; Lees et ai., 1987c), dogs (McKellar et 
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ai., 1994a, 1994b) and calves (Landoni et ai., 1995a, 1995b). These studies used subcutaneous 
tissue cage acute inflammatory models and indicated that following the injection of carrageenan 
into the cages, the concentrations of 12-HETE or LTB4 increased and was accompanied by an 
increase in accumulation of WBC in the inflammatory exudate. The studies in horses and calves 
also demonstrated that the inhibition of COX by NSAIDs led to the increase in LOX products 
due to a shift of metabolic substrate and that the inhibition of COX did not affect exudate WBC 
number significantly. Previous studies in man reported increased concentrations of LTs, 
especially L TB4 in the affected sites or circulating blood in a number of inflammatory diseases, 
including rheumatoid arthritis, psoriasis and inflammatory bowel disease (William, 1994). The 
presence of LOX-derived eicosanoids in inflamed tissues could represent a local control 
mechanism for the recruitment of inflammatory leukocytes. It is believed that LOX inhibitors 
could be useful therapeutic agents and inhibitors of LOX and L T receptors are under 
development. 
1.3. Pharmacology of NSAlDs 
1.3.1. Pharmacodynamics ofNSAIDs 
Nonsteroidal antiinflammatory drugs have been widely used in both human and veterinary 
medicine for centuries for their antiinflammatory, antipyretic, and analgesic effects. Although 
they had been shown to inhibit a wide variety of reactions in a number of experiments, no 
convincing relationship could be established with their underlying effects until 1971, when Vane 
and his colleagues demonstrated that low concentrations of aspirin and indomethacin inhibited 
the enzymatic production of PGs. An understanding of the roles of PGs in the inflammatory 
process has supported the hypothesis that inhibition of the biosynthesis of these autacoids could 
explain a number of the clinical actions of the drugs (Feldberg & Saxena, 1971a, 1971b). 
Numerous subsequent observations have confirmed this hypothesis. Studies in veterinary 
medicine soon followed and in the early 1980s, Lees and Higgins at the Royal Veterinary 
College conducted a number of experiments to investigate the roles ofPGs and mode of action of 
NSAIDs using sponge and tissue-cage acute inflammatory model in ponies (Higgins et al., 1984; 
Higgins & Lees, 1984a 1984b, 1984c; Lees & Higgins 1984; Lees et al., 1987a, 1987b, 1987c). 
Their studies confirmed the above hypothesis in domestic animal species and stimulated further 
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studies of inflammatory mediators and NSAIDs in farm animal speCIes. A number of 
investigations have been carried out in different animal species, including dogs (McKellar et aI., 
1989, 1994a, 1994b) and calves (Landoni et al., 1995a, 1995b, 1996; Lees et al., 1996). These 
experiments established the relationship between inhibition of COX and the antiinflammatory 
effects of NSAIDs. In recent years a large amount of evidence have emerged suggesting that 
NSAIDs may have antiinflammatory and other effects which are independent of COX inhibition 
(McCormack & Brune, 1991; Twomey & Dale, 1992). Landoni et al. (1995a, 1995b, 1996) 
reported that FM, KPF and tolfenamic acid effectively inhibited ~-glucuronidase activity and 
bradykinin-induced swelling in calves in addition to the inhibition of COX. Other actions of 
NSAIDs have been reported but their contribution to the therapeutic effects has not been 
estimated (Abramson & Weissman, 1989; Vane, 1994). 
It is now believed that NSAIDs produce their principal therapeutic and their undesirable side 
effects by inhibition of COX and thus by blocking the formation of COX-derived eicosanoids. 
Since the identification of COX-l and COX-2, interest has been focused on these isoenzymes 
(Kujubu et al., 1991; Xie et. al., 1991; O'Banion et al., 1992; Sirois et al., 1992; DeWitt & 
Meade 1993; Jones et al., 1993; Herschman, 1994; Vane, 1994; Vane & Botting, 1995). The 
inhibition of COX-2 is thought to produce, at least in part, the antipyretic, analgesic, and 
antiinflammatory effects, but the simultaneous inhibition of COX-l may be largely responsible 
for unwanted side effects, particularly those leading to gastric ulcers, that result from decreased 
PG formation. Thus COX-2 is probably the therapeutic target of NSAIDs. Most currently used 
NSAIDs non-selectively inhibit the COX-l and COX-2 isoforms or have modest selectivity for 
the constitutive COX-l isoform. This means that they produce both therapeutic effects and 
unwanted effects simultaneously. An ideal NSAID should possesses good inhibitory effect for 
COX-2 and less or no inhibition of COX-I. Cyclooxygenase-2 selective NSAIDs are now under 
development and it is anticipated that they will be better NSAIDs for antiinflammatory therapy 
(Vane, 1994; Vane & Botting, 1995; Williams & DuBois, 1996). It has been reported that the 
selective COX-2 inhibitor, NS-398, effectively inhibited carrageenan-induced inflammation 
without a concomitant decrease in gastric PG synthesis or the development of gastric lesion in an 
air pouch inflammatory model in the rats (Masferrer et al., 1994). 
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The inhibition of COX by NSAIDs may be reversible or irreversible. Platelets are especially 
susceptible to aspirin-mediated irreversible inactivation of COX because they have little or no 
capacity for protein biosynthesis and thus cannot regenerate the COX enzyme. A single clinical 
dose of aspirin (19 mglkg) given to the horse abolished the serum PLT TXB2 generation for 7 
days and 74 % inhibition was still present after 24 days (Lees et ai., 1987a). The other NSAIDs 
currently used in veterinary practice, including FM, PBZ, KPF, tolfenamic acid etc., are 
competitive and reversible inhibitors. They inhibit PLT COX (COX-I) and carrageenan-induced 
exudate COX (COX-2) reversibly in a number of tested animal species including horses (Lees et 
ai., 1987a, 1987b; 1987c), dogs (McKellar et aI., 1989, 1994b, ) and calves (Lees et al., 1991c; 
Landoni et al., 1995a, 1995b, 1996). 
The mechanisms for the inhibition of COX isoenzymes are not fully clear. In the mice, COX-l 
shares about 62 % amino acid identity with COX-2 (Rosen et ai., 1989; Sirosis & Richards, 
1992). They express differentially in physiological and pathological processes. Aspirin acetylates 
serine 530 of COX-l to prevent the binding of arachidonic acid to the active site of the enzyme 
and thus the ability of the enzyme to generate PGs. In COX-2, aspirin acetylates a homologous 
serine at position 516. Although covalent modification ofCOX-2 by aspirin also blocks the COX 
activity of this isoform, it diverts the metabolism leading to the synthesis of IS-HETE (Lecomte 
et al., 1994; O'Neil et al., 1994). 15-hydroxyeicosatetraenoic acid may be an active 
inflammatory mediator and this may increase the side effects of aspirin. Another study using 
sheep COX-l reported that arginine 120 of COX-l was required for the inhibition by NSAIDs 
containing a carboxylic acid moiety (Mancini et ai., 1995). 
The inhibition of COX activity by NSAIDs leads to the relief of inflammatory symptoms. 
Nonsteroidal antiinflammatory drugs are usually classified as mild analgesics. In some forms of 
postoperative and inflammatory pain which are caused by PGs, the NSAIDs can be superior to 
other analgesics. A good example is FM which can mask the pain of colitis and laminitis in 
horses. Nonsteroidal antiinflammatory drugs are widely used antipyretics. Regulation of body 
temperature requires a delicate balance between the production and loss of heat; the 
hypothalamus regulates the set point at which body temperature is maintained (Saper & Breder, 
1994). During inflammation, the enhanced formation of cytokines, such as IL-lP, IL--6, IFN a 
and p, and TNFa increase the synthesis of PGE2 in circumventricular organs in and near to the 
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preoptic hypothalamic area. The PGE2 thus fonned increases cyclic AMP activity and triggers 
the hypothalamus to elevate body temperature by promoting increases in heat generation and 
decreases in heat loss. Nonsteroidal antiinflammatory drugs suppress this response by inhibiting 
the synthesis of PGE2 (Dascombe, 1985). Prostaglandins cause increased temperature in 
inflammatory foci by dilating the blood vessels to enhance the blood flow in the affected site. 
Nonsteroidal antiinflammatory drugs inhibit PG generation and thus prevent the temperature 
elevation in the inflammatory sites. This has been demonstrated in a number of animal species, 
including horses (Lees et al., 1987b, 1987c) and dogs (McKellar et al., 1994a, 1994b). However, 
NSAIDs do not affect the hyperalgesia, pain or fever caused by injection of PG, consistent with 
the notion that the effects of these agents are due to inhibition of PG synthesis (Davies & 
MacIntyre, 1992). 
For some of the NSAIDs the relationship between COX inhibition, and analgesic and antipyretic 
effects is not significant. For example, CPF and PRT are weak COX inhibitors but they are 
widely used as analgesics and antipyretics. The mode of action of these NSAIDs is unknown. 
Paracetamol has been shown to inhibit COX only in an environment that is low in peroxide. 
Inflammatory sites usually contain increased concentrations of peroxides generated by 
leukocytes and this may prevent PRT from inhibiting COX. However in the central nervous sites, 
such as hypothalamus, low concentrations of peroxide exist and they may allow PRT to inhibit 
COX (Marshall et al., 1987; Hanel & Lands, 1982). This may in part explain the mechanism of 
this NSAID. 
Arachidonic acid also can be converted, via 12-LOX, to 12-HPETE or, via the 5-LOX, to a 
variety of leukotrienes. Nonsteroidal antiinflammatory drugs generally do not inhibit LOXs. As 
shown in Fig. 1.3., inhibition of COX may lead to the accumulation of arachidonic acid which 
can be used by LOXs and thus the increased LOX derived eicosanoids (Kitchen et al., 1985; 
Sedgwick et al., 1987). This may also contribute to the side effect of NSAIDs. Dual inhibitors 
for COX and LOX are under development (Cunningham & Lees, 1994) and they may be 
expected to be more effective NSAIDs for antiinflammatory therapy. 
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1.3.2. Phannacokinetic characteristics ofNSAIDs 
Nonsteroidal antiinflammatory drugs exert their principal therapeutic effects in inflammatory 
sites by inhibition of COX-2 and produce their side effects in the gastrointestinal system, PL T 
and kidney by blockage of COX-I, which leads to gastrointestinal ulceration, disorders of PLT 
aggregation and renal function. For the irreversible inhibitors of COX (such as aspirin), the 
duration of effects is determined by the rate of synthesis of new COX enzymes. The other 
NSAIDs used in veterinary medicine are competitive and reversible inhibitor of COX enzymes 
and their effects are primarily related to the PK clearance of the drugs from the effect sites. Thus 
PK disposition of those NSAIDs are of critical importance to the understanding of their 
therapeutic benefits and risks. 
A number of studies have shown that a range ofNSAIDs used extensively in veterinary medicine 
(PBZ, aspirin, FM, naproxen and CPF ) exhibit marked species differences in PK parameters so 
that the data can not be transposed between species (McKellar et ai., 1990, 1994a; Welsh et ai., 
1993; Cunningham & Lees, 1994; Landoni et ai., 1995a, 1995b, 1996). In general, the 
elimination rates of NSAIDs in ruminants such as calves and sheep are slower than in 
monogastric animal species, such as horses and dogs. 
Increasing attention has been paid to the chirality ofNSAIDs. Of particular interest are the newer 
arylpropionic acid derivatives (CPF and KPF). These drugs are supplied as racemixtures. 
However in the chiral environment of the body, the proportion of enantiomers formed from a 
racemate can vary in different animal species, and both the PK and PD behaviour can differ 
between the enantiomers. Previous studies showed that when rac-CPF was given, the R( -) 
enantiomer was predominant in all species investigated, including horses (Lees et ai., 1991a), 
dogs (McKellar et ai., 1994a), cats, goats, pigs and calves (Delatour et ai., 1993; Lees et ai., 
1996). For KPF both antipodes show similar profiles in man, S( + )KPF is predominant in dogs, 
and R(-)KPF predominates in sheep (Delatour et ai., 1993). Generally for NSAIDs, S(+) 
enantiomer is the eutomer which is responsible for the phannacological effects while R( -) 
enantiomer is the distomer which is an inactive antipode. Therefore the pharmacological effects 
produced by a racemic drug represent the combined effects of the enantiomers formed in the 
particular animal species. When a dosage schedule is made, particular attention should be paid to 
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the enantiomorphism of the drug in the targeted animal species. It has been suggested that non-
enantioselective studies should in future be avoided and racemic mixtures of chiral drugs should 
be considered as combinations of two or more distinct compounds with likely differences in PK, 
PD and toxicological profiles (Landoni & Lees 1996). 
An attractive PK property of many of the drugs used as antiinflammatory agents is that they 
accumulate at sites of inflammation. With the exception of aspirin, most of the NSAIDs serve as 
reversible competitive inhibitors of COX activity. This means that they produce time-dependent 
effects in accordance with the distribution and elimination of the drugs at the sites of therapeutic 
effect. As organic acids, NSAIDs generally are well absorbed p.o., highly bound to plasma 
proteins and excreted either by glomerular filtration or by tubular secretion. Studies using a 
tissue-cage inflammatory model have illustrated that the drug concentrations and AUC in 
inflamed exudate are higher than in non-inflamed transudate, the plasma drug concentrations in 
plasma were initially higher and subsequently lower than in exudate and transudate following 
administration of NSAIDs. This has been shown for FM in horses and calves (Lees and Higgins, 
1984; Lees 1989; Landoni et al., 1995a), PBZ in horses (Lees & Higgins, 1986; Lees et al., 
1986), meloxicam in horse (Lees et al., 1991b), CPF in horses and dogs (McKellar et al., 1994a; 
Lees et al., 1991a, 1994), KPF in calves (Landoni et al., 1995b), tolfenamic acid in dogs and 
calves (McKellar et al., 1994b; Landoni et al., 1996). The mechanism of the high extravascular 
penetration of NSAIDs may be attributed to the high degree of drug binding to plasma proteins. 
The increased vascular permeability in inflammatory sites allows the leakage of plasma protein 
into the extravascular space, with the NSAIDs. Another possible reason is that the acidic 
property of inflammatory exudate has a special affinity to the acidic NSAIDs. Since most of the 
NSAIDs have a high degree of plasma protein binding and their therapeutic target, COX-2, is 
expressed in the inflammatory sites following the injury, exudate PK data may be more useful 
than plasma PK data for predicting appropriate dosage schedules ofNSAIDs for clinical use. 
1.4. Acute inflammatory models for testing NSAIDs in domestic animal species 
Because of the differences between NSAIDs in both PDs and PKs in domestic animal species, 
experiments must be carried out in the target domestic animal species. When developing equine 
models of inflammation, Higgins and Lees proposed that the inflammatory responses should be 
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mild, reproducible and reversible so that the animals can be used repeatedly and cross-over 
studies can be undertaken (Higgins & Lees, 1984a, 1984b, 1984c; Higgins et al., 1987; Lees et 
aI., 1987c). The inflammatory reaction should also be inhibited by NSAIDs in a characteristic 
dose-responsive fashion. Based on these requirements, two experimental exudative models of 
acute non-inflammation, the polyester sponge model and tissue-cage model have been developed 
in the ponies (Higgins et al., 1987). 
The tissue-cage model has now largely supplanted the other model for screening and assessing 
NSAIDs in veterinary domestic animal species. Firstly, the model provides a mild, reproducible 
and reversible inflammatory reaction which is free from uncontrolled incidental factors and 
which causes minimal distress to the experimental animals. Secondly, the animals can be used 
repeatedly so that cross-over studies can be undertaken. Thirdly, this model permits the 
sequential collection of inflammatory exudate for the analysis of drug concentrations, 
inflammatory cells and mediators so that the relationship between drug concentrations and 
therapeutic effects can be established. Finally, the important clinical sign of heat, can be 
quantified by measuring the skin temperature over the cages. 
The choice of tissue cage may vary based on the size of the targeted animals. Multiperforated 
polypropylene practice golf balls placed in the midneck region were most appropriate for the 
large animal species including ponies (Higgins & Lees 1984a, 1984b, 1984c) and calves (Lees et 
al., 1991c, 1996; Landoni et al., 1995a). Each ball had an internal diameter of 41 mm and 
internal volume of 31 ml. Each ball had 25 holes, corresponding to about 9.3 % of total surface 
area, punched in it. In dogs, McKellar and colleagues (1994a, 1994b) implanted tube-like cages 
in the flanks and succeeded in inducing an inflammatory response and collecting exudate. The 
cages were 7.5 cm long with a 1.6 cm external diameter and were made from silastic tubing with 
plugs of silastic glued in either end and holes punched in the barrel of the tube close to each end. 
The cages were subcutaneously implanted using lignocaine infiltration anaesthesia and xylazine 
sedation. In dogs, general anaesthesia was induced. Following the implantation fibrous 
granulation tissue gradually grows into the cages through the holes and a large proportion of the 
interior of each cage is fitted. This granulation tissue is the target for inflammatory induction by 
irritants. The acute inflammation may be generated by intracaveal injection of carrageenan 
solution and maintained by a further injection 8 h later. The effective dose of carrageenan for 
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PGs production and leukocyte migration in this model (golfball model) is 0.5 ml of 1 % solution 
(Higgins & Lees 1984a, 1984c). The changes in skin temperature over the inflamed and non-
inflamed cages may be quantified as a clinical indicator of the inflammatory responses. 
The inflammatory processes have been intensively studied in the equine model (Higgins & Lees 
1984a, 1984b, 1984c; Higgins et ai., 1987; Lees et al., 1984; 1987b, 1987c). In the equine model 
leukocyte migrates into the cage in large numbers in a time dependent fashion and maximum 
numbers were detected at 12 h (20x 1091L) following the injection of carrageenan. After 48 h, the 
number of exudate leukocytes decreased to control values (Higgins & Lees, 1984a, 1984b). 
Prostaglandins including PGE2, 6-keto-PGF til and TXB2 were present in the exudate and 
achieved maximal concentrations at 6-12 h following the carrageenan induction. However the 
predominant PG was PGE2 which reached peak concentrations of about 100 nglml in the 
exudate. The total protein in exudate increased and the concentration was similar to that in 
plasma. Higgins and Lees (1984b) reported that LTB4 in equine exudate was detectable and with 
a mean concentration of 1.7 nglml achieved at 8 h after carrageenan stimulation. 
The carrageenan tissue cage model of acute inflammation has been used to investigate the PDs 
and PKs for a number of NSAIDs in different domestic animal species, at least in horses (Lees & 
Higgins 1984; Lees et al., 1986, 1987b, 1987c, 1991c, 1991b), dogs (McKellar et al., 1994a; 
1994b) and calves (Landoni et al., 1995a; 1995b; 1996; Lees et al., 1996). The results 
demonstrate the expected PD and PK responses. The NSAIDs with antiinflammatory effects 
which inhibit exudate PGE2 and simultaneously inhibit the increase in skin temperature over the 
cages. The NSAIDs with weak antiinflammatory effects do not generally inhibit exudate PGE2 
generation or the inflammatory temperature rise. No NSAID has been shown to effectively block 
the activity of LOX and the recruitment of leukocytes in the inflammatory foci. Most of the 
tested NSAIDs accumulate at the inflammatory sites and this is indicated by a larger AVe in 
exudate than in transudate, and slower elimination rate from exudate than from transudate and 
plasma. 
The tissue cage model has been used to dose responsive PD and PK studies for NSAIDs. 
McKellar et al. (1994b) gave tolfenamic acid to dogs by intramuscular injection at dosage rates 
of 2, 4 and 8 mg/kg of body weight and obtained dose-related differences in drug concentration 
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in exudate and statistically different inhibitory effects for exudate PGE2 between each treatment 
group. 
1.5. Antiinflammatory therapy in veterinary medicine 
Many classes of drug are used to suppress or abolish one or more of the cardinal signs of 
inflammation. The main antiinflammatory groups used in veterinary medicine are corticosteroids 
and NSAIDs. 
1.5.1. Corticosteroids 
The corticosteroids used in veterinary medicine include betamethasone, dexamethasone, 
prednisolone, flumethasone and isoflupredone. In general, corticosteroids have a wider spectrum 
of pharmacological activity than NSAIDs (Fig. 1.3.). Unlike NSAIDs which principally act on 
COX, corticosteroids inhibit both COX and LOXs. They also have inhibitory effects on other 
inflammatory mediators, including histamine, bradykinin, P AF, cytokines, NO, selectins and 
adhesion molecules. They not only inhibit vascular and cellular responses characteristic of acute 
inflammation but also the proliferative, self perpetuating and damaging features of the chronic 
inflammatory process. They are often used for the suppression of inflammatory reactions caused 
by infection, trauma, allergy or other causes. 
Corticosteroids, such as dexamethasone, block the induction of cPLA2 and thus inhibit the 
generation of eicosanoids (Samet et a/., 1995). They inhibit COX-2 in various contexts, 
including transcription and expression of the COX-2 gene and have less inhibitory effect on the 
expression COX-l gene (Herschman, 1994). 
However, corticosteroids have serious potentially toxic side-effects which limit their clinical use. 
This includes atrophy of the adrenal cortex, water and electrolyte retention, metabolic 
disturbances and susceptibility to infection associated with immunosuppression. 
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1.5.2. Nonsteroidal antiinflammatory drugs 
1.5.2.1. Clinical uses ofNSAIDs in veterinary medicine 
Nonsteroidal antiinflammatory drugs are known to exert three types of pharmacological activity, 
analgesia, antipyrexia and antiinflammatory activity. The principal value of these drugs is to 
relieve pain and reduce inflammation. Currently licensed NSAIDs with antiinflammatory and 
analgesic indication in veterinary use in the UK include CPF (horses and dogs), FM (horses, 
cattle and dogs), KPF (horses, cattle, dogs and cats), meclofenamic acid (horses), meloxicam 
(dogs), naproxen (horses and dogs), PBZ (horses, dogs and cats) and tolfenamic acid (dogs and 
cats). Flunixin can be used by the i.v., i.m. and p.o. administration routes while others are used as 
i.v., i.m. or p.o. administration preparations. 
One of most interesting effects of NSAIDs in veterinary medicine is the antiinflammatory action 
although they are often used as analgesics. The reason for this is that inflammation is a common 
process in a wide range of diseases and drugs with this effect may improve the demeanour of 
affected animals. In addition to their classical use for treating musculoskeletal conditions and 
colic in horse, they have been recently extensively used in other species and diseases. For 
example, FM is used for the treatment of musculoskeletal conditions, endotoxemia, and colic in 
horses; for musculoskeletal conditions and control of postoperative pain in dogs; and for mastitis, 
endotoxaemia, and bacterial and viral pneumonia in calves. 
1.5.2.1. Chemical classification ofNSAIDs 
Nonsteroidal antiinflammatory drugs are weak organic acids which contain a heterogeneous 
group of compounds, often chemically unrelated. Based on the chemical structural classes, 
NSAIDs can be classified into three groups. These are 1) carboxylic acids, including salicylates 
(aspirin etc. ), acetic acids ( indomethacin etc. ), propionic acid (CPF, etc. ) and fenamates 
(flunixin etc.); 2) pyrazolones (PBZ etc.) and 3) oxicams (piroxicam etc.). 
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1.5.2.2. Side effects ofNSAIDs 
There are now more than 50 different NSAIDs on the human pharmaceutical market and there is 
a continuing flow of new preparations being introduced. About 10 NSAIDs are available in 
veterinary practice. The fact that so many new compounds have been produced and are still being 
produced is a reflection of the fact that none is ideal in controlling or modifying the signs and 
symptoms of inflammation, particularly in the common inflammatory joint diseases. A particular 
problem is that virtually all NSAIDs can have significant unwanted effects. 
The main side effects ofNSAIDs involve gastro-intestinal irritation and ulceration. Lesions may 
occur throughout the gastro-intestinal tract and may lead to a life-threatening plasma protein-
losing enteropathy in the horse. These side effects are thought to be caused by the inhibition of 
COX-l and thus inhibition of the formation of PGs, especially PGI2 and PGE2• These gastro-
intestinal PGs serve as cytoprotective agents in the gastric mucosa. They promote perfusion of 
gastric and intestinal mucosa and mucus production and have an inhibitory influence on acid 
secretion (Frey, 1992). In addition, p.o. administered drugs produce local irritation which allows 
back diffusion of acid into the gastric mucosa and induces tissue damage. 
Other side effects include vomiting, blood dyscrasias, hepatotoxicity due to cholestatic and 
parenchymal cell damage, thrombocytopaenia, leukopaenia, renal papillary necrosis and 
occasionally skin rashes. 
It is believed that NSAIDs produce their antiinflammatory effects by inhibiting COX-2 and their 
side effects by inhibiting COX-I. It is, therefore, desirable that a NSAID should have good 
inhibitory effects for COX-2 with less inhibition for COX-l in the target animal species. Most 
currently used NSAIDs are non-selective inhibitors of these two isoenzymes. This indicates that 
they produce therapeutic and side effects simultaneously. Selective COX-2 inhibitor of NSAIDs 
are now under development (Vane, 1994; Vane & Botting, 1995). It is anticipated that they 
produce therapeutic effects with less or no COX-I-associated side effects. 
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1.5.3. Investigation ofthe use ofNSAIDs in sheep, goats and donkeys 
Although no NSAIDs have been licensed for use in sheep, goats and donkeys, it is of clinical and 
scientific interests to investigate the potential uses of NSAIDs in these species since 
inflammation is a common pathophysiological process in these animals and undoubtedly the use 
ofNSAIDs will improve the welfare of these animal species. 
The present studies were set up to investigate the potential uses of some NSAIDs in sheep [FM, 
PBZ and CFP (including its enantiomers)], donkeys (FM and PBZ), goats (PBZ and PRT) and 
camels (PRT). In the studies in sheep and donkeys, a subcutaneous tissue-cage model of 
inflammation was used. The effects of the drugs on COX-2 was estimated by measurement of 
PGE2 in carrageenan-induced inflammatory exudate, and exudate LTB4 was quantified to assess 
the inhibitory effects ofNSAIDs on 5-LOX. The effect of the drugs on COX-! was determined 
by measuring TXB2 generation by PL T COX during blood clotting. Changes in skin temperature 
over cages were used as a cardinal sign of acute inflammation. The disposition and distribution 
of the drugs in plasma, exudate and transudate were determined to provide the evidence for 
dosing and withdrawal schedules of the drugs. By application of PKlPD modelling, the 
relationships between drug effects and drug concentrations in plasma and therapeutic sites were 
established and parameters such as IC50 were used to quantitatively estimate and potency of 
therapeutic effects. In addition, the changes in blood leukocyte and PL T numbers were measured 
to estimate the effects of the drugs on the haematological system and the effects of the drugs on 
exudate leukocytes were determined to asses the therapeutic effects on leukocyte accumulation. 
Another purpose of these studies was to elucidate inflammatory mechanisms in the target 
animals using NSAIDs as a tool. Reduced heat generated at the site of inflammation and parallel 
inhibition of eicosanoid synthesis by COX isoenzymes provided an indication of the possible 
role of eicosanoids in acute inflammation. 
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Fig. 1.1. Schematic representation ofthe inflammatory process. 
29 
f ·-
PHOSPHOLIPASE 1 
ENZYMES 
+ 
MEMBRANE 
PHOSPHOLIPIDS ~ , ~ 
[INJURY] 
_ ~__ \ Activation , ---,- -
I COMPLEMENT I I MAST I 
CELLS 
T 
C3a,C5a ~ ~ 
HISTAMINE 5-HT 
ARACHIDONIC ACID PAF ~ 
(COX) (LOX) ~ 
I I 
~_, r 
LTB'J , I LTC4 
[
PGG2
1 
LTD4 
PGH2 
r 
PGI2 
PGE2 
PGD2 
PGF2a 
- ~ 
~ 
--
INCREASED 
VASCULAR 
PERMEABILIT 
" 
Inhibition 
, 
, 
PLATELET 
AGGREGATION 
T 
5-HT 
--- ~ 
IC. LOTTING I 
l_ SYSTEM 
- t 
HAGEMAN FACTOR 
+ PREKALLIKREIN ~ KALLIKREIN 
VASC~ ...... _ 
DILAT
---KININS ...... - KININOGENS 
! 
t 
PGI2 
PGE2 
LTB4 
Fig 1.2. Schematic representation of inflammatory mediator effects on the vasculature. 
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Chapter 2 
General materials and methods 
2.1. Animals 
The animals used in the presented study included sheep (n = 8), goats (n = 6), donkeys (n = 3) 
and camels (n = 6). Their details will be reported in the relevant Chapters. 
2.2. Weighing and dosage rates 
The weights of each individual animal varied between each cross-over experiment and the drug 
administrations were adjusted for each animal according to its weight at about 24 h before the 
cross-over experiment was carried out. 
2.3. Husbandry 
All the animals were stabled in boxes during the experimental procedures with free access to 
water and food. 
2.4. Subcutaneous tissue-cage model of acute inflammation 
The sheep studies were carried out using a subcutaneous tissue-cage acute inflammatory model 
based on that described previously (Higgins & Lees, 1984c; Higgins et al., 1987). Briefly, two 
months before the experiment started, two tissue cages were implanted in the middle of each side 
of the neck of each sheep using standard surgical procedures. The cages were made from 
polypropylene with an external diameter of 2.0 em and had 6 holes sized 0.5 em in diameter cut 
over their surface. Acute inflammation was produced by the injection of 0.3 ml of 1 % sterile 
carrageenan into the cages 15 min before drug administration and exudate was collected from 
cages administered carrageenan. The acute inflammation was maintained by a repeat injection of 
0.2 ml carrageenan (1 %) 8 h after drug administration. A cage in the other side of the neck into 
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which carrageenan was not injected was used for the collection of transudate. A different cage 
was used for carrageenan induction of inflammation on each the cross-over occasions. 
The similar procedures were used for the development of a subcutaneous tissue-cage model of 
acute inflammation in donkeys. A multiperforated polypropylene practice golf ball was placed in 
each side of the midneck region. Each ball had an internal diameter of 41 mm and internal 
volume of 31 ml. Each ball had 25 holes, corresponding to about 9.3 % of total surface area, 
punched in it. The acute inflammatory process was induced by intracaveal injection of 0.5 ml of 
1 % sterile carrageenan into the cages 15 min before drug administration and maintained by a 
further injection of 0.5 ml 1 % carrageenan 8 h following drug treatments. 
2.5. Experimental protocol 
The sheep study was carried out as a multiple factor cross-over using a Latin square design. The 
number of factors and cross-overs were equal to the number of drugs given plus PLB control 
such that each animal received each drug as well as PLB treatment. The wash-out period varied 
based on the elimination rate of drug in plasma in the target animal species. 
The dosage rates were 1.1 mglkg body weight for FM, 4.4 mglkg for PBZ, 4.0 mglkg for rac-
CPF and 2.0 mg/kg for each CPF enantiomer. Placebo was physiological saline at a dose volume 
equivalent to the largest dose volume of the drugs. In the studies using subcutaneous tissue-cage 
acute inflammatory models, the drugs and PLB were given i. v. as a single dose and as a rapid 
bolus, into the right jugular vein according to the cross-over design, 15 min after the injection of 
carrageenan into the cage. 
2.6. Sampling schedule 
2.6.1. Temperature 
Temperature was recorded using a directing-reading infra-red thermometer (Horiba, IT-330 
infrared thermometer, Miyanohigashi, Kyoto, Japan) held approximately 1 cm above each tissue 
cage. 
33 
2.6.2. Plasma 
Blood was collected in 10 ml Lithium Heparin Monovettes (Sarstedt Ltd, Numbrech, Germany). 
These were centrifuged at 1800 x g and 4 °c for 10 min and plasma decanted into polystyrene 
tubes. Tubes were stored at -20°C until analysis ofthe drugs and their metabolites. 
2.6.3. Serum 
Approximately 3 ml of blood was collected in a plastic syringe and immediately transferred into 
a glass tube. The tubes were quickly transferred to a water bath at 37°C for 90 min to allow 
clotting. The tube was then centrifuged at 1800 x g and 4 °c for 10 min. Supernatant (Serum) 
o 
was then transferred into 2 ml plastic tubes and stored at -70 C until analysis of TXB2 
concentration. 
2.6.4. Blood 
Blood for haematology was collected in plastic syringes and immediately transferred into 0.5 ml 
paediatric tubes containing K EDTA. Where possible, haematological determinations were 
carried out on the day of sampling. 
2.6.5. Transudate 
In order to prevent eicosanoidal generation ex vivo, tubes were prepared with the dual COX and 
LOX inhibitor, BW540C, as follows: 
Fifty mg of BW540C was dissolved in 50 ml methanol. Ten microlitres of this solution was 
added to each sample tube and allowed to dry. Prior to use, 50 iu of heparin was also added to 
each tube. 
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Transudate was drawn into a plastic syringe and immediately placed in a tube containing 
BW540C and heparin. This was kept on an ice until centrifuged at 1800 x g and 4 °c for 10 min. 
Supernatant was collected and divided into two aliquots for determination of drugs and their 
metabolites. 
2.6.6. Exudate 
Exudate was collected into tubes prepared as for transudate. A 0.1 ml sample was taken prior to 
centrifugation for haematological determination. Following centrifugation (as for transudate) 0.1 
ml aliquots of the remaining sample were pipetted into separate eppindorf tubes for PGE2, 12-
HETE and LTB4 quantification, and a further sample taken as a spare. The remainder of the 
sample was retained for estimation of the drugs and their metabolites. 
2.7. Drug analysis 
2.7.1. Analysis ofPBZ and OPBZ 
2.7.1.1 Extraction and chromatography 
The PBZ concentrations in plasma, exudate and transudate were determined by HPLC. 
The standard concentrations ofPBZ and OPBZ were prepared in methanol and serial dilutions of 
the initial stock solution were prepared at 1000, 500, 100, 20 and 5 f.Lglml. To prepare the serial 
spikes, a range of standards containing PBZ of 0.00, 0.25, 1.00, 5.00, 25.00 and 100.00 f.Lglml 
and OPBZ of 0.00, 0.10, 0.25, 1.00 and 5.00 Ilglml were made and then 1.0 ml blank plasma (or 
0.2 ml of exudate/transudate) was added. For the sample analysis, a 1 ml sample of plasma (or a 
0.2 ml of exudate/transudate) was pipetted into the appropriate tubes. 
The spikes and samples were acidified with 0.2 ml (0.1 ml for exudate and transudate) citrate 
phosphate buffer (PH 3.0). After mixture using a vortex mixer, 6.0 ml (4 ml for 
exudate/transudate) chloroform was added and the contents mixed for 20 min using a slow rotary 
mixer. Following centrifugation at 1800 x g and 4 °C for 20 min, 4 ml (3 ml for 
3S 
exudate/transudate) of the organic phase was removed and evaporated to 0.5 ml at 50°C under a 
nitrogen stream and tubes were washed down with 0.5 ml of chloroform and further evaporated 
to dryness. The residue was reconstituted in 0.5 ml (0.2 ml for exudate/transudate) methanol and 
fully dissolved by vortexing for 10 seconds (sec), sonicating for 1 min and again vortexing for 10 
sec. 
The chromatography was carried out on a Spectraphysics Automated HPLC system which 
contains a computer (ffiM, OS/2) data handling system with PCI000 chromatography software, 
a gradient pump, an autosampler and a variable UV detector. A CIS ODS Aiphasil 5 column (25 
cm x 4.6 mm) plus a guard column was used. The mobile phase was water and acetonitrile 
containing 0.0007% perchloric acid and degassed with He gas. The gradient began with 50 % of 
acetonitrile and 50 % of water and ended at 80 % of acetonitrile and 20 % of water at 11 min. 
And then the starting gradient (80 % acetonitrile: 20 % water) was restored from 11 to 13 min. 
The injection volume was 20 JlI and the running time was 13 min at a flow rate of 1.5 mllmin. 
The detector was focused on COM2 at single wavelength mode at 254 run. The results were 
calculated using the values of peak area. 
2.7.1.2. Sensitivity and reproducibility of the assay 
Phenylbutazone and OPBZ were well separated by this assay and the retention time was 4.5 min 
for OPBZ and 7.5 min for PBZ. The limit of quantification was 0.05 Jlglml. The percentage 
recovery (mean ± SE) was 97.93 ± 1.97 % for PBZ (n=20) and 96.11 ± 2.42 % for OPBZ (n=20). 
Reported values were corrected for extraction losses. 
To evaluate the reproducibility of the analysis, the intra and inter assays of the spikes were 
carried out. The mean percentage recovery and Co-V ar were calculated as the criteria for 
assessment. The results are given in Table 2.1. and Table 2.2. 
To test the linearity of the assay the standard concentrations and spike concentrations were 
plotted versus the values of the peak area. A good linearity (r2>0.99) was obtained. 
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2.7.2. Analysis ofFM 
The FM concentrations in plasma, exudate and transudate were determined by HPLC using the 
same extraction procedures and HPLC system and column as described above for PBZ. The 
mobile phase was 40 : 40 : 20 acetonitrile: methanol: water containing 0.04% glacial acetic acid 
at a flow rate of 1.5 mllmin and the wavelength was 287 nm. The limit of quantification was 0.05 
Jlg/ml with a good linearity (r2>0.99) for spike concentrations ranging from 0.1 to 25 Ilglml. The 
percentage recovery was 97.46±1.78 % (n=20, mean±SE). Reported values have been corrected 
for extraction losses. The details for sensitivity and reproducibility were given in Table 2.3. 
2.8. Quantification ofTXB2 
2.8.1. Radioimmunoassay procedures 
Serum TXB2 concentrations were determined usmg RIA methods previously validated by 
Higgins & Lees (1984a). Samples were analysed without prior extraction but diluted with buffer. 
The RIA was carried out as follows. 
Buffer preparation: Gelatin (1.00 g) was dissolved in 800 ml water, and 0.1 g sodium azide, 6.61 
g tris hydrochloride and 0.97 g tris base were added. This was made up to 1 L with water. The 
pH was adjusted to 7.4 by adding 1 M Hel or NaOH. Wanning was required to dissolve the 
gelatin. 
Dextran-coated charcoal: Dextran (0.40 g; T -70, Phannacia Biotech Ltd, St. Albans, Herts, 
England) was dissolved in 80 ml water and stirred for approximately 1 h, 2.0 g charcoal 
(neutralised and activated, Sigma Ltd, Poole, Dorset, England) was added and stirred for 0.5 h. 
Water was added and made up to 100 ml. Following storage, it was thoroughly stirred before use. 
The dextran coated charcoal suspension was kept at 0-4 °C for a week at most before use. 
Reconstitution and dilution of anti-TXB2 serum: Stock powder (100 Tests/vial) was dissolved in 
10 ml of buffer. This stock solution was stored at -20°C. When used, it was diluted 10 times 
with buffer. The diluted antiserum was a working solution and was stored at 0-5 °C prior to use. 
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The antiserum was tested using standard curve where the ratio of zero standard counts (Bo) to 
total counts (TC) was in the range of 40-60 %. Appropriate sample dilutions was made such that 
the percentage of tracer binding (8lBo) of the sample (pre-treatment sample or PLB-treated 
sample) was located in the middle of the analytic range of the standard curve. 
Standards: The stock standard solution (1 mg/ml) of TXB2 was prepared in absolute ethanol. A 
portion of it was further diluted in buffer to obtain standard solutions at 10, 5, 2.5, 1.25, 0.625, 
0.32,0.16 and 0.08 ng/ml. 
3 
Tracer: The tracer was (5, 6, 8, 9, 11, 12, 14, 15 (n) H TXB2 (25 Jotci/vial). This was provided 
with the stock solution and was stored in the supervised area at _20°C. The working solution was 
prepared by adding 6 Jotl of tracer to 10 ml buffer. 
Radioimmunoassay protocol: The tubes were numbered In duplicate, and the assay was 
performed as follows: 
Reagents NSB Bo STDs TC Tests 
Standard (Jotl) 100 
Sample (J.Ll) 100 
Buffer (JlI) 300 200 100 500 100 
Antiserum (Jotl) 100 100 100 
Tracer (JlI) 100 100 100 100 100 
NSB: Buffer blank. Bo: Zero standard. SID: Standard and TC: Total count. 
All the tubes were vortexed and incubated at 4 °C for 16-24 h. 
Charcoal/dextran (200 JlI) was added to all tubes except total counts and they were vortexed 
before being incubated at -4 ° C for 10 min. The tubes were centrifuged at 1800 x g for 10 min. 
The supernatant was decanted to 6 ml scintillation vials containing 4 ml scintillant. The vials 
were counted as cpm. 
Calculation: The average cpm for each set of replicated tubes was used and %BlBo was 
calculated using equation 
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% Bi = STD(sample)cpm - NSBcpm x 100 
jBo Bocpm- NSBcpm 
Standard curves were generated by plotting %BlBo as a function of the loglo TXB2 concentration 
and by linear regression, fitted to the equation 
Log TXB2 concentration = b x %BlBo + a 
where 'b' was ratio and 'a' was intercept. Replacement of STD % BlBo with sample %BlBo 
generated the values of TXB2 concentration in the samples. These calculation procedures were 
carried out using the computer programme in Microsoft Excel 5.0 via a function of "GROWTH": 
Sample TXB2 concentration = GROWTH(TXB2 STDs, %BlBo STDs, sample %BlBo) 
2.8.2. Characterisation ofthe assay 
In order to asses the linearity, available analytic range and reproducibility of the RIA, a plot of 
%BlBo versus logarithmic TXB2 concentrations was prepared (Fig. 2.1.). This indicates that the 
available range of the assay was 0.08-5.0 ng/ml. The %BlBo range was 93.91 ± 2.96-1.54 ± 0.95 
%. The concentration of TXB2 which produces 50% of %BlBo (BCso) was 0.34 ± 0.01 ng/ml. 
The linearity (r2) was 0.96 ± 0.01 (mean ± SD, n=9) where the regressive relationship (b) was 
statistically significant (p<0.01). The limit of quantification was 0.08 ng/ml in the standard curve 
so that the actual limit of quantification for the sample was 0.08 ng/ml x dilution times. 
2.9. Quantification ofPGE2 
Concentrations of PGE2 in exudate were determined by RIA using the same procedures as 
described for TXB2 but using PGE2 standard, PGE2 tracer and anti-PGE2 serum. 
The standard curves of 6 assays show that the available analytic range of the assay was 0.08 -
10.0 ng/ml ofPGE2, the %BlBo range was 99.82 ± 1.46 - 3.93 ± 1.90 %, the BCso was 1.12 ± 
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0.04 ng/ml of PGE2 standard and the r2 was 0.98 ± 0.01 and regressive relationship (b) was 
significant (P<O.Ol). (Fig. 2.3.). 
2.10. Quantification ofLTB4 
2.10.1. Radioimmunoassay procedures 
Concentrations of LTB4 in exudate were measured by RIA using LTB4 standard, L TB4 tracer and 
anti-L TB4 serum. The procedures described for the TXB2 RIA were used but with some 
modifications. Before LTB4 tracer was added, the vials were incubated at 4 °C for 30 min. After 
dextran-coated charcoal was added, incubated and centrifuged, 0.3 ml of the supernatant was 
removed into the 6 ml scintillation vials containing 3 ml scintillant. The vials were counted as 
cpm. 
2.10.2. Characterisation of the assay 
To evaluate the characteristics of the assay, 4 assays for standard curves were carried out. The 
plot of %BlBo versus logarithmic LTB4 standard concentrations is given in Fig. 2.3. This 
indicates similar characteristics of the assay to the RIA for TXB2. The linearity was 0.92 ± 0.001 
and the regressive relationship (b) was significant (P<O.OI). The maximal %BlBo was 96.12 ± 
1.44 % and the minimal %BlBo was 2.31 ± 0.78 %. The BCso was 0.47 ± 0.01 nglml. The 
available analytic range was 0.08-5.0 nglml ofL TB4. 
2.11. Haematological determinations 
Haematological variables determined on blood and exudate samples included leukocyte 
(including classification), erythrocyte numbers, haemoglobin concentration, haematocrit and 
PL T count. All values were determined using a Roche, Cobas, Minos, Vet. Automated 
Haematology Analyser (Roche Products LTD, Hertfordshire, England). 
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2.12. Phannacokinetic analysis 
2.12.1. Compartmental modelling 
Compartmental parameters were estimated by non-linear least square regressIon usmg 
PCNONLIN 4.0 software programme (Scientific Consulting Inc., North Carolina, USA) with 
NeIder Mead algorithm. The initial estimates were calculated by the software using the curve 
stripping method of residuals (Gibaldi & Perrier, 1982a) based on the model fitted. 
Two compartmental and three-compartmental models with bolus input and first order output 
were used for the data of plasma drug concentration versus time during model selection, thus, 
Crt) = Ae-at + Be-fJl· 
Where A, P, and B are intercept terms and cr, 1t and ~ are rate constants of fast distribution, slow 
distribution and elimination, respectively. The decision for the best fitting model was made by 
MAlCE based on the AlC (Yamaoka et. al., 1978). The AlC values were calculated from the 
non-linear regression results. In order to strengthen the fitting in the elimination phase of the 
curve, a weighting factor (lover the drug concentrations) was used for the non-linear regression. 
Area under the curve and AUMC were calculated by: 
and 
A B AUe =-+-
0-00 a p 
A B 
AUMCo_oo = a2 + p2 
for the two compartmental model, or 
and 
A P B 
AUe =-+-+-
0-00 a 7r p 
A P B 
AUMC =-+-+-
0-00 a2 7r2 p2 
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for the 3 compartment model. And the MRT was calculated by 
MRT = AUMe 
0-..., AUe 
Plasma distribution half-lives (t! a and t! It) and the elimination half-life (t! 13) were calculated as 
2 2 2 
0.693/a, 0.693ht and 0.693/~, respectively. The Vc was calculated as dose divided by C~ which 
is calculated by summing the intercepts of the exponential equations. Body clearance was 
calculated as dose divided by AUC. Volume of distribution at steady state was calculated as 
MRT x CIB' 
The data for exudate (transudate) drug concentration - time were fitted to a one compartment 
model with first-order input, first-order output and a lag time. 
C(t) = M(e-kIO(t-tlag) _ e-kOI(t-tlag» 
where t1ag is lag time, M is the hybrid parameter, kol is the absorption rate (distribution from 
plasma into tissue-cage fluids) and klO is the elimination rate. Absorption half life was calculated 
as 0.6931ko1> t! klO was calculated as 0.693/k1O and AUC was calculated as 
2 
1 1 AUe =M(---) 
0-..., k k 
10 01 
2.12.2. Non-compartmental modelling 
The drug concentration time data from plasma, exudate and transudate were also analysed by 
non-compartment modelling using PCNONLIN 4.0 software programme. 
The AUC was estimated using a linear trapezoidal equation 
~Ci +Ci_1 AUCo-1a.st=£..J 2 X(ti-ti_l) 
i .. 1 
and 
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AUCO_a> = AUCO_lasl + Cpl 
where C represents the plasma concentration, i-I, and i are adjacent data point times, Clast 
denotes the concentration at the last sampling time or the last detectable concentration. ~ was 
first order rate constant associated with the terminal (log-linear) portion of the curve and was 
estimated using the algorithms as described by Dunne (1985). The AUMC was calculated using 
the equation 
AUMe = ~ C;fi + Ci-\ti_1 (. _ . ) O-iasl ~ 2 X t, t,_I' 
i=2 
The extrapolation to infinity was calculated using 
and 
A UMCo_oo= A UMCo_1ast + A UMC1ast_a> 
Thus MR T was calculated as 
MRT, = A UMCo_lasl 
O-Iast AUe O-Iast 
and 
MRT, = AUMCo_a> 
O-a> AUe 
O-a> 
and MAT was calculated as: 
MAT O-last = MR TO-last p.o. (or tissue cage fluids) - MR TO-last i.v.(plasma)· 
and 
MATo-oo =MRTo-oo p.o. (or tissue cage fluids) - MRTo-co i.v.(plasma)· 
Body clearance was calculated as dose/AUC and Vss was calculated as MRT multiplied by CIa. 
2.12.3. Bioavailability and distribution rate into tissue cage fluids 
Bioavailability was determined using the equation 
F = A Ueoral x Dose;v x 100 
AUC;.v. x Doseoral 
In order to correct for the differences in t t ~ following each route of administration, the above 
equation was corrected as: 
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A UCoral X Doseiv x t tfJi.v. 
F = x 100 
AUCi.v. x Doseoral x t~-/Joral 
1 
The extent of drug distribution into tissue-cage fluids was calculated by: 
AVC 
___ ca.=..ge_ X 100% 
AVCplasma 
where AUCcage is the area under exudate or transudate drug concentration time curve and 
AUCplasma is the area under plasma drug concentration time curve. In consideration of the 
differences of the elimination rates between plasma and tissue-cage fluids, which affects the 
values of AUC, a correction was made by: 
A VCcage x MRTplasma ----..:.~--....!:..:..::.:.;,;",::.. xl 00% 
AVCplasma X MR~age 
where MR T plasma is the mean residence time of the drug in plasma and MR T cage is the MR T of the 
drug in exudate or transudate. 
2.12.4. Units ofPK parameters 
The units of dose, drug concentration and time used for PK modelling were ~glkg body weight, 
~g/ml and h, respectively. Accordingly the units of the parameters were generated as: A, P, and 
B (~g/ml), a, 1t and ~ (h-\ C~ (~glml), t la, t! 1t and t l ~ (h), MRT (h), AVC (~g.h/ml), Vc 
2 2 2 
(mllkg), Vss (mllkg) and CIs (m1Jkglh). 
2.13. Pharmacodynamic analysis 
Pharmacodynamic analysis was carried out using PCNONLIN. The data of drug effect versus 
time were fitted to a Sigmoid inhibitory effect model 
E xTr E = E _ --"Cmax==--__ 
max Tr + ETIo 
and the data of effect versus drug concentration were fitted to a Sigmoid Emax model 
E x Cr E = max 
Cr +Ecr so 
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where E is the drug effect expressed in percentage inhibition, Emax is the maximal inhibitory 
effect, y is the Hill constant, T is the time, ET 50 is the time at which the drug effect declines by 
50 % of the Emax, EC50 (lCso) is the drug concentration producing 50% of the Emax , and C is the 
drug concentration in plasma for the estimation of serum TXB2 inhibition or in exudate for the 
estimation of exudate PGE2 inhibition. 
Percentage inhibition of TXB2 generation was calculated using the equation 
Inhibition (%) = (1- TXBi) x 100 
TXBo 
where TXB j were the TXB2 concentrations following drug administration at sequential sampling 
time i and TXBo was TXB2 concentrations at 20 min prior to drug administration. Percentage 
inhibition of PGE2 generation was calculated as: 
PGE 
Inhibition (%) =(1- 2(drug» X 100 
PGE2(PLB) 
where PGE2(drug) was exudate PGE2 concentration following the drug administration and 
PGE2(PLB) was exudate PGE2 concentration following PLB administration at the same time point 
in the same animal. 
For some drugs with quick elimination rates (PM in the present study), the effects lasted for a 
long time after the drug became undetectable in the associated effect sites. In this case it was 
inapplicable to use the effect against drug concentration for the modelling purposes. The drug 
concentrations were simulated using corresponding PK equations (a two compartment model 
with bolus input and first-order output for the data of plasma drug concentration versus time and 
a one compartment model with first-order input and a lag time for the data of exudate drug 
concentration versus time). Thus: 1) compartmental modelling was carried out to obtain an 
equation for prediction of the drug concentration-time relationship in plasma and exudate, 2) the 
data of drug effect against time was fitted to a Sigmoid inhibitory effect model to obtain Emax and 
ITso for serum TXB2 and exudate PGE2 generation and 3) ITso was used to replace the 
independent variable (time) in the above PK equation to achieve the values ofICso· 
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2.14 . Statistical analysis 
Most PD data in the Latin square design cross-over studies were analysed using ANOV A with 
repeated measurements. Balanced ANOV A was used for the experimental data without missing 
data. The GLM was used for experiments with missing data. These methods took account of 
factors including sequence, period, treatment and time as main effects and their associated two 
factor interactions. The analysis provided tests for differences in the factors and interactions. 
Ideally a model for ANOV A should include the variances from all factors and interactions. 
However practically due to the limited numbers of experimental groups and their nested data, 
and a limit of the ranking, the ANOV A analysis could not fit sufficient factors in a single model. 
Most data were, therefore, analysed using the model: 
Y = Il + treatment + time + animal + treatment x time + treatment x animal + time x animal + e 
where Il is overall mean and e is residual error. This model provided tests for differences 
between treatment groups, time courses, animal individuals and their interactions. One of the 
important interactions was treatment x time, which provided the information for the differences 
of measurements collected at each time point between treatment groups. The effects of 
experimental period, sequence and their interactions were analysed using the model: Y = 1-1 + 
period + sequence + period x sequence + e. In order to analyse effects of initial conditions 
(including the values of pre-treatment and normal concentrations of eicosanoids) and ambient 
temperature on the results, analysis of covariance was carried out by addition of those factors, as 
covariates, to the above model. All factors were treated as fixed effects except for animals which 
were a random factor. 
The statistical analyses were undertaken with ANOV A using a MINIT AB Software package 
(Version 10.1, Minitab Inc., State College, P A, USA). All tests for significance were carried out 
at a 0.05 level unless otherwise stated. Significant differences between treatment groups and 
between treatment x time interaction were further investigated using a Fisher's multiple 
comparison at an individual error rate of 0.05. The Fisher's intervals were calculated as: 
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upper interval = Y + t x s x - + -- Rl 
n1 n2 
and 
lower interval = Y - t x s x - + -- Rl 
n1 n2 
where Y is the mean value, t is the Student's t distribution with a degree of freedom for error 
(0.05) from ANOVA, s is the pooled SD (obtained from ANOVA), and nl and n2 are the number 
of observations in the levels compared. If the mean of the measurements fell within the Fisher's 
interval, it was considered that there was no statistical difference (P>0.05). Otherwise, it was 
statistically different (P<0.05). 
2.15. Drugs and chemicals 
2.15.1. Drugs for administration 
The following drugs and chemicals were purchased: Phenylbutazone for Lv. administration 
(Phenyzone, C-Vet Ltd, Raintree, Essex, England), Phenylbutazone paste for p.o. administration 
(Equipalazone paste, Vet Drug Co., Hondon, England) and FM for i.v. administration (Finadyne, 
Schering-Plough Animal Health, Mildenhall, Suffolk, England). 
Racemic CPF for i. v. administration were a gift from the Grampian Pharmaceutical Company 
(Talkin, Cumbria, Scotland). Excipient was also supplied by Grampian Pharmaceutical Company 
in order to formulate the enantiomers in solution. 
2.15. Chemicals 
The following chemicals were purchased: standards and antiserums of TXB2, PGE2 and LTB4 
(Sigma Ltd, Poole, Dorset, England); (5, 6,8,9, 11, 12, 14, 15 (n) 3H-TXB2, (5, 6, 8, 11, 12, 14, 
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15 (n) 3H-PGE2 and 3H-LTB4 (Amersham Ltd, Little Chalfont, Bucks, England); PBZ, OPBZ, 
rac-CPF standard, PRT, PRT glucuronide and L-NAME (Sigma Ltd, Poole, Dorset, England). 
The following chemicals were gifted: BW540C (Well come Research Laboratories, Beckenham, 
Kent, England), FM standard (Schering-Plough Animal Health, Mildenhall, Suffolk, England), 
(-)(R)-CPF and (+)(S)-CPF (Professor P. Delatour, Ecole Nationale Veterinaire de Lyon, France) 
and PRT sulfate (McNeil Consumer Products, Fort Washington, PA, USA). 
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Table 2.1. Percentage recoveries and coefficients of variation (Co-Var) ofPBZ in plasma spikes 
Cone. Assay 1 Assay 2 Assay 3 Assay 4 Mean SD SE CO-Var 
(J.lglml) (%) (%) (%) (%) (%) (%) 
0.00 N/A N/A N/A N/A N/A N/A N/A N/A 
0.25 85.74 81.95 104.92 89.21 90.46 10.09 5.04 11.15 
1.00 90.83 102.45 90.68 95.20 94.79 5.52 2.76 5.83 
5.00 94.31 99.96 91.81 101.04 96.78 4.44 2.22 4.58 
25.00 88.18 109.10 102.04 99.53 99.71 8.69 4.35 8.72 
100.00 101.83 115.26 103.80 110.79 107.92 6.22 3.11 5.76 
Mean 92.18 101.74 98.65 99.16 
SD 6.26 12.57 6.85 7.96 
SE 2.80 5.62 3.06 3.56 
CO-Var 6.80 12.36 6.94 8.03 
Table 2.2. Percentage recoveries and coefficients of variation of OPBZ in plasma spikes 
Cone. Assay 1 Assay 2 Assay 3 Assay 4 Mean SD SE CO-Var 
(mglml) (%) (%) (%) (%) (%) (%) 
0.00 N/A N/A N/A N/A N/A N/A N/A N/A 
0.10 79.23 110.19 110.95 91.69 98.01 15.36 7.68 15.67 
0.25 88.84 85.38 104.96 89.20 92.10 8.75 4.37 9.50 
0.50 89.40 99.63 86.89 95.75 92.92 5.82 2.91 6.27 
1.00 92.61 77.21 109.55 88.74 92.03 13.39 6.69 14.55 
5.00 110.52 100.20 110.78 100.50 105.50 5.95 2.98 5.64 
Mean 92.12 94.52 104.63 93.18 
SD 11.44 13.11 10.21 4.95 
SE 5.11 5.86 4.56 2.21 
CO-Var 12.41 13.87 9.75 5.31 
Table 2.3. Percentage recoveries and coefficients of variation ofFM in plasma spikes 
Cone. Assay 1 Assay 2 Assay 3 Assay 4 Mean SD SE Co-var 
(J.lglml) (%) (%) (%) (%) (%) (%) (%) (%) 
0.00 N/A N/A N/A N/A N/A N/A N/A N/A 
0.25 95.56 81.44 91.02 87.20 88.81 5.98 2.99 6.74 
1.00 96.88 91.62 103.97 90.24 95.68 6.22 3.11 6.51 
5.00 101.22 98.94 100.05 97.64 99.46 1.53 0.77 1.54 
25.00 111.50 109.98 103.88 98.30 105.92 6.05 3.03 5.71 
Mean 101.29 95.50 99.73 93.35 
SD 7.22 12.03 6.09 5.49 
SE 3.61 6.02 3.04 2.74 
Co-var 7.13 12.60 6.10 5.88 
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Fig. 2.1. Standard curve for percentage tracer binding (%BlBo) versus TXB2 concentrations 
to evaluate the linearity and reproducibility of the RIA (mean ± SD, n=9) 
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51 
~ 
Ee 
co 
--1-0 4) g 
.t::: 
t+o-< 
0 
0.0 
~ .~ 
'"d 
~ 
.~ 
.D 
~ 
~ 
i:i 
4) 
0 
1-0 
4) 
~ 
100 
80 
60 
40 
20 
o 
0.1 1 10 
Logarithmic concentration ofLTB4 (nglml) 
Fig. 2.3. The standard curve of percentage tracer binding versus logarithmic L TB4 to 
evalute the sensitivity linearity and reproducibility of the RIA (n=4, mean ± SE). 
52 
Chapter 3 
Pharmacokinetic and pharmacodynamic studies of flunixin meglumine and 
phenylbutazone in sheep 
3.1. Introduction 
Phenylbutazone (Fig. 3.1.) and FM (Fig. 3.1.) are NSAIDs classified as enolic and carboxylic 
acids, respectively. In common with other NSAIDs, they produce their principal effects by 
inhibiting COX enzymes and thus, blocking the formation of COX derived eicosanoid 
inflammatory mediators, such as PGs which are fundamental to the acute inflammatory process 
(Vane, 1971). PBZ and FM have been used widely for their antiinflammatory and analgesic 
properties to treat musculoskeletal conditions and colic in equine practice (Lees & Higgins, 
1985; Tobin et al., 1986). They are also used routinely in ruminant veterinary practice, in the 
treatment of acute mastitis, endotoxaemia and pneumonia in cattle and goats (Anderson et al., 
1986, 1991; Lohuis et al., 1989), and FM was also used to treat endotoxin-induced reticulorumen 
stasis and tachycardia in cattle (Eades, 1993). Studies in our laboratory in carrageenan-induced 
hyperalgesia have demonstrated that FM is a potent analgesic in sheep (Welsh & Nolan 1994a, 
1994b). The PK of PBZ have not been described in sheep although the plasma kinetics of FM 
have been investigated previously (Welsh et al., 1993). For most NSAIDs their antiinflammatory 
effects last longer than would be expected from the plasma drug disposition. Previous studies in 
horses (Lees et al., 1986; Lees et aI., 1987c) and calves (Landoni et aI., 1995a) showed that FM 
and PBZ have greater penetration into inflamed tissue fluid (exudate) than into non-inflamed 
transudate and are eliminated more slowly from the exudate than from plasma. These findings 
indicate that the relationships between plasma concentrations and effects are complex and that 
tissue kinetics in exudate may provide useful information. 
Sheep COX-l and COX-2 isoenzymes have been identified and purified and are used as a rich 
natural source of COX-1 and COX-2 for inflammatory studies (Ouderaa et al., 1977; Johnson et 
al., 1995). Previous studies in vitro using sheep COX-l and COX-2 illustrated that these two 
isoenzymes had distinguished sensitivity to NSAIDs (Smith & Marnett, 1991; Johnson et al., 
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1995). However in vivo studies on COX isoenzymes and their inhibition by NSAIDs in sheep 
have not been carried out. 
The objectives of the present study were to i) establish the disposition ofPBZ, OPBZ and FM in 
plasma, inflammatory tissue-cage fluids (exudate) and non-inflammatory tissue-cage fluids 
(transudate); ii) investigate the effects of PBZ and FM on COX and LOX enzymes. The 
inhibition of COX by the NSAIDs was estimated by determination of serum TXB2 concentration 
generated by PL T in clotting blood and of exudate PGE2 concentration generated by 
carrageenan-induced inflammation in the subcutaneous tissue-cage. Leukotriene B4 in exudate 
was measured to estimate the effects of the drugs on 5-LOX; iii) investigate the effects of the 
NSAIDs on the recruitment of inflammatory cells in exudate and iv) establish the relationship 
between the drug concentrations and effects using PKlPD modelling. 
3.2. Materials and methods 
3.2.1. Animals 
Eight male sheep weighing 45 ± 5 kg (mean ± SD) and aged approximately 1 year old at the 
beginning of the first cross-over were used. Hay and water were provided ad libitum. 
3.3.2. Experimental protocol 
The study was carried out using a subcutaneous tissue-cage acute inflammatory model as 
described in Chapter 2. A three way cross-over Latin square design was used for the study such 
that each sheep received PLB, FM and PBZ (Table 3.1.). A 21 day wash-out period was allowed 
between each cross-over. Fifteen min after the injection of carrageenan into the cage, FM at 1.1 
mglkg body weight, PBZ at 4.4 mglkg body weight and PLB (normal saline) at a dose volume 
equivalent to FM were administered i.v., as a rapid bolus, into the right jugular vein according to 
the cross-over design. 
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Table 3.1. Cross-over design for i.v. administration of PBZ (A, 4.4 mg/kg), FM (B, 1.1 mglkg) 
and PLB (C, saline) in 8 sheep 
Cross-over occasion 
Sheep No. 1 2 3 
143 A B C 
144 B C A 
145 C A B 
146 C B A 
147 A C B 
148 B A C 
149 A B C 
150 B C A 
All of the injection preparations were made up to an equal volume of 5.0 m1 by addition of 0.9 % physiological 
saline. 
Blood samples were collected at -20 min ( 20 min before drug administration), 5, 15,30,45 min 
and 1,2, 4, 6, 8, 12, 24, 32,48, 72, 96, 120 and 144 h via the left jugular vein. Transudate and 
exudate samples (approximately 1 ml) were collected at -15 min (transudate only) and 2, 4, 8, 
12,24,32,48, 72, 96, 120 and 144 h. All of the samples were processed as described in Chapter 
2. 
The PBZ, OPBZ and FM concentrations in plasma, exudate and transudate was determined by 
HPLC as described in Chapter 2. The quantification of serum TXB2, exudate PGE2 and exudate 
L TB4, and the haematological determinations were carried out according to the methods 
described in Chapter 2. 
3.3.3 Pharmacokinetic and PD analysis 
Pharmacokinetic and PD analysis were carried out following the methods described in Chapter 2. 
Compartmental and non-compartmental modelling were used for concentration time data in 
plasma, exudate and transudate. The ICso of FM for serum TXB2 and exudate PGE2 were 
simulated by the PK equations. 
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3.3.4. Statistics 
The results were expressed in mean ± SE. A three factor ANOV A (treatments of PBZ, FM and 
PLB) with multiple ways (treatments, sheep, times, periods and sequences) was carried out using 
a balanced design routine as described in Chapter 2. The effects of ambient temperature and pre-
treatment values on the experimental parameters were estimated using an analysis of co-variance 
routine. Sheep were treated as random factors and other factors were treated as fixed. The 
differences in measurements collected at each time point between treatment groups, and between 
pre-treatment and post-treatment were further confirmed using Fisher's multiple comparisons 
following the ANOV A. The differences between individual animal, time points, cross-over 
sequences and cross-over periods and their two factor interactions were analysed using the 
ANOV A but without carrying out Fisher's multiple comparisons. 
3.4. Results 
3.4.1. Pharmacokinetics 
3.4.1.1. Phenylbutazone 
The PK data of PBZ and OPBZ in plasma, exudate and transudate are given in Tables 3.2.-3.6. 
and Figs. 3.2. and 3.3. 
Following i.v. administration of PBZ at 4.4 mglkg in sheep, the elimination of drug 
concentration from plasma was very slow (Fig. 3.2.). At 144 h post-administration PBZ was still 
detectable in plasma in 6 animals at a mean concentration of 0.32 ± 0.10 Ilg/ml. Based on the 
MAlCE principle and using the AIC test, the concentration-time curves were best fitted to a three 
compartmental model in 5 animals and a two compartmental model in 3 animals. 
The distribution of PBZ in plasma was rapid in the first phase (t.! a = 0.22 ± 0.05 h) and much 
2 
slower in the second phase (t! 1t = 5.35 ± 1.27 h). The elimination was very slow, indicated by a 
2 
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tl ~ of 17.92 ± 1.74 h, a MRT of 21.63 ± 1.94 h, a slow CIs (4.56 ± 0.53 ml/kg.h) and small Vss 
2 
(98.66 ± 4.67 ml/kg) (Table 3.2. and Fig. 3.2). 
The results analysed by non-compartmental modelling showed that PBZ distributed slowly into 
the tissue-cages although it could be detected by 2 h following administration. Similar values for 
Cmax were achieved in exudate (22.32 ± 1.29) and transudate (22.07 ± 1.57) at 9.50 ± 0.73 hand 
11.50 ± 1.92 h, respectively (Table 3.4). The elimination of PBZ from both tissue-cage fluids 
was slower than from plasma, indicated by the MRT values of 31.60 ± 1.84 h and 31.11 ± 2.41 h 
from exudate and transudate, respectively. This also indicated that PBZ had similar rates of 
penetration and elimination in both exudate and transudate (Table 3.4.). Before about 20 h PBZ 
concentrations in exudate and transudate were lower than in plasma and thereafter, the relative 
concentrations were reversed due to slow elimination from the cages (Fig. 3.2.). 
The data for PBZ in tissue-cage fluids could be best fitted to a one compartment model with first 
order input and output and a lag time (R2 > 0.95 for all data fitted). This illustrated that the 
elimination half lives (t!kIO) ofPBZ were similar in plasma (17.92 ± 1.74 h), exudate (17.82 ± 
2 
1.27 h) and transudate (16.24 ± 1.60 h) (Tables 3.2, 3.3.). A lag time for PBZ of 1.66 ± 0.09 h in 
exudate and 1.89 ± 0.22 h in transudate indicated the slow penetration of PBZ from plasma into 
the tissue-cage fluids. The curves in Fig. 3.2. also showed that 20 h after drug administration, 
PBZ concentration declined at the similar rates in plasma, exudate and transudate although the 
concentrations of PBZ in exudate and transudate were slightly higher than in plasma at most of 
the time points. 
The AUC ratios of exudate and transudate to plasma were high, 84.74 ± 5.91 % and 79.98 ± 4.53 
%, respectively. After correction for MRT, both ratios became smaller: 56.76 ± 3.20 % for 
exudate to plasma and 54.55 ± 3.50 % for transudate to plasma. Pre- or post-correction by MRT, 
the AUC ratios of exudate to plasma were larger than transudate to plasma (Table 3.6.). 
As described in Table 3.5. and Fig. 3.3., the metabolism of PBZ to OPBZ was very slow and 
weak, indicated by the low Cmax values for OPBZ of 1.35 ± 0.16, 0.88 ± 0.14 and 0.82 ± 0.11 
Ilglml in plasma, exudate and transudate, respectively. The AUe ratios of OPBZ to PBZ were 
also very small, about 4.5 % in plasma, exudate and transudate. 
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Table 3.2. Pharrnacokinetic parameters of PBZ and FM in plasma following i.v. administration 
of PBZ (4.4 mglkg) and FM (1.1 mglkg) in sheep using compartmental modelling (n=8, mean ± 
SE) 
Parameters PBZ FM 
A (J.1g/ml) 45.95 ± 2.88 16.71 ± 1.49 
P (J.1g/ml) 20.40 ± 4.01 NA 
B (J.1g/ml) 31.62 ± 4.24 7.80± 1.16 
a (hoi) 4.14 ± 0.97 3.38 ± 0.67 
'It (hoi) 0.1674 ± 0.0415 NA 
P (hoi) 0.0405 ± 0.0045 0.31 ± 0.03 
C; (J.1g/ml) 97.96 ± 3.63 24.51 ± 2.60 
Vc (ml/kg) 45.15 ± 1.59 49.47 ± 6.40 
K21 (hoi) 2.19 ± 0.47 1.29 ± 0.27 
K31 (h
OI
) 0.13 ± 0.03 NA 
K (hoi) 0.10 ± 0.01 0.83 ± 0.08 
10 I 
1.87 ± 0.50 1.58 ± 0.36 K12 (hO ) 
K\3 (hoi) 0.06 ± 0.02 NA 
klo! 7.27 ± 0.91 0.87 ± 0.06 
2 
t1 a 0.22 ± 0.05 0.24 ± 0.03 
2 
t1 1t 5.35 ± 1.27 NA 
2 
t 113 17.92 ± 1.74 2.33 ± 0.18 
2 
AUCo-oo (J.1g.h/ml) 946.23 ± 96.82 30.16 ± 3.25 2 23517.5 ± 3996.4 83.12 ± 9.80 AUMCo-oo (J.1g.h Iml) 
MRTo-oo (h) 21.63 ± 1.94 2.78 ± 0.20 
CIa (ml/kglh) 4.56 ± 0.53 39.67 ± 4.27 
Vss (ml/kg) 98.67 ± 4.67 111.50 ± 17.08 
Parameters for PBZ were derived from a three compartmental model in 5 sheep and data of FM 
were fitted to a two compartmental model. 
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Table 3.3. Phannacokinetic parameters of PBZ in exudate and transudate following i.v. 
administration of PBZ at 4.4 mglkg in sheep using a one compartment model with first order 
input and output and a lag time (n=8, mean ± SE) 
Parameters Exudate Transudate 
Kol (h- I ) 0.36 ± 0.08 0.28 ± 0.07 
KJO (h-I) 0.0402 ± 0.0027 0.0459 ± 0.0048 
Lag time (h) 1.66 ± 0.09 1.89 ± 0.22 
AUCo-oo (flg·hlml) 764.8 ± 76.2 718.0 ± 77.6 
t lkOI (h) 2.71 ± 0.69 3.44 ± 0.62 
l 
tlklO (h) 17.82 ± 1.27 16.24 ±1.60 
l 
!max (h) 9.05 ± 0.80 11.26 ± 1.46 
Cmax (flg/ml) 21.28 ± 1.25 20.72 ± 1.55 
Table 3.4. Phannacokinetic parameters of PBZ in plasma, exudate and transudate following i.v. 
administration ofPBZ at 4.4 mglkg in sheep using non-compartmental modelling (n = 8, mean ± 
SE) 
Parameters Plasma Exudate Transudate 
Cmax (obs) (flg/ml) 77.38 ± 5.45 (c;min) 22.32 ± 1.29 22.07 ± 1.57 
!max (h) NA 9.50 ± 0.73 11.50 ± 1.92 
~ (h- I ) 0.0422 ± 0.0036 0.0254 ± 0.0013 (n=7) 0.0222 ± 0.0059 
t! J3 17.12 ± 1.20 27.72 ± 1.33 (n=7) 31.22 ± 8.30 
l 
AUCO-Iast (flg·hlml) 963.54 ± 95.35 804.01±77.64 761.21 ± 77.53 
AUCo_GO (flg.hlml) 970.32 ± 97.61 829.44 ± 89.12 (n=7) 791.09 ± 91.83 2 26063.60 ± 3435.99 24695.25 ± 4265.92 AUMCo-last (flg.h Iml) 21499.39 ± 3623.75 
AUMCo-oo (flg.h2/m1) 22668.53 ± 4037.94 28745.3 ± 4312.2 (n=7) 34067.17 ± 9522.92 
MRTo-1ast (h) 21.22 ± 1.73 31.60 ± 1.84 31.11 ±2.41 
MRTo-oo (h) 22.07 ± 2.01 33.68 ± 2.54 (n=7) 39.19 ± 5.60 
MAT O-last (h) NA 10.38 ± 0.99 9.90 ± 1.39 
MATo-oo (h) NA 11.81 ± 1. 73(n=7) 17.24 ± 4.58 
~ in exudate and transudate was calculated for the estimation of AUC1ast-oo and AUMC1ast_GO using 
the curve stripping method. 
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Table 3.5. Pharmacokinetic parameters of OPBZ in plasma, exudate and transudate following 
i.v. administration ofPBZ at 4.4 mg/kg in sheep using non-compartmental modelling (n=8, mean 
± SE) 
Parameters Plasma Exudate Transudate 
0.88 ± 0.14 0.82 ± 0.11 Cmax (obs) (~glml) 
tmax (h) 
~ 
t 1 P 
9.88 ± 5.49 
0.0265 ± 0.0014 
26.22 ± 1.63 
18.00 ± 4.90 14.50 ± 2.13 
0.0652 ± 0.00427 (n=5) 0.0164 ± 0.0019 
38.34 ± 10.58 (n=5) 46.79 ± 7.45 
2 
AUCO-Iast (Ilg.hlml) 40.75 ± 4.76 
AUCo-co (llg.h1ml) 41.58 ± 4.71 
2 AUMCO-Iast (Ilg.h Iml) 2 AUMCo_oo (Ilg.h Iml) 
MRTo-last (h) 
MRTo-co (h) 
MATo_last (h) 
1238.4 ± 206.9 
1373.9 ± 215.1 
29.63 ± 2.07 
33.10 ± 2.74 
NA 
32.43 ± 4.42 
33.25 ± 4.24 (n=5) 
1199.0 ± 277.7 
1444.6 ± 542.1 (n=5) 
35.23 ± 2.94 
39.16 ± 8.68 (n=5) 
5.60 ± 2.96 
34.13 ± 2.71 
35.79 ± 2.90 
1406.4 ± 75.4 
1791.9 ± 203.7 
43.04 ± 4.12 
53.00 ± 9.32 
13.40 ± 2.84 
The parameters were derived from non-compartmental modelling, where ~ was calculated for 
estimation of AUClast-co and AUMClast-co using curve the stripping method. 
Table 3.6. Mean ± SE AUC ratios of PBZ, OPBZ and FM, in plasma, exudate and transudate 
following FM (1.1 mg/kg) or PBZ (4.4 mg/kg) given i.v. in 8 sheep. 
Parameters PBZ OPBZ FM 
AUC ratio (%) 
Exudate:plasma 84.74 ± 5.91 81.95 ± 9.62 92.10 ± 8.00 
Transudate:plasma 79.98 ± 4.53 87.86 ± 7.23 97.93 ± 10.00 
AUC ratio (%, OPBZ:PBZ) 
Plasma 4.53 ± 0.67 N/A N/A 
Exudate 4.22 ± 0.54 N/A N/A 
Transudate 4.72 ± 0.53 N/A N/A 
AUC ratio (%, Corrected by MRT) 
Exudate:Plasma 56.76 ± 3.20 66.65 ± 3.13 23.09 ± 2.03 
Transudate:Plasma 54.55 ± 3.50 61.09 ± 5.62 20.59 ± 2.71 
The ratios were calculated using AUCo-last· 
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Fig 3.1. Chemical structure of phenylbutazone and flunixin 
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Fig.3.2. Concentration versus time semilogarithrnic plot of PBZ in plasma (-0- ), 
exudate (-e-) and transudate (-.A.-) in sheep ( n=8, mean ± SE ) following PBZ 
administration i.v. at 4.4 mg/kg. 
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3.4.1.2. Flunixin meglumine 
Phannacokinetic data for FM in plasma, exudate and transudate following FM administered i.v. 
at 1.1 mg/kg in sheep are presented in Tables 3.2., 3.6., 3.7. and 3.8., and Fig. 3.4. 
Following i.v. administration of FM at a single dose rate of 1.1 mg/kg in the sheep, plasma 
concentration declined much more rapidly than PBZ (Fig. 3.4.). Concentrations were detectable 
only for up to 12 h in 5 animals and up to 24 h in 3 animals. Based on the MAICE principle 
using the AlC test, the concentration-time data were best fitted to a two compartmental model in 
7 sheep and to a three compartmental model in 1 sheep. 
Distribution and elimination of FM in plasma were fast, indicated by a t 1 a of 0.24 ± 0.03 h, an 
2 
t1 ~ of 2.33 ± 0.18 h and a MRT of 2.78 ± 0.20 h. Volume of distribution at steady state was 
2 
small (111.50 ± 17.08 ml/kg). This led to a slow CIB' 39.67 ± 4.27 ml/kglh in spite of the 
elimination halflife (Table 3.2.). 
Flunixin meglumine was detectable in exudate and transudate 2 h after administration. During 
the first 8 h the concentrations in exudate and transudate were lower than in plasma. After this 
the concentrations in exudate and transudate were higher than in plasma. Drug concentrations 
were measurable up to 32 h in exudate and 48 h in transudate in most of the animals. The PK 
analyses showed that the elimination of FM from tissue-cages was much slower than from 
plasma, indicated by a MR.T of 12.98 ± 1.02 h for exudate and 15.35 ± 0.65 h for transudate 
whereas MR.T in plasma was only 3.20 ± 0.19 h (Table 3.7. and Fig. 3.4.). 
The penetration ofFM into the tissue cages was very slow indicated by a MAT of 9.79 ± 0.93 h 
for exudate and 12.15 ± 0.70 h for transudate. A Cmax of 1.82 ± 0.22 J.lglml in exudate occurred at 
5.50 ± 0.73 h and a Cmax of 1.58 ± 0.30 J.lglml in transudate at 8.00 ± 0.76 h. During the period 
while FM was distributing into tissue-cages, the concentrations in exudate were higher than in 
transudate, however after Cmax had been achieved these observations were reversed. The data in 
individual animals indicated that in cages with a faster drug penetration rate and a higher Cmax 
the drug was also more quickly eliminated (Table 3.7. and Fig. 3.4.). 
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The concentration-time data of FM in tissue-cage fluids could be best fitted to a one 
compartment model with first order input and output, and a lag time and the parameters are given 
in Table 3.8. A lag time for FM of 1.60 ± 0.06 h in exudate and 1.67 ± 0.12 h in transudate 
illustrated a slow extravascular penetration. The values of t lUO in exudate (8.53 ± 1.04 h) and 
2 
transudate (11.96 ± 1.07 h) were longer than the tl~ in plasma (2.33 ± 0.18 h). These results 
2 
(Table 3.8.) were consistent with the results analysed by non-compartment modelling (Table 
3.7.). 
The AVe ratios of exudate AVe and transudate AVe to plasma AVe were higher than those 
obtained for PBZ, 92.0 ± 8.0 and 97.1 ± 10 %, respectively. Following correction for MRT, the 
AVe ratios were smaller (half those of PBZ) and the ratio of exudate to plasma was larger than 
transudate to plasma (Table 3.6.). 
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Table 3.7. Phannacokinetic parameters of FM in plasma, exudate and transudate following i.v. 
administration of FM at 1.1 mglkg in sheep using non-compartmental modelling (n=8, 
mean±SE) 
Parameters 
Cmax (obs) (llg/m1) 
lmax (h) 
~ (h- I ) 
t! 13 
2 
Plasma 
20.48 ± 1.96 ( c;min ) 
NA 
0.2548 ± 0.0290 
2.93 ± 0.27 
AUCo-Iast (Ilg.hlml) 30.56 ± 3.41 
AUCo-aJ (Ilg.hlml) 30.60 ± 3.42 
AUMCo_Iast (llg.h2/ml) 99.00 ± 13.60 
AUMCo_oo (llg.h2/ml) 100.86 ± 14.47 
MRTo-1ast (h) 3.20 ± 0.19 
MRTo_oo (h) 3.24 ± 0.20 
MATo-Iast (h) NA 
MATo-aJ(h) NA 
Exudate Transudate 
1.82 ± 0.22 1.58 ± 0.30 
5.50 ± 0.73 8.00 ± 0.76 
0.0577 ± 0.0244 (n=3) 0.0885 ± 0.0545 (n=5) 
16.4543 ± 5.4666 (n=3) 21.85 ± 2.59 (n=5) 
27.38 ± 2.88 
26.71 ± 1.59 (n=3) 
356.51 ± 47.03 
347.29 ± 59.86 (n=3) 
12.98 ± 1.02 
13.15 ± 2.43 (n=3) 
9.79 ± 0.93 
9.59 ± 2.58(n=3) 
29.47 ± 4.72 
39.53 ± 8.54 (n=5) 
457.73 ± 78.54 
1054.6 ± 245.1 (n=5) 
15.35 ± 0.65 
26.12 ± 1.40 (n=5) 
12.15 ± 0.70 
22.99 ± 1.18 (n=5) 
~ in exudate and transudate was calculated for the estimation of AUClast-aJ and AUMClast-aJ using 
the curve stripping method. 
Table 3.8. Phannacokinetic parameters of FM in exudate and transudate following i.v. 
administration of FM at 1.1 mglkg in sheep using a one compartment model with first order 
input and output and a lag time (n=8, mean ± SE). 
Parameters Exudate Transudate 
~I (h- I ) 0.91 ± 0.18 0.99 ± 0.23 
KIO (h-I) 0.0925 ± 0.0141 0.0613 ± 0.0054 
Lag time (h) 1.60 ± 0.06 1.67 ± 0.12 
AUCo-aJ (Ilg.hlml) 27.29 ± 3.19 28.92 ± 4.62 
t! kOI (h) 0.94 ± 0.14 0.93 ± 0.15 
2 
t 1 klO (h) 8.53 ± 1.04 11.96 ± 1.07 
2 
!max (h) 4.50 ± 0.45 5.23 ± 0.45 
Cmax (Ilg/ml) 1.80 ± 0.24 1.40 ± 0.24 
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50 
3.4.2. Pharmacodynamics 
3.4.2.1. The effects ofPBZ and FM on inflammatory skin temperature 
The changes in skin temperature (OC) over the cages (expressed by the differences between 
inflamed and non-inflamed tissue-cages) are illustrated in Table 3.9. 
Intracaveal injection of carrageenan led to an increase in skin temperature over the treated cages. 
In the PLB-treated group, the overall mean temperature increased by 0.58 ± 0.12 °C over a period 
of 144 h, with a maximum increase of 1.52 ± 0.33 °C recorded at 4 h. Most of the values 
recorded at each time point were higher than the pre-values and compared with pre-values, a 
significant increase was achieved at 2, 4 and 12 h (P<0.05). 
In the PBZ-treated group, the temperature was higher than the pre-values and PLB-treated group 
at 1 h (P<O.05) and then returned to the pre-values. The temperatures were slightly lower than the 
PLB-treated group in some time points, but no significant differences were achieved (P>0.05). In 
the FM-treated group, there was no significant change in the temperature at any time compared 
to pre-induction values. The temperature was significantly lower than that in the PLB-treated 
group at 2, 4 and 6 h (P<0.05) and it was also lower than in the PBZ-treated group at 1 and 4 h 
(P<O.05). 
The analysis also illustrated that the pre-values and ambient temperature did not exert significant 
influence on the changes caused by carrageenan stimulation and drug administration (P>0.05) 
and that the difference between cross-over periods was not significant (p>O.OS). However the 
differences of individual sheep and treatment x sheep interaction (the response of the sheep to 
treatments) were significant (p<0.05). 
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3.4.2.2. The effects ofPBZ and FM on serum TXB2 generation 
Mean ± SE serum TXB2 concentrations following i.v. administration ofPLB, PBZ and FM in the 
sheep are presented in Fig. 3.5. The percentage inhibition of serum TXB2 against plasma drug 
concentrations is illustrated in Table 3.10. and the PD modelling results are given in Table 3.11. 
There were significant differences in serum TXB2 concentration between the overall means of 
the three treatment groups (p<0.01). The interaction of treatment x time was significantly 
different (P<O.Ol), indicating that the measurements at each time point were significantly 
different between treatment groups. 
Fisher's multiple comparisons were carried out to confirm the source of differences. Compared 
with the pre-values, serum TXB2 generation was attenuated in the PLB-treated group for 12 h 
(P<0.05). The concentrations were higher than the pre-values after 72 h but they were not 
significantly different (P>0.05). Compared with the pre-values and the PLB-treated group, PBZ 
inhibited TXB2 generation for up to 32 h (P<0.05) although the inhibition was partial. From 48 h 
post PBZ administration, the generation of TXB2 was completely restored and on occasion, 
TXB2 concentrations were higher than pre-treatment (P<0.05). By applying a Sigmoid inhibitory 
effect model to the PBZ treated group, Emax was estimated to be 79.94 ± 6.20 % despite high 
plasma concentrations of PBZ (C~ of PBZ was 97.96 ± 3.63 Jlglml). An ICso of 10.86 ± 1.81 
Jlglml occurred 29.96 ± 2.62 h after PBZ treatment. In the FM-treated group, serum TXB2 
generation was abolished for up to. 8 h although FM concentration at 8 h was 0.70 ± 0.28 Jlglml. 
Compared with the pre-values and the PLB-treated group, a significant inhibition was observed 
for up to 32 h (P<0.05) after FM administration. After this TXB2 generation was restored and did 
not differ significantly from the pre-values or PLB-treated group (p>0.05). The Emax was 99.96 ± 
4.0 % and ICso was 0.0053 ± 0.0032 Jlglml occurring at 28.96 ± 1.86 h. The percentage 
inhibition of TXB2 was greater than that in the PBZ-treated group for up to 24 h after drug 
administration (p<0.05). 
The pre-values had significant effects on the inhibitory effects of the drugs (r = -0.34 ± 0.10, p = 
0.001). This suggests a competitive inhibitory nature of the drugs for COX in PLT. There were 
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significant differences of TXB2 inhibition with time, sheep, periods and their two way 
interactions (P<0.05). This may reflect that a number of factors affected the experiments. 
3.4.2.3. The effects ofPBZ and FM on carrageenan-induced PGE2 generation 
The effects of PLB, PBZ and FM on PGE2 generation in carrageenan-induced exudate are 
demonstrated in Tables 3.11. and 3.12. and Fig. 3.6. 
Prostaglandin E2 was not detectable in tissue-cage fluid (below the limit of quantification of 0.8 
nglml) before injection of carrageenan. In the PLB-administered group, PGE2 concentration rose 
steadily to a Cmax of 35.65 ± 4.92 nglml achieved at 12 h which was 4 h after the second injection 
of carrageenan. The changes in exudate PGE2 were time-related (P<O.OOl) and this indicated a 
reversible acute inflammatory response. Prostaglandin E2 in the PLB-treated group was 
detectable over a period of 2-144 h and was significantly higher than the pre-values in the 
exudate from 4 to 120 h following the injection of carrageenan (P<0.05). Exudate PGE2 
concentrations in PBZ-treated group were significantly higher than pre-values from 8 to 48 h but 
no significant generation of exudate PGE2 were observed in FM-treated group at any time point 
compared with the pre-values (P>0.05). 
There were significant differences of overall mean exudate PGE2 concentrations between the 
PLB (16.32 ± 1.70 nglml) and treatment groups of PBZ (10.41 ± 1.55 nglml) and FM (1.72 ± 
0.43 nglml) during a period of 144 h (P<O.OI). The interactions of treatment x time and treatment 
x sheep were significantly different (P<O.OOI) and the concentrations of exudate PGE2 were 
different between individual animals (P<0.001). 
Phenylbutazone attenuated PGE2 generation over a 144 h period, however the inhibition was 
weak and statistical significance was achieved only at 4 and 12 h (P<0.05) when compared with 
the PLB-treated group. In exudate, the Cmax for PBZ of 22.32 ± 1.29 j.lglml produced only 10 % 
inhibition of PGE2 generation. Extrapolation suggested an exudate PBZ concentration > 100 
j.lglml would be required to produce an ICso for exudate PGE2 generation. 
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Flunixin meglumine abolished exudate PGE2 synthesis for up to 4 h and inhibited the PGE2 
generation significantly from 8 h to 32 h compared with PLB-treated group (p<O.OS). The 
inhibitory effects of FM were considerably greater than those of PBZ, and PGE2 concentrations 
in tissue cages from the FM-treated group were significantly lower than in PBZ-treated group up 
to 32 h after drug administration (P<O.OS). After 32 h the inhibition was not statistically 
significant (p>O.OS) compared with the PLB-treated group although the concentrations of PGE2 
in the FM-treated group were much lower than in the PLB-treated group. Flunixin meglumine 
produced greater than SO % of the PGE2 inhibitory effect in all animals up to 144 h at which 
time the last samples were taken. Simulation using the exudate PK equation for FM suggested 
that the drug concentration in exudate at 144 h would have been about 0.00019 ± 0.00012 lJg/ml. 
Phannacodynamic modelling was considered inapplicable to the PBZ-treated group due to the 
weak effect ofPBZ on PGE2 generation. 
Significant differences in exudate PGE2 concentrations were also observed between experimental 
sequences and cross-over periods (P<O.OOl). The capacity of carrageenan-induced exudate PGE2 
generation in the cages was significantly correlated with the treatment results (r = -0.33 ± 0.01, 
P<O.Ol) and this may indicate that high drug concentrations were required to inhibit the high 
concentration of the PGE2 and also indicates the competitive inhibitory nature of the NSAIDs. 
3.4.2.4. The effects ofPBZ and FM on exudate LTB4 generation 
Concentrations ofLTB4 (mean ± SE) in exudate following i.v. administration ofPLB, PBZ and 
FM are given in Table 3.13. 
Following the intracaveal injection of 1 % of the mild irritant carrageenan, exudate LTB4 
generation in all treatment groups increased significantly over a 120 h period (P<O.OS). The 
maximal concentration was 1.63 ± 0.31 ng/ml recorded at 12 h in the PLB-treated group, 1.71 ± 
0.S2 ng/ml at 72 h in the PBZ-treated group and 1.60 ± 0.28 ng/ml at 8 h in FM-treated group. 
The overall means of exudate LTB4 concentration in PBZ-treated (1.37 ± 0.10 ng/ml) and FM-
treated (1.40 ± 0.08 ng/ml) groups were slightly higher than in the PLB-treated (1.26 ± 0.10 
ng/ml) group but the differences were not significant (P>0.05). 
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The overall treatment x time interaction was not' significantly different (P>0.05). However 
significant difference was found at some time points when using Fisher's comparisons. 
Compared with the PLB-administered group a significant increase in exudate LTB4 generation 
was obtained at 48 h in the PBZ-treated group and at 24 and 48 h in the FM-treated group 
(P<0.05). 
There were significant differences in exudate LTB4 generation in experimental sequences, cross-
over periods, time, sheep, and treatment x sheep interaction (P<O.OOl). 
3.4.2.5. The effects ofPBZ and FM on exudate WBC accumulation 
Following the intracaveal administration of carrageenan, the number of WBC in exudate 
increased significantly at 4, 8, 12, 24 and 48 h in the PLB-administered group, and at 8, 12 and 
24 h in the PBZ and FM treated groups (P<0.05). The maximal numbers of WBC (109 celllL) 
were 41.96 ± 8.59 in the PLB treated group, 26.60 ± 5.42 in the PBZ-treated group and 37.49 ± 
7.77 in the FM -treated group, and all occurred at 24 h. The overall mean cell numbers in the 
PBZ-treated group (14.79 ± 79 x 109 celllL) and FM-treated group (16.10 ± 2.45 x 109 cells/L) 
were lower than in the PLB-treated group (22.29 ± 3.00 x 109 ceUs/L) but they were not 
significantly different (P>0.05) due to a large SE. For measurements at each time point, the 
numbers of exudate WBC in the FM-treated group was significantly lower than in the PLB-
treated group at 12 h. The ANOVA confirmed that there were significant differences in WBC 
numbers in individual animals (P<0.05) and the response to the treatments among the individual 
animals was also different (P<O.Ol). (Fig 3.7.). 
3.4.2.6. The effects ofPBZ and FM on WBC and PLT in blood 
The numbers of WBC and PL T in blood were not significantly modified by PBZ or FM at any 
sampling time (p>0.05, Fig. 3.8.). 
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Table 3.9. The effects ofPBZ and FM on inflammatory skin temperature 
Time (h) Placebo Phenylbutazone Flunixin 
Pre-values -0.31 ± 0.46 -0.21 ± 0.84 -0.04 ± 0.44 
1 -0.55 ± 0.62 1.28 ± 0.40ac -0.03 ± 0.52 b 
2 1.20 ± O.44c -0.31 ± 0.40 -0.20 ± 0.67a 
4 1.52 ± 0.33c 0.76 ± 0.47 -0.96 ± 0.43ab 
6 0.91 ± 0.37 0.71 ± 0.52 -0.57 ± 0.44a 
8 0.35 ± 0.54 0.18 ± 0.31 -0.01 ± 0.34 
12 1.06 ± 0.45c -0.01 ± 0.35 0.54 ± 0.40 
24 0.40 ± 0.39 0.65 ± 0.59 0.97 ± 0.32 
32 0.30 ± 0.45 0.32 ± 0.72 0.36 ± 0.43 
48 0.87 ± 0.41 0.51 ± 0.51 0.78 ± 0.46 
72 0.26 ± 0.38 -0.30 ± 0.49 0.80 ± 0.48 
96 0.65 ± 0.51 0.45 ± 0.49 0.36 ± 0.44 
120 0.60 ± 0.31 0.40 ± 0.42 0.37 ± 0.30 
144 0.50 ± 0.38 0.71 ± 0.41 0.18±0.72 
All values (Oe) are mean ± SE in 8 sheep. The values are the differences of the temperature 
between inflamed and non-inflamed tissue-cages (the temperature over inflamed tissue-cage 
minus the temperature over non-inflamed tissue-cages). (a) P<0.05 compared with the PLB-
treated group, (b) P<0.05 compared with the PBZ-treated group. and (c) P<0.05 compared with 
the control values. 
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Table 3.10. Relationship between plasma drug concentrations and percentage TXB2 inhibition in 
serum following i.v. administration of PBZ (4.4 mglkg) and FM (1.1 mglkg) in sheep (n=8, 
mean ± SE) 
Time (h) PBZ-treated group 
Drug conc (~glml) Inhibition (%) 
1 47.53 ± 2.73 73.14 ± 11.78 ac 
2 42.10 ± 2.65 81.29 ± 6.24 ac 
4 38.55 ± 1.64 67.65 ± 6.69 ac 
6 33.60 ± 1.66 76.92 ± 6.37 ac 
8 29.92 ± 1.90 74.57 ± 4.72 ac 
12 23.00±1.75 72.82±5.42 ac 
24 13.04 ± 1.69 39.14 ± 8.42 ac 
32 8.84 ± 1.43 48.96 ± 5.75 ac 
48 4.52 ± 0.86 6.89 ± 7.96 
72 1.93 ± 0.51 -8.75 ± 5.93 
96 0.76 ± 0.23 -7.24± 17.56 
120 0.48±0.1O -26.10±9.91 
144 0.32 ± 0.10 -15.97 ± 7.93 
Flunixin-treated group 
Drug conc (~glml) Inhibition (%) 
6.79 ± 2.31 100.00 ± 0.00 abc 
3.87 ± 1.47 100.00 ± 0.00 abc 
2.31 ± 0.73 100.00 ± 0.00 abc 
1.09 ± 0.42 100.00 ± 0.00 abc 
0.70 ± 0.28 100.00 ± 0.00 abc 
0.24 ± 0.12 99.76 ± 0.24 abc 
0.05 ± 0.01 65.76 ± 7.27 abc 
UD 37.33 ± 4.35 ac 
UD 6.46 ± 5.10 
UD 1.44 ± 8.73 
UD -5.50 ± 4.96 
UD 3.01 ± 4.56 
UD -5.70 ± 9.05 
UD: undetectable (below the limit of quantification of 0.05 ~glml). (a) P< 0.05, compared with 
the PLB-treated group, (b) P<0.05, compared with the PBZ-treated group and (c) P<0.05, 
compared with the group control (pre-treatment values). 
Table 3.11. The effects ofPBZ and FM on serum TXB2 and exudate PGE2 generation 
Thromboxane B2 Prostaglandin E2 
Parameters PBZ FM PBZ FM 
Emax (%) 79.94 ± 6.20 99.96 ± 0.04 <40 100 
1Tso (h) 29.96 ± 2.62 28.96 ± 1.86 NA > 144 
ICso (~glml) 10.86 ± 1.81 0.0053 ± 0.0032 >200 0.00019 ± 0.00012 
Y 3.91 ± 0.37 4.59 ± 0.59 NA NA 
AUCO_72h 2302.96 ± 356.22 3000.14 ± 288.80 NA NA 
All values are mean ±SE in 8 sheep. NI A = not applicable. AVC = area under the curve using 
percentage TXB2 inhibition against time plot. * P<O.OI compared with the PBZ-treated group 
using a paired student t test (two tails). 
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Table 3.12. The effect of PBZ and FM on PGE2 generation in carrageenan-induced inflamed 
exudate in sheep 
Time (h) PLB-treated group PBZ-treated group FM -treated group 
Pre ND ND ND 
2 4.12 ± 2.57 0.18±0.14 0.00 ± 0.00 
4 15.00 ± 5.33 7.17 ± 3.21 * 0.00 ± 0.00* 
8 31.21 ± 3.99 28.90 ± 5.31 0.18 ± 0.18*# 
12 35.65 ± 4.92 22.05 ± 5.12* 1.69 ± 1.45*# 
24 29.07 ± 3.07 24.05 ± 5.77 3.18 ± 2.58*# 
32 19.94 ± 4.67 14.29 ± 5.26 4.71 ± 2.59*# 
48 8.67 ± 2.86 7.43 ± 4.01 2.10 ± 1.34 
72 7.61 ± 4.21 1.60 ± 1.15 1.17 ± 0.48 
96 7.72 ± 4.34 1.63 ± 0.93 1.69 ± 0.85 
120 8.93 ± 4.79 1.56 ± 0.91 2.61 ± 0.98 
All values are mean ± SE expressed in nglml in 8 sheep. NID means undetectable (below the 
limit of quantification of 0.8 nglml). Flunixin meglumine at 1.1 mglkg , PBZ at 4.4 mglkg or 
PLB (0.9% saline) at the same volume as the drugs were given Lv. to the sheep at a single dose 
rate. (*) P<0.05 compared with the PLB-treated group and (#) P<0.05 compared with the PBZ-
treated group. 
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Table 3.13. The effect of PBZ and FM on LTB4 generation in carrageenan-induced inflamed 
exudate in sheep. 
Time (h) PLB-treated group PBZ-treated group FM-treated group 
Pre NA NA NA 
2 1.02 ± 0.30 1.10 ± 0.30 1.10 ± 0.22 
4 1.32 ± 0.31 1.20 ± 0.29 1.39 ± 0.26 
8 1.33 ± 0.36 1.22 ± 0.25 1.60 ± 0.28 
12 1.63 ± 0.31 1.43 ± 0.28 1.55 ± 0.25 
24 1.08 ± 0.25 1.21 ± 0.32 1.48 ± 0.32* 
32 1.18 ± 0.26 1.40 ± 0.35 1.38 ± 0.26 
48 1.13 ± 0.24 1.46 ± 0.37* 1.45 ± 0.38* 
72 1.47 ± 0.41 1.71 ± 0.52 1.26 ± 0.26 # 
96 1.48 ± 0.40 1.61 ± 0.42 1.51 ± 0.30 
120 1.24 ± 0.32 l.46 ± 0.37 l.55 ± 0.31 
144 0.76 ± 0.19 1.23 ± 0.28 0.65 ± 0.09 
All values are mean ± SE expressed in nglml in 8 sheep. Flunixin meglumine at 1.1 mglkg , PBZ 
at 4.4 mglkg or PLB (0.9% saline) at the same volume as the drugs were given Lv. to the sheep 
as a single dose rate.(*) P<0.05 compared with the PLB-treated group and (#) P<0.05 compared 
with the PBZ-treated group. 
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Fig 3.5. Effects of PBZ and FM on serum TXBr All values (nglml) are mean ± SE 
in 8 sheep. (-o-) PLB i.v. (-e-) PBZ i.v. at 4.4 mglkg and (-.-) FM i.v. at 
1.1 mglkg. (a) P<O.05, compared with placebo-treated group, (b) P<O.05, compared 
with PBZ-treated group and (c) P<O.05, compared with the group pre-treatment. 
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3.5. Discussion 
3.5.1 Phannacokinetics 
In the present study, the slow elimination of PBZ has been reported previously in ruminant 
species. Lees et al. (1988) administered PBZ i.v. to cattle at 4.4 mglkg and obtained a t1 ~ of35.9 
2 
h, Debacker et al. (1980) using 5 mglkg in cattle obtained a higher value for t 1 ~ of 55.1 h 
2 
whereas Eberhardson et al. (1979) reported the t1 ~ values as 43.3 and 42.4 h at dose rates of 3 
2 
and 6 mg/kg, respectively. However in the present study, PK values were more like those 
obtained in goats (Chapter 7). In the goat study, PBZ (4.4 mg/kg Lv.) had a t1 ~ of 15.43 h, an 
2 
AUCo-oo of 1228.84Ilg.himl, a CIs of 4.46 mllkglh and a Vss of 87.99 mllkg. 
The plasma disposition ofFM following i.v. administration at a single dose rate of 1.1 mglkg in 
sheep was best described by a two-compartment model in most of the animals. In fact all of the 
animal data could be fitted well to a two-compartment model if r was the criterion for the 
MAlCE test since the R2 values were higher than 0.99 for all animal data fitted. This differs from 
the previous kinetic study ofFM in sheep in our laboratory, where the decline in plasma was best 
fitted to a three compartment model (Welsh et al., 1993). This may be attributable to the 
differences of modelling methods. In the previous study, CSTRIP (Sedman & Wagner, 1976) 
was used for the calculation of estimates. This software program is only useful for curve 
stripping and the AlC was achieved using the equation derived from curve stripping. In the 
present study we used PCNONLIN for the kinetic analyses with a weighting factor 
(1/concentrations) applied to the non-linear estimation. The AlC was calculated from the non-
linear regression results. Since the concentration-time curve is non-linear, the model decision and 
parameter estimation by non-linear methods may be more reliable. 
The plasma drug disposition of FM was previously investigated in cattle following Lv. 
administration and different t1 ~ values were reported by Landoni et al.(199Sa), 6.87 h (2.0 
2 
mglkg); Hardee et al.(1985), 8.1 h (1.1 mglkg) and Anderson et al. (1990), 3.l4 h (1.1 mglkg). In 
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the present study the t 1 ~ of 2.48 h (1.1 mglkg) is shorter than the values [3.81 h (1.0 mglkg)] in 
2 
sheep reported previously in our laboratory (Welsh et al., 1993). However the values of Cis and 
Vss between these two studies are almost identical. It is likely that t1 ~ is a model and algorithm-
2 
dependent parameter and that different models or algorithms may generate different values of p. 
Body clearance and Vss are model independent parameters which are calculated from dose, AUC 
andMRT. 
Distribution into and elimination ofFM from tissue-cage exudate and transudate were very slow. 
The Cmax in exudate was higher and occurred earlier than in transudate but the elimination from 
transudate was slower than from exudate. A larger AUC in transudate than in exudate did not 
reflect greater distribution into the transudate. The concentration-time data indicated that before 
peak concentration was achieved, exudate FM concentration was higher than transudate FM 
concentrations at all sampling times. After 1max the relative concentrations were reversed. Since a 
major part of AUC consists of the AUC in the elimination phase, when a comparison of 
absorption or penetration rate is made, it should be corrected for the elimination rate. Correction 
using t1 ~ was described previously (Gibaldi & Perrier, 1982b). However, the number of 
2 
sampling points for the present drugs in the distribution phase in tissue-cage fluids was 
insufficient to carry out compartmental modelling while non-compartmental modelling was 
carried out. Based on statistical moment theory, the MRT indicates the arithmetic average time 
that each drug molecule remains in the system. Mean residence time is a more reasonable 
parameter for AUC correction in tissue fluids following non-compartmental modelling than t 1 ~. 
2 
When the AUC ratios are corrected for MRT, they become slightly higher for exudate to plasma 
than transudate to plasma. Since the corrected AUe ratios are smaller than the uncorrected, this 
illustrates that most of the AUe in tissue-cage fluids is composed of the area in the elimination 
phase. Thus slow elimination plays an important role in drug persistence in the tissue-cage fluids. 
The distribution for PBZ into exudate and transudate was smaller than for FM. However after the 
AUe ratios were corrected using the MRT, the ratios were double those of FM. This suggests 
that the differences in drug elimination rates of PBZ between plasma and tissue-cage fluids were 
smaller than those of FM. The compartmental modelling also illustrated that the values of-
elimination half lives of FM in exudate and transudate were much slower than in plasma while 
similar values were obtained for PBZ in plasma, exudate and transudate. 
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It was unexpected that the elimination rate from transudate was slower (FM) than or similar 
(PBZ) to the elimination from exudate and that no significant differences in AVe ratios between 
exudate to plasma and transudate to plasma were observed in the present study since in common 
with most of NSAIDs, FM and PBZ have been demonstrated to have slow exudate drug 
elimination rates and high AVe ratios of exudate to plasma compared with transudate in some 
animal species, at least in horses (Lees et al., 1986, 1987c) and calves (Landoni et al., 1995a). 
This suggests a species difference between horses and calves on one hand and sheep on other 
hand. However similar 'unexpected' results have been observed with tolfenamic acid in dogs 
using a similar model (McKellar et al., 1994b). 
In the present study, both compartmental and non-compartmental modelling were carried out for 
the analysis of the drug concentration - time data in plasma, exudate and transudate. In the PK 
analysis for PBZ, compartmental and non-compartmental modelling generated similar 
parameters for plasma kinetics. However the PK parameters of PBZ in tissue-cage fluids were 
not consistent between the results analysed using these two methods. For example, the MRT of 
PBZ in exudate (31.60 ± 1.84 h) and transudate (31.11 ± 2.41 h) using non-compartmental 
modelling were longer than the elimination half lives analysed by compartmental modelling 
(11 was 17.82 ± 1.27 h in exudate and 16.24 ± 1.60 h in transudate). Elimination ofPBZ was 
i kiO 
slow in plasma and tissue-cage fluids. The plasma data were best described by a three 
compartmental model with rapid bolus i.v. input. However there were insufficient concentration-
time points for PBZ in tissue cage fluids to be fitted to a two compartmental model with first 
order input. Therefore the elimination rates may be underestimated. In this case, the parameters 
derived using non-compartmental modelling may be more reliable for the comparisons since as 
discussed previously, non-compartmental modelling generates model-independent parameters. 
In the FM-treated group, the results achieved using both approaches were consistent in plasma, 
exudate and transudate. For example, the MRT of FM in exudate estimated by non-
compartmental modelling was 12.98 h and the t! klO calculated by compartment modelling was 
1 
8.53 h. This agrees with the relationship t! P = 0.693 x MRT (in this case t! P = 0.693 x 12.98 = 
1 1 
8.99 h). 
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The extravascular penetration of the drugs in sheep in the present study was extensive as 
indicated by the high Cmax in exudate and transudate of 22.32 and 22.07 ~g1ml for PBZ, and 
1.82 and 1.58 ~g1ml for FM, respectively. Following administration ofPBZ (4.4 mglkg, i.v.) to 
horses, a Cmax of 12.4 and 6.3 ~g1ml in exudate and transudate, respectively was observed (Lees 
et al., 1986). When FM (1.1 mglkg) was given i.v. to horses, the exudate Cmax was about 0.9 
~g1ml (Lees et al., 1987c) and in calves FM (2.2 mglkg) produced a Cmax of 1.67 ~g1ml in 
exudate and 0.59 ~g1ml in transudate although the elimination (t 1 ~=6.87 h) in plasma was 
2 
slower than the present study (Landoni et al., 1995a). The high extravascular penetration of the 
drugs in sheep suggests a lower plasma protein drug binding in this species since the unbound 
drug in the plasma is available to penetrate into both inflamed and non-inflamed tissue-cage 
fluids while the protein-bound drug can only easily penetrate into the fluids at inflamed sites 
where the inflammatory reaction results in vasodilatation and high capillary permeability. 
Previous studies have shown that the percentage protein binding for PBZ was over 97% in the 
horse (Tobin et al., 1986) but only 60.3% in goats (Boulos et al., 1972). This may explain why 
there were no significant differences in the drug distribution between exudate and transudate in 
the present study although further information on protein binding of these drugs in sheep is 
required. Flunixin has been licensed for use in cows at a dose rate of 2.2 mglkg in the UK. The 
present study indicated that half the dose rate in sheep resulted in higher values for AUC and 
Cmax in plasma, exudate and transudate than previously reported in cattle (Landoni et al., 1995a). 
In addition, exudate PGE2 and skin temperature rise over the inflamed tissue-cages were 
abolished or significantly inhibited for up to 32 h following i. v. administration of FM at 1.1 
mglkg in sheep. This, therefore, suggests that a dose rate of 1.1 mglkg (or 1.0 mglkg) may be 
sufficient in sheep but this must be supported by toxicity data. 
The high distribution into and slow elimination from the tissue-cage fluids is of therapeutic 
interest since it indicates that these drugs reach extravascular sites (including inflammatory foci) 
readily and stay there longer than they do in plasma. This supports the explanation for the long 
therapeutic action ofNSAIDs described previously in the horses (Lees et al., 1987c). 
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3.5.2. Phannacodynamics 
Phenylbutazone produced significant inhibitory effects on COX in equine species (Lees & 
Higgins, 1986; Lees et al., 1987c; Chapter 6) but its inhibitory effects on COX in sheep in the 
present study were poor. Similar results have been observed for PBZ in calves (peter Lees, et al., 
unpublished observations). Species differences in COX inhibition have also been observed for 
other NSAIDs. Carprofen did not affect serum TXB2 or exudate PGE2 generation in dogs 
(McKellar et aI., 1994a) and horses (Lees et al., 1994) whereas it significantly inhibited those 
COX products in sheep (Chapter 4). It is unlikely that different distribution of the drug in plasma 
or in the inflamed tissue cage sites is responsible for these differences because both PBZ and 
CPF achieved considerably higher concentrations in plasma and exudate in the animal species 
where the PD effects were less. It is possible that the phannacological and pathophysiological 
regulation of COX or the properties of the isoenzymes in mono gastric animals differs from that 
in ruminants. It is apparent that when the antiinflammatory effects ofNSAIDs are determined in 
animal experiments based on COX inhibition, species differences must be taken into account. 
Flunixin meglumine was a potent inhibitor of serum TXB2 generation in clotting blood and 
exudate PGE2 generation in stimulated tissue cages in the present study. It abolished or 
significantly inhibited both serum TXB2 and exudate PGE2 generation for up to 32 h. The 
inhibitory effect of FM given by i.v. injection on COX was much stronger than that of PBZ 
although the concentrations of FM in plasma and exudate were much lower than those of PBZ 
over all sampling times. Previous reports showed that FM effectively inhibited serum TXB2 and 
exudate PGE2 in horses (Lees & Higgins, 1984; Lees et al., 1987a) and calves (Landoni et al., 
1995a). 
As described in Chapter 1, there are two isoforms of COX which play different roles III 
physiological and pathological processes. The regulation of these two isoenzymes IS 
phannacologically distinct (Herschman, 1994; Smith et al., 1994; Johnson et al., 1995). 
Inhibition of COX-2 is thought to modulate, at least in part, the antipyretic, analgesic and 
antiinflammatory action of NSAIDs, but the simultaneous inhibition of COX -1 is thought to 
result in unwanted side effects, particularly those leading to gastric ulceration. The present study 
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illustrated that the sensitivities of inhibition by PBZ and FM were different in carrageenan-
induced tissue COX and PL T COX generated during blood coagulation. The ICso for serum 
TXB2 for FM was estimated to be 0.0053 J.1g1ml occurred 28.96 ±1.86 h after FM administration. 
Flunixin meglumine produced 50% inhibition for PGE2 at 144 h when the concentration of FM 
was estimated to be 0.00019 ± 0.00012 J.1g1ml in exudate and even lower in plasma. Greater 
ability against exudate COX than PL T COX may be advantageous since it may confer greater 
therapeutic effect with a wide safety margin. Phenylbutazone had an ICso of 10.86 ± 1.81 J.1g1ml 
against serum TXB2. It did not produce more than 50 % inhibition on exudate PGE2 generation 
at a maximal exudate concentration of 22.32 ± 1.29 J.1g1ml. A low sensitivity to COX-2 may 
confer poorer antiinflammatory activity on a NSAID although COX inhibition does not always 
correlate with PD effect (Lees et al., 1994; McKellar et al., 1994a). This finding confirms 
previous data which established the ICso ofPBZ against COX-1 and COX-2 using human COX-
I and COX cDNA expressed in cultured cells and where the ICso for PBZ was 4.93 J.1g1ml (16.0 
J.1M) against COX-l and over 30.84 J.1g1ml (100 J.1M) against COX-2 (Laneuville et al., 1994). 
The high degree of protein binding for nearly all of the NSAIDs implies that only a small 
fraction of the total drug concentration will be available for inhibition of COX and consequently 
the true ICso may be much lower. If the protein binding is different in plasma, exudate and cell 
culture medium, the true ICso value should be adjusted accordingly. A previous study 
demonstrated that there was no significant difference in total protein between plasma and 
exudate using the same model as that used in present study but in horses (Lees et a/., 1986). 
However, although differences in protein binding and COX-l inhibition have been demonstrated 
between species, protein binding did not account for all the differences in COX-l inhibition 
(Galbraith & McKellar, 1996). 
The suppressant effects of FM on skin temperature rise over the inflammatory focus was 
significant while PBZ did not inhibit the temperature increase in the present study. Previous 
studies in our laboratory using a dog tissue-cage model showed that tolfenamic acid, a NSAID 
with potent antiinflammatory effects, inhibited exudate PGE2 and skin temperature 
simultaneously whereas CPF, another NSAID with no or weak antiinflammatory effects, failed 
to affect both exudate PGE2 generation and elevated skin temperature at a dose rate of 4.0 mglkg 
(McKellar et a/., 1994a, 1994b). It is believed that PGs in exudate mediate an increased blood 
flow and vasodilatation at acute inflammatory sites and contribute to the temperature increase 
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associated with inflammation. It is likely that the increased skin temperature over the inflamed 
cages is a PG-associated symptom in the present model. 
Leukotriene B4 was not inhibited by PBZ or FM, indicating that they do not inhibit 5-LOX in 
vivo. This is not unexpected since PBZ and FM did not inhibit LTB4 or 12-HETE generation in 
previous studies (Landoni et ai., 1995a). In the present study, LTB4 increased slightly throughout 
and significantly at 24 and 48 h following PBZ and FM administration compared with the PLB-
administered group. It has been suggested that inhibition of the COX pathway may lead to higher 
concentrations of LOX derived products by accumulation of substrates and a consequent shift of 
metabolism (Higgs et ai., 1980; Kitchen et al., 1987; Sedgwick et al., 1987). 
Both PBZ and FM attenuated the accumulation of WBC in the inflamed sites and a significant 
decrease in exudate WBC was achieved 12 h after FM treatment (P<0.05). This is consistent with 
the antiinflammatory and antipyretic results in the present study. Previous studies have shown 
that PBZ and FM did not modify exudate WBC concentration in horses (Lees et al., 1987c). The 
differences may be due to the effective drug concentrations achieved in the inflamed sites since 
studies in rats showed that a number of NSAIDs, including PBZ, caused a dose-dependent effect 
on carrageenan-induced exudate WBC numbers, at high doses NSAIDs (EOso = 52.0 mg/kg) 
inhibited oedema and WBC accumulation, however at lower doses (0.05 mglkg) they 
significantly potentiated WBC migration by 20-70% (Higgs et al., 1980). Although the study in 
horses (Lees et al., 1987c) and the present study used the same dose rates ofPBZ and FM, the 
Cmax of both drugs in exudate in the present study were twice as high as reported in horse. This 
also suggests that the PKs and POs ofNSAIDs differ in animal species so that the data can not be 
extrapolated from one animal species to another. It is known that L TB4 is a chemokinetic and 
chemotactic agent for leukocytes (Ford-Hutchinson et al., 1980). However the present study 
showed exudate LTB4 concentrations increased but exudate WBC number decreased in PBZ-
treated and FM -treated groups compared with PLB-treated groups. It is possible that the 
inhibition of vascular permeability or other WBC recruitment factors by the NSAIDs may lead to 
decreased infiltration and accumulation of leukocytes despite higher L TB4 concentrations. 
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3.6. Conclusion 
Phenylbutazone and FM produce their antiinflammatory effects by inhibiting COX and thus 
blocking the fonnation of COX derived eicosanoids. The inhibitory effects of PBZ and FM were 
distinct between inducible COX and PL T COX. Flunixin meglumine but not PBZ was a potent 
COX inhibitor and antiinflammatory drug in sheep in vivo. Flunixin meglumine but not PBZ has 
attractive PK characteristics for clinical use in sheep. Flunixin meglumine readily penetrates into 
and is slowly eliminated from the inflammatory site so that a dose rate of 1.1 mglkg i.v. may 
achieve sufficient drug concentration in plasma and at inflammatory sites to generate therapeutic 
effects. Tolerance studies are still required before final recommendation on dosage rate can be 
made. 
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Chapter 4 
Pharmacological effects of carprofen and its enantiomers in sheep 
4.1. Introduction 
Carprofen (6-chloro-o-methylcarbazole-2-acetic acid) (Fig 4.1) is a NSAID classified as an aryl-
propionic acid. It has been licensed for clinical use in horses (0.7 mglkg) and dogs (2.0-4.0 
mglkg) with indications for inflammation and pain. In animal models of carrageenan-oedema, 
granuloma-pouch, U.V.-induced erythema and bradykinin and histamine-induced capillary 
permeability, CPF was shown to possess a greater antiinflammatory potency than PBZ, 
mefenamic acid and acetyl-salicylic acid (Maeda et al., 1977). It has been demonstrated to 
decrease significantly the carrageenan-induced oedema in horses (Lees et al., 1994). Studies in 
cows with endotoxin-induced mastitis showed that rac-CPF treatment (0.7 mglkg) significantly 
reduced heart rate and rectal temperature and quarter swelling (Lohuis et al., 1991). It has been 
demonstrated that CPF was a effective analgesic in dogs (Nolan & Reid, 1993) and sheep (Welsh 
& Nolan, 1994b, 1995). 
The mode of action of CPF is unknown. It has been classified as a weak inhibitor of COX (Strub 
et al., 1982; Frey, 1992). A previous report that CPF did not substantially modify LT generation 
in rats indicated that it was not an inhibitor for LOX (Baruth et al., 1985). Previous studies using 
a subcutaneous tissue cage model of acute inflammation in dogs (McKellar et aI., 1994a) and 
calves (Lees et al., 1996) showed that CPF did not inhibit exudate PGE2, serum TXB2 or 12-
HETE and this indicates that CPF is inactive against COX isoenzymes (COX-l and COX-2) and 
12-LOX. However, CPF produced moderate suppression of serum TXB2 and exudate PGE2 
synthesis in horses (Lees et al., 1994) and is a weak inhibitor ofPLA2 (Hope & Welton, 1983). 
This also indicates a PO difference for CPF between animal species 
Carprofen is a chiral compound containing an asymmetrical carbon. There are two enantiomeric 
forms, the S( +) and R( -) enantiomers. The body is a chiral environment and stereoselectivity 
exists in a wide range of physiological processes. Therefore each enantiomer may have distinct 
89 
pharmacological properties. The CPF preparations currently available for clinical use are racemic 
mixtures (50:50). Racemic products may be considered as combinations of active drug plus 
isomeric ballast when one enantiomer has little or no therapeutic effect (Ariens, 1986). It has 
been shown that like other 2 aryl-propionates, the S(+)CPF enantiomer is consistently more 
active in anti inflammation but also more toxic than the R( -) isomer in the rats (Gaut et. al., 
1975). Previous reports in horses (Graser et aI., 1991; Lees et al., 1991a), dogs (McKellar et al., 
1994a) and calves (Lees et. al., 1996) showed that R(-)CPF was the predominant enantiomer in 
plasma, exudate and transudate following administration of rac-CPF. 
The purposes of the present study were to investigate the effects of rac-CPF and its enantiomers 
on COX and 5-LOX derived eicosanoids, inflammatory cells and cutaneous inflammatory heat 
following i.v. administration of separate rac-CPF, R(-)CPF and S(+)CPF in sheep using a 
subcutaneous tissue-cage model of inflammation. 
4.2. Materials and methods 
4.2.1. Animals 
Eight male sheep weighing 63 ± 3 kg and aged approximately 1.5 years old at the beginning of 
first cross-over were used. Hay and water were provided ad libitum. 
4.2.2. Preparation of injectable solution ofR(-) and S(+) CPF 
Racemic CPF injectable solution was supplied by Grampian Pharmaceutical Company at a 
concentration of 50 mg/ml (W N). The R(-) or S( +) enantiomer was dissolved in excipient 
solution provided by Grampian Pharmaceutical Company, which contained the same ingredients 
as the rac-CPF solution but without rac-CPF. The concentration for each enantiomer was 25 
mg/ml(WN). 
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4.2.2. Experimental protocol 
The experiments were carried out on a subcutaneous tissue-cage acute inflammatory model as 
described in Chapter 2. The cross-over experiment was coded as QMlZC/03/95 and was started 
two months after the experiment coded QMlZC/11194 (Reported in Chapter 3) using the same 
tissue-cages and animals. 
The study was carried out in a 5 way cross-over Latin square design. An intracaveal injection of 
carrageenan was given 15 min before administration of the test substances. Each sheep received 
i.v. administration of rac-CPF (4.0 mg!kg) , R(-)CPF (2.0 mg!kg) , S(+)CPF (2.0 mg!kg) , L-
NAME (25 mg!kg) and rac-CPF excipient as PLB. Test substances were administered in a single 
rapid bolus, via the right jugular vein according to the cross-over design (The results of L-
NAME treatments were reported in Chapter 4). A four-week washout period was allowed 
between each occasion of the cross-over. (Table. 4.1.) 
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Table 4.1. Cross-over design for i.v. administration of drugs and PLB in 8 sheep 
Cross-over occasion 
Sheep No 1 2 3 4 5 
143 A B C D E 
144 B D E C A 
145 C E A D B 
146 D A B E C 
147 E B C A D 
148 A C D B E 
149 B D E C A 
150 C E A D B 
All drugs and PLB were administered Lv .. A, rac-CPF (4.0 mglkg); B, R(-)CPF (2.0 mglkg); C, 
S(+)CPF (2.0 mglkg); D, L-NAME (25 mglkg) and E, PLB. 
The sampling schedule and processing methods were described in Chapter 2. The plasma 
samples were collected at 20 min prior drug administration (-20 min) and at 5, 15,30,45,60 min 
and 2, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120 and 144 h following drug administration. Serum 
samples for determination of TXB2 were taken at -20 min, 1, 2, 4, 6, 8, 12, 24, 32, 48, 72, 96, 
120 and 144 h. Exudate and transudate samples were harvested at -20 min (transudate only), 2, 4, 
8, 12,24,32,48, 72,96, 120 and 144 h. The values for TXB2, PGE2. LTB4, haematoiogy and the 
temperature record were determined using the methods as described in Chapter 2. 
4.2.3. Pharmacodynamic modelling 
The data for drug effect on serum TXB2 versus time were fitted to a Sigmoidal inhibitory effect 
model using PCNONLIN 4.0 software as described in Chapter 2. 
4.2.4. Statistics 
The results were expressed as mean ± SE. A five factor ANOVA [treatments of rac-CPF, 
R(-)CPF, S(+)CPF, L-NAME and PLB] with multiple ways (treatments, sheep, time, periods and 
sequences) was carried out using GLM routine built in the MINITAB Software package as 
described in Chapter 2. The effects of ambient temperature and pre-treatment values on the 
experimental parameters were estimated using an analysis of co-variance routine built in the 
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GLM model as described in Chapter 2. The differences of the measurements collected at each 
time point between treatment groups, and between pre-treatment and post-treatment were further 
confirmed using Fisher's multiple comparisons following ANOVA. The differences between 
individual animal, time points, cross-over sequences and cross-over periods and their two factor 
interactions were analysed using ANOVA but without carrying out Fisher's multiple 
compansons. 
4.3. Results 
4.3.1. Effects of rac-CPF, R( -)CPF and S( + )CPF on skin temperature over inflammatory sites 
The changes (mean ± SE) in skin temperature between carrageenan-induced and non-treatment 
tissue-cages in the sheep given PLB, rac-CPF, R(-)CPF or S(+)CPF i.v. are presented in Table 
4.2. 
Following intracaveal injection of 1 % carrageenan, the skin temperature over the cages 
increased in a time-related fashion with the development of acute inflammation within the cages. 
In the PLB-treated group, the mean temperature increase was 0.43 ± 0.09 °C over a 144 h period 
and a maximal increase of 1.33 ± 0.49 °C was recorded at 12 h. Most of values recorded at each 
time point were higher than the values recorded 20 min before carrageenan injection (pre-value), 
however statistical significance (P<0.05) was achieved only at 12 h compared with the pre-value 
due to the large SE (pooled SD = 0.84). Compared with the pre-values, there was a significant 
increase (P<0.05) at 12 h in the R(-)CPF-administered group while no significant difference was 
observed at any time point in the rac-CPF- or S(+)CPF-treated groups (P>0.05). These results 
indicate an inhibitory effect of rac-CPF and S(+)CPF on inflammatory temperature while R(-
)CPF did not modify changes in the temperature. 
The analysis illustrated that the changes in skin temperature over the cages were time-related 
(P<O.OI). The differences in basal skin temperature over the cages before carrageenan injection 
(pre-values) had a significant influence on the changes in the temperature following the 
administration of carrageenan and drugs (P = 0.01). The r between the pre-values and post 
carrageenan administration values was 0.13 ± 0.01 (P = 0.01), which indicated that the larger the 
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pre-values were, the larger the change in the post-values. There was no differences between the 
sequences of drug administration over the whole cross-over experiment. The changes in 
temperature were significantly different between the cross-over periods (P<O.Ol) but the ambient 
temperature did not affect the changes in skin temperature over the cages (r=-0.01 ± 0.01, 
P=0.76). 
4.3.2. Effects ofrac-CPF, R(-)CPF and S(+)CPF on serum TXB2 generation 
Mean ± SE serum TXB2 concentrations following i.v. administrations of PLB, rac-CPF, R(-) 
CPF and S(+)CPF in the sheep are shown in Table 4.3. and the percentage inhibition data are 
illustrated in Fig 4.2. 
There were significant differences between the overall means of the four treatment groups 
(P<O.OOl). The treatment x time interactions were significantly different (P<O.OOl), indicating 
that the measurements at each time point differed significantly between the treatment groups. 
Fisher's multiple comparisons were carried out to confirm the further differences as presented in 
Table 4.3. Compared with pre-values, PLB treatment did not alter serum TXB2 concentration at 
any time point (P>O.05), rac-CPF and S(+)CPF treatment decreased serum TXB2 concentrations 
significantly for up to 32 h (P<O.05) whereas R( -)CPF inhibited serum TXB2 generation only at 6 
and 8 h (P<0.05). 
Inter-group comparisons showed that there was no significant difference of TXB2 generation in 
pre-values between treatment groups (P>O.05). Following treatment, the concentrations of 
TXB2 in rac-CPF and S( + )CPF were significantly lower than the values in the R( -)CPF and PLB 
treated group for up to 32 h (p<O.05), rac-CPF administration produced higher inhibitory effects 
than S(+)CPF treatment for up to 6 h (P<O.05), and there were no significant differences in 
serum TXB2 concentrations between the R( -)CPF and PLB treated groups for up to 32 h 
(P>O.05) but thereafter TXB2 concentrations in the R( -)CPF administered group were higher than 
in PLB-administered group (p<O.05). 
Using PD modelling, the data for percentage TXB2 inhibition against time was fitted to a 
sigmoidal inhibitory effect model with a Hill constant and the results are given in Table 4.4. 
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Racemic CPF administration produced an Ernax of 78.84 ± 3.19 % and an 1Tso of 19.00 ± 3.20 h. 
The treatment ofS(+)CPF generated an Ernax of68.10 ± 6.15% and an ITso of 24.40 ± 4.89 h. The 
accumulative inhibitory effect, indicated by the area under percentage inhibition-time curve in a 
period of 1-72 h, was 1663.50 ± 135.98 for rac-CPF and 1733.70 ± 334.93 for S(+)CPF and this 
indicates a similar inhibitory potency of these drug on serum TXB2 generation (P>0.05). There 
were no significant differences for any parameters between these two treatment group (P>0.05). 
The analysis also illustrated that the differences in serum TXB2 inhibition were significant in 
treatment sequence and cross-over period (P<O.OOl). Analysis of co-variance demonstrated that 
the basal serum TXB2 generation during blood clotting (pre-treatment values) had a significant 
effect on TXB2 inhibition (P<0.01) and a coefficient of -0.33 ± 0.01 (P<O.Ol) indicated that the 
higher the pre-values were, the lower inhibitory effect the drug produced. 
4.3.3. Effects ofrac-CPF, R(-)CPF and S(+)CPF on exudate PGE2 generation 
Table 4.5. and Fig. 4.3. demonstrate the changes in PGE2 generation in carrageenan-induced 
inflammatory exudate following i.v. administrations ofPLB, rac-CPF, R(-)CPF and S(+)CPF. 
Before carrageenan injection into the cages the tissue-cage fluid was transudate in which PGE2 
was undetectable (below the analytic limit of quantification). Intracaveal injection of 1 % 
carrageenan induced the generation of a large quantity of PGE2 in the inflammatory exudate in a 
time-related fashion. The increase in exudate PGE2 generation was significant from 4 to 32 h 
(P<0.05) and a peak concentration of 86.24 ± 11.75 ng/ml was achieved at 12 h which was 4 h 
after the second injection of carrageenan into the cages. 
The differences of exudate PGE2 concentrations between the overall means ofPLB (35.35 ± 4.64 
ng/ml), rac-CPF (8.32 ± 2.28 ng/ml), R(-)CPF (36.87 ± 4.67 ng/ml) and S(+)CPF (11.78 ± 2.88 
ng/ml) treatments were significant (P<O.OOl). Fisher's comparisons showed that the values in the 
rac-CPF and S(+)CPF treated groups were significantly different from those in the PLB and R(-
)CPF treated groups (P<O.OOl) and there were no significant differences between rac-CPF and 
S(+)CPF groups or between PLB and R(-)CPF groups (P>0.05). 
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The measurements at each time point between the PLB, rac-CPF, R(-)CPF and S(+)CPF treated 
groups (treatment x time interactions) were significantly different (P<O.OOl). When the post-
values were compared with the pre-values, significant increase (P<0.05) in PGE2 concentrations 
was observed from 2 to 32 h in the PLB-treated and R(-) CPF-treated groups, only at 12 h in the 
rac-CPF-treated group, and at 12 and 24 h in the S(+)CPF-treated group. 
Inter-group comparisons showed that the values at 2 h were not significantly different between 
all treatment groups (P>0.05), exudate PGE2 concentrations were not significantly different 
(P>0.05) between the rac-CPF-treated and S(+)CPF treated groups or between the PLB treated 
and R(-)CPF treated groups at any time point over a period of 144 h. The concentrations of 
exudate PGE2 in the rac-CPF treated and S( + )CPF treated groups were significantly lower than 
the values in the PLB treated and R(-)CPF treated group from 4 to 32 h (P<0.05). 
Analysis of variance showed that the response of exudate PGE2 production to carrageenan 
induction was significantly different between individual sheep (P<O.OOl) and this exerted a 
significant effect on exudate COX inhibition produced by the drug treatments (r = -0.41 ± 0.01, 
P<O.OOl). Again this indicates a competitive inhibitory dynamics. 
The analysis also showed that there were significant differences (P<O.OOl) in exudate PGE2 
generation in treatment sequences, experimental periods and time x sheep interactions. This 
indicates that a number of factors influenced the experiment. 
4.3.4. Effects ofrac-CPF, R(-)CPF and S(+)CPF on exudate LTB4 generation 
Mean ± SE concentrations ofLTB4 in carrageenan-induced inflammatory exudate following i.v. 
administrations ofPLB, rac-CPF, R(-)CPF and S(+)CPF are presented in Table 4.6. 
Leukotriene B4 was undetectable (below the analytical limit of quantification) in the transudate 
before injection of carrageenan into the cages. Following intracaveal injection of carrageenan, 
exudate was generated and L TB4 production increased steadily in a time-related fashion with a 
peak concentration of 1.83 ± 0.44 nglml at 12 h. 
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Analysis of variance showed that there were significant differences (P<O.OOI) in the overall 
mean concentrations of exudate LTB4 between the PLB (1.07 ± 0.07 nglml), rac-CPF (1.20 ± 
0.06), R(-)CPF (1.06 ± 0.08 nglml) and S(+)CPF (1.72 ± 0.18 nglml) groups, however further 
testing using Fisher's multiple comparisons indicated that only the S(+)CPF group significantly 
differed from the other three groups (P<O.OI). Compared with the pre-values, there was a 
significant increase (P<O.OS) in LTB4 concentrations from 4 to 144 h in the rac-CPF, R(-)CPF 
and S(+)CPF groups and from 8 to 120 h in the PLB group. Compared with the PLB group, the 
values in rac-CPF, R( -)CPF and S( + )CPF groups were higher at most of the time points but 
statistical significance was achieved only at 12, 48 and 72 h in the S(+)CPF group. Exudate 
LTB4 concentrations in the S(+)CPF group were also higher than all other groups at 12,48 and 
72 h (P<0.05). The concentrations of exudate L TB4 were not significantly different between the 
PLB, rac-CPF and R( -)CPF groups at any time point (P>O.OS). There were no significant 
differences (P>O.OS) in LTB4 generation with experimental sequences and periods. The response 
of L TB4 generation to carrageenan induction was significantly different between individual 
sheep (P<O.OO 1) but this did not alter the effects of the treatments (r = 0.16, P>O.OS). 
4.3.S. Effects ofrac-CPF, R(-)CPF and S(+)CPF on leukocyte recruitment at inflammatory sites 
The changes in WBC numbers (x 109 cellslL) in carrageenan-induced inflammatory exudate 
following i.v. administrations ofPLB, rac-CPF, R(-)CPF and S(+)CPF are illustrated in Fig 4.4. 
Intracaveal injection of 1 % carrageenan caused a time-related recruitment of WBC in the 
inflammatory exudate. The WBC numbers increased slowly following the first injection of 
carrageenan (S.35 ± 1.02 x 109 cellslL at 4 h and S.49 ± 1.32 x 109 cellslL at 8 h) and steeply 
following the second injection. A plateau was reached in 12-24 h (17.63 ± 3.72-17.03 ± 4.44 x 
109 cells IL) before the rapid drop at 48 h (S.3S ± 0.80 x 109 cellslL). 
There was no significant difference (P>0.05) for WBC accumulation in exudate between the 
overall means of the PLB (10.17 ± 1.48 xl09 cellslL), rac-CPF (11.50 ± 1.92 cellslL), R(-)CPF 
(11.85 ± 1.S8 cellslL) and S(+)CPF (11.69 ± 1.37 cellslL) groups. Compared with the PLB-
treated group for the WBC values at each time point, Lv. administration of rac-CPF, R(-)CPF 
and S( + )CPF led to a slight decrease at 12 h but this was followed an moderate increase at 24 h 
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at which time a significant difference was observed between the rac-CPF and PLB treated group 
(P<0.05). 
The analysis also showed that there were significant differences in exudate WBC numbers in 
experimental sequences and periods (P<0.05). The WBC numbers in carrageenan-induced 
exudate were significantly different between individual animals (P<O.OI) but this did not alter 
the effects of treatments (r=0.014 ± 0.017, P = 0.892). 
4.3.6. Effects ofrac-CPF, R(-)CPF and S(+)CPF on leukocyte and PLT numbers in blood 
Intravenous administrations of rac-CPF, R( -)CPF and S( + )CPF did not modify the numbers of 
leukocytes and PLT significantly in the venous blood at any time point (P>0.05) (Table 4.7, 4.8). 
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Table 4.2. The changes in skin temperature over the cages following i.v. administration ofPLB, 
rac-CPF (4.0 mglkg), R(-)CPF (2.0 mglkg) and S(+)CPF (2.0 mglkg) in sheep 
Time PLB rac-CPF R(-)CPF S(+)CPF 
Pre-values 0.08 ± 0.21 0.03 ± 0.19 -0.12 ± 0.34 0.39 ± 0.32 
1 0.29 ± 0.37 -0.30 ± 0.33 0.09 ± 0.50 -0.12 ± 0.17 
2 0.29 ± 0.27 0.41 ± 0.44 0.65 ± 0.19 0.68 ± 0.26 
4 0.25 ± 0.43 0.55 ± 0.21 0.46 ± 0.46 0.79 ± 0.25 
6 0.72 ± 0.18 0.61 ± 0.36 0.70 ± 0.21 0.59 ± 0.26 
8 0.74 ± 0.18 0.55 ± 0.30 0.58 ± 0.21 0.13 ± 0.31 
12 1.33 ± 0.49* 0.70 ± 0.46 0.86 ± 0.25* 0.85 ± 0.28 
24 0.43 ± 0.26 0.12 ± 0.44 0.01 ± 0.33 0.28 ± 0.33 
32 0.29 ± 0.26 0.54 ± 0.38 0.25 ± 0.28 0.56 ± 0.32 
48 0.16 ± 0.26 0.80 ± 0.26 0.45 ± 0.33 0.55 ± 0.44 
72 0.24 ± 0.30 -0.06 ± 0.41 -0.06 ± 0.24 0.14 ± 0.27 
96 0.05 ± 0.41 0.33 ± 0.26 0.38 ± 0.27 0.49 ± 0.14 
120 0.29 ± 0.29 0.15 ± 0.34 0.43 ± 0.25 -0.08 ± 0.30 
144 0.49 ± 0.31 0.20 ± 0.31 0.70 ± 0.49 0.86 ± 0.20 
The values (OC) are the difference of skin temperature between the cages into which carrageenan 
was injected and the cages into which carrageenan was not injected and expressed in mean ± SE 
in 8 sheep. (*) P<0.05 compared with the measurement prior to carrageenan injection into the 
cages. 
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Table 4.3. Concentrations of serum TXB2 following i.v. administration of PLB, rac-CPF (4.0 
mg/kg), R(-)CPF (2.0 mg/kg) and S(+)CPF (2.0 mg/kg) in sheep. 
Time (h) PLB(P' rac-CPF(t::, R(-)CPF(R' S(+)CPF(S' Group comparisons 
Pre-values 27.13 ± 1.86 29.45 ± 1.96 29.75 ± 2.67 30.61 ± 1.21 (P,C,R,S) 
1 24.99 ± 2.48 5.71 ± 1.16* 27.20 ± 2.53 9.98 ± 3.06* (C)(S)(R,P) 
2 26.36 ± 2.68 7.07 ± 1.21 * 28.72 ± 1.84 11.12 ± 2.43* (C)(S)(R,P) 
4 26.00 ± 2.25 7.83 ± 1.51 * 28.00 ± 3.24 13.21 ± 3.28* (C)(S)(R,P) 
6 25.72 ± 2.19 10.69±3.81* 24.17± 1.92* 14.20 ± 3.49* (C)(S)(R,P) 
8 27.89 ± 2.29 14.50 ± 1.56* 26.30 ± 2.76* 13.64 ± 2.66* (C,S)(R,P) 
12 25.61 ± 2.16 12.57 ± 1.81 * 26.88 ± 3.53 13.89 ± 1.99* (C,S)(R,P) 
24 26.71 ± 2.22 21.45 ± 1.87* 28.85 ± 2.01 20.95 ± 2.76* (C,S)(R,P) 
32 26.36 ± 2.59 23.14 ± 3.46* 29.19 ± 2.29 20.35 ± 3.37* (C,S)(R,P) 
48 24.92 ± 2.59 27.02 ± 1.60 29.12 ± 2.62 28.85 ± 2.22 (C,R,S)(C,P ,S) 
72 27.09 ± 1.66 29.39 ± 1.88 30.93 ± 1.98 29.73 ± 2.07 (C,R,S)(C,P ,S) 
The values (ng/ml) are expressed as mean ± SE in 8 sheep. (*) P<0.05 compared with the 
measurement prior to treatments. Groups in the different brackets are significantly different 
(P<0.05). 
Table 4.4 Pharmacodynamic parameters of TXB2 inhibition following i.v. administrations of 
PLB, rac-CPF (4.0 mg/kg), R(-)CPF (2.0 mg/kg) and S(+)CPF (2.0 mg/kg) in sheep (n=8, mean 
±SE) 
Parameters PLB rac-CPF R(-)CPF S(+)CPF 
Emax (%) 8.71 ± 4.74 78.84 ± 3.19 7.23 ± 6.82 68.10 ± 6.15 
IT 50 (h) N/A 19.00 ± 3.20 N/A 24.40 ± 4.89 
Y N/A 2.49 ± 0.81 N/A 4.77 ± 2.06 
AVCo-last N/A 1663.50 ± 135.98 N/A 1733.70 ± 334.93 
The data of percentage serum TXB2 inhibition against time was fitted to a Sigmoidal inhibitory 
effect model as described in Chapter 2. Emax maximal percentage inhibition. IT 50 = time at which 
the drug produces 50% of Emax. Y = Hill constant. AVC = area under the curve using percentage 
TXB2 inhibition against time plot. NI A = not applicable. 
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Table 4.5. Concentrations of exudate PGE2 following Lv. administration of PLB, rac-CPF (4.0 
mglkg), R(-)CPF (2.0 mglkg) and S(+)CPF (2.0 mglkg) in sheep. 
Time (h) PLB (P) Rac-CPF (C) R(-)CPF (R) S(+)CPF (S) 
Group 
comparisons 
Pre-values un un un un (P,C,R,S) 
2 7.72 ± 6.81 0.34 ± 0.34 2.38 ± 1.39 0.00 ± 0.00 (P,C,R,S) 
4 41.19 ± 13.51 * 6.08 ± 5.89 43.41 ± 13.41 * 15.01 ± 12.00 (C,S)(R,P) 
8 79.78 ± 11.18* 18.01 ± 10.05 86.28 ± 12.31 * 19.58 ± 13.68 (C,S)(R,P) 
12 86.24 ± 11.75* 38.38 ± 14.22* 101.67 ± 7.88* 39.67 ± 14.54* (C,S)(P,R) 
24 62.45 ± 16.07* 11.00 ± 6.10 67.62 ± 13.24* 21.91 ± 9.56* (C,S)(R,P) 
32 38.27 ± 9.78* 8.81 ± 3.93 49.88 ± 15.57* 19.79 ± 7.71 (C,S)(R,P)(S,P) 
48 7.99 ± 3.25 0.66 ± 0.32 20.20 ± 8.57 0.97 ± 0.48 (P,C,S,R) 
72 6.50 ± 3.59 0.00 ± 0.00 7.40 ± 4.81 0.22 ± 0.22 (P,C,S,R) 
96 2.32 ± 1.02 0.00 ± 0.00 9.44 ± 6.73 0.84 ± 0.52 (P,C,S,R) 
120 18.39 ± 18.39 0.35 ± 0.35 0.74 ± 0.45 1.29 ± 0.89 (P,C,S,R) 
144 4.54 ±4.04 0.15 ± 0.15 9.34 ± 7.20 0.35 ± 0.35 (P,C,S,R) 
The values (ng/ml) are expressed in mean ± SE in 8 sheep. (*) P<0.05 compared with the 
measurement prior to treatments. Groups in the different brackets are significantly different 
(P<0.05). un, undetectable. 
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Table 4.6. Concentrations of exudate LTB4 following i.v. administration ofPLB, rac-CPF (4.0 
mg/kg), R(-)CPF (2.0 mg/kg) and S(+)CPF (2.0 mg/kg) in sheep. 
Time (h) PLB rac-CPF R(-)CPF S(+)CPF 
Pre-values UID UID UID UID 
2 0.41 ± 0.09 0.78 ± 0.15 0.52 ± 0.08 0.52 ± 0.12 
4 0.85 ± 0.10 0.89 ± 0.11* 0.84 ± 0.19 1.14 ± 0.19* 
8 1.28 ± 0.19* 1.05 ± 0.05* 1.00 ± 0.23* 1.74 ± 0.31 * 
12 1.83 ± 0.44* 1.88 ± 0.34* 1.35 ± 0.31 * 2.85 ± 0.87*# 
24 1.06 ± 0.15* 1.09 ± 0.18* 0.97 ± 0.18* 1.31 ± 0.17* 
32 1.21 ±0.15* 1.42 ± 0.22* 1.24 ± 0.23* 1.56 ± 0.30* 
48 1.33 ± 0.19* 1.26 ± 0.15* 1.12 ± 0.25* 2.71 ± 1.02*# 
72 1.07 ± 0.24* 1.25 ± 0.11 * 0.89 ± 0.15* 2.70 ± 0.76*# 
96 0.90 ± 0.24* 1.06 ± 0.15* 1.14 ± 0.22* 1.59 ± 0.28* 
120 0.96 ± 0.16* 1.03±0.19* 1.48 ± 0.66* 1.39 ± 0.51 * 
144 0.83 ± 0.09 1.26 ± 0.15* 1.21 ± 0.25* 1.03 ± 0.26* 
The values (ng/ml) are expressed in mean ± SE in 8 sheep. UD, undetectable. (*) P<0.05, 
compared with the measurements prior to carrageenan injection and (#) P<0.05, compared with 
the animals treated with PLB, CPF and R( -)CPF. 
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Table 4.7. Numbers of leukocytes in venous blood following i.v. administration of PLB, rac-
CPF (4.0 mglkg), R(-)CPF (2.0 mglkg) and S(+)CPF (2.0 mglkg) in sheep. 
Time (h) PLB rac-CPF R(-)CPF S(+)CPF 
Pre 7.68 ± 0.69 7.84 ± 0.47 7.24 ± 0.52 7.58 ± 0.67 
4 7.57 ± 0.66 7.33 ± 0.51 7.27 ± 0.73 7.42 ± 0.88 
24 7.68 ± 0.58 7.33 ± 0.48 6.95 ± 0.54 6.61 ± 0.82 
48 6.84 ± 0.59 7.14 ± 0.45 7.25 ± 0.57 6.45 ± 0.48 
The values (x 109 cells/L) are expressed in mean ± SE in 8 sheep. 
Table 4.8. Numbers ofPLT in venous blood following i.v. administration ofPLB, rac-CPF (4.0 
mglkg), R(-)CPF (2.0 mglkg) and S(+)CPF (2.0 mglkg) in sheep. 
Time (h) PLB rac-CPF R(-)CPF S(+)CPF 
Pre-values 179.13 ± 16.77 192.88 ± 18.93 180.38 ± 16.72 197.50 ± 18.97 
4 195.29 ± 18.65 168.57 ± 19.58 161.83 ± 19.81 189.83 ± 13.67 
24 193.75 ± 22.69 188.75 ± 13.68 188.88 ± 22.48 194.00 ± 15.96 
48 201.25 ± 18.87 212.88 ± 16.37 196.63 ± 19.25 208.38 ± 19.51 
The values (xl09 cells/L) are expressed in mean ± SE in 8 sheep. 
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Fig. 4.1. Chemical structure of carprofen 
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Fig. 4.2. Percentage inhibition of serum TXB2 following i.v. administrations of 
CPF (-_-, 4.0 mglkg), R(-)CPF (-.-,2.0 mglkg), S(+)CPF (-6-, 2.0 mglkg) and PLB 
(-0-) in sheep (mean ± SE, n=8). The data points at each time with different numbers of 
asterisks are significantly different (P<0.05). 
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Fig. 4.3. Concentrations versus times plot ofPGE2 following i.v. administration ofPLB 
(-0-), CPF (-e-, 4.0 mglkg), R(-)CPF (-A-, 2.0 mglkg) and S(+)CPF (-_-, 2.0 mglkg) 
in sheep (n=8, mean ± SE). The data points at each time with different numbers 
of asterisks are significantly different (P<0.05). 
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Fig. 4.4. Number (lxl091L) versus time plot of WBC in exudate following i.v. 
adminitrations ofPLB (C:J), CPF (0,4.0 mg/kg), R(-)CPF (!===:l, 2.0 mg/kg) 
and S(+)CPF (2Z2l, 2.0 mglkg) in sheep (N=8, mean ± SE). * P<0.05, compared with 
PLB-treated group. 
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4.4. Discussion 
The present study in sheep showed that i.v. administrations of rac-CPF and S(+)CPF inhibited 
serum TXB2 and exudate PGE2 significantly for up to 32 h and the maximal inhibitory effects on 
the generation of these two COX products were greater than 68 %. In addition, the inhibition of 
PGE2 in exudate was correlated with the inhibition of skin temperature rise over the 
inflammatory foci. This suggests that rac-CPF and S( + )CPF are effective COX inhibitors and 
that they produce their antiinflammatory effects at least in part by inhibition of COX. This differs 
from previous studies in which CPF did not exhibit significant inhibitory effects on carrageenan 
induced exudate PGE2 and serum TXB2 generation in clotting blood in dogs (McKellar et al., 
1994a) and calves (Lees et al., 1996). Furthermore in the horse, although it produced moderate 
suppression of serum TXB2 and exudate PGE2 synthesis, these effects were not related to CPF 
concentrations in plasma or exudate (Lees et ai., 1994). This may reflect a species differences 
between calves, dogs and horses on one hand and sheep on the other hand. It is also possible that 
the differences resulted from the administration routine and dosage rates. The dose rates used in 
the studies in horses and calves were 0.7 mglkg (rac-CPF, i.v.) while the dose rates in the present 
study were 4.0 mglkg for rac-CPF and 2.0 mg/kg for the enantiomers. Although the dose rates 
used in the dogs were 4.0 mglkg for rac-CPF, 2.0 mglkg for R(-)CPF and S(+)CPF, the p.o. 
administration routine achieved relatively low plasma drug concentrations (Cmax was 17.6 J.lg/ml 
for R(-)CPF and 13.6 J.lg/ml for S(+)CPF following p.o. administration ofrac-CPF at 4.0 mg/kg) 
(McKellar et al., 1994a). In the present study, we measured the plasma concentration ofCPFs in 
5 sheep and the concentration at 5 min following rac-CPF given i.v. at 4.0 mglkg was 39.8 Ilglml 
for R(-)CPF and 33.3 J.lg/ml for S(+)CPF (Results not given). However the reported ICso values 
for SSV COX (COX-I) was 13.1 J.lg/ml (48 J.lM) (Baruth et al., 1985) and in the above study in 
dogs, a plasma Cmax for rac-CPF of 31.2 Ilg/ml failed to inhibit serum TXB2 generated by PL T 
COX (COX-I) during blood clotting. These results may also reflect a species difference between 
dogs and sheep. Carprofen and S( + )CPF have been described as relatively weak inhibitors of 
COX in several standard animal models in rats and mice (Baruth et al., 1985). The ICso of rac-
CPF for the COX from SSV was 48 IlM while the ICso for indomethacin was 0.5 IlM. It is also 
about 100 times less potent at inhibiting COX activity in inflammatory cells (in this study, 
human synovial cells and rat peritoneal PMN) than indomethacin (Baruth et al., 1985). 
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Exudate PGE2 is thought to be generated by COX-2 (Masferrer et. ai., 1994) and serum TXB2 
was predominantly generated by COX-l in PLT (Funk et ai., 1991). Racemic CPF and S(+)CPF 
administration effectively inhibited serum TXB2 and exudate PGE2 for up to 32 h. It is likely that 
at 32 h the drug concentrations in exudate may be higher than in plasma since like other acidic 
NSAIDs, rac-CPF and its enantiomers accumulate in inflammatory sites so that the drug 
concentrations in plasma are initially higher and subsequently lower than in exudate (McKellar et 
ai., 1994a; Lees et ai., 1996). This suggests that the effective inhibitory concentrations of rac-
CPF and S(+)CPF for COX-2 would be the same or higher than for COX-l and this also suggests 
that they are non-selective inhibitors for COX isoenzymes. The present study also showed that 
the inhibitory effects of rac-CPF and S( + )CPF on COX were time related and this suggests that 
CPF is a reversible inhibitor for COX. 
In the present study administration of rac-CPF and S(+)CPF caused an increase in LTB4 
generation in exudate. This is not unexpected since arachidonic acid is the substrate for both 
COX and LOX and inhibition of COX may lead to the accumulation of arachidonic acid which is 
available for 5-LOX to catalyse into LTB4. The same results were observed in the sheep 
following administration of FM and PBZ (Chapter 3). The metabolic diversion of arachidonic 
acid has been suggested in previous reports (Higgs et ai., 1980; Kitchen et ai' J 1985). This 
illustrates that rac-CPF and S(+)CPF are not inhibitors of 5-LOX. The inactivity of CPF against 
12-LOX has been also reported in dogs (McKellar et ai., 1994a) and calves (Lees et ai., 1996). 
The increased LTB4 concentration in exudate in the present study may explain the increased 
WBC accumulation in the exudate since LTB4 is a powerful chemokinetic and chemotactic agent 
to WBC (Ford-Hutchinson et ai., 1980). 
Aryl-propionic NSAIDs, including CPF, contain an asymmetric carbon atom and therefore exists 
as two enantiomers. Each enantiomer may have differing pharmacological properties in the chiral 
environment in the body. The enantiomer that has greater biological effect is called the eutomer 
and the enantiomer with lesser biological effect is the distomer. Significant differences in 
potency and biological effects between these enantiomeric pairs have been reported. It was 
believed that the S( + )-isomer is more potent than R( -)-isomer in producing therapeutic and side 
effects. This has, at least, been shown for CPF in rats and mice (Baruth et aI., 1985) and KPF in 
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several experimental animal species and man (Harris & Vavan, 1985) and calves (Landoni et ai., 
1995b). The antiinflammatory differences between the enantiomeric pair of rac-CPF were not 
previously demonstrated in domestic animal species since rac-CPF and its enantiomers did not 
show any significant effects on the tested inflammatory mediators or symptoms (McKellar et ai., 
1994a; Lees et al., 1994; Lees et. al., 1996). 
The present study confirmed that the antiinflammatory effects of the enantiomers of CPF were 
different and that the S( + )CPF was the eutomer and the R( -)CPF the distomer in sheep. Racemic 
CPF contains 50 % of each isomer so that half dose rates of separate isomers are equal to a 
normal dose of rac-CPF for the comparison of enantiomers. Racemic-CPF was shown to have an 
equivalent potency with S( + )CPF in inhibiting inflammatory temperature rise over the cages 
whereas R( -)CPF administration did not affect the temperature. The difference of serum TXB2 
inhibition between rac-CPF and S(+)CPF was very small although significance was achieved for 
up to 6 h (P<0.05). The administration ofR(-)CPF significantly inhibited serum TXB2 generation 
at 6 and 8 h (P<O.05) although the maximal percentage inhibition was only about 8 %. This 
suggests that R( -)CPF contributes inhibitory effects for serum TXB2 generation following the 
administration of rac-CPF. Administration of R(-)CPF not only failed to inhibit exudate PGE2 
generation but also slightly upregulated PGE2 generation in exudate at most of the time points 
although no significant difference was achieved. It is believed that inhibition of COX-2 
modulates the therapeutic action of NSAIDs (the antipyretic, analgesic and antiinflammatory 
effects) and the simultaneous inhibition of COX-l lead to unwanted side effects, particularly 
those causing gastric ulceration and renal papillary necrosis. As mentioned above serum TXB2 
generation is associated with COX-l and exudate PGE2 is produced predominantly by COX-2. It 
is, therefore, likely that following administration of rac-CPF, R( -)CPF does not contribute to the 
therapeutic effects in inflammation but may contribute to some side effects, S( + )CPF is 
conferred with the therapeutic effects and may also predominate in the production of side effects. 
Previous studies showed that CPF was an inhibitor for PLA2 (Hope & Welton, 1983) and was 
more potent than the other NSAIDs as an inhibitor of arachidonic acid release from cellular 
lipids (Georgiadis et ai., 1983). However the present study failed to support these findings. The 
action ofPLA2 is to cause the release of arachidonic acid which can be catalysed into PGs via the 
COX path way or into LTB4 via LOX path way. In the present study administration ofrac-CPF 
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and its active enantiomer, S(+)CPF, lead to an increased LTB4 concentration in exudate. 
Although this was considered to be a result of substrate diversion associated with arachidonic 
acid metabolism, concentrations ofLTB4 would be expected to decrease ifPLA2 were effectively 
inhibited. 
In conclusion CPF is an effective COX inhibitor in sheep, CPF produces antiinflammatory 
effects which are predominately attributed to the inhibitory activity of S(+)CPF on COX 
isoenzymes while the R( -) enantiomer had no therapeutic effects but may be associated with 
some of the side effects of rac-CPF. 
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Chapter 5 
The roles of nitric oxide and its interactions with eicosanoid generation in acute 
inflammation in sheep 
5.1. Introduction 
Nitric oxide is generated during the metabolism of L-arginine by the NADPH-dependent 
enzyme, NOS. A role for NO has been demonstrated in acute inflammation. In mice, NO was 
associated with inflammatory pain and inhibition of NO by L-NAME exhibited antinociceptive 
activity (Moore et ai., 1991). In rats, NO was implicated in the acute inflammatory response 
following footpad injection of carrageenan (Lalenti et al., 1992) or the topical application of 
mustard (Lippe et al., 1993). It was also reported that NO was directly or indirectly linked to 
immune complex-induced tissue injury (Mulligan et ai., 1991). The above findings have been 
confirmed using iNOS knockout mice (Wei et al., 1995). In most cases, inhibition of NOS led to 
decreased inflammatory responses (Moncada et al., 1991). Nitric oxide synthase can be inhibited 
by a group of guanidino-monosubstituted derivatives of L-arginine, including L-NMMA, L-
NAME and L-~ -amino arginine. These NO inhibitors have become a useful tool in the 
investigation of the physiological and pathological significance of NO (Moncada et al., 1991; 
Moore et al., 1991; Rees et al., 1990a, 1 990b ) 
There is evidence showing that the NO interacts with COX. It was reported that NO enhanced 
the generation of PGs and was suggested that the COX isoenzymes were potential receptor 
targets for NO in a renal inflammatory model (Salvemini et al., 1994). It was also found that in 
acute pancreatitis inhibition of NOS caused a inhibition of 6-keto PGF la and TXB2 generation, 
and PLT eicosanoid generation was mediated through a NO-dependent mechanism (Closa et ai., 
1994). 
Nitric oxide may playa role in inflammation in domestic animal species and the modulation of 
NO generation may have therapeutic value. However, there are little data in the literature about 
the role and regulation of NO in domestic animals. In this study we investigated the roles of NO 
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in acute inflammation, the effects of L-NAME on NO generation and the interaction of NO with 
eicosanoid generation using a tissue-cage inflammatory model in sheep in vivo. 
5.2. Material and methods 
5.2.1. Animals 
Eight male sheep weighing 63 ± 3 (mean ± SD) kg and aged approximately 1.5 years old at the 
beginning of first cross-over were used. Hay and water were provided ad libitum. 
5.2.2. Preparation ofL-NAME injectable solution 
The solution ofL-NAME for i.v. administration was prepared as 20 % (WN) in sterile distilled 
water. The solution was prepared within 24 h of injection in each cross-over occasion and stored 
at 0-4°C. 
5.2.3. Experimental protocol 
The experiments were carried out on a subcutaneous tissue-cage acute inflammatory model as 
described in Chapter 2. The cross-over experiment was coded as QMlZC/03/95 and was started 
two months after the experiment coded QMlZC/11194 (Reported in Chapter 3) using the same 
tissue-cages and animals. 
The study was carried out as a 5 way cross-over Latin square design, in which each sheep 
received an injection of carrageenan into a tissue cage 15 min before administration of test 
substances, sheep received Lv. administration of rac-CPF (4.0 mglkg), R(-)CPF (2.0 mglkg) , 
S(+)CPF (2.0 mglkg), L-NAME (25 mglkg) and CPF excipient as PLB, as a single rapid bolus, 
via the right jugular vein according to the cross-over design (see Table 4.1. the first 3 treatments 
were reported in Chapter 4.). A four-week interval was allowed between each occasion of the 
cross-over. 
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The sampling schedule and processing methods were described in Chapters 2 and 4. The values 
of TXB2, PGE2, L TB4, haematology and the skin temperature over the cages were detennined 
using the methods described in Chapter 2. 
5.2.4. Quantification of NO 
5.2.4.1. Reduction of nitrate to nitrite 
The production of NO is associated with the generation of nitrite (NO;) and nitrate, (NO~). 
Nitrite may be detected by chemiluminescence, however in the exudate NO products include 
NO~ which must be reduced to NO; for detection. In the present study, a nitrate reductase was 
used for the reduction. 
All samples (exudate) or standards (NaN02 and NaN03 in serial concentrations of 12.5,5.0,2.5, 
and 1.25 IlM) were prepared in duplicate, a PBS control was included. To each well of the plate, 
30 III of NO; standard, or NO~ standard or sample was added. After this, 30 III of reduction 
buffer [(containing 200llM of ~-nicotinamide adenine dinucleotide phosphate (Sigma Ltd, Poole, 
Dorset, England), 20 IlM of flavin adenine dinucleotide (Sigma Ltd, Poole, Dorset, England) and 
0.5 units of nitrate reductase (Sigma Ltd, Poole, Dorset, England) in phosphate buffer saline] was 
added to each well. Plates were incubated at 37 °C for 30 min and then stored at 4 °C until 
injection. Where the injection is carried out some time after reduction, samples were stored at -20 
°C. 
5.2.4.2. Chemiluminescence analysis 
The analysis was carried out using a chemiluminescence NO analyser (Model 2107, Dasibi 
Environmental Corporation, Glendale, California, USA) and a Chart recorder (Rikadenki, 
Yokogawa, Japan) was attached for the data record. In 100 mV switch, 1 scale in the paper was 
equal to 1 PPB and in 200 m V switch, 1 scale was equal to 2 PPB and so on. 
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The reaction solution was 100 ml (65 ml of acetic acid glacial and 35 ml of 6 % NaI). Prior to 
injection, the reaction solution was heated to boiling under a stream of nitrogen for 20 min until 
the trace in the record was stable. 
The injection volume was 20 I.d. The speed of injection was consistent and delivery was at the 
centre of the reaction solution surface. 
5.2.4.3. Calculation of result 
The scales were converted into PPB and standard concentrations were plotted against PPB. This 
generated a linear curve and the sample results were then calculated using linear regression. 
These procedures were carried out using a computer programmes compiled in Microsoft Excel 
5.0. 
Nitric oxide concentration = GROWTH(Standard NO concentrations, standard PPBs, sample 
PPB) 
5.2.4.4. Statistics 
The results were expressed as mean ± SE. The differences in the measurements collected at each 
time point between treatment groups, and between pre-treatment and post-treatment were 
analysed using ANOVA and Fisher's mUltiple comparisons as described in Chapter 2. 
5.3. Results 
5.3.1. Effects ofL-NAME on NO production in inflammatory exudate 
Nitrite was undetectable in exudate and transudate before nitrate was converted to nitrite. This 
indicated that the majority of the NO products in the tissue-cage fluids in sheep were present in 
the form of nitrate. The plot of nitrite (converted) concentrations versus times is given in Fig. 
5.1. Before carrageenan injection, the concentration of nitrite in the tissue-cage fluids was 
detectable, with a mean value of 2.56 ± 0.32 fJM (NO;). Following intracaveal injection of 
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carrageenan, concentrations of exudate nitrite rose to a mean value of 4.93 ± 0.26 ~M, increasing 
by 89.0 ± 8.8 % over a 96 h period and the concentrations were significantly elevated for up to 
48 h (P<0.01) compared with the pre-values (20 min prior to carrageenan injection). Intravenous 
administration of L-NAME apparently increased the exudate NO concentration to a mean 
concentration of5.18 ± 0.22 ~M and the increase was significant at 2 h compared with the PLB-
administered group (P<0.05). 
5.3.2. Effects ofL-NAME on increased inflammatory skin temperature 
The effects of L-NAME on inflammatory heat production were estimated by measuring the 
changes in skin temperature over the carrageenan-induced and non-induced cages between the 
PLB and L-NAME treated groups. The results are given in Table 5.1. Following the injection of 
carrageenan into the tissue-cages, the skin temperature over the treated cages increased. In the 
PLB-treated group, the overall mean skin temperature over the carrageenan-treated cages was 
0.43 ± 0.09 °C higher than that over the non-treated cages. A maximum increase of 1.33 ± 0.49 
°C was achieved at 12 h, which was the only time that the increase achieved statistical 
significance compared with the pre-values (P<0.05). In the L-NAME administered group, the 
temperature changes were lower than in the PLB-treated group for up to 32 h and the overall 
mean temperature increase was 0.25 ± 0.09 °C. However no statistical significance (P>O.05) was 
achieved at any individual time point or between overall means oftreatrnent groups. 
5.3.3. Effects ofL-NAME on serum TXB2 generation 
Mean ± SE serum. TXB2 concentrations are shown in Fig 5.2. and the percentage inhibition is 
given in Table 5.2. Analysis of variance showed that the difference in overall mean TXB2 
concentrations between the PLB and L-NAME treated groups were significant (P<O.OI). The 
concentrations of serum. TXB2 in the L-NAME treated group were lower than those in the PLB 
treated group at all time points over a 72 h period although statistical significance was only 
achieved at 8 h (P<O.OI). Compared with the pre-values, the L-NAME treated group showed a 
statistically significant decrease in serum TXB2 generation for up to 48 h (P<O.OS). However the 
inhibition of TXB2 generation was only partial, indicated by a maximal percentage inhibition of 
26.32 ± 6.81 occurring at 1 h and an overall mean percentage inhibition of 19.30 ± 1.92 %. 
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5.3.4. Effects ofL-NAME on exudate PGE2 generation 
The injection of carrageenan induced the generation of exudate PGE2 in the tissue-cages. In the 
PLB-administered group, PGE2 concentration rose steadily from an undetectable level (below the 
limit of the analytical quantification) at time zero (15 min before carrageenan injection) to a 
Cmax of 86.24 ± 11.75 nglml at 12 h following carrageenan injection. Compared with the 
controls, the increase in exudate PGE2 was significant for up to 32 h (P<0.05). Intravenous 
administration of L-NAME increased exudate PGE2 generation significantly (P<0.05). The 
overall mean exudate PGE2 concentration over a 144 h period in the L-NAME treated group 
(45.91 ± 5.57 nglml) was significantly higher than that in PLB-treated group (35.35 ± 4.64 
nglml) (P<O.OI). At 12 h, a Cmax for exudate PGE2 of 112.60 ± 12.96 nglml was achieved, which 
was 23 % higher than in the PLB treated group. Compared with the PLB-treated group, the 
increase in exudate PGE2 generation in the L-NAME treated group was significant at 12,24, and 
32 h. (Table 5.3.). 
5.3.5. Effects ofL-NAME on exudate LTB4 generation 
The plot of exudate LTB4 concentration (mean ± SE) versus time following i.v. administration of 
PLB and L-NAME is presented in Fig. 5.3. In the PLB treated group, intracaveal carrageenan 
injection stimulated exudate LTB4 generation from an undetectable level (below the limit of 
analytical quantification) to a Cmax of 1.83 ± 0.44 nglml at 12 h. The concentrations of exudate 
LTB4 were detectable over a 144 h period and the increase was significant from 8 to 120 h post 
carrageenan injection compared with the pre-value (P<0.05). Intravenous administration of L-
NAME caused an increase in carrageenan-induced L TB4 generation. The overall mean value (2-
144 h) for the L-NAME treated group of 1.40 ± 0.13 nglml was significantly higher (P<0.05) 
than that for PLB-treated group (1.07 ± 0.073 nglml). The concentrations of exudate L TB4 in the 
L-NAME treated group were higher than in the PLB treated group at most of the time points 
although the increase was not statistically significant at individual time points due to their large 
SE of the means (P>0.05). 
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5.3.6. Effects ofL-NAME on white blood cell recruitment in exudate 
The results for WBC numbers (mean ± SE, 109 cellslL) in the carrageenan-induced exudate 
following i.v. administration ofPLB and L-NAME are given in Fig. 5.4. 
Intracaveal injection of carrageenan caused a recruitment of WBCs in the inflammatory exudate 
in a time related fashion and a maximum WBC numbers of 17.63 ± 3.67 x 109 cells/L which 
occurred at 12 h. Of the WBC, 59.69 ± 4.63 % were neutrophils over a 48 h period. Intravenous 
administration of L-NAME enhanced the carrageenan-induced WBC accumulation and the 
overall mean WBC numbers of 14.88 ± 2.81 x 109 cellslL (in 4-48 h period) was significantly 
higher than that in the PLB treated group (10.17 ± 1.48 x 109 cellslL) (p<0.01). The exudate 
WBC numbers in the L-NAME treated group were higher than in the PLB treated group at most 
sampling time points but there was a significant increase at 24 h (P<O.Ol), at which time the 
maximum WBC numbers for the L-NAME treated group (37.47 ± 10.21 x 109 cellslL) was 
achieved. 
5.3.7. Effects ofL-NAME on WBC and PLT in venous blood 
The mean ± SE ofWBC and PLT numbers in venous blood are given in Table 5.4. Blood WBC 
numbers in the L-NAME treated group were higher than the values obtained before 
administration of L-NAME and in the PLB-treated group at all sampling points. Statistical 
significance was achieved at 4 and 24 h compared with the pre-administration values (P<0.05). 
The results also showed that L-NAME attenuated the PLT numbers in blood and the effect was 
significant at 4 h compared with the PLB-treated group (P<O.OS). 
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Table 5.1. Changes in skin temperature (OC) over the cages following i.v. administration ofPLB 
and L-NAME (25 mglkg) in 8 sheep (mean ± SE) 
Time PLB-treated group L-NAME-treated group 
(h) (OC, mean ± SE) eC, mean ± SE) 
Pre-values 0.08 ± 0.21 0.44 ± 0.27 
1 0.29 ± 0.37 -0.19 ± 0.27 
2 0.29 ± 0.27 0.06 ± 0.32 
4 0.25 ± 0.43 0.14 ± 0.29 
6 0.72 ± 0.18 0.29 ± 0.14 
8 0.74 ± 0.18 0.38 ± 0.57 
12 1.33 ± 0.49* 0.40 ± 0.42 
24 0.43 ± 0.26 -0.07 ± 0.33 
32 0.29 ± 0.26 0.06 ± 0.24 
48 0.16 ± 0.26 0.29 ± 0.31 
72 0.24 ± 0.30 0.04 ± 0.23 
96 0.05 ± 0.41 0.54 ± 0.38 
120 0.29 ± 0.29 0.72 ± 0.93 
144 0.49 ± 0.31 0.58 ± 0.34 
The values are the differences of the temperature between inflamed and non-inflamed tissue-
cages (the temperature over the inflamed tissue-cage minus the temperature over the non-
inflamed tissue-cages). Pre-values were the measurements 5 min prior to carrageenan injection. 
(*) P<0.05, compared with the pre-value. 
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Table 5.2. Changes in concentrations of serum TXB2 following i.v. administration of PLB and 
L-NAME (25 mg/kg) in sheep (N=8, mean ± SE) 
Time PLB-treated group L-NAME-treated group 
(h) (ng/ml, mean ± SE) (ng/ml, mean ± SE) 
Pre-values 27.13 ± 1.86 29.97 ± 1.68 
1 24.99 ± 2.48 22.45 ± 2.90* 
2 26.36 ± 2.68 23.74 ± 2.42* 
4 26.00 ± 2.25 23.81 ±3.11* 
6 25.72 ± 2.19 23.78 ± 2.13* 
8 27.89 ± 2.29 22.96 ± 2.74*# 
12 25.61 ± 2.16 23.97 ± 2.88* 
24 26.71 ± 2.22 26.60 ± 2.16* 
32 26.36 ± 2.59 26.16 ± 2.60* 
48 24.92 ± 2.59 23.41 ± 2.24* 
72 27.09 ± 1.66 26.78 ± 2.05 
Pre-values were the measurements 5 min prior to carrageenan injection. (*) P<0.05, compared 
with the control value and (#) P<0.05, compared with the PLB treated group. 
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Table 5.3. Changes in concentrations of PGE2 in exudate following i.v. administration of PLB 
and L-NAME (25 mglkg) in 8 sheep (mean ± SE) 
Times PLB-treated group L-NAME-treated group 
(h) (nglml, mean ± SE) (nglml, mean ± SE) 
Pre-values <0.8 <0.8 
2 7.72 ± 6.81 4.95 ± 3.32 
4 41.19 ± 13.51 * 34.21 ± 11.63* 
8 79.78± 11.18* 100.01 ± 13.16* 
12 86.24 ± 11.75* 112.60 ± 12.96*# 
24 62.45 ± 16.07* 83.07 ± 13.65*# 
32 38.27 ± 9.78* 76.49 ± 13.60*# 
48 7.99 ± 3.25 25.14 ± 11.90* 
72 6.50 ± 3.59 9.23 ± 5.26 
96 2.32 ± 1.02 5.72 ± 5.30 
120 18.39 ± 18.39 8.92 ± 8.92 
144 4.54 ± 4.04 9.09 ± 6.22 
The measurements 5 min before carrageenan injection were used as pre-values. (*) P<0.05, 
compared with the control value and (I) P<0.05, compared with the PLB treated group. 
Table 5.4. Changes in the numbers (109 cells /L) of WBC and PLT in venous blood following 
i.v. administration ofPLB and L-NAME (25 mglkg) in 8 sheep (mean ± SE) 
Time Blood WBC number Blood PLT number 
(h) PLB-treated L-NAME-treated PLB-treated L-NAME-treated 
Pre-values 7.68 ± 0.69 6.01 ± 1.07 179.13 ± 16.77 170.00 ± 28.35 
4.00 7.57 ± 0.66 7.55 ± 0.88* 195.29 ± 18.65 171.40±21.01# 
24.00 7.68 ± 0.58 8.27 ± 0.42* 193.75 ± 22.69 189.63 ± 17.14 
48.00 6.84 ± 0.59 7.11 ± 0.68 201.25 ± 18.87 196.63 ± 16.96 
The measurements 5 min before carrageenan injection were used as pre-values. (*) P<0.05, 
compared with the controls and (~ P<0.05 compared with the PLB-treatedgroup. 
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5.4. Discussion 
Nitric oxide is derived from the guanidino nitrogen atom of L-arginine by the enzymatic action 
of NOS. There are at least two major isofonns of NOS. The constitutive enzyme (cNOS) is 
calcium-dependent and produces basal NO for the physiological process, such as homeostatic 
mechanisms. The inducible enzyme (iNOS) is calcium-independent and expressed following 
induction of various inflammatory agents (such as cytokines, LPS and carrageenan). Inducible 
NOS produces a large quantity of NO which is involved in defensive processes, especially 
inflammation (Moncada et al., 1991). In the present study, prior to the injection of carrageenan 
into the cages the concentration of nitrate (including a small amount of nitrite) was 2.56 ± 0.32 
J.lM and this may represent basal NO generated by eNOS. Following the injection of 
carrageenan, the concentration of nitrate (including nitrite) increased rapidly to a maximum value 
of 5.79 ± 0.01 J.lM at 2 h. This suggests that more than half of the NO in the inflammatory 
exudate was produced by iNOS and that the carrageenan tissue-cage model was appropriate for 
the study of NOS. 
It has been reported that guanidino-monosubstituted derivatives of L-arginine, L-NAME, L-
NMMA and L-~-amino arginine competitively inhibit both iNOS and cNOS in vitro and in 
vivo in rats and mice. Their effects include decrease in the formation of NO breakdown products 
(nitrate and nitrite) and inhibition of NO associated changes, such as inflammation, PLT 
aggregation and hypotensive responses (Rees at al., 1990a, 1990b; Moncada et al., 1991). 
It was unexpected that in the present study in sheep Lv. administration of L-NAME caused an 
increase in NO formation in the exudate. This suggests surprising species differences. The 
mechanism underlying this finding is unknown. Previous reports illustrated that L-NAME, which 
is a potent inhibitor for endothelial NO synthesis (Rees et al., 1990a), did not affect NO 
production in the neutrophil (McCall et al. 1990). In the present acute inflammatory model a 
large portion (59.69 ± 4.63 %) of the inflammatory cells accumulating in the exudate were 
neutrophils. But while this could explain a low response it can not explain the increase in NO 
generation following L-NAME administration. It is possible that L-NAME was rapidly 
126 
converted into L-arginine by metabolic enzyme systems in the sheep thus more substrate was 
available for the biosynthesis of NO. A metabolic study is required to confinn this hypothesis. 
The initial intention in the present study was to use the inhibitory effect of L-NAME on NO 
generation, as a tool, to demonstrate the role of NO in acute inflammation. However the increase 
in NO production and the parallel changes in the inflammatory mediators does implicate NO as a 
mediator of inflammation in this species 
Previous studies have indicated that inhibition of endogenous NO production by NOS inhibitors 
attenuates PG release and that an increase of NO generation by exogenously administering NO 
donors (glyceryl trinitrate and sodium nitroprusside) directly stimulates COX-2 activity to 
enhance PG generation. These results also suggested that COX isoenzymes are the receptor of 
NO (Salvemini et al., 1993, 1994). The present study confinned these findings since an increased 
NO production in the L-NAME treated group paralleled an enhanced PGE2 generation in the 
exudate compared with the PLB-treated group. Prostaglandin E2 and LTB4 are fonned from the 
same substrate, arachidonic acid, by the action of COX and 5-LOX, respectively. The 
phenomenon of metabolic shift between COX and LOX has been proposed (Higgs et al., 1980; 
Kitchen et al., 1985; Sedgwick et al., 1987). Our previous studies (Chapters 3 and 4) illustrated 
that inhibition of COX activity by NSAIDs [FM and S(+)CPF] led to an increase in LTB4 
production in exudate by the metabolic diversion of arachidonic acid. However in the present 
study an increased NO production was accompanied by a rise in LTB4 generation. This suggests 
that NO activated both COX and LOX or that NO may upregulate the activity of PLA2, a 
proximal site in arachidonic acid metabolism since activation of PLA2 releases arachidonic acid 
to provide an additional substrate for COX and LOX. This finding also suggests that both COX 
and LOX may be targets of NO. Prostaglandin E2 and L TB4 are important eicosanoids which 
initialise and maintain acute inflammation and the pro-inflammatory effects of NO may be 
amplified by increased PGE2 and L TB4 generation. 
Nitric oxide has been demonstrated to have a role in regulation of PL T function. It inhibits PL T 
aggregation and adhesion to collagen fibrils, endothelial cell matrix and endothelial cell 
mono layers via a cyclic GMP-dependent mechanism (Radomski et al., 1987a, 1987b, 1990; 
Moncada et al., 1991). During the process of aggregation and adhesion, PL T produce and release 
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a number of bioactive substances, such as TXA2, via various enzyme systems present in PL T. In 
the present study, i.v. administration ofL-NAME caused an increased NO production in exudate 
and transudate, and an inhibition of TXB2 (a breakdown product of TXA2) in the serum. This 
also indicates an increased NO generation in serum and agrees with the findings in previous 
publications. It is possible that the effect of NO on COX is isoenzyme selective since PLT COX 
is COX-l (Funk et ai., 1991) and carrageenan-induced exudate PGE2 is predominantly 
synthesised by COX-2 (Masferrer et at., 1994). It has been reported that COX isoenzymes are 
pharmacologically specific for some NSAIDs (Laneuville, et at., 1994; Masferrer et al., 1994; 
Williams & DuBois, 1996). However there is no published data on the isoenzyme selectivity of 
NO for COX-l and COX-2. 
Nitric oxide has been shown to be involved in mammalian immunological defence mechanisms 
(Moncada et aI., 1991; Mulligan et at., 1991; Liew 1994; Wei et at., 1995). It is a powerful 
vasodilator and NO generated by iNOS is cytotoxic for tumour cells and invasive organisms. The 
present study showed that NO production and leukocyte accumulation increased simultaneously 
in inflammatory exudate. The accumulation of leukocytes may result from increased vascular 
permeability and increased L TB4 and PGE2 concentration induced by NO. Vasodilatation 
facilitates infiltration of inflammatory cells, and L TB4 is a powerful chemokinetic and 
chemotactic agent for those cells (Ford-Hutchinson et al. 1980). Furthermore vascular 
permeability can be caused by PGE2. These findings agree with a previous report in which 
inhibition of NO synthase by L-NMMA inhibited neutrophil chemotaxis (Kaplan et al., 1990). 
In conclusion, NO appeared to play a role in acute inflammatory process in sheep by 
upregulating the activity of COX-2, 5-LOX and the accumulation of WBC. This suggests that 
combining iNOS-COX-2 inhibitors may prove to be a powerful strategy which may provide a 
broader antiinflammatory spectrum than NSAIDs. The finding that L-NAME increases NO 
production in inflammatory sites suggests a species difference in the metabolism of L-arginine 
analogues. Data concerning the inhibitory effects of L-arginine analogues on NO generation can 
not be extrapolated between animal species. 
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Chapter 6 
Pharmacokinetics and pharmacodynamics of phenylbutazone and flunixin meglumine in 
donkeys 
6.1. Introduction 
Phenylbutazone and FM are the NSAIDs used extensively in equine medicine. They have been 
shown to have common PK and PD characteristics with other NSAIDs in experimental and 
domestic animal species (Vane 1971; Lees & Higgins 1984, 1986; Lees et al., 1986, 1987a, 
1987b, 1987c, 1991c; Tobin et ai, 1986; McKellar et al., 1989; Landoni et al., 1995a). Previous 
results showed that PBZ and FM produce their therapeutic effects (antipyrexia, analgesia and 
antiinflammation) and side effects (including ulceration) by inhibition of the COX enzyme 
system and thus blockage of the synthesis ofPGs and TXs which are the important inflammatory 
mediators for initialisation and maintenance of acute inflammation. Like other acidic NSAIDs, 
they accumulate in the acidic site of inflammation following administration so that when a 
dosage schedule is determined particular attention should be paid to their PK behaviour at the 
therapeutic site. Recently, the clinical uses of PBZ and FM have been extended to other animal 
species and other diseased conditions (Anderson., 1988; Selman., 1988; Kopcha & Ahl, 1989; 
Lees, 1989; Landoni et al., 1995a). 
However, the pharmacological use of PBZ and FM has not been described in donkeys (Equus 
asinus), and neither their action and nor disposition in this species have been studied. Previous 
studies have shown that NSAIDs exhibit marked species differences in PK parameters so that the 
data can not be transposed between species (McKellar et al., 1990, 1994a, 1994b; Lees et al .. 
1991d; Welsh et al., 1993; Cunningham & Lees, 1994; Landoni et al., 1995a, 1995b, 1996), and 
the potency of PBZ for COX inhibition is different between some animal species (p. Lees, 
personal communication. Also see Chapter 3 and 4). 
The first purpose of the present study was to investigate the distribution and elimination of PBZ, 
OPBZ (an active metabolite ofPBZ) andFM in plasma, inflamed tissue-cage fluid (exudate) and 
non-inflamed tissue-cage fluid (transudate). A second objective was to investigate the effects of 
PBZ and FM on COX isoenzymes, 12-LOX, inflammatory skin temperature and recruitment of 
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inflammatory cells. Finally the roles of COX and 12-LOX in carrageenan-induced acute 
inflammation in donkeys were investigated using the NSAIDs as a tool. 
6.2. Materials and methods 
6.2.1. Animals 
Three female donkeys, named Cheeky, Frisky and Pinky, aged 7-15 years, weighing 160-200 kg 
at the beginning of the cross-over experiment were used. Hay and water were provided ad 
libitum. 
6.2.2. Experimental protocol 
The donkeys were prepared with a subcutaneously implanted tissue-cage on each side of the neck 
and acute inflammatory responses were initialised by intracaveal injection of 0.5 ml of 1 % 
carrageenan 20 min prior to drug administration at -20 min and maintained by a further injection 
of carrageenan solution as described in Chapter 2. 
The study was carried out as a three-way cross over such that each donkey was given i.v. PBZ at 
4.4 mg/kg, FM at 1.1 mglkg or PLB (physiological saline) at a volume equivalent to FM. A three 
week wash-out period was allowed between each cross-over occasion. 
Plasma, blood, serum, transudate and exudate were harvested and processed as described in 
Chapter 2. The plasma samples were collected at 15 min before drug administration (-15 min), 
5, 15, 30, 45 min and 1, 2, 3, 4, 6, 8, 12, 32, 24 and 48 h after drug administration. Serum 
samples for determination of TXB2 concentrations were harvested at -15 min, 1, 2, 4, 6, 8, 12, 
24, 32 and 48 h. Exudate and transudate were taken at -15 min (transudate only), 2, 4, 8, 12,24, 
32 and 48 h. Blood samples for haematological determination were collected at -15 min, 6, 24, 
32 and 48 h, and exudate samples for haematological determination were harvested at 2, 4, 8, 12, 
24, 32 and 48 h. Skin temperature over the cages was recorded at -20 min, 1,2, 3, 4, 5, 6, 8, 12, 
24, 32 and 48 h. 
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Phenylbutazone, OPBZ and FM concentrations were determined by HPLC using a chloroform 
extraction procedure as described in Chapter 2. Thromboxane B2 and PGE2 were measured using 
a dextran-coated charcoal RIA as described in Chapter 2 and 12-HETE was measured by RlA 
using a commercially available kit (AMI 12-HETE [3H] RIA Kit, Advanced Magnetics 
Cambridge, MA, USA). For the RIA, the samples were not extracted prior to the assay but 
diluted with RIA buffer as described previously. Haematological determination and skin 
temperature measurements were carried out as described in Chapter 2. 
6.2.3. Pharmacokinetic and PD analysis 
Pharmacokinetic and PD analysis was carried out using PCNONLIN 4.2 software as described in 
Chapter 2. Compartmental PK modelling was used for analysis of plasma data and the best fit 
model was determined using AlC (Yamaoka et al 1978). Non-compartmental modelling analyses 
were used for the transudate and exudate data. Areas under the zero- and first-moment curves 
were calculated from 0 to the time of last detectable sample. Pharmacodynamic analysis to 
determine the relationship between drug effects and drug concentration was fitted to a Sigmoid 
inhibitory model as described in Chapter 2. 
6.2.4. Statistical analysis 
Results are expressed as mean ± SE. A multiple factor ANOV A was carried out as described in 
Chapter 2 and Chapter 3 to determine differences of treatments, time points, sheep, sequences, 
periods, and their associated two factor interactions. The differences of the measurements 
collected at each time point between treatment groups and between pre-treatment and post-
treatment were confirmed using Fisher's multiple comparisons following the ANOVA. Analysis 
of co-variance was carried out to establish the relationship between ambient temperature or pre-
treatment values and the effects of treatments. 
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6.3. Results 
6.3.1. Disposition ofPBZ and OPBZ in plasma, exudate and transudate 
The PK parameters (mean ± SE) for PBZ and OPBZ following Lv. administration ofPBZ at 4.4 
mglkg are given in Table 6.1. and the concentration time curves are presented in Fig 6.1. and 6.2. 
Following i.v. administration ofPBZ, the C; ofPBZ was 59.45 ± 2.04 J.lglml and this declined 
quickly. It was not detectable after 6 h in one animal and after 12 h in two animals. The 
concentration time data for PBZ in plasma was best fitted to a two compartment model with the 
equation: C (t) = 40.98e-9.95t + 18.46e-1.l9t• Phenylbutazone was rapidly distributed and eliminated 
from plasma as indicated by a short t 1 a of 0.09 ± 0.02 h, t 113 of 0.63 ± 0.13 h and MRT of 0.69 
2 2 
± 0.12 h. The mean Vss ofPBZ was small (147 ± 18 mIlkg). The conversion ofPBZ to OPBZ 
was rapid, mean C
max of 4.03 ± 0.51 J.lglml for OPBZ in plasma occurred at 0.57 ± 0.10 h and the 
AVC ratio of OPBZ to PBZ was 67 %. The tll3 of OPBZ was 1.81 ± 0.02 h which was about 
2 
three times as long as that ofPBZ. 
The distribution of PBZ into exudate was greater than into transudate, indicated by the AVC 
ratio of 42 ± 3 % for exudate to plasma and of 26 ± 4 % for transudate to plasma. 
Phenylbutazone and OPBZ were eliminated much more slowly from exudate and transudate than 
from plasma and the values ofMRT were considerably longer in cage fluids. 
6.3.2. Disposition ofFM in plasma, exudate and transudate 
The mean ± SE PK parameters ofFM are shown in Table 6.2. and the concentration time courses 
are illustrated in Fig 6.3. 
Following Lv. administration, FM followed a bi-expenontial decay in plasma (C = 17.20e-2.57t + 
5.1ge-o.36t). Flunixin meglumine was detectable until 32 h in all of the animals. The distribution 
and elimination ofFM were slower than those ofPBZ, t1 a and t! 13 were 0.28 ± 0.02 hand 2.09 
2 2 
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± 0.45 h, respectively. The Vss and CIa were small, 171.07 ± 12.62 mllkg and 50.27 ± 9.42 
ml/kglh, respectively. 
Flunixin meglumine penetrated into tissue-cage fluids readily with a AUC ratio of 47 ± 13 % for 
exudate to plasma and of 55 ± 6 % for transudate to plasma. The Cmax ofFM in exudate was 1.30 
± 0.32 Ilglml which was slightly higher than in transudate (1.09 ± 0.26 Ilglml). The MRT ofFM 
in exudate were about 5 times as long as that in plasma and slightly longer than that in 
transudate. 
6.3.3. Effects ofPBZ and FM on increased inflammatory skin temperature 
Table 6.3. illustrates the temperature difference between the cage administered carrageenan and 
the cage without irritant following i.v. administration ofPLB, PBZ and FM in donkeys. 
Intracaveal injection of the mild irritant carrageenan increased mean skin temperature by 0.8 ± 
0.2 °C compared with the cage without irritant during the 48 h period. A maximal increase of 1.6 
± 0.2 °C was recorded at 3 h. The temperature rose less in PBZ (0.4 ± 0.4 °C) and FM (0.4 ± 0.2 
°C) treatment groups. Compared with the PLB-treated group, the overall temperature changes in 
FM-treated and PBZ-treated groups were significantly different (P<0.05) up to 8 h but not 
thereafter. 
6.3.4. Effects ofPBZ and FM on serum TXB2 generation 
The Effect of PBZ and FM on TXB2 generation is illustrated in Fig. 6.4. and the values 
expressed in percentage inhibition are given in Table 6.4. 
The overall means for serum TXB2 concentrations in the PBZ treated group (35.97 ± 4.35 nglml) 
and the FM-treated group (17.08 ± 4.14 ng/ml) were significantly lower (P<O.OI) than in the 
PLB-treated group (47.58 ± 3.97 nglml). The inhibition of serum TXB2 generation by PBZ and 
FM was time-related (P<O.OI) and this suggests a reversible inhibition of COX by PBZ and FM 
in this species. 
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Phenylbutazone produced a maximal reversible TXB2 inhibition of 86.06 ± 2.66 % at 1 h and 
thereafter TXB2 generation was gradually restored. Compared with the PLB-treated group and 
pre-values (IS min prior to drug administration), the inhibition was significant at 1, 2 and 6 h 
(P<O.OS) and there was no significant rebound during a period of 48 h. Flunixin meglumine 
generated over 90 % inhibitory effect on serum TXB2 for 6 h and maximal inhibition was 93.32 
± I.S6 % occurring at 6 h. Compared with the PLB-treated group and the pre-value, the 
inhibition was significant for up to 12 h (P<O.OS), however there appeared to be a significant 
rebound effect after 32 h. The inhibitory effect of FM was significantly higher than that of PBZ 
from 4 to 12 h (P<O.OS). In the plasma, the ICso was 1.06 ~glml and 1.86 ~glml for PBZ and 
OPBZ, respectively, and the leso for FM was 0.11 ~glml. 
6.3.S. Effects ofPBZ and FM on PGE2 generation in exudate 
Mean ± SE exudate PGE2 concentrations following administration of PLB, PBZ and FM are 
shown in Fig. 6.S. 
Following the injection of carrageenan into the tissue-cages, exudate PGE2 concentrations 
increased steadily over a 48 h period. The maximal concentration was 3.33 ± 0.S9 nglml 
achieved at 24 h and the increase was significant from 4 to 32 h (P<O.OS). The overall mean 
PGE2 concentrations in PBZ-administered group (1.48 ± 0.32 nglm1) and FM-administered 
group (0.87 ± 0.3S nglml) were significantly lower (P<0.05) than in the PLB-administered group 
(2.07 ± 0.34 nglml). Compared with the PLB-administered group, PBZ and FM produced 
significant inhibition at 4 and 8 h (P<0.05). Flunixin meglumine produced higher inhibitory 
effect than PBZ during a 2-32 h period and statistical difference was determined at 8 h (P<O.OS). 
In the exudate, the ICso following PBZ treatment was 0.32 J.1g1ml PBZ and 0.33 J.1g1ml OPBZ and 
the ICso for FM was 0.05 ~glml. 
6.3.6. Effects ofPBZ and FM on 12-HETE in exudate 
As shown in Table 6.S., neither PBZ nor FM modified the generation of 12-HETE m 
carrageenan-induced exudate. 
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6.3.7. Effects ofPBZ and FM on the numbers ofWBC and PLT 
Neither PBZ nor FM modified the numbers of WBC and PLT in venous blood, or WBC in 
inflammatory exudate (Data not shown). 
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Table 6.1. Pharmacokinetic parameters of PBZ and OPBZ in plasma, exudate and transudate 
following i.v. administration ofPBZ at 4.4 mglkg in donkeys (n = 3, mean ± SE). 
Parameters Fluids PBZ OPBZ 
C~ (J.tglml) Plasma 59.45 ± 2.04 NA 
Cmax (J.tglml) Plasma NA 4.03 ± 0.51 
Exudate 1.48 ± 0.56 0.72 ± 0.32 
Transudate 1.10 ± 0.38 0.85 ± 0.16 
tmax (h) (Observed) Plasma NA 0.57 ± 0.098 
Exudate 5.33 ± 3.33 3.33 ± 0.67 
Transudate 2.00± 0.00 3.33 ± 0.67 
AUCO-last (J.tg.himl) Plasma 19.21 ± 2.11 12.86 ± 1.87 
Exudate 7.97 ± 0.77 7.02 ± 2.33 
Transudate 4.95 ± 0.54 6.43 ± 1.81 
AUCo-co (J.tg.himl) Plasma 20.53±1.27 NA 
AUCratio (J.tg.himl) Exudate:Plasma 0.42 ± 0.03 0.53 ± 0.11 
Transudate:Plasma 0.26 ± 0.04 0.48 ± 0.06 
tl a (h) Plasma 0.09±0.02 NA 
2 
t1 j3 (h) Plasma 0.63 ± 0.13 1.81 ± 0.021 
2 
CIa (mllh.kg) Plasma 214.18 ± 18.04 NA 
MRT O-last (h) Plasma 0.69 ± 0.12 NA 
Exudate 10.17 ± 3.37 8.24± 0.96 
Transudate 10.87 ± 5.26 5.48 ± 0.46 
MRTo_co (h) Plasma 0.68±0.04 NA 
Vss (ml/kg) Plasma 146.67 ± 17.63 NA 
In plasma the PK analyses were carried out by compartmental modelling. The data of PBZ was 
fitted to a two compartment model with bolus iv injection and OPBZ was fitted to a one 
compartment model with first order input. In exudate and transudate the analysis was by non-
compartmental modelling with extravascular administration. AUe ratios were calculated using 
AUCO-last. NA = not applicable. 
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Table 6.2. Phannacokinetic parameters of FM in plasma, exudate and transudate following i.v. 
administration ofFM at 1.1 mglkg in donkeys (n = 3, Mean ± SE). 
Parameters Plasma Exudate Transudate 
C~ (Ilg/ml) 22.39 ± 0.52 NA NA 
Cmax (Ilg/ml) NA 1.30 ± 0.32 1.09 ± 0.26 
tmax (h) (Observed) NA 2.63 ± 0.17 6.00 ± 3.06 
AUC O-Iast (Ilg·h/ml) 23.63 ± 5.02 10.26 ± 2.17 13.38 ± 4.56 
AUC O-al (Ilg·h/ml) 23.80 ± 4.99 NA NA 
AUCratio (Cage fluids/plasma) NA 0.47 ± 0.13 0.55 ± 0.06 
t! a (h) 0.28 ± 0.02 NA NA 
2 
t ! ~ (h) (by non-compartment) 4.50 ± 0.09 NA NA 
2 
t! ~ (h) (by compartment) 2.09 ± 0.45 NA NA 
2 
MRTO-Iast (h) 3.42 ± 0.51 18.21 ± 3.30 14.33 ± 2.12 
MRTO-al (h) 3.71 ± 0.42 NA NA 
CIa (ml/kg/h) 50.27 ± 9.42 NA NA 
Vss (ml/kg) 171.07 ± 12.62 NA NA 
Concentration time data were fitted to a two compartment model and the data in tissue-cage 
fluids were analysed using non-compartmental modelling with extravascular administration. 
AUC ratios were calculated using AUCO_Iast. NA = not applicable. 
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Table 6.3. The changes in skin temperature over the cages following i.v. administration ofPLB, 
PBZ (4.4 mglkg) and FM (1.1 mglkg) in donkeys (n=3, mean ± SE). 
Time (h) PLB-treated group PBZ-treated group FM-treated group 
Pre-treatment 0.3 ± 0.3 0.6 ± 1.0 -0.7 ± 0.3 
1 0.5 ± 0.3 -0.2 ± 0.3 -0.5 ± 0.5 
2 -0.1 ± 0.2 -0.1 ± 0.2 -0.3 ±0.6 
3 1.6 ± 0.2 0.3 ± 0.1 0.1 ± 0.8 
4 1.5±1.1 0.3 ± 0.4 -0.3 ± 0.5 
6 0.4 ± 0.5 -0.2 ±0.3 0.3 ± 0.4 
8 0.4 ± 0.3 0.0 ± 0.4 0.8 ± 0.3 
12 0.5 ± 0.3 0.5 ± 0.6 0.9 ± 0.3 
24 1.5 ± 0.4 0.9 ± 0.5 0.6 ±0.8 
32 -0.3 ± 1.0 1.2 ± 0.8 0.5 ± 0.6 
48 2.0 ± 1.3 1.7 ± 0.3 1.4 ± 1.3 
Overall 0.8 ± 0.2 0.4 ± 0.4* 0.4 ± 0.2* 
The values cae) are the difference of skin temperature between carrageenan injected cages and 
the cages which did not receive carrageenan. * Significant difference compared with PLB-treated 
group (P<0.05). 
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Table 6.4. Percentage inhibition of serum TXB2 following i.v. administration of PBZ (4.4 
mg/kg) and FM (1.1 mg/kg) in donkeys (n = 3, Mean ± SE). 
Time (h) 
1 
2 
4 
6 
8 
12 
24 
32 
48 
Percentage inhibition of TXB2 
PBZ-treated group FM -treated group 
86.06 ± 2.66* 91.47 ± 4.90* 
69.48 ± 11.14* 91.08 ± 0.35* 
24.05 ± 23.84 91.49 ± 1.04* 
33.42 ± 11.87* 93.32 ± 1.56* 
5.28 ± 12.14 85.45 ± 7.16* 
7.66 ± 10.91 77.43 ± 5.27* 
5.63 ± 7.77 15.97 ± 20.23 
9.24±7.67 -13.l9±17.47 
-1.66 ± 13.20 -18.82 ± 15.67 
* Significant difference compared with PLB-treated group (P<0.05) 
Table 6.5. Concentrations of 12-HETE in exudate following i.v. administration of PLB, PBZ 
(4.4 mg/kg) and FM (1.1 mg/kg) in donkeys (n=3, mean ± SE). 
Time Concentrations of 12-HETE acid (pglm1) 
(h) PLB group PBZ group FM group 
2 452±64 418±97 409±99 
4 653 ± 125 483 ± 126 562 ± 27 
8 734±168 508±117 761±98 
12 400±25 488±85 460±64 
24 368 ± 69 336 ± 57 467 ± 102 
32 482 ± 169 344 ± 28 497 ± 141 
48 587 ± 202 346 ± 59 548 ± 190 
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Fig. 6.1. Time course ofPBZ in plasma (-.-), exudate (-e-) and transudate 
(-0-) following i.v. adminstration ofPBZ at 4.4 mg/kg in donkeys (n=3, mean ± SE). 
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Fig. 6.2. Time courses ofOPBZ in plasma {-A-}, exudate {-e-} and transudate {-o-} 
following i.v. administration ofPBZ at 4.4 mg/kg in donkeys {n=3, mean ± SE}. 
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Fig. 6.3. Concentration versus time plot ofFM in plasma (-.-), exudate(-e-) and 
transudate (-0-) following Lv. administration ofFM at 1.1 mg/kg in donkeys 
(n=3, mean ± SE). 
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Fig. 6.4. Serum TXB2 concentration versus time plot following i.v. adminstrations 
ofPLB (saline, -0-), PBZ (4.4 mg/kg, -.-) and FM (1.1 mg/kg, -.A.-) in donkeys 
(n=3, mean ± SE). The data points at each time with different numbers of asterisks 
are significantly different (P<O.OS). (+) compared with the pre-value, P<O.OS. 
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Fig. 6.5. Exudate PGE2 concentration following Lv. adminstration ofPLB (saline, -0-), 
PBZ (4.4 mg/kg, -.-) and FM (1.1 mg!kg, -.6..-) in donkeys (n=3, mean ± SE). (*) compared 
with the PLB-treated group, p<O.05 and (+) compared with the PBZ-treated group, P<O.05. 
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6.4. Discussion 
The PK of PBZ have been extensively studied in horses and it has been shown to produce a dose 
dependent kinetics (Tobin et aI., 1986). Following i.v. administration in horses at a single dose 
rate of 4.4 mg/kg, PBZ exhibited at! 13 of 3.5-6.1 h (Piperno et al., 1968; Lees et al., 1986, 
2 
1987c; Maitho et ai., 1986). In the present study the elimination of PBZ was almost 10 times 
faster than that reported in the horse (ponies) following the same dose and route of 
administration (Lees et al 1986, Maitho et al 1986). The CIB of PBZ from Welsh mountain 
ponies was 25 - 26 mllh.kg (Maitho et ai, 1986) whereas in donkeys in the present study CIB was 
214 mllh.kg. Based on the relative areas under the curves for OPBZ and PBZ and the ratios of 
OPBZ to PBZ in donkeys (67 %) and ponies (8 %) (Lees et al., 1986), it would appear that ring 
hydroxylation occurs more rapidly in the donkey which may account for the shorter half-life of 
PBZ, although it is also possible that OPBZ is eliminated more slowly in donkeys than horses. 
The distribution of PBZ into tissue-cage fluids was slower and less extensive in donkeys 
compared to horses (Lees et al. , 1986, 1987a). In the present study, the Cmax ofPBZ was 1.48 ± 
0.56 ~g/ml in exudate and 1.10 ± 0.38 ~glml in transudate while the same values in horse were 
12.4 ± 1.3 ~glml and 6.3 ~glml in exudate and transudate, respectively. The ratios of AUC in 
donkeys was 42 ± 3 % for exudate to plasma and 26 ± 4 % for transudate to plasma, which were 
smaller than in horses (83 ± 4 % and 32 ± 4, respectively). This may be due to the quick 
elimination of PBZ and OPBZ in plasma of donkeys so that most of the drug molecules in 
plasma were cleared before they could readily penetrate into the tissue-cage fluids. 
The plasma kinetic parameters for FM in donkeys in the present study were similar to those in 
horses following a same dose rate (1.1 mg/kg), administration routine and PK analysis method 
(compartmental modelling) (Lees et al., 1987a). Thus t! 13 (2.09 ± 0.45 h in donkeys and 1.94 ± 
2 
0.24 h in horses), CIs (50.27 ± 9.42 mllkglh in donkeys and 57.3 ± 0.7 mllkglh in horses) and 
AUCo_Iast (23.63 ± 5.02 ~g.h/ml in the donkeys and 19.43 ± 2.28 ~g.h/ml in horses) were similar. 
It is interesting that in the present study t! 13 derived from non-compartmental modelling (4.50 ± 
2 
0.09 h) was twice as long as that derived from compartmental modelling using the same software 
(pCNONLIN 4.2). As mentioned in Chapter 3, t! 13 is a model-dependent parameter and when 
2 
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comparisons are made, particular attention should be paid to the analysis methods since both 
compartmental and non-compartmental PK modelling have been widely accepted and used. 
It was unexpected that FM did not show significant difference of AUC ratios between exudate to 
plasma and transudate to plasma in the present study. Penetration of FM into exudate in the 
present study in donkeys was similar to the data in horses reported previously (Lees & Higgins, 
1984; Lees et al., 1987c), indicated by an exudate Cmax of 1.3 J.1g1ml in donkeys and of 0.9 J.1g1ml 
in horses. However in the horse study, the penetration ofFM into transudate was lower than into 
exudate whereas in the present donkey study the penetration of FM into exudate and transudate 
was similar. 
In the present study, PBZ and FM exerted significant inhibitory effects on serum TXB2, exudate 
PGE2 and skin temperature over the inflammatory cages but did not modify the generation of 12-
HETE in exudate. This suggests that PBZ and FM produce their effects at least partially by 
reversible inhibition of COX. The percentage inhibition of exudate PGEz was still higher than 50 
% at 8 h in the PBZ-treated group and 12 h in the FM-treated group, and were therefore much 
longer than the values of t! ~ in plasma. This indicates that PBZ and FM could exert therapeutic 
2 
effects for longer than their plasma kinetics would suggest. This may be partially explained by 
their accumulation in the inflammatory sites. This was in agreement with previous reports in the 
horse (Lees & Higgins, 1984; Lees et al., 1987c). The results also showed that the pathway for 
inhibition of PGE2 generation was more sensitive than for TXB2. In inflammatory exudate the 
IC
so 
(without correcting for binding to proteins) for PGE2 was 0.32 J.1g/ml for PBZ (including 
0.33 J.1g1ml of OPBZ) and 0.05 J.1g1ml for FM while the ICso for TXB2 generation was 1.06 J.1g1ml 
for PBZ (including 1.86 J.1g1ml of OPBZ) and 0.11 J.1g1ml for FM. Both PGE2 and TXB2 are 
derived from PGH2 by the action of COX. However PGE2 is formed via the endoperoxide 
isomerase and TXB2 via TX synthetase pathways. It is possible that PBZ/OPBZ and FM block 
both COX and endoperoxide isomerase. It is more likely that PBZ, OPBZ and FM act 
differentially on COX-1 and COX-2 isoenzymes; blockade of ex vivo serum TXB2 synthesis is 
likely to reflect drug action on the constitutive enzyme COX-l in PLT whilst inhibition of the 
inducible enzyme COX-2 generated by inflammatory cells probably accounts for decreased 
generation of exudate PGEz- In the study in sheep described in Chapter 3 the results for FM 
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agreed with the findings in the present study in donkeys while the results for PBZ were quite 
different. Previous studies in calves using the same inflammatory model showed that FM 
preferentially inhibited COX-l (ICso was 0.024 ± 0.004 J.1g1ml for serum TXB2 and 0.074 ± 
0.006 J.1g1ml for exudate PGE2) (Landoni et al., 1995a). Another study using human COX-l and 
COX-2 cDNAs expressed in cultured cells illustrated that PBZ selectively inhibited COX-l 
(Laneuville et al., 1994). This may reflect species differences. 
In conclusion, the present study demonstrated that PBZ and FM are effective inhibitors for COX 
and that they produce their pharmacological effects by inhibition of COX isoenzymes and thus 
the formation of PGs and TXs in donkeys. The PK of PBZ in donkeys were characterised by 
rapid elimination and were very different from those described in horses while FM in donkeys 
shares similar PK characteristics with horses when administered at the same dose rates. It seems 
likely that dosage interval of PBZ should be shorter in the donkeys whereas the dose of FM used 
in horses can be extended to donkeys. Tolerance studies are, however, required for both drugs in 
donkeys before firm recommendations can be made. 
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Chapter 7 
Pharmacokinetic and Pharmacodynamic Studies on Phenylbutazone and 
Oxyphenbutazone in Goats 
7.1. Introduction 
Phenylbutazone is a NSAID which has not been extensively used in goats, however experimental 
studies and clinical investigations in cattle and other ruminants have indicated that NSAIDs are 
potentially useful drugs to treat arthritis, mastitis, pyrexia, endotoxaemia, viral respiratory 
diseases and other inflammatory conditions (Mercer & Teske, 1977; Giri et al., 1984; Anderson 
et al., 1985; Anderson 1988; Selman 1988; Kopcha & Ahl, 1989) and the disposition ofPBZ has 
been determined in cattle (Eberhardson et at., 1979; DeBacker et al., 1980; Martin & Anderson, 
1984; Lees et al., 1988; Williams et al., 1990). It is believed that eicosanoid generation and 
release are fundamental to the acute inflammatory process and that PBZ produces its effect by 
inhibiting the COX enzyme system which generates a number of eicosanoids, such as PGE2 and 
TXA2 (Vane, 1971; Lees et al., 1987c). Previous studies on the fate ofPBZ in goats illustrated 
that the elimination of PBZ from the plasma was slow and age-dependent following high dose 
i.v. administration of 10 mglkg or 33 mglkg (Boulos et al., 1972; Eltom et ai., 1993). There are 
no published data on the bioavailability and mode action ofPBZ in the goats. 
In the present study, we have investigated the PK and TXB2 inhibition in the goat following PBZ 
administered i.v. and p.o. at a dose rate of 4.4 mglkg. 
7.2. Materials and Methods 
7.2.1 Animals and experimental protocol 
Six mixed breed goats ( 3 males and 3 female) aged between 4-5 years and weighing between 
45 and 92 kg were used for the experiment. All animals had ad libitum access to hay and water 
throughout the study. The study was carried out as a 3 way cross-over with two animals per 
treatment per period such that each animal received PBZ Lv. and p.o. and PLB treatment. 
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Animals were randomised for group by ballot and the interval between treatments was 3 weeks. 
Phenylbutazone for i.v. (Phenyzene, C-Vet Ltd, Braintree, Essex, England) or p.o (Equipalazone 
paste, Vet Drug Co., Hondon, England) administration was given at single dosage of 4.4 mglkg. 
Placebo (0.9% NaCl) was administered i.v. at a volume of 1.0 ml. 
Blood samples for measurement of PBZ and OPBZ concentration in the plasma were collected 
into 10 ml Lithium Heparin Monovettes (Sarstedt Ltd, Numbrecht, Gennany) at 5 min before 
drug administration (-5 min) and 2,5, 10, 15,30,45 min and 1,2,4,6,8, 12,24,32,48, 72, 96, 
120 and 144 h after drug administration. Blood was centrifuged at 1800 x g and 4 °c for 20 min 
and plasma was decanted into polystyrene tubes. The tubes were stored at -20°C until analysis. 
Blood samples for TXB2 assay were collected at -5 min and 1,2,4, 6, 8, 12,24, 32, 48, 72, 96, 
120 and 144 h and processed as described in Chapter 2. 
7.2.2. Analyses of Samples. 
Plasma concentrations of PBZ and OPBZ were estimated by HPLC and the measurement of 
TXB2 was by RIA as described in Chapter 2. 
7.2.3. Pharmacokinetic Analysis 
Pharmacokinetic analysis was carried out as described in Chapter 2. Briefly, the plasma 
concentration-time data of PBZ and OPBZ for each individual animal were analysed by 
compartmental modelling using a non-linear estimation computer software programme, 
PCNONLIN 4.2 and the best fit model was detennined as MAlCE based on AlC (Yamaoka et 
al., 1978). The AUC was calculated by the trapezoidal rule. The MRT and MAT were estimated 
using non-compartmental analyses. Body clearance and V ss were estimated using compartmental 
approach. Bioavailability was corrected using t!~, which corrected for the differences in t! ~ 
2 2 
following each route of administration. 
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7.3. Results 
7.3.1. Phannacokinetics ofPBZ and OPBZ in the plasma. 
The PK parameters of PBZ and OPBZ following i.v. and p.o. administration are given in Table 
7.1. The disposition ofPBZ in plasma following i.v. administration at a dose rate of 4.4 mg/kg 
was best described by a two compartment model. The plasma concentration versus time plot is 
shown in Fig. 7.1. Phenylbutazone was eliminated slowly from plasma as indicated by a long t1 ~ 
2 
of 15.34 ± 1.15 h; a large AVC of 1229 J.1g.hJml; a long MRT of 22 h and a slow CIB of 4.5 
ml/kglh. Following administration of PBZ paste, the disposition was best fitted by a one 
compartment model with first order input and output. The plasma concentration of PBZ versus 
time plot is given in Fig. 7.1. The absorption ofPBZ was relatively slow with a MAT of 10.43 ± 
3.51 h and a Cmax of 27.23 ± 2.58 J.1g1ml occurring at 3.47 ± 0.39 h. In some animals, there were 
double peaks in the plasma concentration time course which may represent rumen by-pass by a 
proportion of the administered drug. The bioavailability was 82 ± 6% without correction and 61 
± 7 % corrected by t 1~. The elimination of PBZ was slower following p.o. than i.v. 
2 
administration. The data for OPBZ disposition following i.v. and p.o. administration was best 
fitted to a one compartment model with first order input and output and the plasma concentration 
time curve of OPBZ is given in Fig. 7.1. This demonstrated a relatively low concentration of 
OPBZ in the plasma with Cmax of 0.46 ± 0.09 J.1g1ml following p.o. administration. 
Oxyphenbutazone was not detectable in most of the goats 48 h after drug administration while 
PBZ was still detectable at 144 h after administration. The AVC ratios of OPBZ to PBZ were 
very small, 0.02 for Lv. and 0.016 for p.o. administration. 
7.3.2. The effects ofPBZ on serum TXB2 generation 
The mean ± SE concentration ofTXB2 in serum following i.v. and p.o. administration ofPBZ is 
presented in Fig. 7.2. and the percentage inhibition is given in Table 7.2. The generation of TXB2 
by PL T COX was inhibited by PBZ in a time-related fashion. A maximal inhibition of 70.63 ± 
150 
11.96 % was achieved at 1 h following Lv. administration of PBZ and this decreased thereafter. 
Compared with TXB2 concentration before drug administration, significant inhibition (p<0.05) 
occurred at 1,2,4,6, 8 and 12 h. Following p.o. administration ofPBZ, the generation ofTXB2 
was also inhibited. The maximal inhibition, 64.34 ± 9.09 %, occurred at 2 h and inhibition was 
statistically significant (p<0.05) at 2, 4, 6, 8 and 12 h compared with the pre-values. 
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Table 7.1. Phannacokinetic parameters ofPBZ and OPBZ in plasma following i.v. and p.o. 
administration ofPBZ at 4.4 mglkg in goats (n=6, mean ± SE). 
Parameters Administration Pheny lbutazone Oxyphenbutazone 
routes 
Cmax (~g1ml) p.o. 27.23 ± 2.58 0.46 ± 0.09 
C~ (~g1ml) l.v. 122.79 ± 14.33 NA 
!max (h) p.o. 3.47 ± 0.39 8.24 ± 0.94 
l.v. NA 1.47 ± 0.21 
AUCo_oo (~g.hJml) p.o. 981.43 ± 167.63 13.43 ± 2.36 
l.v. 1228.84 ± 219.41 19.37 ± 2.60 
AUCratio (OPBZIPBZ) p.o. 0.016 ± 0.004 NA 
l.v. 0.02 ± 0.01 NA 
F (Not corrected) % p.o. 82 ±6 NA 
F (Corrected) % p.o. 61 ± 7 NA 
t1 kO! (h) p.o. 0.69 ± 0.11 3.45 ± 0.84 
2 
t 1 a (h) l.v. 0.29 ± 0.03 NA 
2 
t 1 k!O (h) p.o. 21.99 ± 3.32 14.31 ± 4.07 
2 
t113 (h) l.v. 15.34 ± 1.15 21.66 ± 1.67 
2 
MRTo-oo (h) p.o. 32.00 ± 4.77 17.51 ± 6.81 
l.v .. 21.58 ± 1.65 30.51 ± 2.59 
MATo-oo (h) p.o. 10.43 ± 3.51 NA 
CIa (ml/kglh) l.v. 4.46 ± 1.12 NA 
V ss (ml/kg) l.v. 87.99 ± 13.35 NA 
NA = not applicable. 
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Table 7.2. The percentage inhibition of serum TXB2 following i.v. and p.o. administration of 
PBZ at 4.4 mglkg in goats (n=6, mean ± SE). 
Time (h) PBZ (i.v.) PBZ (p.o.) 
1 70.63 ± 11.96* 49.02 ± 15.41 
2 61.82 ± 12.37* 64.34 ±9.09* 
4 54.83 ± 11.80* 61.06 ± 11.83* 
6 53.64 ± 12.02* 59.29 ± 7.17* 
8 50.16 ± 12.35* 53.49 ± 10.28* 
12 50.14 ± 12.08* 58.11 ± 8.25* 
24 7.90 ± 8.28 35.19 ± 15.74 
32 0.99± 12.10 44.17 ± 11.43 
48 -9.74 ± 18.21 17.71 ± 16.88 
72 -14.24 ± 16.46 27.25 ± 9.05 
96 -13.27 ± 8.69 -12.20 ± 21.32 
120 -39.60 ± 0.93 16.36 ± 48.15 
144 -34.23 ± 22.10 29.83 ± 43.64 
* P<0.05 Compared with pre-administration using one-way ANOVA with Dunnett's 
comparisons. 
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Fig 7.1. The concentration-time curves ofPBZ (-.-) and OPBZ (-.-) following PBZ 
p.o. ( a) and Lv. (b) administration at 4.4 mg/kg in goats (n=6, mean ± SE). 
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Fig 7.2. Changes in mean ± SE of serum TXB2 concentrations (ng/ml) following 
i.v. (-.-, n=5) and oral (-.-, n=6) administration ofPBZ at 4.4 mg/kg in goats. 
(*) P< 0.05, compared with the pre-values. (-0-), PLB i.v. 
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7.4. Discussion 
It has been reported that the elimination ofPBZ from the plasma in ruminants was slower than in 
horses. A t1 ~ of 15.9 ± 1.5 h was demonstrated in goats when a dose rate of 10 mglkg was given 
1 
i.v. (Eltom et al., 1993) and a t1 ~ of 51.2 ± 6.8 h was obtained in cattle following i.v. 
1 
administration of PBZ at 4.4 mglkg (Lees et al., 1988). In the horse, t 1 ~ was reported to be 6.11 
2 
± 0.84 h following i.v. administration of 4.4 mglkg (Lees et al., 1987a, 1987c). Boulos et a/., 
(1972) gave PBZ to goats i.v. at dose rate of33 mglkg and obtained a t1 ~ of 14.5 h. It has been 
2 
shown that following PBZ at 10 mglkg i. v. in the adult goat, the AVCo-Q) and t 1 ~ were 880 ± 84 
2 
f.lg.hlml and 15.9 ± 1.5 h, respectively (Eltom et al., 1993). In the present study, following 4.4 
mg/kg i.v. in goats, the AVCo-Q) and t1 ~ were 1228.8 ± 219.4 Ilg.hlml and 15.3 ± 1.1 h, 
2 
respectively. These findings suggest that the elimination of PBZ in goats is dose independent. It 
is not clear why the AVC following a 10 mglkg dose rate was smaller than the AVC following 
the 4.4 mglkg dose rate; but the studies were undertaken in different animals, in different 
laboratories and on different occasions. 
Although PBZ was detectable at 144 h, the data for plasma PBZ concentrations over a sampling 
time of 2 min to 144 h did not pennit a three compartment model to be fitted for Lv. 
administration or a two compartment model for p.o. administration. Moreover, Vss was very low 
and this suggested that most of the drug entering the body stayed in the extra and transcellular 
compartment and that inter and intra cellular distribution was small. Concentrations of the 
hydroxylated metabolite, OPBZ, in the plasma were quite low and the AVC ratios of OPBZ to 
PBZ were very small, about 0.02: 1 following i.v. or p.o. administration. In our HPLC traces, no 
peaks apart from PBZ and OPBZ were found in the plasma samples over a 20 min analytical 
time using a gradient mobile phase. It may be that hydroxylation in the liver was weak, or that 
excretion of hydroxylated metabolites was extremely rapid. Previous reports in cattle showed 
that hydroxylated metabolites of PBZ, OPBZ and y-hydroxy PBZ in the urine but not PBZ itself 
were much higher than those in plasma for 168 h (Lees et a/., 1988). 
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The present study showed that absorption of PBZ following p.o. administration was relatively 
slow with a MAT of 10.43 ± 3.51 h and that the bioavailability (61%) was slightly higher than 
that reported in cattle (54%), (Lees et al., 1988). The apparent t! 13 (p.o.) was about 7 h longer 
2 
than the actual t! 13 (i.v.). This probably resulted from continued drug absorption processes in the 
2 
gastrointestinal tract after Cmax was achieved. The Cmax following p.o. administration was about 5 
times lower than that following i.v. administration and this probably explains a lower maximal 
TXB2 inhibition after p.o. administration in the goat. The results suggested that because of the 
low bioavailability, higher dose rates may be required for p.o. administration to achieve and 
maintain adequate concentrations of active drug in plasma. Data for PBZ PK and PD in inflamed 
sites and tolerance data are required to confirm the appropriate dose for use in goats. 
Eicosanoid generation is fundamental to the inflammatory process and the many components of 
inflammation, such as fever and pain, may be caused or exacerbated by eicosanoids. Inhibition of 
the formation of eicosanoids produces relief from the symptoms of inflammation. Arachidonic 
acid may be generated following several stimuli including thrombin during the blood clotting 
process. The arachidonic acid thus produced is further converted via the COX enzyme pathway 
into PGs and via TX synthetase to TXA2 and its stable hydrolysate, TXB2. A number of studies 
have illustrated that inhibition of TXB2 generation in PL T by some NSAIDs correlates with 
inhibition of other COX products, such as PGE2, in inflamed tissues (McKellar et al., 1994b) 
since most of NSAID currently used in clinical practice are non-selective inhibitors for COX-l 
and COX-2 isoenzymes (Laneuville et al., 1994; Williams & DuBois, 1996). For instance, CPF 
which had little or no inhibitory effects on TXB2 generation, failed to inhibit PGE2 in inflamed 
exudate (McKellar et al., 1994a). The generation ofTX can be used as an indicator ofPLT COX 
activity and may be used to estimate the likely inhibitory effect ofNSAIDs on COX in inflamed 
tissues although this must be confirmed by the use of appropriate models of inflammation and in 
clinical trials. After the administration of PBZ to goats, the generation of TXB2 in PL Twas 
significantly inhibited (p<0.05 ) between 1 and 12 h (Lv.) and between 2 and 12 h (p.o.). It was 
partially or fully restored after 24 h following PBZ administration, which indicated the inhibition 
was reversible. The plasma concentration of PBZ was comparatively high at 24 h following 
administration, with a mean value of 17.99 ~glml after i.v. and 14.54 ~glml after p.o. 
administration, at which time TXB2 concentrations were largely restored. Moreover, a very high 
plasma concentration of PBZ, 60.85 ~glml which occurred at 1 h following PBZ Lv., failed to 
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abolish TXB2 generation completely. Also in horse total PBZ plasma concentrations were much 
lower with the same dose rate of drug than in the goat, yet inhibition of TXB2 was greater (Lees 
et aI., 1 987a, 1987c). This may be due to species differences between goats and horses. 
Prediction of antiinflammatory effects of NSAIDs based on PL T COX inhibitory activity is 
however speCUlative. There are different isoforms of COx. The COX in PLT may be COX-l 
which is a constitutive enzyme present in a wide range of tissues. Its function is believed to be 
related to physiological activities such as maintaining homeostasis. The COX in inflammatory 
sites may be COX-2, an inducible form of COX, which is responsible for generation of 
eicosanoids to develop and maintain acute inflammatory responses (Kujubu et al., 1991; 
Simmons et al., 1991; Xie et al., 1991; Flecher et ai., 1992; Meade et ai., 1993). In studies in 
donkeys it was demonstrated that the total PBZ concentrations required to inhibit exudate PGE2 
in inflamed tissues were much lower than those required to inhibit serum TXB2 generated by 
PL T COX (See Chapter 6). This suggested that an isoenzyme selectivity could be involved. 
Elimination of some NSAIDs from inflamed sites is much slower than from plasma and this may 
also contribute to the differences seen in plasma and inflammatory exudate (Lees et al., 1986, 
1987c; McKellar, et ai., 1994a, 1994b; Landoni et ai., 1995a, 1995b). 
The present results suggest that PBZ may be a useful NSAID in goats when administrated at 4.4 
mglkg by the Lv. or p.o. routes although further studies are required to determine its safety in this 
species. 
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Chapter 8 
Comparative pharmacokinetics of paracetamol (acetaminophen) and its 
sulphate and glucuronide metabolites in desert camels and goats. 
8.1. Introduction 
Paracetamol (acetaminophen) is a well recognised analgesic and antipyretic agent (Clark, 1979; 
Winter et al., 1979) which has also been shown to have antiinflammatory activity in animals and 
man (Lokken & Skjelbred, 1980; Mburu et al., 1988) 
Its mode of action has not been fully characterised and although it is known to be a weak 
inhibitor of COX in the periphery (Mattammal et al., 1979) it may have a more potent effect on 
enzymes in the central nervous system (Marshall et al., 1987). The PK of PRT have been 
reported in several animal species including man (Rawlins et al., 1977), dog (Orner & 
Mohammed, 1984) pig (Bailie et al., 1987) and horse (Greenblatt & Engelking, 1988). In man 
and several other species PRT is metabolised primarily by glucuronide and sulphate conjugation 
(Prescott, 1980; Gregus et al., 1988). However it has been shown that there are large interspecies 
differences in the metabolic fate ofPRT. As well as the major detoxifying conjugation pathways 
to the glucuronide and sulphate metabolites there is a metabolic pathway which generates a toxic 
reactive electrophilic intermediate, N-acetyl-p-benzoquinoneimine (Fig. 8.1.). This metabolite is 
further biotransformed and detoxified to PR T glutathione conjugates including cysteine and 
cysteinylglycine conjugates (Gregus et al., 1988). When the glutathione metabolic pathway is 
saturated, N-acetyl-p-benzoquinoneimine binds covalently to vital hepatic macromolecules 
which result in dose-dependent hepatic necrosis (Jollow et al., 1973). The ratios of the 
detoxification and toxification pathways for the metabolism ofPRT have been shown to correlate 
with species susceptibility to hepatotoxicity (Gregus et al., 1988). 
Previous reports have demonstrated differences between camels and goats in the activities of 
drug metabolising enzymes (EI Sheikh et al., 1986; EI Sheikh et al., 1988; El Sheikh et al., 1991) 
which indicate that camels have lower metabolising capability for some drugs than goats. The 
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present study was carried out to detennine the PK ofPRT and its major detoxifying metabolites, 
glucuronide and sulphate, in desert camels and goats. 
8.2. Materials and methods 
8.2.1. Animals and experimental protocol 
Six female desert camels weighing approximately 200 kg and aged two years and six female 
goats weighing approximately 25 kg and aged one year were used. Animals were given hay and 
water ad libitum and the diet was supplemented with pelleted concentrates and mineral blocks. 
Two experiments were run in parallel in two phases such that all the camels and goats were 
administered PRT i.m. and ten days later all the animals received PRT i.v. For each experiment 
PRT (pure compound) was dissolved in sterile normal saline (1 gl70 ml) and was administered at 
a dose rate of 5 mglkg to camels or 10 mglkg to goats. Blood (5 ml) was collected into 
heparinised tubes before and at 5 (i.v.) 10, 15 (i.v.) 20, 30,40 (i.v.) 45 (i.m.), 60, 90, 120, 150, 
210 (i.v.) and 240 (i.m.) min after administration ofPRT. Blood was centrifuged at 900 x g for 
10 min at 5 °C and plasma harvested and stored at -20°C until analysed. 
8.2.2. Measurement of drug concentrations 
The concentrations of PRT, PRT glucuronide and PRT sulphate in plasma were determined by 
HPLC (Wang et al., 1985). Paracetamol and PRT glucuronide were supplied by Sigma Ltd 
(Poole, Dorset, UK) and PRT sulphate was supplied by McNeil Consumer Products (Fort 
Washington, PA, USA). Plasma samples (0.25 ml) were precipitated with 6% perchloric acid and 
the supernatant removed for direct application to the HPLC system. A 25 cm x 4.6 mm CIB 
column (Alphasil5 ODS) and guard column were used. The mobile phase was 7.5% acetonitrile 
in 50 mM phosphate buffer containing 50 mM Na2S04 (PH 2.45) at a flow rate of 1.5 mllmin. 
The retention times for PRT glucuronide, PRT sulphate and PRT were 3.5, 5.3 and 6.5 min, 
respectively and recoveries and limits of quantification were 116.54 ± 2.49, 0.1 ~glml (n=20), 
98.48 ± 2.60, 0.1 ~glml (n=20) and 98.97 ± 2.17, 0.1 Jlglml (n=20), respectively. Intra (n=18) 
and inter (n=4) assay co-efficients of variation were all less than 10% over the concentration 
ranges 0.1 - 2.5 Jlglml (PRT), 0.2 - 75 Jlglml (PRT glucuronide), 0.2 - 25 ~glml (PRT sulphate). 
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8.2.3. Data Analysis 
The data from each individual animal for the parent PRT and the metabolites studied were 
analysed using non-compartmental model analysis (PCNONLIN version 4.2) as described in 
Chapter 2. This programme used algorithms to determine the first-order rate constant associated 
with the terminal (log-linear) portion of the curve (Beta) for the estimation of area under the 
concentration time curve from zero time to infinity (Dunne, 1985). The parameters derived from 
non-compartmental modelling were determined using a linear trapezoidal method as described in 
Chapter 2. Bioavailability was estimated from the equation described by Gibaldi and Perrier 
(1982b): 
AUCoral xt1p . F = 2 I.V. 
AUCi.v .xt t floral 
This method assumes that a change in t! ~ from one study period to the next in the same subject 
2 
reflects a change in clearance and is not mediated by a change in apparent volume of distribution. 
Statistical comparisons ofPK parameters within each animal species were made using Wilcoxon 
signed rank test and between each species using Mann Whitney U-test. Differences were 
considered significant when P < 0.05. 
8.3. Results 
The plasma concentration versus time curves for PRT and its glucuronide and sulphate 
metabolites following administration of PRT by the i.v. and i.m. routes to camels and goats are 
shown in Figs. 8.2 - 8.5. Parent PRT concentrations fell rapidly in both animal species and in the 
camel the sulphate metabolite initially predominated in plasma whereas in the goat the 
glucuronide metabolite was dominant in plasma. In the camel the glucuronide metabolite formed 
a large component of the plasma metabolite profile and from approximately 120 min following 
i.v. administration the glucuronide predominated. Following i.m. administration sulphate and 
glucuronide plasma concentration curves predominated and converged such that at the last 
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sampling time (210 min) mean sulphate and glucuronide concentrations were similar. In the goat 
the sulphate metabolite formed a minor component of the total plasma metabolite disposition 
profile (approximately 3.89 % of the AUCO_last of the glucuronide). 
The PK parameters for PRT following Lv. administration in camels and goats are given in Table 
8.1. Paracetamol was cleared much more slowly (21.9 ± 1.4 mllmin.kg) in camels than in goats 
(52.8 ± 7.3 mllmin.kg) although the Vss were similar (1210 ± 42 ml/kg camels vs 1418 ± 138 
ml/kg goats) in both species. 
The PK data for the glucuronide and sulphate metabolites following i.v. administration ofPRT to 
camels and goats are given in Table 8.2. Since a large proportion of the metabolite disposition 
curve appeared to lie after the last sampling time an accurate description of ~ (the slope of the 
elimination curve) could not be determined, consequently all values were determined from zero 
time to the last sampling time. In camels the time to Cmax was twice as long for the glucuronide 
metabolite than the sulphate, however the MRT of the glucuronide was also longer and it is 
apparent that the AUC for the glucuronide would be relatively greater compared to the sulphate 
if the disposition curves had been taken to infinity. In three animals for which ~ could be 
determined AUCo-oo was 3241.6 ± 726.4 ~g.minJml for the glucuronide and 1514.8 ± 266.1 
~g.minJml for the sulphate. 
In goats the plasma disposition curves were more completely defined and consequently the PK 
parameters from zero time to last sample are more accurate. In the goat the glucuronide 
metabolite predominated in plasma and produced an AUCO_1ast which was 3.8 times as large as 
that achieved in the camel (1.9 times when corrected for dose of PRT administered). The 
sulphate metabolite formed a very much smaller component of the total plasma metabolite 
profile in the goat than in the camel. 
The PK data for PRT and both measured metabolites following Lm. administration to camels and 
goats are given in Table 8.3. The plasma metabolite profiles were qualitatively similar following 
i.m. administration compared to Lv. administration with an absorption phase for parent drug and 
a longer lag phase for the metabolites attributable to absorption of parent drug. The MAT was 
longer in camels than goats. The bioavailability could only be determined accurately for five 
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camels and four goats in which Lv. and i.m. Beta values could be estimated. In these animals Fo_ 
last using the t! ~ correction method for PRT given by the i.m. route was 71 ± 17% in goats and 
2 
105 ± 26% in camels. 
8.4. Discussion 
In the present study large differences in the plasma PK ofPRT and its metabolites in camels and 
goats were observed. In the camel sulphate metabolism predominated and although the 
concentrations of glucuronide were higher than sulphate from 120 h after i.v. administration this 
appeared to be due to slower excretion of the glucuronide. In goats the glucuronide metabolite 
predominated in plasma. The plasma metabolite concentrations depend upon their rate of 
generation, volume of distribution and clearance. Thus a metabolite could be dominant (represent 
the main mass fraction in terms of PRT transformation) and have a lower plasma concentration 
than a metabolite formed to a lesser extent but with a smaller volume of distribution and/or lower 
clearance. It is therefore important to take this into account when considering the relative 
metabolite concentrations in plasma. 
In both species the parent PRT had a very rapid clearance (21.9 ± 1.4 mllmin.kg - camel vs. 52.8 
± 7.3 mllmin.kg - goat) and the differences in clearance between species were significant (P < 
0.01). The extent of distribution was similar in both species. The clearance of PRT was faster in 
both ruminant species than in man (5.45 ± 0.20 mllmin.kg) and horses (4.61 ± 1.29 mllmin.kg) 
(Prescott,1980; Greenblatt and Engelking, 1988) and since very low concentrations ofPRT «2.5 
Jlg/ml) were present from 50 min after administration by either route in both species, it may be 
that the analgesic and antipyretic effects of the drug are short in these species. 
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Table 8.1. Phannacokinetic data (mean ± SE) for PRT following i.v. administration to camels (n 
= 6) and goats (n = 5). 
Parameters Camel Goats 
Dose (mg/kg) 5 10 
~ (min-I) 0.016 ± 0.001 0.123 ± 0.092 
AUCo_1ast (~g.minlml) 220.6 ± 11.8 202.4 ± 28.3 
AUCo-«> (~g.minlml) 232.3 ± 13.1 205.3 ± 29.3 
MRTo_last (min) 46.3 ± 2.0 26.2 ± 2.3 
MR T 0-«> (min) 55.9 ± 2.7 27.8 ± 2.6 
CIs (mllmin.kg) 21.9± 1.4 52.8 ± 7.3 
Vss (ml/kg) 1210±42 1418 ± 138 
Cis = Dose/AVC; Vss= Cia x MRT 
Table 8.2. Pharmacokinetic data (mean ± SE) for PRT major metabolites following i.v. 
administration ofPRT to camels at 5 mg/kg (n = 6) and goats at 10 mg/kg (n = 6). 
Parameter Camels Goats 
B Glucuronide Sulphate B Glucuronide Sulphate 
t (min) 34.17 ± 6.64 15.83 ± 2.01 18.33 ± 1.67 13.33 ± 4.01 
max 
Cmax (~glml) 9.23 ± 1.34 17.87 ± 1.34 55.05 ± 7.0 2.55 ± 0.44 
AVCo_1ast (~g.minlml) 1145.8 ± 124.7 1452.8 ± 357.9 4391.1 ± 551.4 170.9 ± 35.8 
MRT (min) 82.7 ± 0.6 66.3 ± 5.5 60.7 ± 1.5 5.29 ± 5.7 
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Table 8.3. Phannacokinetic data (mean ± SE) for PRT and its major metabolites following i.m. administration of PRT to camels at 5 mg/kg 
(n=6) and goats at 10 mglkg (n=5). 
Parameter 
t (min) 
max 
Cmax (Jlglml) 
AUCO-Iast (J.1g.minlml) 
MRT(min) 
MAT (min) 
FO_last (%) 
*n=5 
tn=4 
Camels 
Paracetamol (3-Glucuronide 
23.33 ±4.94 120.00 ± 7.75 
4.05 ± 0.74 7.03 ± 1.40 
371.8 ± 49.8 1057.8 ± 194.0 
72.4± 3.0 114.5 ± 2.0 
26.1 ± l.7 
105 ± 26* 
Goats 
Sulphate Paracetamol (3-Glucuronide Sulphate 
76.67 ± 8.82 14.00± 4.00 36.00± 3.67 37.00± 5.15 
13.08 ± 2.51 4.67 ± 0.47 44.53 ± 5.60 1.84 ± 0.42 
1729.1 ± 301.7 198.7 ± 18.7 3856.1 ± 258.0 123.5 ± 35.0 
100.2 ± 3.2 36.2± 3.8 74.4 ± 4.8 58.7 ± 5.4 
1O.0± 2.2 
71 ± 17t 
--
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Fig. 8.2. Concentration- time curves of PRT (-.-), PRT glucuronide 
(-e-) and PRT sulfate (-.-) in plasma following i.v. administration 
ofPRT at a single dose rate of 5.0 mg/kg in the camels (n=6, mean ± SE). 
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Fig. 8.3. Concentration versus time plot for PRT (-.-), PRT glucuronide 
(-e-) and PRT sulfate (-.-) in plasma following Lm. administration of 
PRT at a single dose rate of 5.0 mglkg in camels (n=6, mean ± SE). 
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Fig. 8.4. Concentration versus time plot for PRT (-.-), PRT glucuronide (-e-) and 
PRT sulfate (-.-) in plasma following i.v. administration ofPRT at a single dose rate 
of 10 mg/kg in goats (n=6, mean ± SE). 
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Fig. 8.5. Concentration versus time plot for PRT (-.-), PRT glucuronide 
(-e-) and PRT sulfate (-A-) in plasma following i.m. administration of 
PRT at a single dose rate of 10 mg/kg in goats (n=6, mean ± SE). 
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Care must be exercised when comparing data from different animal species given different doses 
of PRT. In the present study PRT was administered at 5 mglkg to camels and 10 mglkg to goats 
and in the studies by Prescott (1980) and Greenblatt and Engelking (1988) it was administered at 
12 mglkg in man and approximately 9-15 mglkg in ponies. Paracetamol metabolism has been 
shown to be both age (Levy et al., 1975) and dose (Prescott, 1980) dependent and the dose may 
have affected the metabolism and elimination ofPRT in the above studies. It is unlikely however 
that the dose affected the absolute comparisons made between camels and goats since the goats 
received the larger dose and had more rapid clearance, although these comparisons may have 
been affected quantitatively. All animals used in the present studies were healthy mature adults 
and the influence of immaturity of metabolising mechanisms was not a feature of the present 
study. The doses ofPRT used in the present study were selected empirically, 10 mglkg is within 
the dose range used in man and the lower dose of 5 mglkg has been recommended for infants 
since infants have lower metabolising capacity. The lower dose used in the camel took 
cognisance of the known high susceptibility of the camel to drug toxicity (Ali, 1988). The lower 
dose used in camels was also chosen because solubility of PRT (pure compound) in saline was 
limited (to about 1 g170 ml) and the dose volume required to administer 10 mglkg would have 
been excessive. 
Ruminants generally have more active glucuronidation and sulphation processes for xenobiotics 
than monogastric species (Smith et al., 1984; Short et al., 1988) and although there is relatively 
little information on metabolism in the camel, it has been shown to have lower ethoxycoumarin-
o-deethylase and glutathione-s-transferase activity than sheep or goats (El Sheikh et al., 1991). 
The activity of the glutathione-s-transferase could be of importance in PRT overdosage in the 
camel since glutathione conjugation is thought to be a limiting step in removal of intoxicating 
metabolites of PRT (Gregus et ai., 1988). Unfortunately it was beyond the scope of the present 
study to characterise the glutathione and hydrolysed glutathione products of PRT metabolism. 
Since these products are largely excreted in the bile of several species and very low plasma 
concentrations occur biliary cannulation would be required to accurately describe their 
generation (Gregus et al., 1988). 
In the present study PRT had a relatively large volume of distribution (1210 ± 42 ml/kg in 
camels and 1418 ± 138 ml/kg in goats) compared with other antipyretic analgesics in domestic 
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animals which generally have volumes of distribution of less than 300 ml/kg. The larger Vss for 
PRT has also been reported in man [897 ± 94 ml/kg (Prescott, 1980)] and in ponies [2510 ml/kg 
(Greenblatt & Engelking, 1988)] and may be due to the more lipophilic, phenolic structure of 
PRT compared with the carboxylic acid structures of other NSAIDs. The larger volume of 
distribution of PRT may contribute to its known central analgesic and antipyretic activity by 
permitting a larger amount of drug to gain access to the site of action. 
In the present study all animals had free access to water and were considered to be well hydrated 
at all times. Hydration is known to affect the Vss of drugs in camels and the distribution volume 
of antipyrine has been shown to be doubled in dehydrated camels (Ben-Zvi et al., 1994). In the 
same study oxidative metabolism was also reduced in dehydrated camels, and it may be 
important to assess the degree of hydration in camels before administration of potentially toxic 
drugs known to be metabolised by the liver. 
The present study was carried out as a two phase study with i.m. administration ten days before 
i.v. administration in the same animals. The design has the drawback that period differences 
which could occur because of enzyme induction or other factors are not controlled. A more 
appropriate design where bioavailability is being examined incorporates a cross-over sequence 
such that half the animals receive the drug by each route on each occasion. While the 
experimental design used in the present study precludes an accurate determination of the absolute 
bioavailability ofPRT given Lm. to camels or goats, it does suggest that rapid enzyme induction 
to PRT metabolism may occur in the camel. Since the ratio of glucuronide:PRT changed from 
2.82 ± 0.31 following i.m. administration to 5.20 ± 0.50 following Lv. administration and there 
was a smaller change in ratios of sulphate: PRT it is possible that induction occurred in the 
glucuronidation pathway in the camel. The ratios of glucuronide: PRT and sulphate: PRT did 
not change significantly (p > 0.05) in goats between the phases of the study suggesting that 
induction did not take place in this species. It has been demonstrated that in man where first pass 
metabolism occurs following p.o. administration, the metabolic pathway may be dose-dependent 
and inducible (Rawlins et al., 1977; Perucca & Richens, 1979). 
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In conclusion, the present study demonstrated large differences in PK and metabolism ofPRT in 
camels and goats and confirms the danger of extrapolating dosages of potentially toxic drugs 
from man and laboratory animal species to ruminant species (van Miert 1989). 
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Chapter 9 
General discussion 
9.1. The acute inflammatory process and PK and PD of the tested NSAIDs 
Higgins and Lees (1984a, 1984b, 1984c) developed a subcutaneous tissue-cage implantation 
equine model of acute inflammation for investigating the inflammatory process and PK and PD 
of NSAIDs. Following the successful application in equine species (Lees et al., 1987c), it was 
soon used in other animal species, including dogs (McKellar et al., 1994a, 1994b) and cattle 
(Landoni et al., 1995a; Lees et al., 1996). This model is now often referred to as the 'tissue-cage 
model' and has become a standard model for testing PK and PD of NSAIDs in veterinary 
science. In the present study, we adapted the model for sheep with some modification. In the 
equine and bovine, the model incorporated a tissue-cage comprising a ball with an internal 
volume of 31 ml and inflammation was initialised and maintained by intracaveal injection of 0.5 
ml 1 % carrageenan. In the ovine model, differences of body size between sheep and ponies or 
cattle led to the application of a smaller ball for implantation. The ball was sized 2.0 cm in 
diameter with an internal volume of 4.2 ml and two balls were implanted in each side of the neck 
of the sheep. The acute inflammation was stimulated by injection of 0.3 ml of 1 % carrageenan 
into the cages and maintained by a further injection of 0.2 ml carrageenan after 8 h. Following 
the injection of the mild irritant, carrageenan, the acute inflammatory processes developed well. 
About 1 ml of exudate and transudate could be consistently harvested from the target cages at 2 h 
intervals and this was sufficient for the analysis of inflammatory mediators and drug 
concentration. The concentration of exudate PGE2 rose from an undetectable level to 35 nglml at 
12 h and was accompanied with the increase in exudate LTB4 generation and skin temperature 
over the cages. The concentrations of exudate PGE2 in sheep was lower than the reported 
concentrations in the equine model (197.0 ± 64.9 nglml at 12 h) (Higgins & Lees, 1984a), but the 
infiltration of WBC in the present study (a peak number of 41.95 ± 8.95 x 109 cellslL at 24 h) 
was more intensive than in the equine model (peak value of 21.8 ± 4.1 cellslL at 12 h) (Higgins 
et al., 1987). 
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The present study demonstrated that the changes in inflammatory processes were mild, 
reproducible, reversible and time-dependent, indicated by the changes in inflammatory 
mediators, cells and skin temperature over the cages. The sheep were kept after use and 
apparently recovered from the inflammatory lessons completely. The animals were used 
repeatedly and cross-over studies undertaken in an ethically acceptable way. In the present study, 
two experiments incorporated a total of 8 cross-overs over a 12 month period. No tissue-cages 
were damaged or became unusable over the period of use. Although there were differences of 
serum TXB2 and PGE2 generation between cross-overs, the changes occurred in all animals, 
were associated with age or environment and were parallel effectively controlled by the Latin 
square cross-over design and appropriate ANDV A. 
In order to estimate the pain caused by intracaveal injection of carrageenan and needle puncture 
for sampling, the thresholds to noxious mechanical and thermal stimulation were measured using 
a method reported previously (Nolan et al., 1987). The results showed that in the PLB-treated 
group there was no significant differences in mechanical and thermal thresholds between the 
control values (measurements before carrageenan injection) and the values after carrageenan 
injection and repeated sampling over a period of 2-96 h (P>0.05) (data are not reported in this 
thesis). This is the first time that pain has been investigated in the tissue-cage model and the 
findings indicate that pain is not intense even when the acute inflammatory process is well 
developed in the tissue-cages. This supports the original objectives outlined by Higgins and Lees 
(Higgins et al., 1984; Higgins & Lees. 1984a, 1984c; Higgins at al., 1987; Lees et al .• 1987c). in 
which their objectives were to develop an acute inflammatory model without causing distress to 
the animals. This also suggests that this model is not suitable for testing the analgesic properties 
ofNSAIDs. 
It is interesting to notice that the overall mean values of serum TXB2 and exudate PGE2 in the 
PLB-treated group in the second experiment (26.16 ± 0.62 and 35.35 ± 4.64 ng/ml. respectively) 
(reported in Chapter 4) were significantly higher (P<O.OI) than in the first experiment (19.10 ± 
10.20 and 16.32 ± 1.07 ng/mi. respectively) (reported in Chapter 3). The reason for this is not 
clear. It is possible that repeated injection of carrageenan facilitates the generation of exudate 
PGE2 by increasing the extension of fibrovascular granulation tissue into the perforated cages. It 
has been reported that in the tissue-cage model, fibrovascular granulation tissue is subject to 
175 
stimulation of irritants (Higgins & Lees, 1984c; Higgins et al., 1987). However this can not 
explain the increase in serum TXB2 generation since this was generated ex vivo in clotting blood. 
It, therefore, is likely that the increase is by enzymatic induction since COX derived eicosanoids 
are involved in host defensive mechanisms and after inhibition by NSAIDs, the body may 
regulate its defensive function by enhancing the activity or quantity of COX isoenzymes. This 
explanation was supported by the results that the overall mean concentration of exudate L TB4 in 
the second experiment (1.07 ± 0.07 nglml) was somewhat lower than in the first experiment 
(1.26 ± 0.09 ng/ml) and that 5-LOX was not inhibited by PBZ and FM. If this is true, it suggests 
that the body may develop "resistance" to inhibition of COX by repeated use of NSAIDs. It is 
also possible that the activity and quantity of COX in sheep is age-dependent since at the 
beginning of the first cross-over experiment the sheep were about one year old whereas they 
were about one and half years old at beginning of the second cross-over experiment. 
The mechanisms of carrageenan-induced tissue-cage in inflammation were studied in the ponies 
(Higgins & Lees 1984a, 1984b, 1984c; Higgins et al., 1987; Lees at el., 1987c), dogs (McKellar 
et al., 1994a, 1994b) and cattle (Landoni et al., 1995a; Lees et al., 1996). Following the 
implantation of tissue-cages, they became encased in fibrous tissue. Capillaries grew rapidly into 
the cavity through the perforation until a mass of fibrovascular granulation tissue filled the centre 
of the cages. The tissue in the cages was subject to carrageenan stimulation. Carrageenan is 
derived from the seaweed Chondrus crispus. The active fraction is a sulphated polymer of D-
galactose bearing structural resemblance to chondroitin sulphate A. This provided a mild 
irritation which developed an acute inflammation. 
Leukocyte infiltration into exudate occurred following intracaveal injection of carrageenan 
solution. The cells were predominately neutrophils and lymphocytes. Cell numbers rose at 4, 8, 
12 and 24 h and decreased thereafter. The second injection of carrageenan at 8 h strengthened the 
recruitment ofWBC (18.33 ± 4.10 x 109 cellslL at 8 h and 41.95 ± 8.95 x 109 cellslL at 24 h). 
The maximal concentration of PGE2 and LTB4 in exudate occurred at 12 h which was 4 h 
following the second injection of carrageenan. This suggested that the dose rate of carrageenan 
used in the present study (0.3 ml for the first injection and 0.2 ml for the second injection) was 
appropriate since it caused acute and reversible inflammatory responses. 
176 
The present study showed that arachidonic acid metabolites play an important role in the acute 
inflammatory processes. Following the injection of carrageenan, the metabolism of arachidonic 
acid was extensive. Both COX and LOX metabolic pathways of arachidonic acid were activated, 
as indicated by the increased concentrations of PGE2, L TB4 and 12-HETE in the inflammatory 
exudate. The increase in exudate PGE2 was correlated with an increase in skin temperature over 
the cages and the inhibition of exudate PGE2 by PBZ, FM and CPF produced an inhibition of the 
temperature rise. For example, FM abolished exudate PGE2 generation for up to 8 h and 
accordingly the increase in skin temperature over the cage was completely inhibited for up to 8 h 
(Chapter 3). Phenylbutazone attenuated exudate PGE2 generation and simultaneously attenuated 
the increase in skin temperature. It is possible that COX derived eicosanoids, including PGs and 
TXs, accounted for the increase in skin temperature since PGs are powerful vasodilators which 
increase local blood flow and cause an increased temperature in the inflammatory sites. The 
increased temperature may also be augmented by increased energetic metabolism caused by the 
vasodilatation in the inflammatory sites. Previous studies of CPF in dogs (McKellar et al., 
1994a) showed that CPF did not inhibit exudate PGE2 or skin temperature over the cages. The 
present studies supports the belief that PBZ and FM produce their therapeutic effects by 
inhibition of COX isoenzymes. However in the experiment reported in Chapter 4, the increase in 
skin temperature over the cage was not as high as in the experiment illustrated in Chapter 3 
whereas the increase in exudate PGE2 was more intensive. The inhibition of exudate PGE2 by 
rac-CPF and S( + )CPF was not consistently correlated with the changes in temperature. The 
reason for this may be that following 3 cross-overs (Chapter 3), the tissue-cages became old and 
encased in more fibrous tissue and thus less responsive to the changes in inflammatory 
temperature. It is also possible that in addition to PGs, other factors contribute to the increased 
inflammatory temperature since inflammation is a very complicated process and a wide range of 
factors are involved. Previous studies on PBZ and FM in ponies (Lees at al., 1987c) and 
tolfenamic acid in dogs (McKellar et al., 1994b) showed that these NSAID produced more than 
90 % inhibitory effect for exudate PGE2 but that inhibition of skin temperature was moderate 
only. 
It is believed that inhibition of COX by NSAIDs leads to metabolic diversion of arachidonic acid 
to increase LOX-derived eicosanoids, such as 12-HETE and LTB4 (Higgs et al., 1980; Higgins & 
Lees, 1984b; Sedgwick et al., 1987). This may be considered as a side effect ofNSAID treatment 
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since LTB4 and 12-HETE are a powerful chemokinetic, chemotactic and chamoattractant agents 
for WBC (Ford-Hutchison et al., 1980; Higgins & Lees, 1984b; Levine et al., 1984; Lees et al., 
1987c; Sedgwick et al., 1987; William, 1994). There is a general belief that NSAIDs relieve the 
symptoms of chronic inflammatory joint diseases while they do not retard the rate of 
development of the organic disease process and may even hasten the progress of disease (Tobin 
et al., 1986). Metabolic diversion appeared to occur in the present study in sheep (Chapter 3 and 
4). However the changes in exudate WBC recruitment were different between the tested 
NSAIDs. Phenylbutazone and FM treatments increased L TB4 generation in exudate and this was 
accompanied by an attenuated exudate WBC accumulation, while rac-CPF and S( + )CPF 
treatments increased LTB4 generation and WBC recruitment in exudate simultaneously. The 
mechanisms included in these changes are unknown. The findings with rac-CPF and S( + )CPF 
treatment were expected since increased L TB4 would be expected to lead to an increase in WBC 
recruitment. The findings for the PBZ and FM treatments were unexpected and may be explained 
as follows: 1) Although PGE2 has been considered as a weak chemokinetic and chemotactic 
agent in vitro (Kitchen, et al., 1985; Sedgwick et al., 1987), in vivo it is a powerful vasodilator. 
Increased local blood flow and vascular permeability may have facilitated infiltration of WBC 
into the inflammatory sites and thus the NSAIDs may downregulate WBC accumulation in 
inflammatory exudate by inhibiting exudate COX. 2) The NSAIDs may block leukocyte 
migration directly since PBZ and FM have been shown to inhibit zymosan-activated PMN and 
mononuclear leukocyte movement in vitro (Dawson et al., 1987; Sedgwick et al., 1987) and to 
inhibit LTB4 - directed migration of canine PMN in vitro and ex vivo. 3) Recruitment ofWBC to 
inflammatory sites is a complicated process and a number of chemical mediators are involved, 
including P AF, complements and adhesion molecules. Phenylbutazone and FM may affect some 
of these mediators and thus modify WBC recruitment in inflammatory sites. 
Research has now identified two isoforms of COX existing in mammalian cells, named COX-1 
and COX-2 (Kujubu et al., 1991; Xie et. al., 1991; O'Banion et al., 1992; Sirois et al., 1992; 
DeWitt & Meade, 1993; Jones et al., 1993; Herschman, 1994). Cyclooxygenase-l is a 
constitutive enzyme and generates a basal level of PGs which modulate physiological processes, 
such as homeostasis while COX-2 is an inducible enzyme and generates PGs during 
inflammation following stimulation. Prostaglandin E2 has been shown to be the predominant PG 
present in acute inflammatory exudate in ponies (Higgins et al., 1984; Higgins & Lees 1984a). 
178 
There are several reasons why the exudate PGE2 in the present study was predominantly 
generated by COX-2. Firstly, COX-2 is an inducible enzyme which does not express unless 
stimulated (Williams & DuBois, 1996). In the present study, exudate PGE2 was undetectable 
prior to carrageenan injection and it increased sharply following carrageenan injection. Secondly, 
the concentration time course of exudate PGE2 generation showed that exudate PGE2 was 
associated with COX-2. It has been demonstrated using molecular biological methods that COX-
I and COX-2 associated PGD2 generation occurs in two temporally distinct periods in activated 
mast cells. The first phase, catalysed by COX-I, was completed in 30 min. This was followed by 
a 15-fold induction of steady-state transcripts of COX-2 and reached a peak at about 6 h while 
the expression of COX-l did not change during this period (Kawada et al., 1995; Murakami et 
al., 1995). The present study and other studies (Higgins et al., 1984; Higgins & Less, 1984a; 
McKellar et ai., 1994a, 1994b; Landoni et al., 1995a) showed that PGE2 concentration in exudate 
increased markedly to a maximum which occurred at 6-12 h following injection of carrageenan. 
This corresponds with the above in vitro fmdings. Thirdly, COX-l and COX-2 isoenzymes are 
pharmacologically distinct for NSAIDs (Meade et al., 1993; Herschman, 1994; Laneuville et aJ., 
1994; Johnson et aI., 1995; Williams & DuBois, 1996). In the present study in Chapter 3, PBZ 
and FM produced differential inhibitory effects on carrageenan-induced exudate PGE2 and PL T 
COX (COX-I). The selective inhibition ofPBZ for serum TXB2 and exudate PGE2 in the present 
experiment was in accordance with the results of in vitro experiments using COX-l and COX-2 
cDNAs (Laneuville et aJ., 1994). Finally, in a study using a rat carrageenan subcutaneous air 
pouch model, the selective COX-2 inhibitor (NS-398) significantly reduced exudate PGE2 
generation and subsequent inflammation (Masferrer et al., 1994). In the present study we 
simultaneously tested the inhibitory effects of the NSAIDs on serum TXB2. It has been shown 
that serum TXB2 was predominantly generated by COX-l in PLT (Funk et aJ., 1991). 
Cyclooxygenase-2 is thought to be the therapeutic target for NSAIDs and inhibition of COX-2 
by NSAIDs generates antipyretic, analgesic and antiinflammatory action but the simultaneous 
inhibition of COX-! results in unwanted side effects, particularly those leading to gastric ulcers 
(Herschman, 1994; Williams and DuBois, 1996). Therefore the inhibitory selectivity for serum 
TXB2 and exudate PGE2 is a convenient and important criterion used for testing the therapeutic 
and side effects ofNSAIDs in vivo. 
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The results in Chapter 3 and 4 showed that following two injections of carrageenan solution into 
the tissue-cages, concentrations of PGE2 increased in a time-related fashion. Exudate PGE2 
concentration decreased sharply after 32 h in both cross-over experiments and inter-animal 
differences were very large (Co-Var > 93 % in Chapter 3 and> 99 % in Chapter 4). The results 
in Chapter 4 showed that exudate PGE2 generation was not significant after 32 h compared with 
the pre-values although the exudate PGE2 was detectable. This indicates that from 32 h after 
carrageenan injection the model was less reliable for evaluating COX inhibitors. This may 
explain the fact that in the experiments in sheep FM, rac-CPF and S( + )CPF all produced 
significant inhibitory effect for exudate PGE2 from 4 to 32 h although FM inhibited exudate 
PGE2 generation by more than 50 % up to 144 h and the concentration of exudate PGE2 in the 
rac-CPF and S(+)CPF groups were lower than that in the PLB group from 32 h to 144 h. For 
some of the NSAIDs with slow elimination rates the drug concentrations were high at or after 32 
h following drug administration. This suggests that a third or fourth injection of carrageenan into 
the tissue-cage may be required to achieve reliable information regarding COX inhibition in 
inflammatory exudate after administration ofNSAIDs at certain dose rates. However care should 
be taken since it has not been determined whether the inflammatory responses in the tissue-cage 
are still reversible following more than two repetitions of carrageenan injection. It is possible that 
an appropriate reversible inflammatory response may be achieved by adjusting the dose rate of 
carrageenan for the repeat administrations. However, long term stimulation may lead to a chronic 
inflammatory lesion. 
The present study showed that NO plays a role in the acute inflammatory process in sheep. 
Increased NO concentration in exudate was correlated with the generation of PGE2 and L TB4 in 
exudate. Nitric oxide is believed to be a vasodilator and to playa role in inflammation (Moncada 
et al., 1991, Wei et al., 1995). The present study agrees with the finding that COX isoenzymes 
are potential receptor targets for NO (Salvemini et al., 1994) and also suggests that NO 
stimulates the activity of 5-LOX. Therefore NO may serve as a pro-inflammatory mediator in the 
tissue-cage inflammatory model in sheep and it is possible that a combination of COX-2 and 
iNOS inhibitors will provide wider antiinflammatory effects than NSAIDs alone. 
As reported and discussed in Chapters 3, 4 and 6, the inhibition of PLT COX (COX-I) and 
exudate COX (COX-2) by PBZ, rac-CPF and S(+)CPF was different in each target species. The 
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mechanism for this finding is not clear. It is unlikely that the differences resulted from 
differences in drug concentration in plasma and exudate since Cmax values of PBZ in the sheep 
were higher than in horses and donkeys. For example, Cmax ofPBZ in exudate was 22.32 Ilglml 
in sheep, 12.40 Ilglml in horses and 1.30 Ilglml in donkeys whereas PBZ inhibited exudate PGE2 
effectively in the horses (Lees et ai., 1987c) and donkeys (Chapter 6) but not in sheep (see 
Chapter 3). It is possible that the gene sequences of COX isoenzymes are different between 
animal species. It is also possible that the concentrations of peroxide in exudate and serum are 
different between animal species since peroxides interrupt the inhibitory effects of NSAIDs, 
especially the weak inhibitors of COX (Marshall et ai., 1987; Hanel & Lands, 1982). This 
suggests that the PD data for some NSAIDs can not be extrapolated between animal species. 
However FM did not show species differences for the inhibitory effect on the COX enzyme. It 
abolished or effectively inhibited serum TXB2 and exudate PGE2 at a dose rate of ~ 1.1 mglkg, 
in all tested animal species including horses (1.1 mglkg) (Lees & Higgins 1984; Lees et ai., 
1987a, 1987c), calves at 1.1 - 6.6 mglkg by Lees et al. (1991c) and at 2.2 mglkg by Landoni et 
ai. (1995a) and dogs (0.55-1.65 mglkg) (McKellar et ai., 1989). 
Inhibition of WBCs and PLT in venous blood may be associated with some side effects of 
NSAIDs since such inhibition is associated with immuno-suppression and blood dyscrasias. The 
present studies demonstrated that none of the tested NSAIDs modified the numbers of WBC and 
PL T in venous blood in the tested animal species. The NSAIDs in the present study were given 
as a single dose and the dose rates were determined following clinical recommendations in 
horses (PBZ and FM) or dogs (CPF). Thrombocytopaenia and leukopaenia may occur during the 
treatment with NSAIDs, especially PBZ in horses (Lees & Higgins, 1985). However this 
happens only at high dose rates or following repeated administration for a long duration. 
In the present study, the PK ofPBZ was investigated in sheep, goats and donkeys and the results 
showed inter-species differences and similarities. The elimination ofPBZ in plasma (Chapter 6), 
exudate and transudate in the donkey study was faster than in horses (Piperno et ai., 1968; Lees 
et ai., 1986; Maitho et ai., 1986; Lees et ai., 1987c). The elimination of plasma PBZ in sheep 
was similar to the values in goats but it was faster than in the large ruminant species, such as 
cattle (Lees et al., 1988). This may reflect a difference of hydroxylation function between animal 
species since the hydroxylated metabolite ofPBZ, OPBZ in donkeys was more predominant th~ 
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in the horse and the ratios ofOPBZ to PBZ in both goats (Chapter 7) and sheep (Chapter 3) were 
very low «5 %). 
In the present study the plasma kinetics of FM demonstrated less inter-species differences 
compared with PBZ. The elimination of FM from plasma in the donkeys (t! J3 = 2.09 ± 0.45 h, 
2 
Chapter 7) was similar to that in horses (t! J3 = 1.94 ± 0.24 h, Lees et al., 1987a, 1987c) and was 
2 
also similar to that in sheep (2.33 ± 0.18 h). These values were shorter than the values reported in 
calves but the dose rate used in calves (Landoni et al., 1995a) was double that used in sheep. 
Because of the physicochemical properties including weak acid nature and high protein binding, 
NSAIDs accumulate in inflammatory sites so that the elimination of NSAIDs in exudate is 
slower than in plasma and transudate. This has, at least, been shown for FM in horses and calves 
(Lees & Higgins, 1984; Lees, 1989; Landoni et al., 1995a), PBZ in horses (Lees & Higgins, 
1986; Lees et al., 1986), meloxicam in horses (Lees et a/., 1991b), CPF in dogs and calves 
(McKellar et al., 1994a; Lees et al., 1996), KPF in calves (Landoni et al., 1995b) and tolfenamic 
acid in calves (Landoni et al., 1996). In the present study, the elimination of PBZ and FM in 
exudate and transudate was slower than in plasma in all tested animals but the greater penetration 
in exudate than in transudate was achieved only for PBZ in donkeys. This may be explained by 
the intensive extravascular penetration for the NSAIDs in sheep. Flunixin meglumine and PBZ 
achieved a higher concentrations in exudate and transudate in sheep compared with the results 
reported in horses (Lees et al., 1986) and calves (Landoni et al., 1995a). This may also reflect a 
lower protein binding of the NSAIDs in sheep. The slower elimination of NSAIDs in exudate 
than in plasma may explain why NSAIDs ofie,n exert longer antiinflammatory effects than their 
plasma concentration would indicate. This may be of therapeutic interest since it confers more 
opportunity on the NSAIDs to produce their therapeutic effects. When determining the dose rates 
of a NSAID, particular attention should be paid to its kinetic behaviour in inflammatory sites. 
The percentage inhibitory effect for serum TXB2 produced by PBZ and FM declined in a 
sigmoidal fashion while the drug concentrations in plasma decayed exponentially (Fig. 9.1.). 
Thus it is difficult to predict the phannacological responses from PK parameters. 
PhannacokineticlPD modelling has been widely used to establish the relationship between drug 
effect and concentration. When the phannacological effects are associated with the plasma 
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(central compartment) or some other pharmacokinetically identifiable compartment, the effect-
drug concentration data can be directly fitted to a PD model, such as sigmoid effect model 
(Gibaldi & Perrier, 1982d) and this may generate reliable results. If the pharmacological effects 
take place in other sites where the determination of the drug concentration is not possible, a 
mamillary effect compartment model may be used. This model assumes that the effect 
compartment is a separate compartment linked to the plasma compartment by a first-order 
process and receives a negligible mass of drug (Sheiner et al., 1979; Whitting et al., 1980; 
Gibaldi & Perrier, 1982d). Recently effect compartment models have been used for NSAIDs to 
establish the relationship between the antiinflammatory effects and the drug concentrations 
(Toutain et al., 1994; Landoni et al., 1995a, 1995b; 1996). Since it predicts PK in the effect 
compartment using plasma drug kinetics and for most of the NSAIDs the plasma kinetics are 
different from the exudate kinetics, the parameters generated may be somewhat misleading. In 
the present study, the effect of the NSAIDs on serum TXB2 is associated with the plasma or 
central compartment and the effect on PGE2 takes place in the tissue-cage exudate so that both 
pharmacological responses and drug concentrations are measurable. However, some NSAIDs, 
especially FM, has a longer inhibitory effects on exudate PGE2 and serum TXB2 than detectable 
drug concentrations would predict. For example FM was not detectable in plasma after 24 h in 
most animals while it produced 37.33 % inhibitory effect for serum TXB2 generation in the 
sheep (Chapter 3). Pharmacodynamic fitting using drug effect against drug concentration is not 
applicable. In order to link drug effect and concentration, we applied the methods described in 
Chapter 2. The results showed that this method was practicable and reliable because it used drug 
effect and concentration directly determined in the associated sites or compartment. The 
elimination ofPBZ in sheep was very slow so that the drug concentrations were detectable over a 
period of 144 h in plasma and exudate. We, therefore, used two methods to obtain the PD 
parameters for this drug. Firstly a Sigmoid inhibitory effect model using drug effect-
concentration data was directly fitted and secondly the method described in Chapter 2 to link PK 
and PD was used. The results showed that both methods generated similar PD parameters. For 
example, in the estimation of the relationship between inhibitory effect of PBZ on serum TXB2 
and the drug concentration, the former method generated an Emax of 81 % and an ICso of 9.98 
Ilglml while the latter method produced an Emax of 80 % and an ICso of 10.10 Ilg/ml. These 
methods, therefore, appear to be reliable for PKJPD modelling when the drug concentration and 
effects are identifiable. 
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9.2. Potential use ofPBZ, FM and CPF in sheep 
The present study in sheep showed that PBZ inhibits COX-l and has a very weak inhibitory 
effect for COX-2. It did not significantly inhibit skin temperature over the cages. This suggests 
that PBZ has poor antiinflammatory and antipyretic effects in sheep. It may possess side effect, 
such as ulceration and loss of protein associated with COX-l inhibition if it is used for a long 
duration although further confirmation of tolerance is required in sheep. It has been reported that 
the toxicity of PBZ is different between species, it has narrow therapeutic index in the horse but 
is relatively safe in the dogs (Tobin et al., 1986; Lees, 1992). The PK study in sheep showed that 
the elimination ofPBZ from plasma, exudate and transudate was very slow but that accumulation 
of the drug in the inflammatory site was not significant. Compartmental modelling showed PBZ 
had similar values for elimination half life in plasma (t 1 ~ = 17.92 ± 1.74 h), exudate (t1 KIO = 
2 2 
17.82 ± 1.27 h) and transudate (t1 KIO = 16.24 ± 1.60 h), and the concentration time curves 
2 
confirmed that PBZ declined at same rates in plasma, exudate and transudate (Fig. 3.2.). The 
predicted residue times may be very long for PBZ in sheep since at 144 h after drug 
administration PBZ was detectable in all body fluids tested at relatively high concentrations (> 
0.2 J.1g1ml). If the PBZ concentration in plasma following i.v. administration ofPBZ at 4.4 mglkg 
is extrapolated using the three compartmental model described in Table 3.2., the concentration 
would be 0.0053 ± 0.0023 J.1g1ml at 10 days and 0.00022 ± 0.0001 J.1g1ml at 14 days. Sheep are 
important food producing animals. If PBZ is used in this species for the purpose of food 
provision, the withdrawal periods may be very long. Therefore PBZ can not be recommended for 
clinical use in sheep based on the present studies. 
Flunixin meglumine inhibits COX-l and COX-2 intensely with a modest selectivity for COX-2 
in the inflammatory exudate in sheep. The ICso for COX-2 was very low and it produced 50 % of 
inhibitory effect for longer than 144 h following an i. v. administration at a single dose rate of 1.1 
mg/kg in this species. It also abolished or significantly inhibited the increase in skin temperature 
over the inflammatory foci. The PK properties of FM are also attractive. It steadily penetrated 
into and was slowly eliminated from the inflammatory exudate so that the elimination from 
exudate was slower than from plasma. The drug became undetectable (below 0.05 J.1g1ml) at 24 h 
in plasma and at 72 h in exudate and transudate. Extrapolation based on the compartmental 
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model equation described in Chapter 3 predicted that at 144 h, the drug concentration would be 
3.67x 10-15 J.Lglml in plasma, 0.00019 J.Lglml in exudate and 0.00093 J.Lglml in transudate. This 
suggests that a short residue time and withdrawal time may be appropriate in sheep. It has been 
demonstrated that FM had the greatest antiinflammatory and analgesic effects in horse among a 
group of NSAIDs, including meclofenamic acid, PBZ, naproxen and salicylate (Deegen, 1992) 
and that FM is relatively safe in horses (Lees & Higgins, 1985). Flunixin meglumine has been 
licensed in cattle in UK at 2.2 mg/kg, for administration i.v. once daily for up to 5 days and it has 
been widely used for the treatment of acute inflammation and other diseases including 
respiratory disease, fog fever, gastroenteritis, mastitis, endoxemia, anaphylactic reactions, 
arthropathies, bacterial and viral pneumonia (Espinasse, 1992). It is likely that FM is a useful 
NSAID for clinical use in sheep although tolerance studies are required before it can be 
recommended. Since the present study showed that an i.v. dose rate of 1.1 mglkg was sufficient 
to abolish or inhibit COX-l for up to 32 h and to produce over 50 % of inhibition for COX-2 for 
up to 144 h, it appears that the dose rate should be lower than 1.1 mglkg ifFM is repeatedly used 
in sheep. 
In the present study in sheep CPF non-selectively inhibited COX-l and COX-2 at an i.v. dose 
rate of 4.0 mg/kg and simultaneously inhibited skin temperature rise over the inflammatory sites. 
Further studies in our laboratory showed that CPF was an effective analgesic in sheep and that 
the analgesic effect was equal to FM (Welsh & Nolan, 1994b, 1995). Also in a study in dogs, 
CPF provided profound analgesia which was as effective and of longer duration than that 
produced by papaveretum, and was associated with significantly less postoperative sedation and 
a quicker return to the nonnal conscious state (Nolan & Reid, 1993). However at 4.0 mglkg CPF 
did not significantly inhibit COX-lor COX-2 in dogs (McKellar et al., 1994a). Carprofen may 
be considered as a conventional NSAID with potent antiinflammatory and analgesic effects in 
sheep. However, the elimination of CPF in sheep was very slow. Following CPF administration 
ivat 0.7 and 4.0 mglkg in the sheep, plasma t1 J3 was 26.1 hand 33.7 h, respectively (Welsh et 
2 
al., 1992). In the present study rac-CPF was detectable at relative high plasma drug 
concentrations (> 1. 0 J.Lglml) at 144 h after i. v. administration of rac-CPF at 4.0 mglkg in sheep 
(Data not reported). This suggests that the withdrawal period of CPF may be long when used in 
sheep for food provision. Slower elimination ofR(-)CPF than S(+)CPF has been shown in horses 
(Graser et al., 1991; Lees et al., 1991a), dogs (McKellar et al., 1994a), calves (Lees et. al., 1996) 
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and sheep in the present study (Data not reported). The S( + )CPF enantiomers contributes to the 
therapeutic effects and the R( -)CPF enantiomers may have side effects with less or no therapeutic 
effects. It may be desirable to develop a preparation containing the S( + )CPF enantiomer only for 
veterinary clinical use. 
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Fig. 9.1. Relationship between percentage serumTXB2 inhibition and plasma 
drug concentration following PBZ (a), (4.4 mglkg) and FM (b), (1.1 mglkg) 
administered Lv. in 8 sheep (mean ± SE). Both PBZ and FM inhibit serum TXB2 
generation for up to 32 h (P<O.05). 
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Appendix A 
Pharmacokinetics and pharmacodynamics of phenylbutazone and flunixin meglumine in 
sheep 
Experimental code: QMlZCI11194 
Table A-I. 
The concentrations (!Jglml) of phenylbutazone (PBZ) in plasma following intravenous (i.v.) 
administration of PBZ at 4.4 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
0.08 89.42 39.55 74.08 81.67 86.60 80.85 78.91 86.34 
0.25 76.99 36.79 52.81 66.92 76.02 65.38 58.93 63.45 
0.50 64.90 41.12 59.51 61.16 63.11 52.98 50.63 53.08 
0.75 59.29 35.40 38.17 46.78 59.79 51.29 49.01 53.62 
1.00 59.15 38.79 37.76 50.38 56.62 44.56 44.37 48.64 
2.00 54.08 40.53 27.88 44.65 47.01 38.57 43.28 40.77 
4.00 45.86 41.18 31.16 40.49 39.59 40.34 35.30 34.53 
6.00 40.89 37.85 25.01 35.36 32.75 32.79 32.45 31.74 
8.00 37.89 31.55 23.59 34.26 28.01 28.77 29.90g 25.35 
12.00 32.54 19.06 16.40 24.14 23.75 23.61 25.26 19.22 
24.00 22.06 8.88 7.67 14.39 12.42 15.29 15.12 8.49 
32.00 14.05 6.32 4.55 12.57 6.90 11.61 8.80 5.91 
48.00 7.71 2.99 1.56 7.33 2.51 6.20 5.50 2.34 
72.00 3.90 0.77 0.34 3.39 1.00 3.13 2.36 0.55 
96.00 1.66 0.22 0.09 1.39 0.25 1.21 1.11 0.15 
120.00 0.90 0.25 0.02 0.34 0.11 0.57 0.53 0.69 
144.00 0.49 0.09 0.00 0.73 0.07 0.31 0.22 0.00 
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Table A-2. 
The concentrations (~glml) of phenylbutazone (PBZ) in exudate following intravenous (i.v.) 
administration ofPBZ at 4.4 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.86 1.21 4.75 2.26 7.30 2.70 20.35 3.34 
4 9.18 10.09 11.09 18.19 19.26 15.57 19.97 19.14 
8 16.85 18.82 17.10 20.64 25.87 21.71 28.11 20.65 
12 23.71 18.l3 12.24 14.59 19.81 23.18 27.42 21.16 
24 16.32 14.97 8.94 16.17 14.09 l3.80 19.31 18.26 
32 13.93 1O.l3 3.65 9.69 7.60 14.37 16.88 8.44 
48 3.74 5.13 2.60 6.73 3.89 4.03 8.24 5.05 
72 4.84 2.00 0.78 2.23 1.30 5.77 5.44 0.76 
96 2.85 0.72 0.22 1.50 1.69 2.22 2.06 0.65 
120 1.72 0.26 0.11 0.58 1.26 1.l3 0.17 0.29 
144 UD UD 0.07 0.24 trussmg 0.34 mIsssmg 0.12 
UD = undetectable «0.05 ~glml) 
Table A-3. 
The concentrations (~glml) of phenylbutazone (PBZ) in transudate following intravenous 
administration ofPBZ at 4.4 rnglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.52 2.86 1.87 0.49 2.12 2.10 2.49 2.61 
4 12.14 9.51 8.19 2.70 16.41 6.00 missing 21.23 
8 22.41 15.80 19.08 14.61 24.23 11.06 21.17 26.06 
12 27.69 20.12 18.35 missing 21.52 l3.88 21.16 22.17 
24 20.21 11.86 11.25 24.35 5.78 13.63 14.64 12.64 
32 l3.39 5.78 5.35 15.97 6.47 10.04 13.20 7.46 
48 3.51 4.02 2.64 12.47 8.30 missing 5.77 3.17 
72 3.43 1.29 1.00 6.66 2.09 2.44 3.00 1.23 
96 3.51 0.31 0.04 3.20 missing 1.48 1.50 0.26 
120 0.11 0.11 0.02 0.95 0.18 0.84 0.23 0.10 
144 missing 0.10 mIssmg 0.83 0.45 0.50 mIssmg missing 
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Table A-4. 
The concentrations (J.lglml) of oxyphenbutazone in plasma following intravenous administration 
of phenylbutazone at 4.4 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
0.08 0.40 0.16 0.51 0.35 0.45 0.24 0.34 0.58 
0.25 0.58 0.29 1.24 0.61 0.84 0.41 0.69 0.95 
0.50 0.74 0.61 0.91 0.83 1.05 0.46 0.65 1.20 
0.75 0.83 0.65 1.04 0.81 1.15 0.52 0.03 1.43 
1.00 0.85 0.82 1.03 0.96 1.11 0.54 0.84 1.39 
2.00 0.92 1.00 0.73 1.05 1.29 0.53 1.07 1.10 
4.00 0.89 1.68 1.30 1.34 1.12 0.53 1.07 1.85 
6.00 1.05 1.53 1.13 1.23 1.02 0.51 1.08 1.79 
8.00 1.10 1.16 1.12 1.19 0.11 0.47 mIssmg 1.28 
12.00 0.93 0.77 0.74 0.99 0.84 0.31 1.06 1.26 
24.00 0.68 0.48 0.63 0.71 0.73 0.38 0.76 0.71 
32.00 0.55 0.33 0.44 0.54 0.45 0.31 un 0.45 
48.00 0.25 0.21 0.16 0.24 1.93 0.13 0.30 0.18 
72.00 0.12 0.07 0.06 0.11 0.07 0.09 0.10 0.06 
96.00 0.06 0.04 0.02 0.08 un 0.06 0.07 un 
120.00 0.07 un un un un un 0.05 un 
144.00 un un un un un UN un un 
un = undetectable «0.05 J.lglml) 
Table A-S. 
The concentrations (J.lg/ml) of oxyphenbutazone in exudate following intravenous administration 
of phenylbutazone at 4.4 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 un UD 0.21 0.05 0.12 un 0.37 0.06 
4 0.16 0.29 0.54 0.53 0.59 0.16 0.37 0.68 
8 0.35 0.67 0.81 0.64 0.83 0.24 0.28 1.30 
12 0.54 0.42 0.65 0.54 0.74 0.25 0.76 0.61 
24 0.50 0.66 0.52 0.80 0.61 0.24 0.55 1.40 
32 0.41 0.42 0.13 0.51 0.48 0.24 0.48 0.43 
48 1.53 0.24 0.24 0.29 0.27 0.23 0.28 0.15 
72 0.17 0.12 0.05 0.10 0.05 0.09 0.09 0.12 
96 0.07 0.04 UD 0.08 un 0.05 0.07 un 
120 0.06 UD un un un un un 0.06 
144 0.35 un UD un mIssmg un mIssmg 0.08 
UD = undetectable «0.05 J,1g/ml) 
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Table A-6. 
The concentrations (~g/ml) of oxyphenbutazone in transudate following intravenous 
administration of phenylbutazone at 4.4 mg/kg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.06 0.08 0.07 0.07 0.05 un 0.05 un 
4 0.19 0.27 0.31 0.09 0.45 0.06 0.06 0.74 
8 0.48 0.81 0.80 0.45 0.69 0.09 0.60 1.17 
12 0.76 1.19 0.85 mlssmg 0.68 0.16 0.73 1.25 
24 0.57 0.98 0.65 0.84 0.19 0.24 0.58 0.78 
32 0.41 0.43 0.28 0.74 0.39 0.17 0.62 0.38 
48 0.28 0.37 0.21 0.49 0.36 mlssmg 0.28 0.14 
72 0.11 0.06 0.10 0.21 0.12 0.10 0.13 0.07 
96 0.16 0.04 0.09 0.08 mlssmg 0.16 0.08 0.11 
120 0.08 0.09 0.05 0.07 0.09 0.17 0.07 0.11 
144 mlssmg un mlssmg un 0.06 0.03 missing missing 
UD = undetectable «0.05 ~g1ml) 
Table A-7. 
The concentrations (~g1ml) of flunixin meglumine (FM) in plasma following intravenous 
administration ofFM at 1.1 mg/kg in sheep. 
Animal numbers 
Time (b) 143 144 145 146 147 148 149 150 
0.08 16.51 26.89 22.18 14.12 22.95 24.19 11.90 25.10 
0.25 11.56 18.33 16.61 10.66 12.71 16.78 7.93 19.60 
0.50 8.74 13.19 12.08 5.13 10.55 11.79 6.63 13.89 
0.75 6.15 10.11 9.37 5.18 8.06 9.81 5.42 11.72 
1.00 4.79 9.40 7.82 4.09 6.55 8.21 3.89 9.58 
2.00 2.74 5.60 4.40 2.14 3.42 5.25 2.05 5.33 
4.00 1.40 3.13 2.27 2.20 1.28 2.98 2.12 3.11 
6.00 0.80 1.89 1.14 0.84 0.66 1.48 0.79 1.15 
8.00 0.50 1.12 1.09 0.48 0.33 0.75 0.64 0.72 
12.00 0.13 0.26 0.26 0.19 0.07 0.38 0.21 0.41 
24.00 un 0.06 un un un 0.06 un 0.06 
32.00 un un un un un 0.05 un un 
48.00 un un un un un un un un 
UD = undetectable «0.05 ~g1ml) 
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Table A-S. 
The concentrations (~g/ml) of flunixin meglumine (FM) in exudate following intravenous 
administration of FM at 1.1 mg/kg in sheep. 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
2 0.37 0.80 0.64 0.49 0.85 0.40 0.20 1.86 
4 0.97 2.66 1.77 1.03 2.04 1.12 0.83 2.70 
8 0.89 2.55 1.47 1.52 1.45 1.57 1.32 1.92 
12 0.36 1.35 1.15 1.01 0.48 1.47 0.89 0.82 
24 0.25 0.80 0.59 0.51 0.20 0.69 0.44 0.23 
32 0.20 0.26 0.17 0.41 un 0.30 0.32 un 
48 un un un un un un un un 
UD = undetectable «0.05 ~g/ml) 
Table A-9. 
The concentrations (~g/ml) of flunixin meglumine (FM) in transudate following intravenous 
administration ofFM at 1.1 mg/kg in sheep. 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
2 0.32 0.33 0.56 0.63 0.45 0.55 0.17 0.38 
4 0.91 2.62 1.33 1.07 1.44 1.78 0.97 0.07 
8 0.98 3.55 1.43 1.11 1.11 1.01 1.00 1.27 
12 0.50 1.83 0.59 1.05 0.89 1.89 0.90 0.87 
24 0.24 1.50 0.81 0.51 0.50 0.67 0.71 0.40 
32 0.14 0.33 0.16 un 0.25 0.41 0.31 0.19 
48 0.09 0.23 un un 0.19 0.25 0.19 un 
UD = undetectable «0.05 ~g/ml) 
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Table A-lO 
The changes in skin temperature (OC) over the cages following intravenous administration of 
placebo in sheep (the values are expressed as the difference between inflamed and non-inflamed 
cages). 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min -0.2 -1.8 -1.7 -1.7 1.8 0.7 0.2 0.2 
Ih 0.0 -3.6 0.6 0.3 1.9 0.2 -1.8 -2.0 
2h 0.4 1.2 1.4 1.3 -1.1 3.4 1.4 1.6 
4h 2.0 0.9 2.9 0.7 0.1 2.3 1.3 2.0 
6h 0.0 0.6 2.5 -0.4 0.2 2.3 0.7 1.4 
8h 1.1 1.5 -1.0 -2.7 0.4 2.0 1.1 0.4 
12h 0.0 2.2 1.9 -0.5 -0.4 2.7 2.1 0.5 
24h 0.7 0.4 1.6 -0.9 -1.0 1.2 -0.6 1.8 
32h 0.9 0.5 1.5 -2.4 -0.3 1.3 -0.3 1.2 
48h -0.1 1.7 0.5 -0.3 -0.1 2.9 0.4 2.0 
72h 2.2 0.7 0.3 -0.8 -0.8 -0.1 -0.7 1.3 
96h 0.9 0.9 1.7 0.3 0.4 1.3 -0.6 0.3 
120h -0.1 0.2 0.1 -0.5 -0.8 -1.0 0.2 1.9 
144h -0.1 0.2 1.4 0.8 -0.1 -1.0 0.2 2.6 
Table A-ll 
The changes in skin temperature (OC) over the cages following intravenous administration of 
phenylbutazone at 4.4 mg/kg in sheep (the values are expressed as the difference between 
inflamed and non-inflamed cages). 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min -1.1 0.8 2.8 -1.5 -4.5 -1.1 2.5 0.4 
Ih -0.3 1.8 0.7 0.9 1.6 3.4 1.7 0.4 
2h -0.3 0.2 -0.9 -1.3 1.3 -2.2 0.8 -0.1 
4h -0.2 2.6 0.0 -1.1 2.2 -0.2 1.5 1.3 
6h 2.9 0.2 0.7 -0.9 -0.8 0.0 2.9 0.7 
8h 0.2 0.9 -0.7 -0.4 -1.3 1.0 0.9 0.8 
12h -1.5 0.3 -0.4 1.0 0.0 0.2 -1.1 1.4 
24h -0.6 0.5 1.2 -0.3 4.4 -0.8 0.8 0.0 
32h -1.2 0.9 2.8 0.7 -3.2 -1.2 2.0 1.8 
48h -0.8 0.2 2.9 -1.8 0.8 1.8 0.6 0.4 
72h -0.6 -0.3 0.3 -2.2 1.4 -2.3 1.3 0.0 
96h 1.0 -0.8 2.9 0.5 0.9 -1.8 0.9 0.0 
120h 1.2 0.5 1.1 -0.1 -1.8 -0.6 1.1 1.8 
144h 2.3 0.5 0.7 -0.1 1.2 -0.9 2.3 -0.3 
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Table A-12 
The changes in skin temperature eC) over the cages following intravenous administration of 
flunixin meglumine at 1.1 mglkg in sheep (the values are expressed as the difference between 
inflamed and non-inflamed cages). 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min -0.2 -1.2 1.5 -2.0 -0.4 1.7 -0.2 0.5 
1h 2.3 -1.3 0.1 0.7 -0.4 1.1 -2.6 -0.2 
2h -1.8 0.2 -0.5 -2.1 1.8 3.4 -1.3 -1.3 
4h -0.2 -0.1 -0.2 -1.1 -2.0 -2.5 O.S -2.4 
6h -0.2 0.5 0.4 -1.6 -0.2 -2.0 0.9 -2.4 
Sh -0.6 -1.9 0.9 -0.2 -0.2 0.9 0.9 0.1 
12h 1.6 0.4 1.2 0.4 0.0 1.4 1.2 -1.9 
24h 2.2 -0.4 1.9 0.1 1.1 1.4 1.3 0.2 
32h -1.6 -2.0 0.8 1.5 0.1 -1.1 -1.0 0.4 
4Sh 3.7 0.7 0.0 0.7 -0.1 -0.6 1.3 0.6 
72h 0.5 0.0 1.3 1.0 -1.2 3.4 1.5 -0.1 
96h 1.9 -1.3 -0.2 -0.4 -0.4 2.4 0.8 0.1 
120h -0.7 -1.3 0.9 -1.2 -0.5 0.4 -1.1 0.5 
144h -2.0 -1.4 0.9 -3.0 -0.6 2.5 -0.5 2.7 
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Table A-13. 
The concentrations (ng/ml) of serum thromboxane B2 following intravenous administration of 
placebo in sheep. 
Animal number 
Time 143 144 145 146 147 148 149 150 
-20 min 20.36 20.09 23.78 20.02 10.91 19.65 30.55 22.07 
Ih 8.87 19.08 19.06 9.21 7.76 16.29 8.42 19.03 
2h 17.04 20.70 16.36 8.03 9.75 18.89 3l.86 19.03 
4h 16.35 17.37 22.97 13.36 9.74 18.11 29.19 16.83 
6h 14.12 13.92 16.78 11.79 6.43 15.99 29.33 17.84 
8h 16.42 18.56 15.89 11.03 8.73 16.48 29.50 17.13 
12 h 11.43 13.74 12.57 8.41 7.60 14.82 28.95 13.43 
24 h 12.70 17.73 16.34 13.44 7.84 18.09 30.00 14.57 
32 h 14.95 17.04 24.21 14.30 15.91 19.57 28.61 21.89 
48 h 17.03 2l.06 25.37 17.11 10.62 20.69 29.58 22.59 
72 h 20.79 20.24 25.79 18.30 16.48 21.05 31.93 27.42 
96h 21.56 22.14 31.71 21.56 20.93 22.86 31.00 24.14 
120h 24.87 22.12 21.83 21.87 20.92 22.67 32.34 26.17 
144 h 23.99 24.56 26.38 22.71 23.75 24.35 32.03 22.65 
Table A-14. 
The concentrations (ng/ml) of serum thromboxane B2 following intravenous administration of 
phenylbutazone at 4.4 mglkg in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min 11.48 27.33 31.51 18.28 20.79 14.89 44.42 27.28 
Ih UD 7.25 1.40 5.02 3.49 1.43 11.04 28.70 
2h UD 7.54 1.37 4.01 2.37 UD 17.07 12.54 
4h 2.96 12.09 2.65 4.84 5.72 2.21 30.09 11.95 
6h 2.96 7.12 1.37 2.78 3.47 UD 21.38 13.21 
8h 2.24 9.57 2.50 4.65 4.68 1.66 14.78 13.27 
12 h 1.49 8.12 3.44 4.31 10.52 1.83 13.65 12.72 
24h 7.17 14.75 11.27 8.96 17.85 4.07 41.70 21.45 
32 h 3.24 15.57 10.33 11.82 12.91 6.04 21.68 20.25 
48 h 9.22 28.68 20.13 18.83 20.41 9.83 58.71 26.28 
72h 16.10 23.94 28.47 20.53 22.09 17.24 51.74 27.55 
96h 18.18 26.42 26.21 19.84 37.02 16.79 5.68 29.34 
120h 17.88 26.18 33.62 24.43 36.97 17.19 52.22 28.93 
144h 17.27 24.39 28.38 25.70 26.72 15.94 51.57 28.84 
UD = undetectable «0.8 nglml) 
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Table A-15. 
The concentrations (nglml) of serum thromboxane B2 following intravenous administration of 
flunixin meglumine at 1.1 mglkg in sheep. 
Animal number 
Time 143 144 145 146 147 148 149 150 
-20 mins 11.12 25.27 22.45 22.01 21.55 22.81 35.47 29.81 
Ih un un un un un un un un 
2h un un un un un un un un 
4h un un un un un un un un 
6h un un un un un un un un 
8h un un un un un un un un 
12 h un un un un un un 0.67 un 
24 h 1.92 4.73 13.88 3.18 10.74 4.79 22.32 8.32 
32 h 6.44 15.04 17.71 10.27 15.14 10.68 27.19 19.27 
48 h 8.86 27.28 27.07 18.15 19.17 18.30 33.96 27.63 
72 h 6.75 30.12 31.12 17.28 17.58 23.56 38.32 29.39 
96 h 10.59 29.84 28.51 23.58 17.52 24.46 35.00 32.60 
120 h 9.32 28.25 27.17 21.24 18.88 20.35 33.85 26.99 
144 h 17.80 28.35 26.26 19.54 17.69 24.57 33.21 25.09 
un = undetectable «0.8 nglml) 
Table A-16. 
The concentrations (nglml) of exudate prostaglandin E2 following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min un UD un un un un UD un 
2h 0.32 UD 0.28 un 1.81 UD 19.55 11.00 
4h 1.41 16.05 2.29 3.88 27.64 2.08 41.10 25.52 
8h 38.79 27.14 28.31 45.88 29.56 42.44 27.62 
12 h 55.40 27.68 34.72 9.25 46.60 37.69 43.09 30.79 
24h 33.71 32.53 32.76 17.06 44.16 22.80 28.71 20.85 
32 h 45.47 12.08 11.71 9.29 26.53 7.66 30.80 16.01 
48h 6.89 3.83 0.88 2.91 16.53 0.68 20.50 17.09 
72h 1.28 0.92 0.49 1.41 3.98 0.00 31.08 21.69 
96h 1.15 0.00 0.513 5.42 0.00 0.00 25.35 29.31 
120h 1.95 0.00 0.75 5.91 1.02 0.52 31.80 29.50 
144 h 8.33 2.12 0.47 
un = undetectable «0.8 nglml) 
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Table A-I7. 
The concentrations (ng/ml) of exudate prostaglandin E2 following intravenous administration of 
phenylbutazone at 4.4 mglkg in sheep. 
Animal number 
Time 143 144 145 146 147 148 149 150 
-20 min UD UD 1.80 UD UD UD UD UD 
2h 0.33 UD 1.11 un un un un un 
4h 1.04 1.59 22.23 16.52 0.49 14.69 0.05 0.73 
8h 39.66 41.17 37.53 40.26 8.20 39.01 7.45 17.90 
12 h 43.63 17.84 7.67 37.88 8.32 33.26 7.65 20.16 
24h 41.33 2.69 35.l1 37.93 4.91 31.04 6.63 32.73 
32 h 37.21 1.72 21.12 7.99 1.34 34.94 2.31 7.62 
48 h 6.58 0.00 21.03 0.99 0.24 29.26 0.28 1.07 
72 h 0.96 0.00 9.56 0.00 0.40 1.15 0.26 0.43 
96h 0.59 0.00 7.11 0.00 4.24 0.27 0.23 0.59 
120 h 1.15 0.00 7.61 0.00 0.06 0.66 2.31 0.73 
144 h 1.15 0.00 1.78 1.02 
un = undetectable «0.8 ng/ml) 
Table A-IS. 
The concentrations (ng/ml) of exudate prostaglandin E2 following intravenous administration of 
flunixin meglumine at 1.1 mglkg in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min un un un un un un UD UD 
2h un un un un un un un un 
4h un un UD un un UD UD un 
8h un un un 1.47 un un un un 
12 h 1.00 un UD 11.79 un un 0.42 0.28 
24h 0.77 un un 21.01 un un 3.45 0.23 
32 h 3.96 un un 19.68 1.42 un 12.20 0.46 
48 h 2.33 un un 2.02 0.51 un 11.19 0.75 
72 h 1.61 UD UD 0.92 0.43 UD 3.29 3.l0 
96 h 6.37 UD un 1.94 0.58 un 4.33 0.31 
120h 4.31 UD UD 2.25 0.75 un 6.88 4.06 
144h 9.70 UD un un 0.74 un un un 
UD = undetectable «0.8 nglml) 
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Table A-19. 
The concentrations (nglml) of exudate leukotriene B4 following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.45 0.46 2.57 1.80 0.54 0.20 0.50 1.61 
4 0.60 0.85 1.91 2.99 1.32 0.23 0.97 1.67 
8 0.71 0.99 2.26 3.44 0.53 0.55 0.92 1.21 
12 0.88 2.05 1.90 3.25 1.04 0.66 1.04 2.20 
24 0.45 1.09 2.08 2.22 0.51 0.39 0.74 1.12 
32 0.90 0.73 2.01 2.43 1.01 0.29 0.55 1.51 
48 0.80 0.83 2.24 1.77 0.57 0.28 0.94 1.58 
72 0.97 0.76 2.61 3.46 0.47 0.26 1.02 2.17 
96 0.95 0.77 1.85 3.85 0.74 0.33 1.06 2.25 
120 0.71 0.51 1.57 3.08 1.05 0.35 0.84 1.77 
144 0.70 1.11 0.46 
Table A-20. 
The concentrations (nglml) of exudate leukotriene B4 following intravenous administration of 
phenylbutazone at 4.4 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 1.67 0.35 0.60 0.32 2.21 1.08 2.28 0.27 
4 2.12 0.37 0.85 0.52 2.50 0.88 1.82 0.54 
8 1.38 0.82 0.96 0.84 2.64 0.76 1.83 0.55 
12 1.76 0.72 1.66 1.05 2.63 0.90 2.30 0.43 
24 1.93 0.40 0.79 0.53 2.43 0.74 2.48 0.43 
32 1.58 0.44 0.67 0.54 2.73 1.79 2.81 0.62 
48 1.94 0.33 0.82 0.53 2.53 1.64 3.20 0.69 
72 2.28 0.59 0.72 0.55 4.46 1.60 3.08 0.40 
96 1.92 0.44 1.06 0.50 3.40 1.65 3.22 0.68 
120 1.92 0.46 1.07 0.48 2.44 1.49 3.33 0.53 
144 0.79 0.94 2.06 1.14 
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Table A-21. 
The concentrations (ng/ml) of exudate leukotriene B4 following intravenous administration of 
flunixin meglumine at 1.1 mg/kg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.79 2.06 0.39 0.70 0.59 1.90 0.87 1.47 
4 1.07 2.42 0.55 0.98 0.66 2.16 1.07 2.17 
8 1.31 2.47 0.62 1.28 0.56 2.08 1.82 2.67 
12 1.31 1.82 0.58 1.44 0.57 2.52 1.84 2.30 
24 0.68 2.70 0.59 1.17 0.32 2.26 1.81 2.33 
32 0.73 2.24 0.68 0.84 0.59 2.23 1.77 1.91 
48 0.65 2.14 0.46 0.65 0.34 3.20 1.62 2.53 
72 0.81 2.26 0.49 0.79 0.37 1.70 1.58 2.06 
96 1.25 2.56 0.77 0.55 0.53 2.28 1.66 2.45 
120 1.03 0.69 1.14 1.16 3.08 1.54 2.21 
144 0.80 0.65 0.51 
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Table A-22. 
Leukocyte numbers (x 109 cellslL) in exudate following intravenous administration of placebo in 
sheep. 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
4 4.9 3.3 6.3 5.0 7.1 6.3 10.6 29.9 
8 12.3 7.5 8.9 10.2 40.5 29.1 15.6 22.5 
12 23.2 19.9 25.1 14.6 23.8 64.8 26.1 15.7 
24 37.6 26.1 18.0 68.7 24.5 89.2 23.2 48.3 
48 5.6 14.5 3.8 12.6 18.9 18.9 26.1 
Table A-23. 
Leukocyte numbers (x 109 cellslL) in exudate following intravenous administration of 
phenylbutazone at 4.4 mglkg in sheep. 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
4 4.6 10.4 4.5 6.2 8.3 2.5 7.8 7.7 
8 10.8 4.8 13.0 16.7 10.2 12.1 17.1 12.8 
12 17.8 16.0 14.1 32.2 7.7 17.9 37.7 18.8 
24 26.0 47.7 40.5 17.5 14.5 42.8 5.4 18.4 
48 7.2 12.8 17.4 7.7 3.1 5.7 5.6 7.4 
Table A-24. 
Leukocyte numbers (x 109 cells/L) in exudate following intravenous administration offlunixin 
meglumine at 1.1 mglkg in sheep. 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
4 2.4 5.6 8.0 4.6 7.4 9.7 1.9 6.1 
8 10.5 14.5 12.3 18.4 7.0 25.1 5.6 9.2 
12 15.7 10.5 28.4 23.3 17.8 17.1 6.5 6.5 
24 34.3 31.0 42.7 64.5 15.4 74.4 22.1 15.5 
48 9.1 6.2 10.8 19.6 4.7 8.1 7.6 3.7 
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Table A-25. 
Leukocyte numbers (x 109 cellslL) in venous blood following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min 6.0 5.7 7.2 5.4 8.6 6.1 6.9 7.3 
4h 5.6 5.2 7.0 5.8 7.2 5.6 6.8 9.1 
24h 7.2 6.9 8.6 6.8 10.0 9.1 6.9 10.9 
48 h 6.4 5.8 7.5 5.7 8.7 6.3 6.4 10.0 
Table A-26. 
Leukocyte numbers (x 109 cellslL) in venous blood following intravenous administration of 
phenylbutazone at 4.4 mglkg in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min 6.4 5.4 5.6 4.4 8.4 CLOT 7.1 9.5 
4h 6.2 8.2 6.1 4.6 9.2 6.4 6.4 6.8 
24h 7.2 9.1 5.8 6.2 9.3 8.3 6.8 9.3 
48h 6.5 6.3 5.9 5.5 9.1 7.3 5.4 8.7 
Table A-27. 
Leukocyte numbers (x 109 cellslL) in venous blood following intravenous administration of 
flunixin meglumine at 1.1 mglkg in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min 4.5 5.9 6.6 5.5 7.8 6.4 6.1 9.6 
4h 4.5 5.0 8.9 5.1 7.0 7.2 5.7 9.3 
24h 5.9 5.8 8.3 6.4 9.2 8.0 3.6 10.7 
48h 5.2 9.8 7.1 5.2 7.5 7.1 10.0 9.8 
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Table A-28. 
Platelet numbers (x 109 cells/L) in venous blood following intravenous administration of placebo 
in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min 199.0 216.0 270.0 254.0 234.0 245.0 116.0 73.0 
4h 211.0 239.0 278.0 227.0 234.0 201.0 139.0 47.0 
24h 217.0 213.0 301.0 224.0 214.0 240.0 196.0 31.0 
48 h 207.0 252.0 309.0 226.0 278.0 231.0 135.0 45.0 
Table A-29. 
Platelet numbers (x 109 cells/L) in venous blood following intravenous administration of 
phenylbutazone at 4.4 mglkg in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min 229.0 241.0 256.0 93.0 183.0 265.0 78.0 
4h 217.0 159.0 254.0 210.0 259.0 184.0 202.0 95.0 
24h 225.0 222.0 263.0 217.0 265.0 186.0 72.0 75.0 
48 h 227.0 219.0 274.0 218.0 242.0 241.0 70.0 81.0 
Table A-30. 
Platelet numbers (x 109 cellslL) in venous blood following intravenous administration offlunixin 
meglumine at 1.1 mglkg in sheep. 
Animal numbers 
Time 143 144 145 146 147 148 149 150 
-20 min 188.0 254.0 246.0 149.0 260.0 36.0 220.0 73.0 
4 239.0 252.0 169.0 247.0 154.0 212.0 
24 198.0 232.0 124.0 164.0 233.0 90.0 36.0 67.0 
48 197.0 253.0 248.0 167.0 241.0 158.0 159.0 70.0 
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Table B-1. 
Appendix B 
Pharmacodynamics of carprofen and its enantiomers in sheep 
Expermental code: QMlZC/03/95 
Skin temperature (OC) over the cages following intravenous administration of placebo in sheep 
(Values are expressed as the difference between inflamed and non-inflamed tissue-cages). 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 -0.8 0.0 0.3 0.2 0.8 0.0 
1 -0.6 -0.8 -1.2 1.1 1.0 0.2 1.7 0.9 
2 -0.7 0.8 0.6 0.5 1.5 -0.1 0.4 -0.7 
4 1.4 -2.4 -0.4 0.7 0.5 0.1 1.3 0.8 
6 1.0 0.1 1.6 0.1 0.9 0.6 1.1 0.4 
8 1.0 0.7 1.7 0.3 0.2 0.5 1.1 0.4 
12 1.7 0.2 1.1 1.4 0.1 0.4 1.3 4.4 
24 0.1 -0.3 -0.6 1.0 0.1 0.7 0.8 1.6 
32 0.9 OJ -0.3 -0.1 -0.5 -0.2 0.5 1.7 
48 1.1 -0.7 -0.2 -0.1 -0.8 0.7 0.2 1.1 
72 1.3 0.7 0.4 -1.0 0.5 0.7 -1.1 0.4 
96 1.5 -1.9 -0.7 -0.2 1.1 -0.8 0.5 0.9 
120 1.0 -0.2 -0.8 -0.2 1.1 -0.5 0.6 1.3 
144 -0.8 -0.7 0.8 1.4 1.2 0.0 0.8 1.2 
Table B-2. 
Skin temperature eC) over the cages following intravenous administration of racemic carprofen 
at 4.0 mglkg in sheep (Values are expressed as the difference between inflamed and non-
inflamed tissue-cages). 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
-OJ3 -0.6 -0.3 -0.2 0.6 0.4 0.3 
1 -1.5 -0.3 -0.3 -0.1 1.0 -0.6 
2 -1.0 0.0 2.3 -0.7 -0.4 -0.1 2.0 1.2 
4 0.1 0.0 1.3 -0.2 1.0 1.1 0.9 0.2 
6 0.4 0.1 2.9 0.2 0.7 0.6 -0.6 0.6 
8 -0.1 0.0 2.3 -0.3 0.5 1.3 0.2 0.5 
12 1.0 -1.4 1.4 0.7 0.2 2.1 -0.7 2.3 
24 1.4 -0.5 0.8 -1.1 0.4 1.9 -1.7 -0.2 
32 0.0 -1.3 0.8 2.5 0.9 0.9 0.6 -0.1 
48 1.3 0.6 0.7 0.4 1.6 1.8 0.5 -0.5 
72 -1.7 0.0 1.8 0.9 -0.9 0.8 -0.6 -0.8 
96 0.0 -0.1 0.5 1.8 0.0 1.0 -0.5 -0.1 
120 0.0 1.5 0.3 -1.1 -0.1 0.3 
144 1.8 -1.1 0.6 -0.1 0.3 -0.2 0.8 -0.5 
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Table 8-3. 
Skin temperature (OC) over the cages following intravenous administration of R( -) carprofen at 
2.0 mg/kg in sheep (Values are expressed as the difference between inflamed and non-inflamed 
tissue-cages ). 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
-0.33 0.5 -0.7 0.5 -0.9 -1 0.9 
1 -2.1 2.2 0.2 -0.7 0 0.1 0.9 
2 1 1 0.2 0.8 1.4 0.3 -0.3 0.8 
4 -0.8 1.2 0.3 0.7 0.1 0.3 -1.2 3.1 
6 -0.4 0.7 0.5 1.7 0.5 0.6 0.8 1.2 
8 1.8 0.7 -0.1 0.6 0.6 0.2 0.8 0 
12 0.6 0.8 0.3 1.9 0.5 0.8 2 0 
24 1.4 -0.5 -0.4 0.4 -0.5 -1.5 1 0.2 
32 0.8 -0.1 -1.2 0.5 0.5 0.2 1.5 -0.2 
48 1.8 -0.4 0.5 0.7 1.1 -0.5 1.2 -0.8 
72 0.2 -0.6 -0.7 -0.2 0.6 -0.7 1.2 -0.3 
96 0.1 -0.2 0.4 0.2 1.8 -0.4 1.2 -0.1 
120 0.8 0.1 0.8 1.1 -0.6 0.4 
144 1.4 -2.1 0.8 2.2 0.6 -0.4 2 1.1 
Table 8-4. 
Skin temperature (OC) over the cages following intravenous administration of S( +) carprofen at 
2.0 mg/kg in sheep (Values are expressed as the difference between inflamed and non-inflamed 
tissue-cages). 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
-0.33 0.6 -0.7 1.3 0.9 -0.7 0.1 1.2 
1 0.1 -0.8 0.2 -0.5 0.1 0.2 
2 1.6 0.6 1.5 -0.2 1.2 0.5 0.6 -0.4 
4 0.7 -0.2 1.7 0.4 0.7 2.0 0.4 0.6 
6 0.2 0.0 0.7 -0.6 1.2 1.3 0.4 1.5 
8 1.2 0.1 0.1 0.3 -1.5 -0.1 1.3 -0.4 
12 0.6 0.8 2.4 0.9 1.0 -0.1 1.2 0.0 
24 0.0 0.2 1.4 -1.8 0.6 0.3 0.7 0.8 
32 0.5 -0.2 1.3 1.1 -0.8 2.0 0.7 -0.1 
48 1.0 0.2 -1.2 0.4 0.4 3.2 0.0 0.4 
72 0.5 -0.4 0.7 -1.4 0.1 0.5 1.0 0.1 
96 0.6 0.0 0.5 1.2 0.0 0.6 0.7 0.3 
120 -0.7 0.0 1.1 -0.9 -0.3 0.3 
144 0.0 0.6 0.7 1.5 0.6 0.9 0.8 1.8 
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Table B-5. 
Skin temperature (OC) over the cages following intravenous administration of ~ -nitro-L-
arginine methyl ester at 25 mglkg in sheep (Values are expressed as the difference between 
inflamed and non-inflamed tissue-cages). 
Animal numbers 
Time(h} 143 144 145 146 147 148 149 150 
-0.33 -0.1 0.8 1.0 1.4 -0.4 -0.7 1.1 0.4 
1 0.1 0.5 -1.4 0.2 -1.0 0.3 0.0 
2 -0.6 0.4 0.1 0.1 0.1 1.5 0.5 -1.6 
4 1.0 -0.1 -0.3 -0.9 -0.6 0.7 -0.1 1.4 
6 0.3 0.9 0.1 0.7 0.4 0.3 -0.2 -0.2 
8 0.3 4.1 -0.4 -0.5 -0.2 0.4 -1.2 0.5 
12 0.3 3.0 -0.3 -0.6 0.1 0.6 -0.7 0.8 
24 -1.0 0.2 -0.4 1.4 -0.3 -0.1 1.0 -1.4 
32 -0.6 1.0 -1.1 0.1 0.0 0.5 0.6 0.0 
48 0.2 1.8 -0.2 1.0 -0.5 0.9 -0.8 -0.1 
72 1.1 -0.6 -0.4 0.1 -0.9 0.4 0.5 0.1 
96 0.1 2.4 -0.7 1.4 -0.1 1.1 0.7 -0.6 
120 3.3 -1.0 0.7 -0.1 
144 0.2 1.9 -1.1 1.0 0.2 0.7 0.1 1.6 
Table B-6. 
Concentrations of serum thromboxane B2 (nglml) following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 20.24 32.37 26.67 27.89 24.22 20.23 32.70 32.70 
1 15.35 33.04 27.83 19.98 19.17 20.53 32.56 31.46 
2 16.46 35.51 32.20 20.15 19.13 22.42 33.95 31.00 
4 14.03 32.00 29.24 23.19 20.28 27.59 29.68 31.98 
6 14.96 33.14 29.17 23.14 20.14 24.24 31.16 29.83 
8 16.27 31.91 28.34 21.91 35.72 25.48 34.01 29.45 
12 15.08 30.42 29.00 22.67 22.06 22.00 33.38 30.30 
24 15.38 32.27 31.33 22.46 25.94 25.09 35.26 25.92 
32 14.65 32.25 31.88 20.44 26.19 19.77 35.23 30.48 
48 20.62 33.24 17.72 15.28 21.74 25.22 34.84 30.71 
72 24.11 29.71 31.14 19.56 23.83 26.07 34.42 27.90 
96 21.99 45.84 23.28 34.10 34.89 16.71 61.02 50.99 
120 16.26 51.47 25.62 31.98 22.70 23.56 57.67 49.18 
144 24.45 40.63 55.46 28.82 28.25 35.99 60.17 50.62 
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Table B-7. 
Concentrations of serum thromboxane B2 (ng/ml) following intravenous administration of 
racemic carprofen at 4.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 27.43 29.07 30.96 32.46 17.05 32.16 31.09 35.35 
1 2.97 3.95 6.06 7.33 1.61 8.50 3.81 11.47 
2 5.24 4.23 9.48 8.92 2.49 10.65 4.15 11.41 
4 5.86 9.78 1.26 10.78 3.93 8.79 7.19 15.06 
6 7.86 21.82 4.59 8.48 
8 12.63 15.99 16.47 16.31 5.29 19.52 12.39 17.38 
12 6.45 5.82 14.86 19.84 9.81 10.83 15.66 17.28 
24 24.62 17.64 28.42 25.47 11.79 21.79 23.54 18.34 
32 16.66 26.68 30.45 42.58 12.31 19.82 16.29 20.29 
48 30.09 29.31 27.95 21.63 18.51 27.62 31.32 29.76 
72 30.46 28.82 25.51 31.64 18.33 33.99 34.65 31.74 
96 41.07 40.42 44.57 44.46 23.06 30.93 36.11 32.38 
120 48.96 38.73 36.59 3.48 31.69 32.74 31.86 
144 39.20 37.83 15.06 33.12 35.02 
Table B-8. 
Concentrations of serum thromboxane B2 (ng/ml) following intravenous administration ofR( -) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 22.69 38.67 27.74 38.27 18.99 27.40 37.68 26.58 
1 28.93 35.89 16.31 31.65 17.57 25.61 33.89 27.75 
2 29.43 33.38 22.24 32.49 21.86 28.99 35.99 25.34 
4 28.65 38.11 9.57 31.94 22.35 30.69 37.16 25.51 
6 27.72 19.60 17.75 25.00 30.07 24.89 
8 27.79 36.39 18.67 34.94 17.66 25.14 23.50 
12 31.52 39.13 7.61 27.66 21.38 27.99 37.07 22.68 
24 30.09 39.07 23.93 29.59 22.59 23.11 33.67 28.74 
32 26.67 39.43 18.86 33.08 27.51 25.83 35.52 26.62 
48 25.99 41.24 26.98 32.31 20.07 23.21 38.05 25.09 
72 36.04 38.94 28.91 33.08 24.61 26.78 28.13 
96 27.78 39.45 16.21 33.42 18.57 24.09 39.23 29.31 
120 40.19 5.12 32.40 20.91 28.43 
144 31.98 32.18 24.32 38.62 26.52 
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Table B-9. 
Concentrations of serum thromboxane B2 (nglml) following intravenous administration ofS(+) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 28.05 32.63 29.28 25.90 30.16 29.07 36.86 32.96 
1 7.27 7.08 3.66 1.13 3.77 27.07 17.19 12.64 
2 9.36 7.64 7.96 1.19 6.41 20.74 18.88 16.81 
4 10.96 9.57 2.63 3.66 20.33 23.52 21.79 
6 13.33 2.81 11.83 21.26 21.79 
8 14.84 7.19 15.69 3.84 10.28 19.86 23.79 
12 13.02 13.89 12.76 3.89 11.29 13.93 22.85 19.51 
24 23.20 14.76 25.76 10.44 10.48 26.41 27.04 29.49 
32 22.74 14.76 27.98 11.22 7.99 28.18 29.55 
48 27.87 24.47 31.57 17.16 27.09 38.08 32.03 32.52 
72 32.05 22.67 33.64 19.41 27.73 33.70 34.69 33.91 
96 31.86 34.08 15.71 27.36 29.92 35.50 
120 28.17 30.58 34.74 15.38 33.73 20.31 33.67 
144 30.08 15.52 33.12 17.40 36.01 35.24 
Table B-I0. 
Concentrations of serum thromboxane B2 (nglml) following intravenous administration ofNG-
nitro-L-arginine methyl ester at 25 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 20.07 32.14 26.11 29.96 31.63 32.18 34.98 32.68 
1 12.61 27.63 15.12 25.53 12.66 25.25 35.53 25.30 
2 13.11 27.57 16.17 25.56 19.77 27.48 33.81 26.43 
4 12.44 28.51 15.04 27.59 13.59 32.23 34.56 26.55 
6 18.33 26.52 17.95 27.57 15.65 26.62 33.55 24.02 
8 11.45 28.55 21.82 25.82 12.41 23.25 34.18 26.16 
12 14.61 29.75 13.97 27.33 14.67 31.68 32.79 26.94 
24 21.52 31.07 15.86 28.57 25.65 32.54 33.85 23.78 
32 18.30 32.63 15.99 29.40 19.32 33.25 34.12 26.23 
48 18.66 28.15 12.02 28.86 18.03 27.62 28.38 25.56 
72 18.70 31.87 23.39 30.02 20.03 27.50 35.51 27.20 
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Table B-11. 
Concentrations of exudate prostaglandin E2 (nglml) following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 un 2.17 4.34 UD un un 55.25 un 
4 21.59 11.35 90.61 12.13 47.98 14.85 89.86 un 
8 93.24 68.26 111.43 94.86 101.35 96.56 57.72 14.81 
12 115.32 78.97 108.90 97.74 97.61 112.64 61.34 17.35 
24 110.86 68.39 89.06 102.19 51.85 9.78 5.05 
32 76.11 38.45 40.02 75.24 12.75 47.22 5.59 10.80 
48 1.93 9.38 14.52 2.31 un 19.79 
72 4.19 1.90 un un 15.30 un 24.10 
96 4.96 2.29 un 2.02 
120 un un 55.18 
144 2.09 un un 1.46 un un un 32.74 
un = undetectable «0.8 nglml) 
Table B-12. 
Concentrations of exudate prostaglandin E2 (ng/ml) following intravenous administration of 
racemic carprofen at 4.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 un un un 2.73 un un un un 
4 un un un 47.27 un 1.36 un un 
8 20.49 un 2.67 80.94 un 35.43 4.57 un 
12 106.70 un 39.26 52.17 un 82.12 26.79 un 
24 22.22 un 12.97 un 41.80 un un 
32 23.39 un 4.24 12.66 un 27.42 un 2.80 
48 1.13 un un 1.65 un 1.84 un un 
72 un un un un un un un un 
96 un un un un un un un 
120 un un un un un 1.76 
144 1.17 un un un un un un un 
UD = undetectable «0.8 nglml) 
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Table B-13. 
Concentrations of exudate prostaglandin E2 (ng/ml) following intravenous administration of R( -) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 UD UD UD 2.12 UD un 6.79 10.15 
4 99.11 36.36 un 74.99 4.28 30.43 84.44 17.70 
8 129.17 88.98 90.59 109.74 53.56 89.32 109.35 19.56 
12 138.34 107.29 79.43 92.45 90.40 85.70 118.05 
24 128.58 86.88 56.30 59.35 27.93 52.41 107.83 21.72 
32 124.97 74.02 16.04 35.36 59.81 1.41 37.54 
48 69.92 7.49 un 23.32 11.10 1.54 6.80 41.42 
72 11.34 un un 7.22 un un 1.23 39.40 
96 6.10 2.36 un 6.26 un 1.93 49.41 
120 1.99 un un un 1.70 
144 1.88 un un 6.15 un 1.68 5.64 59.35 
UD = undetectable «0.8 ng/ml) 
Table B-14. 
Concentrations of exudate prostaglandin E2 (ng/ml) following intravenous administration of S( +) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 un un un un un un un un 
4 un un 6.05 16.20 un un UD 97.82 
8 11.72 8.31 114.67 11.35 un 2.81 7.80 un 
12 57.66 42.17 130.64 33.04 UD 29.76 12.04 12.07 
24 7.33 12.73 81.07 7.07 un 28.30 2.51 36.30 
32 7.23 14.21 38.97 un 53.44 UD 24.66 
48 2.56 un 2.79 2.42 un un UD un 
72 UD un un 1.76 un un UD UD 
96 un 2.16 2.06 un un 
120 un 1.94 un UD 4.52 
144 UD 2.11 un un UD un 
UD = undetectable «0.8 ng/ml) 
236 
Table B-15. 
Concentrations of exudate prostaglandin E2 (nglml) following intravenous administration ofNG-
nitro-L-arginine methyl ester at 25 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 un un un 16.02 un un un 23.60 
4 31.51 13.54 90.85 80.54 6.48 9.12 25.03 16.64 
8 144.60 94.46 150.79 103.49 69.11 102.75 99.08 35.83 
12 156.07 132.48 148.99 105.36 75.26 121.38 114.08 47.21 
24 153.52 114.40 42.16 71.24 48.21 98.62 87.87 48.51 
32 143.52 59.84 58.99 57.08 70.63 68.90 
48 98.21 4.56 4.77 43.08 un 9.74 4.35 36.42 
72 7.16 un un 27.29 UD 1.56 UD 37.83 
96 UD 21.59 1.27 un 
120 UD 26.77 UD 
144 UD UD UD 26.67 UD UD un 46.02 
UD = undetectable «0.8 nglml) 
Table B-16. 
Concentrations of exudate leukotriene B4 (nglml) following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.45 0.55 un UD 0.60 0.54 0.55 0.57 
4 0.73 1.21 0.49 0.79 1.26 0.51 0.85 0.98 
8 0.82 0.96 0.89 0.91 1.62 1.06 2.35 1.66 
12 0.81 1.68 1.27 1.48 1.81 4.51 2.50 0.60 
24 0.59 1.44 0.97 0.83 0.83 1.28 1.84 0.73 
32 0.67 1.09 1.23 0.76 1.55 1.45 1.74 
48 2.24 0.86 0.88 1.65 1.03 1.39 1.25 
72 0.99 1.30 0.56 0.64 2.16 un 1.74 1.16 
96 0.78 1.71 un 1.07 1.20 0.63 
120 0.70 0.68 1.36 1.10 
144 0.89 1.02 1.01 0.48 0.81 1.08 0.88 0.44 
un = undetectable «0.16 nglml) 
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Table 8-17. 
Concentrations of exudate leukotriene B4 (nglml) following intravenous administration of 
racemic carprofen at 4.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.68 1.61 0.91 0.59 0.60 0.40 0.70 
4 1.03 0.61 1.23 1.21 0.42 0.82 0.67 1.12 
8 1.22 1.05 1.24 0.87 0.93 1.01 1.20 0.87 
12 1.82 1.71 3.92 1.07 1.12 1.45 2.59 1.35 
24 0.56 0.87 1.79 1.00 1.41 0.91 
32 0.95 0.79 2.50 0.93 2.00 1.01 1.94 1.26 
48 1.20 0.94 1.64 1.54 1.03 0.52 1.49 1.75 
72 0.81 1.28 1.35 1.69 1.17 1.02 1.69 1.02 
96 0.75 0.80 1.39 1.61 1.09 0.70 
120 1.10 0.86 1.54 0.63 
144 0.89 0.89 1.41 0.91 1.90 1.14 1.87 1.10 
Table 8-18. 
Concentrations of exudate leukotriene B4 (nglml) following intravenous administration ofR(-) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.33 0.67 0.49 0.40 0.29 0.32 0.94 0.75 
4 0.00 1.14 0.52 1.76 0.54 0.69 1.12 0.98 
8 0.55 1.16 0.56 0.33 0.76 0.88 2.36 1.43 
12 1.02 1.13 0.53 2.86 0.87 0.92 2.12 
24 0.75 1.05 0.68 0.51 0.91 0.92 1.99 
32 0.53 1.09 0.83 2.40 1.03 1.63 1.18 
48 1.29 1.02 0.78 1.19 0.76 0.86 0.35 2.68 
72 1.74 0.61 0.58 1.02 1.05 1.03 0.78 0.31 
96 1.44 0.75 0.67 1.29 0.71 0.88 2.25 
120 4.76 0.87 0.94 0.93 0.80 0.58 
144 1.04 1.83 0.56 2.64 0.75 0.88 0.78 1.18 
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Table B-19. 
Concentrations of exudate leukotriene B4 (nglml) following intravenous administration of S( +) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 un un 0.92 0.53 0.58 0.58 0.63 0.90 
4 0.96 0.37 0.84 1.68 1.10 0.90 1.20 2.06 
8 0.56 0.73 2.06 1.22 2.95 1.60 1.99 2.83 
12 0.92 1.53 2.27 8.51 2.00 0.98 3.68 2.94 
24 0.52 1.10 1.99 1.44 1.38 0.93 1.18 1.95 
32 0.54 2.53 1.31 1.22 0.80 2.54 1.94 
48 0.52 0.44 4.61 0.95 8.98 1.54 1.60 3.01 
72 6.55 0.62 2.l3 1.74 5.21 0.87 1.33 3.17 
96 2.39 1.55 1.17 1.25 
120 0.97 0.48 3.88 0.94 1.29 0.77 
144 0.27 0.72 1.25 2.14 0.99 0.83 
Table B-20. 
Concentrations of exudate leukotriene B4 (nglml) following intravenous administration ofNG-
nitro-L-arginine methyl ester at 25 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
2 0.57 0.43 0.62 0.94 0.38 un 0.42 1.89 
4 0.67 1.57 0.56 1.42 0.30 0.40 0.57 2.07 
8 1.04 0.97 0.73 1.33 0.99 0.88 0.97 2.62 
12 1.36 1.33 0.91 2.26 1.65 1.72 2.51 8.87 
24 1.35 1.25 0.64 1.19 0.88 1.12 1.76 4.49 
32 1.33 1.14 0.96 2.01 1.23 1.86 
48 1.42 0.96 0.90 1.39 0.70 1.18 2.26 3.19 
72 1.11 1.25 1.73 1.23 0.69 1.06 1.18 3.15 
96 0.78 1.60 1.14 3.55 
120 0.69 1.60 1.27 
144 0.86 0.63 0.89 1.88 0.92 0.82 1.29 2.57 
un = undetectable «0.16 nglml) 
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Table B-21. 
Numbers of exudate leukocytes (x 109 cellslL) following intravenous administration of placebo 
in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
4 2.4 2.5 3.6 5.3 9.1 4.9 10.2 4.8 
8 4.1 4.9 8.8 4.5 0.0 12.1 6.8 2.7 
12 8.3 10.5 l3.1 9.1 32.6 26.2 9.9 31.3 
24 14.9 5.6 11.1 17.0 38.1 8.1 6.9 34.5 
48 4.2 3.9 9.1 4.2 8.8 3.6 5.0 4.0 
Table B-22. 
Numbers of exudate leukocytes (x 109 cellslL) following intravenous administration of racemic 
carprofen at 4.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
4 2.9 0.9 6.2 2.6 2.5 5.5 3.5 7.5 
8 6.2 1.7 5.9 4.4 2.0 27.1 10.3 10.4 
12 0.0 4.2 13.4 15.0 6.1 29.0 12.9 16.8 
24 6.5 33.6 20.3 29.2 l3.9 64.2 23.0 17.2 
48 2.9 4.6 10.5 2.4 7.4 16.2 7.5 3.5 
Table B-23. 
Numbers of exudate leukocytes (x 109 cells/L) following intravenous administration ofR(-) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
4 2.1 3.2 7.9 15.3 3.6 4.4 5.0 
8 5.7 5.8 10.6 2.1 5.5 6.0 19.3 5.4 
12 9.3 0.0 12.3 15.4 13.7 20.2 27.8 
24 10.0 11.4 23.3 23.7 12.3 26.6 46.0 
48 11.3 8.6 4.8 16.7 11.7 7.9 
Table B-24. 
Numbers of exudate leukocytes (x 109 cells/L) following intravenous administration ofS(+) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
4 7.9 5.9 7.2 5.2 6.4 4.0 10.6 2.6 
8 11.8 6.5 6.6 10.7 4.5 2.7 8.7 1.0 
12 16.7 14.4 28.5 22.3 15.6 5.4 l3.5 8.8 
24 21.6 10.4 35.0 19.4 18.2 31.4 12.2 33.7 
48 4.7 4.4 4.6 l3.2 5.8 7.3 10.2 8.1 
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Table B-25. 
Numbers of exudate leukocytes (x 109 cellslL) following intravenous administration of ~ -nitro-
L-arginine methyl ester at 25 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
4 3.8 5.3 5.3 11.7 3.9 4.7 2.9 14.6 
8 5.7 3.8 12.8 27.9 3.3 15.6 7.1 3.6 
12 6.6 6.9 21.0 49.2 8.3 25.1 10.6 
24 13.3 40.7 45.2 73.2 14.9 68.6 6.4 
48 3.4 5.0 4.1 10.9 15.0 9.1 0.0 10.8 
Table B-26. 
Numbers ofleukocytes (x 109 cells/L) in venous blood following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 6.0 6.4 9.1 5.8 7.2 6.4 11.1 9.4 
4 6.1 5.9 8.2 8.0 5.6 10.2 9.0 
24 6.6 6.4 7.8 5.6 8.9 6.5 9.7 9.9 
48 6.1 6.1 8.4 3.9 8.8 6.0 6.9 8.5 
Table B-27. 
Numbers of leukocytes (x 109 cells/L) in venous blood following intravenous administration of 
racemic carprofen at 4.0 mglkg in sheep. 
Time (h) 
-0.33 
4 
24 
48 
143 
7.0 
7.4 
6.3 
6.7 
Table B-28. 
144 
5.2 
4.9 
4.8 
5.6 
145 
8.8 
6.5 
8.9 
7.5 
Animal numbers 
146 147 
7.5 8.0 
7.1 
7.4 
6.0 
7.9 
9.7 
148 
7.9 
8.1 
7.5 
7.1 
149 
9.1 
8.7 
6.9 
6.6 
150 
9.2 
8.6 
8.9 
7.9 
Numbers ofleukocytes (x 109 cellslL) in venous blood following intravenous administration of 
R( -) carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 8.3 6.3 6.6 5.5 10.2 6.4 7.7 6.9 
4 7.3 6.1 5.1 9.2 9.6 6.3 
24 8.6 6.0 6.4 5.2 9.7 6.9 5.6 7.2 
48 7.7 7.4 5.8 4.9 9.4 6.0 9.3 7.5 
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Table B-29. 
Numbers ofleukocytes (x 109 cellslL) in venous blood following intravenous administration of 
S(+) carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 7 5.5 7.1 4.7 9.9 9.9 7.7 8.8 
4 7.1 8.0 4.3 5.8 9.1 10.2 
24 6.6 5.8 7.5 4.0 2.8 9.5 8.0 8.7 
48 6.4 5.6 6.6 3.9 6.2 8.0 6.6 8.3 
Table B-30. 
Numbers ofleukocytes (x 109 cellslL) in venous blood following intravenous administration of 
W-nitro-L-arginine methyl ester at 25 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 6.2 7.2 0.0 5.9 6.6 9.0 7.2 
4 6.1 6.7 7.3 10.1 
24 9.1 7.8 7.4 7.6 8.7 10.2 7.1 
48 6.1 6.8 5.8 6.1 6.5 11.0 7.5 
Table B-31. 
Numbers of platelets (x 109 cellslL) in venous blood following intravenous administration of 
placebo in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 195 203 124 199 262 184 120 146 
4 197 228 218 264 185 165 110 
24 227 245 246 174 260 198 99 101 
48 234 248 246 177 238 213 99 155 
Table B-32. 
Numbers of platelets (x 109 cellslL) in venous blood following intravenous administration of 
racemic carprofen at 4.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 215 225 209 218 209 241 79 147 
4 221 205 128 183 224 117 102 
24 215 212 205 192 234 181 160 111 
48 223 252 199 219 240 234 231 105 
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Table B-33. 
Numbers of platelets (xl09 cells/L) in venous blood following intravenous administration ofR(-) 
carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 179 177 152 152 255 232 105 191 
4 162 112 143 250 130 174 
24 172 241 194 156 244 223 53 228 
48 221 192 234 154 238 221 81 232 
Table B-34. 
Numbers of platelets (x 109 cells/L) in venous blood following intravenous administration of 
S(+) carprofen at 2.0 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 167 265 202 176 265 234 118 153 
4 193 184 165 146 241 210 
24 208 208 242 195 183 252 118 146 
48 231 258 243 242 160 262 145 126 
Table B-35. 
Numbers of platelets (x 109 cellsIL) in venous blood following intravenous administration ofW-
nitro-L-arginine methyl ester at 25 mglkg in sheep. 
Animal numbers 
Time (h) 143 144 145 146 147 148 149 150 
-0.33 227 228 0 179 227 205 103 191 
4 217 167 214 156 103 
24 186 243 195 159 256 192 99 187 
48 202 239 204 217 258 188 103 162 
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Table 8-36. 
Concentrations of nitrite in exudate following intravenous administration of placebo in sheep 
(Values are expressed as IlM of NO; and NO; was reduced into NO;). 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
-0.33 3.34 3.22 2.86 2.74 1.07 1.67 1.91 3.69 
2 10.24 8.96 8.32 3.09 3.93 3.35 4.27 4.20 
4 8.80 8.00 7.36 3.51 4.35 3.18 2.93 3.35 
8 7.04 7.04 6.72 4.52 4.77 3.51 4.10 3.51 
12 7.68 6.40 7.04 3.18 5.02 3.43 3.51 4.02 
24 7.04 4.32 6.72 2.68 5.35 5.02 3.35 2.84 
48 9.60 6.72 6.72 3.01 4.43 3.01 3.26 3.26 
72 3.18 5.35 5.19 2.51 2.84 
96 2.76 4.94 7.19 2.34 3.18 
Table 8-37. 
Concentrations of nitrite in exudate following intravenous administration ofNG -nitro-L-arginine 
methyl ester in sheep (Values are expressed as IlM of NO; and NO; was reduced into NO;). 
Animal numbers 
Time(h) 143 144 145 146 147 148 149 150 
-0.33 3.34 3.22 2.86 2.74 1.07 1.67 1.91 3.69 
2 6.72 7.17 6.72 6.94 5.60 6.72 6.05 10.30 
4 5.38 4.70 7.84 5.38 4.93 6.72 3.02 5.82 
8 5.38 4.70 5.82 8.29 5.15 5.38 6.27 5.82 
12 4.70 4.48 4.03 4.26 2.69 2.91 3.14 11.20 
24 3.81 2.91 2.69 4.26 2.69 3.58 4.26 7.39 
48 4.03 3.14 3.58 4.93 6.27 4.48 3.14 7.62 
72 5.38 4.48 3.14 4.70 5.38 4.03 4.93 6.27 
96 5.82 4.03 3.58 7.17 4.70 3.81 3.14 7.84 
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AppendixC 
Pharmacokinetics and pharmacodynamics of phenylbutazone and flunixin meglumine in 
donkeys 
Table C-l. 
Concentrations (~glml) of phenylbutazone (PBZ), oxyphenbutazone (OPBZ) and flunixin 
meglumine (FM) in plasma following intravenous administration of PBZ (4.4 mglkg), FM (1.1 
mglkg) in donkeys. 
Phenylbutazone Oxyphenbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
0.08 39.16 34.61 37.18 1.32 1.75 2.35 18.09 19.95 18.23 
0.25 19.58 20.92 18.12 2.37 3.50 3.92 12.41 17.66 14.12 
0.50 10.09 14.87 9.31 3.03 4.70 4.13 7.60 10.80 8.33 
0.75 7.14 8.32 5.50 2.92 4.61 3.76 6.78 7.85 5.43 
1 5.37 6.43 3.31 3.06 4.98 2.88 4.87 6.83 4.82 
2 2.34 2.13 1.40 2.22 3.17 2.38 2.88 3.80 1.87 
3 l.32 l.06 0.62 l.94 2.00 l.39 l.64 3.24 l.08 
4 0.69 0.56 0.19 0.89 1.48 0.79 1.15 1.55 0.62 
6 0.26 0.18 0.06 0.49 0.50 0.37 0.51 1.22 0.25 
8 0.16 0.09 un 0.38 0.29 un 0.26 0.74 0.15 
12 un un un 0.11 0.09 un 0.13 0.48 0.07 
24 un un un un un un 0.07 0.12 un 
32 un un un un un un un un un 
un = undetectable «0.05 ~glml). 
Table C-2. 
Concentrations (~glml) of phenylbutazone (PBZ), oxyphenbutazone (OPBZ) and flunixin 
meglumine (FM) in exudate following intravenous administration ofPBZ (4.4 mglkg), FM (1.1 
mglkg) in donkeys. 
Phenylbutazone Oxyphenbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
2 0.20 2.33 1.67 0.08 1.26 0.58 1.09 1.94 0.77 
4 0.38 0.97 0.75 0.25 1.32 0.58 0.87 1.21 0.88 
8 0.53 0.33 0.67 0.34 0.49 0.36 0.37 
12 0.43 0.14 0.06 0.21 0.20 0.14 UD 0.21 
24 0.14 UD 0.05 0.06 UD 0.04 0.15 UD 
32 0.09 UD UD UD UD UD 0.15 UD UD 
48 0.07 UD UD UD UD UD UD UD UD 
UD = undetectable «0.05 ~g1ml). 
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Table C-3. 
Concentrations (J.lglml) of phenylbutazone (PBZ), oxyphenbutazone (OPBZ) and flunixin 
meglumine (FM) in transudate following intravenous administration ofPBZ (4.4 mg!k.g), FM 
(1.1 mg!k.g) in donkeys. 
Phenylbutazone Oxyphenbutazone Flunixin meglumine 
Time(h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
2 0.37 1.28 1.66 0.12 1.02 0.58 0.17 0.27 1.48 
4 0.77 0.90 0.44 0.84 1.12 0.47 0.55 1.13 0.48 
8 0.41 0.32 0.71 0.36 0.10 1.10 0.34 
12 0.13 0.13 0.05 0.14 0.20 0.13 0.60 1.06 0.09 
24 0.06 UD 0.05 UD UD UD 0.08 0.12 0.05 
32 0.07 UD UD UD UD UD 0.08 0.27 0.05 
48 0.07 UD UD UD UD UD 0.15 0.17 0.05 
UD = undetectable «0.05 J.lglml). 
Table C-4. 
Skin temperature (OC) over cages following intravenous administration of placebo, 
phenylbutazone (4.4 mglkg) and flunixin meglumine (1.1 mglkg) in donkeys (Values are 
expressed as the difference between inflamed and non-inflamed tissue-cages). 
Placebo Phenylbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
--0.33 -0.1 0.9 0.0 2.5 -0.9 0.2 -0.4 -0.9 
1 0.3 1.0 0.2 0.0 -0.8 0.1 0.1 -0.1 -1.4 
2 0.4 0.4 -1.2 -0.2 -0.4 0.2 0.3 0.3 -1.5 
3 1.3 1.4 2.0 0.1 0.5 0.2 0.6 1.2 -1.5 
4 3.7 0.4 0.3 1.0 -0.1 0.0 -0.3 0.5 -1.1 
6 1.1 0.6 -0.5 0.3 -0.7 -0.3 1.0 0.4 -0.4 
8 0.9 0.3 -0.1 -0.7 0.0 0.6 1.0 1.2 0.1 
12 1.1 0.0 0.5 -0.2 0.0 1.8 0.4 1.3 1.0 
24 2.2 1.2 1.1 1.7 0.9 0.1 1.3 -1.0 1.5 
32 -2.3 1.0 0.5 2.7 0.0 1.0 0.3 -0.4 1.6 
48 4.5 1.1 0.3 2.2 1.8 1.1 0.3 0.0 3.9 
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Table c-s. 
Concentrations of serum thromboxane B2 (nglml) following intravenous administration of 
placebo, phenylbutazone (4.4 mglkg) and flunixin meglumine (1.1 mglkg) in donkeys. 
Placebo Phenylbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
-0.33 46.50 90.50 34.80 41.05 41.50 32.60 21.65 80.50 28.55 
1 31.70 87.00 35.10 4.90 14.40 3.20 5.80 0.00 1.55 
2 43.80 78.00 27.20 6.25 39.25 7.25 3.60 7.30 0.00 
4 45.05 89.00 32.70 15.75 90.50 20.80 4.00 9.00 2.15 
6 43.80 70.00 32.50 17.35 60.00 23.20 3.65 0.00 2.65 
8 47.05 74.00 32.70 42.20 53.00 33.20 6.10 2.25 9.05 
12 37.80 86.00 31.20 28.55 75.00 32.20 8.50 11.65 9.90 
24 36.00 62.00 26.50 44.33 66.00 26.00 26.60 34.20 32.60 
32 35.25 64.00 28.35 38.30 57.00 30.90 29.65 92.50 31.45 
48 36.60 48.00 23.40 51.00 61.00 29.65 32.65 61.00 33.35 
Table C-6. 
Concentrations of exudate prostaglandin E2 (nglml) following intravenous administration of 
placebo, phenylbutazone (4.4 mglkg) and flunixin meglumine (1.1 mglkg) in donkeys. 
Placebo Phenylbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
2 0.17 0.19 1.19 un un un un un 
4 2.83 1.68 1.13 un un 0.03 un un un 
8 4.23 1.26 1.19 un 1.42 un un un 
12 4.48 2.52 2.99 3.36 2.38 2.99 un 3.56 2.00 
24 4.48 0.13 3.36 2.83 2.25 un un 3.56 
32 2.83 3.36 3.99 1.78 1.78 un 3.56 
48 1.50 1.13 1.19 0.63 0.19 un 3.76 
UD = undetectable «0.8 nglml). 
Table C-7. 
Concentrations of exudate 12-hydroxyeicosatetraenoic acid (nglml) following intravenous 
administration of placebo, phenylbutazone (4.4 mglkg) and flunixin meglumine (1.1 mglkg) in 
donkeys. 
Placebo Phenylbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
2 394.87 580.37 380.36 252.30 407.43 593.56 528.94 212.83 485.43 
4 495.96 900.85 562.16 230.36 605.29 613.70 558.62 610.75 517.58 
8 527.65 939.64 364.80 651.52 859.61 663.12 
12 420.74 428.05 350.08 491.86 339.33 633.55 392.39 400.39 589.34 
24 282.62 452.62 283.06 451.09 275.08 364.97 569.75 
32 274.39 689.32 293.46 389.80 348.13 355.77 639.02 
48 328.70 986.35 446.41 272.74 463.34 301.21 357.20 738.96 
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Table C-S. 
Numbers of exudate leukocytes (x 109 celllL) following intravenous administration of placebo, 
phenylbutazone (4.4 mglkg) and flunixin meglumine (1.1 mglkg) in donkeys. 
Placebo Phenylbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
2 6.90 6.90 3.40 0.70 41.80 2.l0 
4 5.60 2.60 2.10 1.20 0.70 
8 7.90 0.50 2.20 3.10 2.80 3.70 1.70 14.10 2.60 
12 44.10 12.40 3.20 14.10 42.40 1.40 21.60 4.90 
24 29.30 7.20 17.50 8.80 18.40 33.30 3.90 
32 11.20 1.70 2.70 13.50 5.20 9.30 14.80 1.60 
48 7.70 3.50 2.10 5.10 3.80 3.90 4.70 2.20 2.60 
Table C-9. 
Numbers (x 109 celllL) ofleukocytes in venous blood following intravenous administration of 
placebo, phenylbutazone (4.4 mglkg) and flunixin meglumine (1.1 mglkg) in donkeys. 
Placebo Phenylbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
-0.33 9.50 9.70 5.10 10.50 9.00 4.60 9.00 11.00 4.70 
6 9.10 8.40 4.80 9.90 8.50 4.60 9.60 10.20 5.50 
24 10.70 9.60 6.10 10.20 8.20 5.60 10.60 5.10 
32 9.70 11.10 6.00 10.50 8.50 6.80 11.00 11.10 5.80 
48 9.00 11.70 7.70 5.50 10.10 5.50 
Table C-IO. 
Numbers (x 109 celllL) of platelets in venous blood following intravenous administration of 
placebo, phenylbutazone (4.4 mglkg) and flunixin meglumine (1.1 mglkg) in donkeys. 
Placebo Phenylbutazone Flunixin meglumine 
Time (h) Cheeky Frisky Pinky Cheeky Frisky Pinky Cheeky Frisky Pinky 
-0.33 144.00 154.00 88.00 111.00 206.00 95.00 136.00 146.00 120.00 
6 144.00 191.00 110.00 130.00 229.00 107.00 138.00 202.00 134.00 
24 152.00 180.00 111.00 108.00 216.00 117.00 144.00 126.00 
32 144.00 156.00 101.00 112.00 146.00 84.00 136.00 100.00 
48 145.00 179.00 193.00 107.00 121.00 126.00 
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Appendix D 
Experimental code: QMlZC/OS/94 
Study on pharmacokinetics, bioavailability and serum thromboxane B2 inhibition of 
phenylbutazone in goats 
Table D-l. 
Concentrations of phenylbutazone (PBZ) in plasma following PBZ administered orally at 4.4 
mg/kg in goats. 
Animal numbers 
Time (h) G7 GI0 Gll G13 G72 G74 
Pre. UD un un un UD UD 
0.25 7.56 4.50 5.38 10.45 12.76 
0.50 16.01 17.27 9.80 7.86 18.89 16.54 
0.75 21.35 17.98 13.49 5.74 21.64 22.24 
1 26.33 19.94 13.30 9.79 23.85 23.04 
2 29.33 14.31 18.75 15.31 28.58 17.41 
4 30.53 26.07 27.25 16.61 28.94 27.81 
6 31.10 21.44 24.55 18.97 26.75 28.64 
8 27.62 21.97 25.86 18.91 24.24 24.46 
12 14.46 17.92 22.92 15.84 34.80 27.41 
24 14.95 9.70 17.31 8.51 14.01 22.77 
34 6.76 15.04 5.57 9.32 19.04 
48 2.47 9.83 1.78 4.54 12.07 
72 1.93 0.74 1.17 1.88 7.24 
96 1.68 3.27 
120 0.65 1.63 
144 0.26 0.85 
UD = undetectable «0.05 Jlg/ml). 
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Table D-2. 
Concentrations of oxyphenbutazone in plasma following phenylbutazone administered orally at 
4.4 mglkg in goats. 
Animal numbers 
Time (h) G7 GI0 GIl G13 G72 G74 
Pre. UD UD UD UD UD UD 
0.25 UD UD UD UD UD UD 
0.50 UD 0.09 UD UD 0.08 UD 
0.75 UD 0.14 0.07 UD 0.13 UD 
1 0.07 0.20 0.17 UD 0.17 UD 
2 0.15 0.22 0.35 0.17 0.32 0.10 
4 0.25 0.65 0.45 0.25 0.47 0.11 
6 0.26 0.62 0.54 0.50 0.66 0.14 
8 0.22 0.79 0.63 0.18 0.11 0.33 
12 0.27 1.12 0.48 0.47 0.41 0.20 
24 0.16 0.32 0.30 0.18 0.36 0.18 
34 0.28 0.26 UD 0.22 0.15 
48 0.07 UD UD 0.01 0.13 
72 0.08 UD UD UD UD 0.07 
96 UD UD 
120 UD UD 
144 UD UD 
UD = undetectable «0.05 Ilglml). 
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Table D-3. 
Concentrations of phenylbutazone (PBZ) in plasma following PBZ administered intravenously at 
4.4 mglkg in goats. 
Animal numbers 
Time (h) G7 G10 G11 G13 G72 G74 
Pre. UD UD UD UD UD UD 
0.03 93.99 124.59 170.87 69.92 131.62 146.39 
0.08 86.29 127.40 59.20 132.97 
0.17 86.10 91.78 107.63 43.84 99.26 114.41 
0.25 74.53 77.15 145.65 41.67 86.74 106.77 
0.50 62.81 74.50 94.95 37.96 78.56 91.49 
0.75 57.76 65.70 84.51 33.43 66.26 84.60 
. 1 53.50 58.17 75.15 30.81 65.41 82.08 
2 42.21 47.78 66.76 25.43 49.16 67.75 
4 33.47 42.34 59.98 17.53 43.57 57.17 
6 33.24 35.81 45.83 20.46 38.22 55.19 
8 31.02 33.35 46.09 15.07 34.85 55.02 
12 24.90 28.15 37.11 12.66 29.77 46.64 
24 14.63 14.78 23.92 6.09 17.01 31.48 
34 10.83 10.44 18.18 3.81 13.35 25.38 
48 5.05 5.27 8.25 1.57 7.63 18.43 
72 2.06 1.82 2.77 0.41 2.76 3.21 
96 0.58 1.00 
120 0.22 0.29 
144 0.06 0.11 
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Table D-4. 
Concentrations of oxyphenbutazone in plasma following phenylbutazone administered 
intravenously at 4.4 mg/kg in goats. 
Animal numbers 
Time (h) G7 G10 GIl G13 G72 G74 
Pre. UD UD UD UD UD UD 
0.03 UD 0.19 0.30 UD UD UD 
0.08 0.l0 0.42 0.17 0.38 UD 
0.17 0.19 0.46 0.72 0.21 0.49 0.21 
0.25 0.21 0.66 1.24 0.28 0.57 0.24 
0.50 0.25 0.90 1.30 0.26 0.70 0.32 
0.75 0.22 0.93 1.39 0.45 0.68 0.38 
1 0.23 0.89 1.47 0.47 0.69 0.37 
2 0.27 0.90 1.52 0.39 0.62 0.45 
4 0.24 0.95 1.65 0.43 0.61 0.16 
6 0.35 0.86 1.39 0.35 0.63 0.47 
8 0.43 1.06 1.34 0.49 0.18 0.42 
12 0.43 0.86 1.09 0.60 0.55 0.61 
24 0.12 0.41 0.76 0.12 0.37 0.23 
34 0.08 0.23 0.50 0.10 0.19 0.14 
48 UD 0.09 0.33 UD 0.13 0.15 
72 UD UD 0.06 0.06 UD UD 
96 UD UD 
120 UD UD 
144 UD UD 
UD = undetectable «0.05 Ilg/ml). 
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Table D-5. 
Concentrations of serum thromboxane B2 (ng/ml) following placebo administered intravenously 
in goats. 
Animal numbers 
Time (h) G7 GI0 G11 G13 G72 G74 
-0.08 96.92 274.98 119.75 137.77 28l.14 149.78 
1 21.41 125.19 13.86 158.20 205.24 58.19 
2 18.20 128.30 12.67 52.03 204.49 4l.11 
4 154.47 105.85 10.13 62.42 22l.64 35.35 
6 149.78 116.90 33.48 53.65 187.82 40.93 
8 210.37 151.74 20.00 77.26 209.61 45.00 
12 134.05 129.44 18.04 6l.14 185.60 55.26 
24 272.94 186.68 18.60 125.42 290.55 69.27 
32 208.12 151.34 23.15 110.19 224.49 67.33 
48 153.64 188.82 43.08 108.84 246.90 209.68 
72 180.47 208.89 49.47 117.32 264.43 100.73 
96 108.71 200.14 
120 42.50 197.40 
144 31.77 170.47 
Table D-6. 
Concentrations of serum thromboxane B2 (ng/ml) following phenylbutazone administered 
intravenously at 4.4 mg/kg in goats. 
Animal numbers 
Time (h) G7 GI0 G11 G13 G72 G74 
-0.08 109.06 166.72 405.22 193.52 257.24 175.03 
1 9.63 12.93 312.09 17.50 49.82 94.84 
2 25.29 20.40 368.31 37.32 65.38 101.63 
4 20.77 28.84 388.12 74.17 115.93 97.11 
6 17.89 40.56 315.96 38.08 158.83 136.55 
8 22.70 45.00 419.51 71.55 160.50 84.62 
12 22.03 56.76 326.85 32.57 174.19 139.49 
24 87.41 112.08 397.49 162.78 248.73 221.15 
32 79.43 135.77 398.72 142.81 310.73 256.96 
48 83.00 182.72 385.43 137.13 290.26 339.41 
72 66.75 274.10 406.16 154.83 339.31 258.48 
96 203.33 269.04 
120 234.28 356.71 
144 186.95 402.15 
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Appendix E 
Experimental Code: QMlZC/lO/94 
Comparative pharmacokinetics of paracetamol (acetaminophen) and its 
sulphate and glucuronide metabolites in desert camels and goats. 
Table E-l. 
Concentrations of paracetamol in serum following intramuscular administration of paracetamol 
at 5 mg/kg in camels. 
Animal numbers 
Time (min) Cl C2 C3 C4 C5 C6 
Pre 0.00 0.00 0.00 0.00 0.00 0.00 
10 3.18 7.34 3.10 3.46 1.27 3.40 
20 3.53 6.88 3.40 3.98 1.65 3.19 
30 4.11 5.63 3.35 4.15 1.72 2.72 
40 3.83 5.63 2.90 3.71 1.90 2.47 
60 3.39 3.91 2.30 3.44 1.40 1.64 
90 2.43 2.96 1.73 2.15 1.28 1.18 
120 1.33 1.58 1.19 1.23 0.95 0.68 
150 0.75 1.02 0.68 0.89 0.65 0.43 
180 0.53 0.65 0.53 0.59 0.44 0.86 
210 0.35 0.33 0.41 0.35 0.38 0.19 
Table E-2. 
Concentrations of paracetamol ~-glucuronide in serum following intramuscular administration of 
paracetamol at 5 mg/kg in camels. 
Animal numbers 
Time (min) Cl C2 C3 C4 C5 C6 
Pre 0.00 0.00 0.00 0.00 0.00 0.00 
10 0.56 2.36 0.79 2.37 0.37 0.61 
20 2.70 5.11 1.45 2.80 1.12 1.28 
30 3.38 6.04 1.82 3.51 1.19 1.87 
40 3.61 8.21 2.10 3.92 3.26 2.86 
60 6.27 10.95 3.30 6.35 3.93 3.31 
90 8.59 12.59 4.11 6.84 5.37 3.21 
120 9.15 11.22 4.21 6.66 5.64 3.35 
150 7.21 8.16 3.77 7.26 4.65 2.49 
180 6.50 7.19 3.42 6.89 3.76 2.39 
210 5.57 5.93 3.15 6.15 3.09 1.88 
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Table E-3. 
Concentrations of paracetamol sulphate in serum following intramuscular administration of 
paracetamol at 5 mglkg in camels. 
Animal numbers 
Time (min) Cl C2 C3 C4 C5 C6 
Pre 0.00 0.00 0.00 0.00 0.00 0.00 
10 4.78 6.72 2.27 8.21 1.09 2.99 
20 9.19 11.83 5.02 9.39 1.93 4.71 
30 10.38 10.75 5.70 11.09 3.01 5.26 
40 10.29 14.70 5.72 9.73 4.19 7.55 
60 16.35 16.17 9.19 18.25 4.38 7.33 
90 20.43 16.63 10.44 15.36 5.61 6.21 
120 9.22 11.34 9.77 11.25 4.85 5.60 
150 9.82 6.83 7.55 13.51 3.60 3.33 
180 8.82 5.95 5.71 10.95 3.57 2.70 
210 5.95 3.53 5.01 7.87 2.14 1.19 
Table E-4. 
Concentrations of paracetamol in serum following intravenous administration of paracetamol at 5 
mglkg in camels. 
Animal numbers 
Time (min) Cl C2 C3 C4 C5 C6 
Pre 0.00 0.12 0.00 0.00 0.00 0.00 
5 8.44 14.16 8.81 10.32 7.13 mlssmg 
10 5.57 6.02 5.79 8.04 5.90 6.18 
15 3.10 4.13 3.59 3.84 4.07 5.65 
20 2.99 2.62 2.90 2.76 3.39 4.35 
30 1.97 2.41 2.06 2.28 2.54 2.98 
40 1.11 1.62 1.68 1.96 1.98 2.10 
60 0.70 0.99 0.98 1.06 1.59 1.74 
90 0.40 0.72 0.59 0.75 0.84 1.11 
120 0.23 0.43 0.44 0.37 0.61 0.58 
150 0.31 0.32 0.32 0.30 0.36 0.36 
180 0.11 0.21 0.20 0.20 0.25 0.25 
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Table E-S. 
Concentrations ofparacetamol ~-glucuronide in serum following intravenous administration of 
paracetamol at 5 mg/kg in camels. 
Animal numbers 
Time (min) C1 C2 C3 C4 C5 C6 
Pre 0.00 0.00 0.00 0.00 0.00 0.00 
5 3.97 6.34 1.86 1.97 4.04 mIssmg 
10 5.79 9.94 4.11 5.74 6.89 5.92 
15 6.99 11.25 5.65 6.79 7.17 8.21 
20 7.58 13.18 5.73 6.88 8.26 8.10 
30 7.34 15.29 6.59 6.96 8.81 7.33 
40 6.80 10.71 6.65 7.02 10.25 7.38 
60 6.25 9.91 5.45 6.75 10.60 7.38 
90 5.60 9.33 4.57 5.82 7.95 6.76 
120 4.95 8.83 3.99 4.28 6.59 7.17 
150 4.63 7.15 3.42 4.85 6.00 4.49 
180 3.28 5.69 2.48 3.88 4.97 4.28 
Table E-6. 
Concentrations of paracetamol sulphate in serum following intravenous administration of 
paracetamol at 5 mglkg in camels. 
Animal numbers 
Time (min) C1 C2 C3 C4 C5 C6 
Pre 0.00 0.00 0.00 0.00 0.00 0.00 
5 10.52 8.07 6.41 7.76 9.95 mIssmg 
10 14.00 14.56 11.41 17.48 12.98 13.80 
15 17.00 20.67 12.14 15.04 10.79 19.04 
20 20.18 15.60 15.00 15.00 12.50 20.75 
30 15.25 13.77 13.64 17.14 12.34 17.21 
40 11.66 7.89 13.29 11.68 12.04 16.86 
60 6.20 5.53 9.09 10.22 11.73 17.74 
90 5.53 5.26 6.42 7.31 8.16 11.83 
120 3.23 3.91 4.98 4.26 6.01 10.89 
150 3.27 2.95 3.59 4.91 4.88 5.56 
180 1.75 1.99 2.26 3.32 2.67 4.13 
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Table E-7. 
Concentrations ofparacetamol in serum following intramusular administration ofparacetamol at 
10 mglkg in goats. 
Animal numbers 
Time (min) Gl G2 G3 G4 G5 
Pre 0.00 0.00 0.00 0.00 0.00 
10 4.91 5.77 4.98 4.76 2.78 
20 3.90 4.79 4.69 4.38 2.86 
30 2.44 2.66 3.02 3.94 2.91 
45 1.38 1.48 1.28 3.24 2.23 
60 0.69 0.60 0.64 1.91 1.43 
90 0.25 0.10 0.14 0.64 mIssmg 
120 0.10 un 0.09 0.25 0.37 
150 un un un 0.12 0.17 
240 un un un 0.09 142.11 
un = undetectable «0.11lg/m1). 
Table E-8. 
Concentrations of paracetamol ~-glucuronide in serum following intramusular administration of 
paracetamol at 10 mglkg in goats. 
Animal numbers 
Time (min) G1 G2 G3 G4 G5 
Pre 0.00 0.00 0.00 0.00 0.00 
10 20.24 19.49 21.24 12.53 8.19 
20 45.24 44.58 44.56 25.33 13.52 
30 56.41 47.39 54.31 31.66 19.32 
45 48.33 39.06 44.91 38.64 25.89 
60 38.75 29.74 34.82 36.21 25.49 
90 21.93 16.63 20.19 20.62 mIssmg 
120 12.99 8.41 10.44 9.60 17.47 
150 8.43 6.02 6.79 5.98 7.28 
240 2.83 1.89 2.75 1.52 5.04 
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Table E-9. 
Concentrations ofparacetamolsulphate in serum following intramusular administration of 
paracetamol at 10 mglkg in goats. 
Animal numbers 
Time (min) G1 G2 G3 G4 G5 
Pre 0.00 0.45 0.00 0.05 0.00 
10 0.66 0.64 0.31 0.98 0.14 
20 1.34 1.80 0.85 2.12 0.56 
30 1.66 1.57 1.16 2.29 0.37 
45 2.60 1.80 1.03 2.94 0.71 
60 1.05 0.90 0.57 2.64 0.45 
90 0.70 0.51 0.29 1.32 mIssmg 
120 0.23 0.28 0.10 0.42 missing 
150 un 0.42 0.10 0.28 0.17 
240 un 0.18 un 0.10 un 
un = undetectable «0.1 J.lglml). 
Table E-IO. 
Concentrations of paracetamol in serum following intravenous administration of paracetamol at 
10 mglkg in goats. 
Animal numbers 
Time (min) G1 G2 G3 G4 G5 G6 
Pre 0.00 0.00 0.00 0.00 0.00 0.00 
5 11.96 8.03 13.37 13.09 8.63 8.63 
10 5.13 6.39 9.85 6.65 6.76 6.76 
20 2.75 3.28 6.88 4.18 5.67 5.67 
30 1.71 2.37 4.11 2.07 3.64 3.64 
40 0.76 1.13 2.54 1.10 2.07 2.07 
60 0.29 0.35 0.94 0.44 1.01 1.01 
90 0.10 0.10 0.27 mIssmg 0.73 0.73 
120 un UD un 0.13 0.24 0.24 
150 UD UD un 0.10 0.11 0.11 
210 UD UD UD un UD UD 
UD = undetectable «0.1 J.lglml). 
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Table E-ll. 
Concentrations of paracetamol ~-glucuronide in serum following intravenous administration of 
paracetamol at 10 mglkg in goats. 
Animal numbers 
Time (min) Gl G2 G3 G4 G5 G6 
Pre 0.00 0.00 0.00 0.00 0.00 0.00 
5.00 19.00 31.44 25.32 26.77 51.66 72.14 
10.00 51.18 33.86 38.46 41.28 54.04 77.99 
20.00 55.45 32.65 47.27 51.42 56.77 85.54 
30.00 52.43 32.81 45.07 50.83 55.39 79.78 
40.00 39.95 30.08 34.21 34.96 48.93 59.82 
60.00 27.88 23.75 25.99 21.71 39.77 43.39 
90.00 17.89 13.27 15.93 mIssmg 28.32 33.91 
120.00 11.37 9.40 7.01 8.04 18.74 13.61 
150.00 7.16 4.98 4.21 6.80 9.79 8.32 
210.00 3.18 2.03 2.60 2.31 6.44 4.16 
Table E-12. 
Concentrations of paracetamol sulphate in serum following intravenous administration of 
paracetamol at 10 mg/kg in goats. 
Time (min) GI G2 
Pre 0.00 0.00 
5 1.21 1.10 
10 2.91 0.68 
20 2.36 0.57 
30 2.86 0.63 
40 1.56 0.44 
60 1.65 0.27 
90 0.71 0.24 
120 1.04 
150 0.31 
210 0.79 
UD = undetectable «0.1 J.lglml). 
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Animal numbers 
G3 G4 G5 
0.00 0.00 0.00 
2.09 0.81 1.52 
2.75 2.08 1.57 
3.57 2.08 1.78 
3.95 2.00 1.50 
2.54 1.14 1.36 
1.63 0.84 1.19 
0.54 0.67 
0.39 0.24 
0.13 0.10 
0.14 un 
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